





















For	 reabsorption	 to	occur,	 they	must	be	 transported	across	 the	phospholipid	bilayers	of	 the	
tubular	epithelium	by	 selective	 transport	 systems.	Mutations	 in	 these	 transport	 systems	can	
lead	 to	 disease	 though	 a	 conferred	 lack	 of	 amino	 acid	 re-absorption.	 One	 such	 disease	 is	
cystinuria,	caused	by	mutations	in	SLC3A1	and	SLC7A9,	which	encode	the	two	protein	subunits	
of	System	b0,+,	 rBAT	and	b0,+AT,	respectively.	 In	healthy	 individuals	System	b0,+	mediates	Na+-
independent	reabsorption	of	dibasic	amino	acids,	and	the	cysteine	dimer,	cystine,	in	exchange	
for	 neutral	 amino	 acids.	 In	 cystinuric	 patients,	 these	 amino	 acids	 are	 not	 sufficiently	 re-
absorbed	causing	a	dibasic	aminoaciduria	and	the	precipitation	of	cystine	crystals,	 leading	to	
the	formation	of	renal	calculi.		




of	 rBAT	 against	 the	 crystal	 structure	 of	 B.	 cereus	 oligo-1,6-glucosidase	 (PDB	 code	 1UOK),	
predicted	the	location	of	these	mutations	in	the	extracellular	domain	of	the	protein.		
When	 rBAT	 cRNA	 was	 injected	 into	 Xenopus	 oocytes,	 uptake	 of	 the	 prototypical	
System	b0,+	substrate	[3H]arginine	was	observed,	following	the	association	of	human	rBAT	with	
an	 endogenous	 oocyte	 light	 chain.	 	 A	 series	 of	 techniques	 was	 optimised	 to	 allow	 the	
characterisation	 of	 FLAG-tagged	 rBAT	 function	 and	 expression	 in	 oocytes,	 1-6	 days	 post-
injection	of	cRNA.	
Mutations	in	rBAT	lead	to	a	mis-folding	of	the	protein	and	its	early	degradation	in	the	
ER,	 preventing	 successful	 trafficking	 of	 the	 System	 b0,+	 heterodimer	 to	 the	 renal	 epithelial	
membrane.	This	aberrant	trafficking	leads	to	reduced	rBAT	expression	and	System	b0,+	activity	
in	oocytes.	Functional	characterisation	of	 the	novel	mutant	proteins	 led	to	a	decrease	 in	 the	




proteins	 at	 the	 plasma	membrane	of	 oocytes.	Western	 blotting	 of	 total	membrane	proteins	
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The	principal	 function	of	the	kidney	 is	 to	 filter	waste	products	 from	the	bloodstream	
whilst	 retaining	 essential	 molecules.	 Blood	 enters	 the	 glomerulus	 through	 the	 afferent	
arteriole	and	solutes	and	water	are	filtered	from	the	capillaries	across	the	glomerular	barrier.	
The	glomerular	barrier	is	a	complex	membrane	that	allows	sieving	of	small	molecules	(<50kDa)	
that	 can	 pass	 through	 the	 porous	 layers	 (Haraldsson	 et	 al.,	 2008).	 The	 charge	 and	
conformation	of	molecules	are	also	putatively	implicated	in	their	ability	to	freely	pass	into	the	
renal	 filtrate.	 However,	 it	 is	 clear	 that	 molecular	 weight	 plays	 the	 biggest	 role	 in	 filtration	
(Haraldsson	 et	 al.,	 2008).	 Ions	 and	 molecules	 contained	 in	 the	 filtrate	 are	 selectively	
reabsorbed	through	various	transport	pathways.		
Amino	 acids	 are	 small	 molecules	 that	 are	 required	 in	 all	 cells	 of	 the	 body	 for	 the	
synthesis	of	all	proteins,	purines	and	pyrimidines,	and	as	energy	metabolites	(Castagna	et	al.,	
1997;	 Bröer,	 2008).	 Most	 amino	 acids	 exist	 in	 a	 zwitterionic	 form	 at	 neutral	 pH.	 These	








energy	 is	 not	 required	 for	 transport.	 However,	 active	 transport	 systems	 move	 molecules	
against	their	electrochemical	gradient	through	energy	coupling	mechanisms.	Active	transport	
systems	 are	 classified	 as	 primary,	 secondary,	 or	 tertiary,	 based	 upon	 their	 specific	 energy	
source	(Hediger	et	al.,	2004).	Primary	active	transport	systems	directly	utilise	energy	from	the	
hydrolysis	of	ATP	to	create	an	electrochemical	gradient,	and	secondary	active	transporters	use	
this	 gradient	 to	 co-transport	 ions	 and	molecules.	 This	 allows	 the	 desired	movement	 of	 the	
transported	molecules,	creating	a	concentration	gradient	(Hediger	et	al.,	2004).	Tertiary	active	
transport	 systems	 utilise	 this	 concentration	 gradient	 for	 the	 exchange	 of	 other	 molecules.	
Transport	 systems	 can	be	 further	 classified	 according	 to	 the	direction	of	 the	 co-transport	of	
ions	 and	 molecules.	 Symporters	 transport	 the	 substrates	 in	 the	 same	 direction,	 whereas	
antiporters	mediate	the	obligatory	exchange	of	two	or	more	substrates	(Lolkema	et	al.,	1995).	
	 2	
The	 expression	 pattern	 of	 transport	 proteins	 varies	 dramatically	 along	 the	 length	 of	 the	




(Van	 Slyke	 and	Meyer,	 1913),	 Oxender	 and	 Christensen	 (1963)	 reported	 that	 two	 different	
“agencies”	were	 responsible	 for	 the	selective	movement	of	amino	acids	 in	Ehrlich	cells.	Two	
distinct	 transport	 systems	 were	 identified:	 System	 A,	 which	 transported	 alanine	 and	 small,	
polar	amino	acids,	and	System	L,	which	preferred	leucine	and	large,	hydrophobic	amino	acids	
(Oxender	&	 Christensen,	 1963).	 A	 further	 15	 amino	 acid	 transport	 systems	 have	 since	 been	
described,	the	nomenclature	of	which	describes	their	respective	substrate	specificities	(Bröer,	
2008).	For	example,	System	ASC	prefers	the	amino	acid	substrates	alanine,	serine,	and	cysteine	




al.	 (1984)	 were	 in	 non-epithelial	 cell	 lines,	 and	 largely	 reflect	 the	 systems	 present	 in	 the	
basolateral	 membrane	 of	 polarised	 cells	 (Bröer,	 2008).	 Ultimately,	 work	 following	 the	
discoveries	of	Halvor	Christensen	has	led	to	the	identification	of	17	different	epithelial	amino	
acid	transport	systems,	classified	by	their	selectivity,	and	ion-coupling	mechanism	of	transport	
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systems	 is	 identified	 as:	 H,	 high	 (<100μM);	 M,	 medium	 (100μM-1mM);	 L,	 low	 (>1mM).	 S,	
symport;	 A,	 antiport;	 U,	 uniport;	 Ub,	 ubiquitous;	 AM,	 apical	 membrane;	 BM,	 basolateral	























































































































































































































of	 different	 transport	 systems.	 The	 disorders	 associated	 with	 mutations	 in	 the	 transport	
proteins	are	denoted	 in	red	next	to	their	respective	transport	systems.	β-Ala,	β-alanine;	Tau,	






One	 renal	 proximal	 tubular	 transport	 system,	 b0,+,	 named	 to	 reflect	 its	 Na+-
independent	(small	“b”)	exchange	of	neutral	(0)	and	dibasic	(+)	amino	acids,	is	responsible	for	
the	 reabsorption	of	dibasic	amino	acids,	and	the	cysteine	dimer,	 cystine	 (Wells	and	Hediger,	
1992).	First	 reported	 in	1988	 in	mouse	blastocysts,	 system	b0,+	was	 identified	due	 to	 its	Na+-






the	 lumen	 of	 the	 nephron	 into	 the	 cytoplasm	 of	 the	 epithelial	 cell	 where	 it	 is	 cleaved	 into	
monomeric	 cysteine	 and	 transported	 into	 the	 bloodstream	 through	 distinct	 basolateral	
transport	systems	(Figure	1.1).	 It	has	been	demonstrated	through	rat	kidney	micro-perfusion	
data	that	>90%	of	cystine	reabsorption	occurs	in	the	early	proximal	tubule	(Volkl	&	Silbernagl,	
1982).	 This	 corresponds	 to	 the	 renal	 localisation	 of	 system	b0,+,	 identified	 through	Northern	
blotting.	 In	 the	 renal	proximal	 tubule,	 the	dibasic	amino	acids	and	cystine	are	 reabsorbed	 in	
exchange	 for	neutral	amino	acids,	which	are	effluxed	 into	 the	 lumen	of	 the	proximal	 tubule.	
These	amino	acids	 can	be,	 in	 turn,	 reabsorbed	via	Na+-dependent	apical	 symporters	 such	as	











Uptake	(5-497μM)	 36	 Rabbit	 1	
Uptake	(10-200μM)	 60	 Rabbit	 2	
Uptake	(10-200μM)	 43	 Human	 3	
Uptake	(5-497μM)	 30	 Human	 1	




Uptake	(15μM)	 --	 Rat	 4	
Uptake	(50μM),		
cis-inhibition	(99%	cystine,	98%	arginine,	90%	leucine;	5mM)	 --	 Human	 3	
Uptake	(10μM-10mM)		
cis-inhibition	(96%	arginine	99%,	cystine	99%	leucine,	99%	alanine;	5mM)	 105	 Rabbit	 2	
Lysine	 Yes	
Uptake	(15μM)	 --	 Human	 1	
cis-inhibition	(90%	phenylalanine;	1mM)	 --	 Rat	 5	
cis-inhibition	(95%	arginine,	97%	cystine,	98%	leucine,	99%	alanine;	5mM)	 --	 Rabbit	 2	
Uptake	(15μM),		
cis-inhibition	(97%	cystine,	98%	alanine,	97%	leucine;	2mM)	 --	 Rat	 4	
Ornithine	 Yes	
cis-inhibition	(96%	arginine	98%	cystine,	98%	leucine,	99%	alanine;	5mM)	 --	 Rabbit	 2	
Uptake	(15μM)	 --	 Rat	 4	
Neutral		
(zwitterionic)	 Leucine	 Yes	
Uptake	(15μM)	 --	 Rat	 4	
Uptake	(50μM),		
cis-inhibition	(95%	cystine,	85%	arginine,	98%	leucine;	5mM)	 --	 Human	 3	
Uptake	(10-100μM)	 22	 Rat	 5	
cis-inhibition	(92%	arginine	97%	cystine,	97%	leucine,	99%	alanine;	5mM)	 --	 Rabbit	 2	




Uptake	(10-100μM)	 29	 Rat	 5	
cis-inhibition	(75%	arginine	60%	cystine,	55%	leucine,	80%	alanine;	5mM)	 --	 Rabbit	 2	
Methionine	 Yes	
Uptake	(15μM)	 --	 Human	 1	
Uptake	(10-100μM)	 71	 Rat	 5	
Uptake	(15μM)	 --	 Rat	 4	
Glutamine	 Yes	
Uptake	(50μM)	 --	 Rat	 5	
Uptake	(15μM)	 --	 Rat	 4	
Asparagine	 Yes	 Uptake	(15μM)	 --	 Rat	 4	
Histidine	 Yes	
Uptake	(10-100μM)	 167	 Rat	 5	
cis-inhibition	(52%	arginine,	76%	cystine,	75%	leucine,	85%	alanine;	5mM)	 --	 Rabbit	 2	
Uptake	(15μM)	 --	 Rat	 4	
Serine	 Yes	
Uptake	(15μM)	 --	 Human	 1	




Uptake	(15μM)	 --	 Human	 1	
cis-inhibition	(50%	arginine,	80%	cystine,	80%	leucine,	60%	alanine;	5mM)	 --	 Rabbit	 2	
Uptake	(10-100μM)	 50	 Rat	 5	
Uptake	(50μM)	 --	 Rabbit	 2	
Uptake	(15μM)	 --	 Rat	 4	
Threonine	 Yes	(weak)	 cis-inhibition	(40%	arginine,	65%	cystine,	75%	leucine,	87%	alanine;	5mM)	 --	 Rabbit	 2	
Cysteine	 Yes	(weak)	 cis-inhibition	(50%	arginine,	80%	leucine,	90%	alanine;	5mM)	 --	 Rabbit	 2	
Valine	 Yes	(weak)	 cis-inhibition	(46%	arginine,	68%	cystine,	60%	leucine,	80%	alanine;	5mM)	 --	 Rabbit	 2	
D-isomer	
Ornithine	 Yes	(weak)	 cis-inhibition	(40%	arginine,	60%	cystine,	45%	leucine,	80%	alanine;	5mM)	 --	 Rabbit	 2	
Lysine	 Yes	(weak)	 cis-inhibition	(75%	arginine	75%	cystine,	60%	leucine,	90%	alanine;	5mM)	 --	 Rabbit	 2	
10	
cis-inhibition	(80%	cystine;	2mM)	 --	 Rat	 4	
Cyclic	 Proline	 No	
cis-inhibition	(2%	arginine,	1%	cystine,	4%	leucine,	5%	alanine;	5mM)	 --	 Rabbit	 2	




acid	 No	 Uptake	(15μM)	 --	 Rat	 4	
Glutamic	
acid	 No	
Uptake	(50μM)	 --	 Rabbit	 2	
Uptake	(50μM)	 --	 Rat	 5	
cis-inhibition	(0%	cystine,	8%	arginine,	4%	leucine;	5mM)	 --	 Human	 3	




Uptake	(50μM)	 --	 Rat	 5	
Uptake	(50μM),		
cis-inhibition	(20%	arginine,	25%	cystine,	12%	leucine,	10%	alanine;	5mM)	 --	 Rabbit	 2	











classed	 as	 heterodimeric	 transport	 systems,	 functioning	 via	 the	 interaction	 of	 two	 distinct	
protein	 subunits:	 a	 heavy	 chain	 and	 a	 light	 chain.	 These	 are:	 System	 asc	 (CD98	 and	 asc1),	
System	b0,+	 (rBAT	and	b0,+AT),	System	L	 (CD98	and	LAT1	or	LAT2),	System	xc-	 (CD98	and	xCT),	
and	 System	 y+L	 (CD98	 and	 y+LAT1	 or	 y+LAT2)	 (Table	 1.1).	 The	 “heavy	 chains”	 of	 the	
heterodimeric	 transport	 systems	are	members	of	 the	mammalian	 SLC3	 family	of	 amino	acid	
transporters,	of	which	there	are	only	2:	SLC3A1	(rBAT)	and	SLC3A2	(CD98).	These	glycosylated	
proteins	are	covalently	bonded	to	their	respective	“light	chains”,	members	of	the	SLC7	family	




b0,+-like	 amino	 acid	 transport	 activity	 when	 expressed	 in	 Xenopus	 oocytes.	 (Bertran	 et	 al.,	
1992b;	Bertran	et	al.,	1992c;	Tate	et	al.,	1992;	Wells	&	Hediger,	1992;	Bertran	et	al.,	1993;	Lee	
et	al.,	1993).	Wells	and	Hediger	(1992)	isolated	a	cDNA	from	rat	kidney	tissue	that	encoded	a	
protein	 that	 induced	high	affinity	 (Km=	63.7µM)	cystine	 transport	 in	 the	oocyte.	They	named	
this	 protein	 D2	 and	 localised	 the	mRNA	 to	 the	 kidney	 and	 intestine	 through	 Northern	 blot	
analysis.	 Following	 estimation	 of	 the	 protein	 topology	 of	 D2,	 the	 group	 predicted	 only	 one	
transmembrane	 domain	 in	 the	 structure,	 therefore	 classifying	 it	 as	 a	 Type-II	 Membrane	
Glycoprotein	(Figure	1.2A).	Since	its	discovery,	hydrophilicity	modelling	has	further	supported	
the	 presence	 of	 only	 one	 TMD,	 reinforcing	 the	 belief	 that	 rBAT	 modulates	 transporter	
function,	 and	 possesses	 no	 transport	 function	 alone	 (Palacin,	 1994).	 The	 DNA	 sequence	 of	
rBAT	 showed	sequence	homology	with	bacterial	 glucosidases,	but	 the	protein	demonstrated	
no	enzymatic	activity,	following	investigation	of	a	range	of	sugars	(Wells	and	Hediger,	1991).		





rat	 renal	protein	with	 similar	 functional	properties:	NAA-Tr	 (neutral	 amino	acid	 transporter).	
Sequencing	studies	predicted	a	four	TMD	structure	and	a	shared	structural	motif	with	nicotinic	
ligand-gated	 ion	 channels	 was	 hypothesised	 (Figure	 1.2B).	 They	 used	 the	 deduced	 cDNA	
sequence	to	plot	the	calculated	hydrophilicity	in	different	regions	of	the	protein,	and	identified	
four	putative	 transmembrane	domains,	with	 intracellular	N	and	C	termini	 (Tate	et	al.,	1992).	
12	
This	 model	 was	 also	 reported	 in	 an	 investigation	 by	 Gasparini	 et	 al.	 (1995).	 A	 schematic	
representation	of	 the	 four	transmembrane	domain	model	of	 rBAT	 is	depicted	 in	Figure	1.2B,	
based	 upon	 the	 findings	 of	 Tate	 et	 al.	 (1992).	 However,	 this	 model	 has	 now	 become	
redundant,	as	the	single	transmembrane	domain	topological	morphology	of	rBAT	has	become	
widely-accepted	(Figure	1.2A).	Despite	the	differences	in	the	predicted	membrane	topology	of	
the	 proteins,	 it	 became	 apparent	 that	 the	 three	 groups	 had	 isolated	 the	 same	 protein	 in	
different	mammalian	species	(Segawa	et	al.,	1997).		
Today,	 this	 protein	 is	 universally	 known	as	 rBAT,	 and	 the	mRNA	has	been	 shown	by	
northern	blot	to	mainly	localise	to	the	kidney	and	small	intestine,	with	low	levels	of	detection	
in	the	brain,	liver,	and	pancreas	(Bertran	et	al.,	1992b;	Bertran	et	al.,	1992c;	Tate	et	al.,	1992;	
Wells	 &	 Hediger,	 1992;	 Bertran	 et	 al.,	 1993;	 Lee	 et	 al.,	 1993).	 Protein	 expression	 has	 been	
localised	 to	 the	 renal	 proximal	 tubular	 and	 small	 intestinal	 epithelium	 through	
immunohistochemical	detection	of	the	protein	in	rat	tissues	(Furriols	et	al.,	1993;	Pickel	et	al.,	
1993;	 Albers	 et	 al.,	 1999).	 Furthermore,	 it	 has	 been	 localised	 to	 the	 apical	 membrane	 of	 a	
human	intestinal	epithelial	cell	line,	Caco-2	(Anderson	et	al.,	2004).		
CD98	was	first	discovered	by	Haynes	et	al.	(1981)	as	a	lymphocytic	surface	antigen	in	a	
hybridoma	 cell	 line.	 The	 identified	 protein	 was,	 in	 fact,	 a	 heterodimeric	 molecule,	 with	 a	
glycosylated	 heavy	 chain	 (80kDa)	 and	 non-glycosylated	 light	 chain	 (38kDa)	 associated	 via	 a	
disulphide	bond	(Luscher	et	al.,	1985).	However,	the	function	of	the	heterodimer	remained	a	
mystery.	 Due	 to	 the	 high	 levels	 of	 CD98	 expression	 in	 malignant	 human	 cells,	 and	 rapidly	
dividing	cell	lines,	it	was	postulated	to	be	a	growth	factor	(Yagita	et	al.,	1986).	Additionally,	it	
was	 discovered	 that	 the	 anti-CD98	 antibody	 inhibited	 the	 exchange	 of	 Na+	 and	 Ca2+	 in	
sarcolemmal	 vesicles,	 which	 led	 to	 the	 hypothesis	 that	 this	 was	 an	 ion	 exchange	 channel	
(Michalak	et	al.,	1986).	Between	1987	and	1989,	the	mouse	and	human	cDNA	encoding	CD98	
were	isolated	(Quackenbush	et	al.,	1987;	Parmacek	et	al.,	1989).	It	was	identified	that	human	
CD98	 was	 a	 529	 amino	 acid	 glycoprotein,	 with	 only	 one	 predicted	 transmembrane	 domain	
(Quackenbush	 et	 al.,	 1987).	 Human	 CD98	 was	 predicted	 to	 have	 4	 sites	 of	 N-glycosylation,	
whilst	 the	 mouse	 protein	 had	 9	 putative	 N-glycosylation	 sites	 (Parmacek	 et	 al.,	 1989).	
However,	 these	 proteins	 were	 found	 to	 have	 77%	 sequence	 identity,	 and	 be	 expressed	
ubiquitously.	The	mRNA	for	CD98	was	detected	in	all	murine	tissues	investigated.	These	were:	
brain,	liver,	kidney,	lung,	heart,	muscle,	and	testis	(Parmacek	et	al.,	1989).	
Following	 the	 identification	 of	 rBAT,	 and	 the	 prediction	 that	 it	 contained	 only	 one	
transmembrane	domain,	with	a	large,	glycosylated	extracellular	domain,	the	sequence	identity	
between	these	 two	proteins	was	 investigated.	 It	was	discovered	 that	 the	 two	proteins,	 rBAT	
and	CD98,	shared	30%	sequence	identity	and	50%	similarity	(Figure	1.3)	(Bertran	et	al.,	1992b).	
As	 the	 function	 of	 CD98	 remained	 unknown,	 the	 cRNA	 for	 this	 protein	 was	 injected	 into	
13	
Xenopus	 oocytes	 to	 investigate	whether	 amino	 acid	 transport	 function	was	 induced,	 as	 had	
been	observed	with	the	structurally	related	protein,	 rBAT	(Bertran	et	al.,	1992a;	Wells	et	al.,	
1992).	 Upon	 expression	 of	 CD98	 in	 oocytes,	 3-fold	 stimulation	 in	 y+L	 activity	 was	 observed	
(Bertran	et	al.,	1992a;	Wells	et	al.,	1992).	This	transport	of	neutral	and	dibasic	amino	acids	was	
shown	 to	 be	 saturable,	 and	 differed	 from	 the	 System	 b0,+	 activity	 induced	 upon	 rBAT	
expression	 in	 several	ways.	 Firstly	 the	 transport	 of	 neutral	 amino	 acids	was	 observed	 to	 be	






greatly.	 Whilst	 the	 expression	 of	 CD98	 appears	 to	 be	 ubiquitous,	 rBAT	 mRNA	 localises	
predominantly	to	the	renal	proximal	tubule	and	 intestinal	epithelium	(Parmacek	et	al.,	1989;	
Bertran	et	al.,	1992a;	Bertran	et	al.,	1992b;	Tate	et	al.,	1992;	Wells	&	Hediger,	1992;	Wells	et	
al.,	 1992;	 Lee	 et	 al.,	 1993).	Additionally,	 studies	 into	 the	expression	of	 these	proteins	 in	 the	









topology	models	 have	been	proposed	 for	 rBAT.	A,	 Single	 transmembrane	domain	model	 for	
rBAT	with	a	 large	extracellular	domain	 showing	homology	 to	B.	 cereus	oligo-1,6-glucosidase.	
The	residue	numbers	at	the	boundary	of	the	different	domains	are	provided.	The	domains	are	
coloured	 according	 to	 the	 structure	 of	 the	 glucosidase	 enzymes,	 discussed	 in	 section	 1.9.	
Based	 upon	 the	 model	 by	 Bertran	 et	 al.	 (1992)	 and	 Rius	 and	 Chillarón	 (2012);	 B,	 Four-
transmembrane	domain	model	of	rBAT.	The	residue	numbers	at	the	N-	and	C-termini	of	each	


































rBAT      MAEDKSKRDSIEMSMKGCQTNNGFVHNEDILEQTPDPGSSTDNLKHSTRGI--------- 
CD98      MSQDT------EVDMKEVELNE--------LEPEKQPMNAASGAAMSLAGAEKNGLVKIK 
       *::*.      *:.**  : *:        **   :* .::..   *  *             
 
rBAT      LGSQEPDFKGVQPYAGMPKEVLFQFSGQ---ARYRIPREILFWLTVASVLVLIAATIAII 
CD98      VAEDEAEAAAAAKFTGLSKEELLKVAGSPGWVRTRWALLLLFWL---GWLGMLAGAVVII 
       :..:*.:  ..  ::*:.** *::.:*.   .* * .  :****   . * ::*.::.**   
 
rBAT            ALSPKCLD-----WWQEGPMYQIYPRSFKDSNKDGNGDLKGIQDKLDYITALNIKTVWIT  
CD98            VRAPRCRELPAQKWWHTGALYRI--GDLQAFQGHGAGNLAGLKGRLDYLSSLKVKGLVLG                  
                . :*.* :     **: *.:*.*   .::  :  * *:* *::..***:::*::* : :    
 
rBAT            SFYKSSLKDFRYGVEDFREVDPIFGTMEDFENLVAAIHDKGLKLIIDFIPNHTSDKHIWF  
CD98            PIHKNQKDDV--AQTDLLQIDPNFGSKEDFDSLLQSAKKKSIRVILDLTPNYR-------                  
                .::*.. .*.  .  *: ::** **: ***:.*: : :.*.:.:*:*: **:           
 
rBAT            QLSRTRTGKYTDYYIWHDCTHENGKTIPPNNWLSVYGNSSWHFDEVRNQCYFHQFMKEQP  
CD98            ------------------------------------GENSWFFTQV--------------                                                      
                                                    *:.**.* :*                 
 
rBAT            DLNFRNPDVQEEIKEILRFWLTKGVDGFSLDAVKFLLEAKHLRDEIQVNKTQIPDTVTQY  
CD98            ------DTVATKVKDALEFWLQAGVDGFQVRDIENLKDASSFLAEWQ-------------                          
                        *  ::*: * ***  *****.:  :: * :*. :  * *                
 
rBAT            SELYHDFTTTQVGMHDIVRSFRQTMDQYSTEPGRYRFMGTEAYAESIDRTVMYYGLPFIQ  
CD98            ---------------NITKGFSED-----------RLLIAGTNSSDLQQI-----LSLLE                                 
                               :*...* :            *:: : : :..::.      *.:::   
 
rBAT            EAD--FPFNNYLSMLDTVSGNSVYEVITSWMENMPEGKWPNWMIGGPDSSRLTSRLGNQY  
CD98            SNKDLLLTSSYLSDSGS-TGEHTKSLVTQYL-NATGNRWCSWSL--SQARLLTSFLPAQL                  
                . .  :  ..***  .: :*: . .::*.:: * . ..* .* :  .::  *** *  *    
 
rBAT            VNVMNMLLFTLPGTPITYYGEEIGMGNIVAANLNESYDINTLRSKSP-MQWDNSSNAGFS  
CD98            LRLYQLMLFTLPGTPVFSYGDEIGL---------DAAALPGQPMEAPVMLWDESSFPDIP                  
                :.: :::********:  **:***:         ::  :     ::* * **:** ..:.   
 
rBAT            EASNTWLPTNSDYHTVNVDVQKTQPRSALKLYQDLSLLHANELLLNRGWFCHLRNDSHYV  
CD98            GAVSA---------NMTVKGQSEDPGSLLSLFRRLSDQRSKERSLLHGDFHAFSAGPELF                   
                 * .:         .:.*. *. :* * *.*:. **  .::*  * .* *  :  ..  .   
 
rBAT            VYTRELDGIDRIFIVVLNFGESTL---LNLHNM--ISGLPAKIRIRLSTNSA-DKGSKVD  
CD98            SYIRHWDQNER-FLVVLNFGDVGLSAGLQASDLPASASLPAKADLLLSTQPGREEGSPLE                   
                * *  *  :* *:******:  *   *:  ::   :.****  : ***:.. ::** ::   
 
rBAT            TSGIFLDKGEGLIFEHNTKNLLHRQTAFRDRCFVSNRACYSSVLNILYTSC  
CD98            LERLKLEPHEGLLL----------------------RFPYAA---------                   





symbols	 are	 displayed	 below	 aligned	 residues.	 *,	 Fully-conserved	 residues;	 :,	 conservation	
between	groups	with	strongly	similar	properties	(scoring	>0.5	in	the	Gonnet	PAM	250	matrix);	










isolated	was	 for	 the	protein	LAT1,	shown	to	 induce	classic	System	L	 transport	characteristics	
(Table	 1.1)	when	 co-expressed	with	 CD98	 in	 the	 oocytes	 (Kanai	 et	 al.,	 1998).	 The	 uptake	 of	
[14C]leucine	 was	 strongly	 inhibited	 by	 2mM	 isoleucine,	 phenylalanine,	 and	 the	 System	 L-
specific	 inhibitor	 2-amino-2-norbornanecarboxylic	 acid	 (BCH)	 (Kanai	 et	 al.,	 1998).	 Shortly	
following	this	discovery,	the	human	and	mouse	cDNAs	for	y+LAT1	and	y+LAT2	were	identified	
through	 expression	 cloning	with	 CD98	 in	Xenopus	 oocytes	 and	 shown	 to	 induce	 System	 y+L	
activity	(Torrents	et	al.,	1998;	Pfeiffer	et	al.,	1999b).	Subsequently,	3	additional	light	chains	for	
CD98	 have	 been	 identified	 (Table	 1.1).	 These	 are:	 xCT	 (System	 xc-	 (Sato	 et	 al.,	 1999)),	 LAT2	
(System	L	 (Pineda	 et	al.,	1999;	Segawa	 et	al.,	1999)),	and	asc1	 (System	asc	 (Fukasawa	 et	al.,	
2000)).		
The	 first	 light	chain	to	associate	with	rBAT	was	discovered	 in	1999	from	a	rat	kidney	
cDNA	library,	 isolated	due	to	its	high	sequence	identity	(43%,	Figure	1.4)	with	LAT1	and	LAT2	
(Chairoungdua	 et	 al.,	 1999).	 As	 the	 associated	 transporter	 of	 system	 b0,+,	 this	 light	 chain	 is	
known	as	b0,+AT	(Chairoungdua	et	al.,	1999).	Northern	blot	analysis	detected	expression	of	the	
mRNA	 in	 the	 kidney	 and	 small	 intestine	 of	 rat	 tissue	 samples,	 and	 the	 protein	 was	
immunolocalised	 to	 the	 apical	membrane	 of	 renal	 proximal	 tubules.	 In	 the	 rat	 renal	 tissue,	
expression	of	 the	protein	 appeared	higher	 in	 the	proximal	 convoluted	 tubules	 (S1)	 than	 the	
straight	tubules	(S2>S3)	(Chairoungdua	et	al.,	1999).	When	the	cDNA	for	this	protein	was	co-
transfected	 with	 rBAT	 in	 COS-7	 cells,	 a	 large	 (6-fold)	 induction	 of	 [14C]cystine	 uptake	 was	
observed,	which	was	absent	when	the	proteins	were	expressed	in	 isolation	(Chairoungdua	et	
al.,	1999).	Shortly	following	this	discovery,	the	mouse	and	human	cDNAs	for	b0,+AT	were	also	
isolated	 (Pfeiffer	 et	 al.,	 1999a).	 Northern	 blot	 analysis	 showed	 localisation	 of	 mouse	 b0,+AT	
mRNA	 to	 the	 kidney	 and	 small	 intestine	 with	 an	 expression	 gradient	 in	 the	 renal	 proximal	
tubule	 of	 S1>	 S2>	 S3,	 confirming	 the	 findings	 of	 Chairoungdua	 et	 al.	 (1999).	 This	 reported	
expression	pattern	of	b0,+AT	directly	 contradicts	 that	of	 rBAT.	Northern	blot	analysis	of	 rBAT	




transport	 systems	have	a	conserved	cystine	 residue	 (Cys144	 in	b0,+AT,	Figure	1.4),	which	can	
17	





or	 the	 cDNA	 for	 either	 protein	 alone.	 Cells	 co-transfected	with	CD98	and	b0,+AT,	 showed	no	
induced	 uptake	 of	 [14C]cystine,	 indicating	 that	 b0,+AT	 associated	 specifically	 with	 rBAT	
(Chairoungdua	 et	 al.,	 1999).	 However,	 Rajan	 et	 al.	 (2000)	 demonstrated	 that,	 when	 co-
expressed	in	human	retinal	pigment	epithelial	(HRPE)	cells,	the	association	of	human	CD98	and	
rabbit	or	mouse	b0,+AT	can	induce	System	b0,+	activity.	They	identified	Na+-independent	uptake	
of	1μM	[3H]arginine	via	 rBAT-b0,+AT	and	CD98-b0,+AT,	which	was	 inhibited	 in	 the	presence	of	
2mM	unlabelled	competitor	compounds	in	the	same	profile	(Rajan	et	al.,	2000).	Transport	was	
inhibited	in	the	presence	of	neutral	and	cationic	amino	acids,	and	unaffected	by	the	presence	
of	 glutamate	 or	 MeAIB,	 consistent	 with	 the	 substrate	 specificity	 of	 System	 b0,+	 (Table	 1.1)	
(Rajan	 et	 al.,	 2000).	 When	 concentration-dependent	 uptake	 of	 System	 b0,+	 substrates	 was	
measured,	it	was	identified	that	although	the	two	induced	transport	systems	showed	the	same	
substrate	 selectivity	 profile,	 the	 measured	 affinities	 were	 different.	 The	 affinity	 (Km)	 for	









b0,+AT         MGDTGLRKRR--------------------EDEKSIQSQEPKTTSLQKELGLISGISIIV  
xCT           ----MVRKPVVSTISKGGYLQG--NVNGRLPSLGNKEPPGQEKVQLKRKVTLLRGVSIII 
y+LAT1        -MVDSTEYEVASQPEVET------------SPLGDGASPGPEQVKLKKEISLLNGVCLIV 
y+LAT2        MEAREPGRPTPTYHLVPNTSQS--QVE---EDVSSPPQRSSETMQLKKEISLLNGVSLVV 
LAT1          MAGAGPKRRALAAPAAEEKEEAREKMLAAKSADGSAPAGEGEGVTLQRNITLLNGVAIIV 
asc1          -MAGHTQQPSGRGNPRPAPSP---------SPVPGTVPGASERVALKKEIGLLSACTIII 
LAT2          -MEEGARHRNNTEKKHPGGGE---------SDASPEAGSGGGGVALKKEIGLVSACGIIV                                                               
                                                           *:.:: *: .  :::   
b0,+AT         GTIIGSGIFVSPKSVLSNTEAVGPCLIIWAACGVLATLGALCFAELGTMITKSGGEYPYL 
xCT           GTIIGAGIFISPKGVLQNTGSVGMSLTIWTVCGVLSLFGALSYAELGTTIKKSGGHYTYI 
y+LAT1        GNMIGSGIFVSPKGVLIYSASFGLSLVIWAVGGLFSVFGALCYAELGTTIKKSGASYAYI                         
y+LAT2        GNMIGSGIFVSPKGVLVHTASYGMSLIVWAIGGLFSVVGALCYAELGTTITKSGASYAYI 
LAT1          GTIIGSGIFVTPTGVLKEAGSPGLALVVWAACGVFSIVGALCYAELGTTISKSGGDYAYM 
asc1          GNIIGSGIFISPKGVLEHSGSVGLALFVWVLGGGVTALGSLCYAELGVAIPKSGGDYAYV 
LAT2          GNIIGSGIFVSPKGVLENAGSVGLALIVWIVTGFITVVGALCYAELGVTIPKSGGDYSYV                  
        *.:**:***::*..**  : : * .* :*   * .: .*:*.:****. * ***. *.*:  
b0,+AT         MEAYGPIPAYLFSWASLIVIKPTSFAIICLSFSEYVCAPFYVGCKPPQIVVKCLAAAAIL 
xCT           LEVFGPLPAFVRVWVELLIIRPAATAVISLAFGRYILEPFFIQCEIPELAIKLITAVGIT 
y+LAT1        LEAFGGFLAFIRLWTSLLIIEPTSQAIIAITFANYMVQPLFPSCFAPYAASRLLAAACIC 
y+LAT2        LEAFGGFIAFIRLWVSLLVVEPTGQAIIAITFANYIIQPSFPSCDPPYLACRLLAAACIC 
LAT1          LEVYGSLPAFLKLWIELLIIRPSSQYIVALVFATYLLKPLFPTCPVPEEAAKLVACLCVL 
asc1          TEIFGGLAGFLLLWSAVLIMYPTSLAVISMTFSNYVLQPVFPNCIPPTTASRVLSMACLM 
LAT2          KDIFGGLAGFLRLWIAVLVIYPTNQAVIALTFSNYVLQPLFPTCFPPESGLRLLAAICLL                   
         : :* : .::  *  :::: *:   ::.: *. *:  * :  *  *    . ::   :   
b0,+AT         FISTVNSLSVRLGSYVQNIFTAAKLVIVAIIIISGLVLLAQGNTKNFD--NSFEG-AQLS 
xCT           VVMVLNSMSVSWSARIQIFLTFCKLTAILIIIVPGVMQLIKGQTQNFK--DAFSG-RDSS 
y+LAT1        LLTFINCAYVKWGTLVQDIFTYAKVLALIAVIVAGIVRLGQGASTHFE--NSFEG-SSFA 
y+LAT2        LLTFVNCAYVKWGTRVQDTFTYAKVVALIAIIVMGLVKLCQGHSEHFQ--DAFEG-SSWD 
LAT1          LLTAVNCYSVKAATRVQDAFAAAKLLALALIILLGFVQIGKGDVSNLDPNFSFEG-TKLD 
asc1          LLTWVNSSSVRWATRIQDMFTGGKLLALSLIIGVGLLQIFQGHFEELRPSNAFAFWMTPS 
LAT2          LLTWVNCSSVRWATRVQDIFTAGKLLALALIIIMGIVQICKGEYFWLEPKNAFEDFQEPD                  
        .:  :*.  *  .: :*  ::  *:  :  :*  *.: : :*    :    :*         
b0,+AT         VGAISLAFYNGLWAYDGWNQLNYITEELRNPYRNLPLAIIIGIPLVTACYILMNVSYFTV 
xCT           ITRLPLAFYYGMYAYAGWFYLNFVTEEVENPEKTIPLAICISMAIVTIGYVLTNVAYFTT 
y+LAT1        VGDIALALYSALFSYSGWDTLNYVTEEIKNPERNLPLSIGISMPIVTIIYILTNVAYYTV 
y+LAT2        MGNLSLALYSALFSYSGWDTLNFVTEEIKNPERNLPLAIGISMPIVTLIYILTNVAYYTV 
LAT1          VGNIVLALYSGLFAYGGWNYLNFVTEEMINPYRNLPLAIIISLPIVTLVYVLTNLAYFTT 
asc1          VGHLALAFLQGSFAFSGWNFLNYVTEEMVDARKNLPRAIFISIPLVTFVYTFTNIAYFTA 
LAT2          IGLVALAFLQGSFAYGGWNFLNYVTEELVDPYKNLPRAIFISIPLVTFVYVFANVAYVTA                  
        :  : **:  . ::: **  **::***: :. ..:* :* *.:.:**  * : *::* *.  
b0,+AT         MTATELLQSQAVAVTFGDRVLYPASWIVPLFVAFSTIGAANGTCFTAGRLIYVAGREGHM 
xCT           INAEELLLSNAVAVTFSERLLGNFSLAVPIFVALSCFGSMNGGVFAVSRLFYVASREGHL 
y+LAT1        LDMRDILASDAVAVTFADQIFGIFNWIIPLSVALSCFGGLNASIVAASRLFFVGSREGHL 
y+LAT2        LNISDVLSSDAVAVTFADQTFGMFSWTIPIAVALSCFGGLNASIFASSRLFFVGSREGHL 
LAT1          LSTEQMLSSEAVAVDFGNYHLGVMSWIIPVFVGLSCFGSVNGSLFTSSRLFFVGSREGHL 
asc1          MSPQELLSSNAVAVTFGEKLLGYFSWVMPVSVALSTFGGINGYLFTYSRLCFSGAREGHL 
LAT2          MSPQELLASNAVAVTFGEKLLGVMAWIMPISVALSTFGGVNGSLFTSSRLFFAGAREGHL                  
        :   ::* *:**** *.:  :      :*: *.:* :*. *.  .: .** : ..****:  
b0,+AT         LKVLSYISVRRLTPAPAIIFYGIIATIYIIPGDINSLVNYFSFAAWLFYGLTILGLIVMR 
xCT           PEILSMIHVRKHTPLPAVIVLHPLTMIMLFSGDLDSLLNFLSFARWLFIGLAVAGLIYLR 
y+LAT1        PDAICMIHVERFTPVPSLLFNGIMALIYLCVEDIFQLINYYSFSYWFFVGLSIVGQLYLR 
y+LAT2        PDLLSMIHIERFTPIPALLFNCTMALIYLIVEDVFQLINYFSFSYWFFVGLSVVGQLYLR 
LAT1          PSILSMIHPQLLTPVPSLVFTCVMTLLYAFSKDIFSVINFFSFFNWLCVALAIIGMIWLR 
asc1          PSLLAMIHVRHCTPIPALLVCCGATAVIMLVGDTYTLINYVSFINYLCYGVTILGLLLLR 
LAT2          PSVLAMIHVKRCTPIPALLFTCISTLLMLVTSDMYTLINYVGFINYLFYGGTVAGQIVLR                   
         . :. *     ** *:::.    : :     *   ::*: .*  ::  . :: * : :*  
b0,+AT         FTRKELERPIKVPVVIPVLMTLISVFLVLAPIISKPTWEYLYCVLFILSGLLFYFLFVHY 
xCT           YKCPDMHRPFKVPLFIPALFSFTCLFMVALSLYSDPF-STGIGFVITLTGVPAYYLFIIW 
y+LAT1        WKEPDRPRPLKLSVFFPIVFCLCTIFLVAVPLYSDTI-NSLIGIAIALSGLPFYFLIIRV 
y+LAT2        WKEPKRPRPLKLSVFFPIVFCICSVFLVIVPLFTDTI-NSLIGIGIALSGVPFYFMGVYL 
LAT1          HRKPELERPIKVNLALPVFFILACLFLIAVSFWKTPV-ECGIGFTIILSGLPVYFFGVWW 
asc1          WRRPALHRPIKVNLLIPVAYLVFWAFLLVFSFISEPM-VCGVGVIIILTGVPIFFLGVFW 
LAT2          WKKPDIPRPIKINLLFPIIYLLFWAFLLVFSLWSEPV-VCGIGLAIMLTGVPVYFLGVYW                         
                **:*: : :*    .   *::  .: . .       . : *:*:  ::: :    
b0,+AT         ----KFGWAQKISKPITMHLQMLMEVVPPE-----------EDPE--------------- 
xCT           --DKKPRWFRIMSEKITRTLQIILEVV-PE-----------EDKL--------------- 
y+LAT1        PEHKRPLYLRRIVGSATRYLQVLCMSVAAE-----------MDLEDGGEMPKQRDPKSN- 
y+LAT2        PESRRPLFIRNVLAAITRGTQQLCFCVLTE-----------LDVAEEKKDERKTD----- 
LAT1          --KNKPKWLLQGIFSTTVLCQKLMQVV----------------PQET------------- 
asc1          --RSKPKCVHRLTESMTHWGQELCFVVYPQ-----------DAPEEEENGPCPPSLLPAT 
LAT           --QHKPKCFSDFIELLTLVSQKMCVVVYPEVERGSGTEEANEDMEEQQQPMYQPTPTKDK                      











human	 b0,+AT	 (NM_001243036.1),	 xCT	 (NM_014331.3),	 y+LAT1	 (NM_001126105.2),	 y+LAT2	
(NM_001076785.2),	LAT1	(NM_003486.5),	asc1	(NM_019849.2),	and	LAT2	(NM_001267037.1).	
Consensus	 symbols	 are	 displayed	 below	 aligned	 residues:	 *,	 fully-conserved	 residues;	 :,	
conservation	between	groups	with	strongly	similar	properties;	.,	conservation	between	groups	
with	weakly	similar	properties.	The	conserved	GXG	and	GWXXL	motifs	that	flank	the	unwound	
regions	 in	 transmembrane	 domains	 1	 and	 6,	 respectively,	 are	 highlighted	 in	 black.	 These	







prevalence	 worldwide	 of	 1:7000	 (Thomas	 et	 al.,	 2014).	 Cystinuria	 was	 first	 reported	 in	 the	
literature	 in	 1810,	 when	 an	 insoluble	 renal	 calculus	 of	 “cystic	 oxide”,	 weighing	 270g,	 and	
coated	in	a	“phosphate	of	lime”	was	removed	from	the	bladder	of	a	5	year	old	boy	(Wollaston,	
1810;	Knox,	1958).	However,	 it	was	a	century	 later	when	Sir	Archibald	Garrod	made	the	 link	
between	the	observations	on	this	chronic	stone-forming	condition,	further	identified	in	other	
patients,	 with	 Mendel’s	 theories	 of	 genetic	 inheritance	 (Garrod,	 1908).	 At	 the	 time,	 the	





a	 component	of	 the	 calculi	 (Dent	 et	 al.,	 1954;	Knox,	 1958).	 The	 second	key	breakthrough	 in	
uncovering	 the	 pathophysiology	 of	 cystinuria	 was	 made	 by	 Charles	 Dent	 in	 1951,	 when	 he	
reported	the	presence	of	hexagonal	crystals	that	had	formed	through	cystine	deposition	in	the	
renal	tubules,	not,	as	previously	suspected,	in	the	bladder	(Dent	&	Rose,	1951;	Knox,	1958).	It	
was	 concluded	 that	 the	 basis	 of	 the	 disease	 pathology	 was	 attributable	 to	 a	 lack	 of	
reabsorption	of	 cystine	 (Dent	&	Rose,	1951;	Knox,	1958).	 This	 led	 to	 the	understanding	 that	
the	cause	of	elevated	amino	acids	in	the	urine	was	a	defective	transport	system,	as	opposed	to	
a	metabolic	pathway.		
The	 identification	 of	 System	 b0,+	 by	 Van	 Winkle	 (1988),	 the	 only	 transport	 system	
known	to	reabsorb	cystine	from	the	filtrate	in	the	proximal	tubule,	and	the	expression	cloning	
of	rBAT	in	Xenopus	oocytes	in	the	early	1990s,	led	to	the	identification	of	the	transport	system	
responsible	 for	 the	 pathophysiology	 of	 cystinuria	 (Silbernagl,	 1988;	 Bertran	 et	 al.,	 1992b;	
Bertran	et	al.,	1992c;	Tate	et	al.,	1992;	Wells	&	Hediger,	1992;	Bertran	et	al.,	1993;	Lee	et	al.,	
1993).	 Cystinuria	 is	 caused	 by	 defects	 in	 the	 apical	 proximal	 tubular	 transport	 system,	 b0,+,	
which	 leads	 to	 an	 incomplete	 reabsorption	 of	 dibasic	 amino	 acids	 arginine,	 lysine	 and	
ornithine,	 and	 the	 cysteine	 dimer,	 cystine.	 This	 causes	 precipitation	 of	 cystine	 and	 the	
formation	of	renal	calculi,	along	with	a	dibasic	aminoaciduria.		
Cystinuria	was	originally	thought	to	be	an	autosomal	recessive	condition	(Harris	et	al.,	
1955).	That	 is,	 a	patient	must	have	 inherited	 two	mutated	alleles	 in	order	 to	present	with	a	
disease	 phenotype.	 However,	 it	 soon	 became	 apparent	 that	 some	 obligate	 heterozygote	




as	 a	 purely	 recessive	 trait,	 with	 obligate	 heterozygote	 relatives	 of	 the	 affected	 probands,	
showing	normal	urinary	amino	acid	profiles	(Harris	et	al.,	1955).	Conversely,	non-Type	obligate	
heterozygotes	have	elevated	urinary	levels	of	arginine,	cystine,	lysine	and	ornithine,	indicating	
a	 dominant	 inheritance	pattern	of	mutations	 (Harris	 et	 al.,	 1955).	 In	 one	 attempt	 at	 the	 re-
classification	of	cystinuric	patients,	the	non-Type	I	individuals	were	further	classified	as	Type	II	
and	Type	III	(Rosenberg	et	al.,	1966).	Type	II	cystinuria	displays	a	more	severe	phenotype	than	
Type	 III	 (Rosenberg	 et	 al.,	 1966).	 However,	 it	 became	 apparent	 that	 the	 penetrance	 of	
phenotype	in	some	patients	and	their	obligate	heterozygote	relatives	was	highly	variable	and	it	
was	 difficult	 to	 classify	 patients	 using	 the	 established	 nomenclature	 (Harris	 et	 al.,	 1955;	
Rosenberg	et	al.,	1966;	Dello	Strologo	et	al.,	2002).	 
During	 the	 1990s	 linkage	 analysis	 identified	 the	 two	 genes	 involved	 in	 cystinuria	
through	maximum	LOD	scoring	of	microsatellite	markers	 (Pras	et	al.,	1994;	Yan	et	al.,	1994).	
The	gene	encoding	rBAT	was	 located	to	the	short	arm	of	chromosome	2,	coinciding	with	the	





al.,	 1999).	 Defects	 in	 either	 of	 the	 two	 genes	 encoding	 the	 subunits	 of	 the	 heterodimeric	
transport	system,	can	cause	an	abnormality	in	transport	(Chillarón	et	al.,	2010).		
Following	 the	 identification	 of	 the	 two	 genes	 involved	 in	 this	 disease,	 a	 modern	
classification	system	was	introduced,	which	is	now	widely	used	in	the	literature	(Dello	Strologo	
et	 al.,	 2002).	 Patients	 with	 mutations	 in	 SLC3A1	 are	 classed	 as	 type	 “A”,	 and	 those	 with	
mutations	 in	 SLC7A9,	 type	 “B”.	 Thus,	 patients	 can	 be	 classified	 as	 Type	 AA,	 BB,	 or	 AB,	
depending	 on	 the	 chromosomal	 location	 of	 their	 specific	 mutations	 (Dello	 Strologo	 et	 al.,	
2002;	Gucev	et	al.,	2011).			
1.7	Current	therapies	for	cystinuria	
To	 limit	 the	 formation	 of	 cystine	 calculi	 in	 the	 renal	 filtrate	 and	 urine	 of	 cystinuric	
patients,	treatments	aim	to	increase	the	solubility	of	the	cysteine	dimer	(Figure	1.5A).	Dietary	
modifications	can	be	undertaken	to	reduce	the	recurrence	of	stone	formation	through	limiting	
dietary	 intake	 of	 sodium,	 which	 has	 been	 shown	 to	 increase	 urinary	 cystine	 excretion,	 and	
animal	 proteins,	 due	 to	 their	 high	 cystine	 and	 methionine	 content	 (Goldfarb	 et	 al.,	 2006).	
Despite	the	presence	of	System	b0,+	in	the	apical	membrane	of	the	small	intestine,	patients	do	
not	 suffer	 deficiencies	 in	 the	 dibasic	 amino	 acids	 or	 cystine	 due	 to	 the	 presence	 of	 peptide	





pH	7.5	 (Dent	 et	al.,	 1965;	Chillarón	 et	al.,	 2010).	The	 solubility	of	 cystine	 in	water	at	25°C	 is	
only	 460μM	 (O'Neil,	 2006).	 Through	 a	 combination	 of	 hyperdiuresis,	 to	 lower	 the	 absolute	
concentration	of	cystine,	and	alkalinisation	of	the	renal	filtrate,	to	increase	the	solubility	of	the	
filtered	 dimer,	 the	 recurrence	 of	 cystine	 stones	 can	 be	 lowered	 (Chillarón	 et	 al.,	 2010).	






through	 conjugation	 via	 disulphide	 bond	 formation	 (Figure	 1.5C-E).	 These	 cysteine-drug	
conjugates	 are	 predicted	 to	 be	 x50	 more	 soluble	 in	 urine	 than	 the	 cystine	 dimer	 (Lotz	 &	
Bartter,	 1965;	 Goldfarb	 et	 al.,	 2006;	 Chillarón	 et	 al.,	 2010).	 Captopril	 is	 an	 Angiotensin	
Converting	Enzyme	 inhibitor	 (ACEi),	commonly	prescribed	 for	 the	treatment	of	hypertension,	
by	 preventing	 the	 conversion	 of	 angiotensin	 I	 to	 angiotensin	 II	 (Goldfarb	 et	 al.,	 2006).	 As	 a	
widely	 prescribed	 drug,	 the	 side	 effect	 profile	 associated	 with	 captopril	 treatment	 is	 low.	
However,	 it	 has	 been	 reported	 that	 the	 efficacy	 of	 captopril	 on	 cystine	 conjugation	 in	
cystinuria	 is	 not	 established	 (Goldfarb	 et	 al.,	 2006).	 This	 is	 because	 concentrations	 in	 the	
plasma,	and	consequently	the	renal	filtrate,	do	not	reach	sufficient	levels	to	provide	adequate	
conjugation	 of	 cystine	 (Goldfarb	 et	 al.,	 2006;	 Chillarón	 et	 al.,	 2010;	 Thomas	 et	 al.,	 2014).	 D-
Penicillamine	and	tiopronin	 (Figure	1.5D)	are	both	 thiol-containing	 immunomodulating	drugs	




It	 has	 been	 reported	 that	 >50%	 of	 patients	 with	 cystinuria	 will	 pass	 stones	
spontaneously.	 For	 large	 stones	 >5mm	 in	 diameter	 urological	 interventions	 are	 required.	
However,	 Extracorporeal	 Shockwave	 Lithotripsy	 (ESWL)	 is	 not	 thought	 to	 be	 effective	 in	 the	








Figure	 1.5:	 The	molecular	 structure	 of	 cystine	 and	 cystine-drug	 conjugates.	 The	molecular	
structure	of	cysteine	(A),	which	can	form	a	dipeptide	via	a	peptide	bond	with	another	amino	
acid	(B),	or	a	dimer	via	a	disulphide	bond	to	form	cystine	(C).	Using	thiol-containing	drugs	(D),	




























































of	 amino	 acid	 reabsorption	 in	 the	 proximal	 tubule.	 Hartnup	 disorder	 (OMIM	 234500)	 was	
named	 after	 the	 patient	 Eddie	 Hartnup,	 who	 first	 presented	 with	 the	 disease	 in	 1956,	
displaying	symptoms	of	a	“pellagra-like	rash”	and	cerebral	ataxia	(Baron	et	al.,	1956).	Hartnup	
disease	 is	 an	 autosomal	 recessive	 condition	 that	 affects	 around	 1:30,000	 in	 European	
populations	 caused	 by	 mutations	 in	 SLC6A19,	 encoding	 the	 apical	 membrane	 transporter	
B0AT1	 (Figure	 1.1)	 (Bröer,	 2009).	 B0AT1	 is	 an	 apical	 membrane	 protein	 that	 mediates	 Na+-
dependent	 transport	 of	 neutral	 amino	 acids	 (Table	 1.1).	 	 Also	 located	 in	 the	 small	 intestine,	
mutations	in	this	transporter	affects	the	absorption	of	ingested	neutral	amino	acids	from	the	
diet.	 However,	 through	 the	 administration	 of	 a	 high	 protein	 diet,	 most	 patients	 remain	
asymptomatic,	 as	 the	 deficiency	 is	 compensated	 by	 the	 absorption	 of	 oligopeptides	 by	 the	
apical	peptide	transporter,	PepT1	(Bröer,	2009).	Patients	remain	largely	asymptomatic	despite	
the	presence	of	a	neutral	aminoaciduria,	notably	tryptophan	(Bröer,	2008,	2009).	
Lysinuric	 Protein	 Intolerance	 (LPI,	 OMIM:	 222700)	 occurs	 in	 around	 1:60,000	 of	 the	
population	in	Finland,	where	the	prevalence	is	highest	(Torrents	et	al.,	1999).	LPI	is	caused	by	
mutations	 in	the	 light	chain	of	a	basolateral	heterodimeric	transport	system,	y+L	(Figure	1.1),	
namely	 SLC7A7,	 the	 gene	 encoding	 y+LAT1	 (Torrents	 et	 al.,	 1999).	 To	 date,	 no	 pathogenic	
mutations	have	been	reported	in	SLC3A2,	the	gene	encoding	CD98	(Stenson	et	al.,	2014).	It	is	
considered	 that	 due	 to	 the	 ubiquitous	 distribution	 of	 CD98	 in	mammalian	 systems,	 and	 the	
association	 of	 this	 heavy	 chain	 with	 many	 different	 light	 chains,	 mutations	 in	 this	 protein	
would	have	fatal	consequences	 in	foetal	development	(Palacin	et	al.,	2005).	Unlike	cystinuria	
and	 Hartnup	 disorder,	 mutations	 in	 the	 Na+-dependent	 exchanger	 of	 extracellular	 neutral	
amino	acids	and	intracellular	dibasic	amino	acids	cause	a	multi-organ	phenotype	(Palacin	et	al.,	
2004).	LPI	was	first	described	by	Perheentupa	and	Visakorpi	(1965)	as	a	dibasic	aminoaciduria.	
In	LPI	patients,	 lysine	 is	present	 in	the	urine	at	a	concentration	10-fold	greater	than	arginine	
and	 30-fold	 greater	 than	 ornithine,	 respectively	 (Palacin	 et	 al.,	 2004).	 Unlike	 cystinuria,	 no	
renal	 stone	 formation	 is	associated	with	 the	aminoaciduria	as	System	y+L	does	not	 transport	
poorly-soluble	 cystine.	 Plasma	 concentrations	 of	 the	 dibasic	 amino	 acids	 are	 sub-normal	 as	
peptide	 transport	 cannot	 compensate	 for	 a	 lack	 of	 function	 of	 this	 basolateral	 transport	
system,	 as	 it	 can	with	 apical	 transport	 systems	 b0,+	 and	 B0	(Palacin	 et	 al.,	 2004).	 The	 clinical	
presentation	of	LPI	 includes	protein	malnutrition,	which	occurs	 in	 infants	after	weaning.	This	
leads	 to	 a	 failure	 to	 thrive,	 osteoporosis,	 hypotonia,	 and	mental	 retardation	 (Palacin	 et	 al.,	
2004).	Arginine	and	ornithine	are	key	components	in	the	urea	cycle.	Therefore,	a	deficiency	in	
these	amino	acids	 can	 lead	 to	post-prandial	hyperammonemia	when	patients	are	 fed	a	high	
protein	 diet.	 LPI	 patients	 can	 be	 treated	 with	 a	 low-protein	 diet	 and	 the	 urea	 cycle	
25	
intermediate,	 citrulline.	 This	prevents	hyperammonemia,	which	 can	 induce	 coma	and	death.	
However,	the	lysine	deficiency	remains	and	leads	to	poor	growth	and	osteoporosis	(Palacin	et	
al.,	2004).	
Other	 inherited	 disorders	 of	 amino	 acid	 transport	 include	 iminoglycinuria	 (OMIM:	
242600),	 and	 dicarboxylic	 aminoaciduria	 (OMIM:	 222730)	 (Bröer,	 2008).	 Both	 of	 these	




glycosidic	 bond	 between	 carbohydrate	 molecules	 and	 are	 found	 across	 archeal,	 bacterial,	
eukaryotic	and	viral	domains	of	life	(Lombard	et	al.,	2014).	The	GH	enzymes	are	divided	into	14	




enzymes	 (Pujadas	&	 Palau,	 2001).	 The	 conserved	 secondary	 structure	 is	 composed	 of	 three	
domains,	A-C	(Figure	1.6)	(Ramasubbu	et	al.,	1996).	The	N-terminal	domain,	Domain	A,	of	clan	
GH-H	 consists	 of	 a	 (β/α)8,	 or	 triosephosphate	 isomerase	 (TIM)	 barrel,	 a	 protein	 fold	 first	
identified	in	the	muscle	of	chickens	(Banner	et	al.,	1975;	Brayer	et	al.,	1995).	In	a	TIM	barrel,	
the	 polypeptide	 chain	 consists	 of	 eight	 parallel	 β	 sheets,	 linked	 by	 α	 helices	 (Figure	 1.7)	
(Banner	et	al.,	1975).	Domain	B	is	a	loop-rich	subdomain	inserted	between	β3	and	α3,	which,	
together	with	Domain	A,	forms	the	cleft	of	the	enzyme	active	site	(Janecek	et	al.,	1997).	Within	
this	 cleft,	 exists	 a	 “catalytic	 triad”,	 first	 discovered	 in	 Taka	Amylase	A	 from	Apergillus	 oyzae	
(Matsuura	 et	 al.,	 1984).	 This	 consists	 of	 three	 highly	 conserved	 residues	 that	 act	 as	 a	
nucleophile	 (Asp),	 proton	 donor	 (Glu),	 and	 transition-state	 stabiliser	 (Asp)	 (Matsuura	 et	 al.,	
1984).	 Finally,	 Domain	 C,	 the	 C-terminal	 domain,	 is	 an	 anti-parallel	 β	 sheet	 (Figure	 1.7)	
(Janecek	et	al.,	1997).	It	has	been	suggested	that	the	strict	conservation	of	secondary	structure	
within	 the	 families	 of	 the	 GH-H	 clan	 is	 due	 to	 the	 presence	 of	 seven	 conserved	 sequence	
regions	 (CSR)	 (Table	 1.3),	 which	 are	 distributed	 throughout	 the	 protein	 (Toda	 et	 al.,	 1982;	
Friedberg,	1983;	Rogers,	1985;	Nakajima	et	al.,	1986;	Janecek,	1992,	1994).	
In	 addition	 to	 alpha	 amylases,	 clan	 GH-H	 also	 includes	 oligo-1,6-glucosidases	 and	
neopullulanases	 (Watanabe	 et	 al.,	 1990).	Oligo-1,6-glucosidase	 from	Bacillus	 cereus	 is	 a	 558	
amino	acid	enzyme	(PDB	code	1UOK,	Figure	1.6).	Like	the	other	glycoside	hydrolases	belonging	
to	 clan	GH-H,	 this	 enzyme	 consists	 of	 the	 three	domains	A,	 B	 and	C	with	 an	 insertion	of	 an	






Figure	 1.6:	 The	 characteristic	 structural	 domains	 of	 the	GH-H	 clan	 of	 enzymes.	 The	 crystal	
structure	of	oligo-1,6-glucosidase	(PDB	code	1UOK;	Watanabe	et	al.,	1997).	Domains	A1	(red)	
and	 A2	 (green)	 display	 a	 (β/α)8	 structural	 fold,	 which	 is	 interrupted	 by	 loop-rich	 domain	 B	
(yellow).	The	cleft	formed	by	the	interruption	of	the	(β/α)8	fold	forms	the	enzyme	active	site.	





















































Figure	1.7:	 The	TIM	barrel	 conserved	 throughout	 the	GH-H	 clan	of	 enzymes.	 	A,	Schematic	
diagram	 of	 the	 top-view	 of	 a	 triosephosphate	 isomerase	 (TIM)	 barrel	 displaying	 the	
characteristic	 (β/α)8	 fold.	Squares	 represent	β	sheets	and	circles	 represent	α	helices;	B,	Top-
view	 of	 the	 TIM	 barrel	 isolated	 from	 the	 crystal	 structure	 of	B.	 cereus	oligo-1,6-glucosidase	
(PDB	 code	1UOK;	Watanabe	et	al.,	1997).	Domains	B	 and	C	have	been	 removed;	β1α1,	 red;	


















Table	 1.3:	 The	 seven	 conserved	 sequence	 regions	 of	 the	 GH	 enzyme	 clan.	 The	 seven	
identified	 conserved	 sequence	 regions	 (CSR)	 are	 the	 principal	 sites	 of	 primary	 sequence	
similarity	in	the	GH-H	clan	of	enzymes.	The	conserved	sequence	regions	are	numbered	in	order	













In	 2007,	 the	 extracellular	 domain	 of	 CD98	 was	 crystallised	 and	 the	 structure	







The	 crystal	 structure	 of	 rBAT	 has	 not	 yet	 been	 resolved.	 This	 is	 mainly	 due	 to	 the	
difficulties	 in	 yielding	 large	 quantities	 of	 hydrophobic	 eukaryotic	 membrane	 proteins.	
Additionally,	 the	 hydrophobic	 proteins	 must	 be	 extracted	 from	 the	 membrane	 using	
detergents,	which	disrupt	 the	native	 folding	of	 the	proteins	 (White	&	Wimley,	1999).	Due	to	
this,	 the	 vast	majority	 of	 crystal	 structures	 of	membrane	 proteins	 in	 the	 Protein	 Data	 Bank	
(PDB)	 are	 from	 lower	 prokaryotic	 organisms,	 harvested	 in	 large	 quantities	 of	 the	 proteins	
through	 recombinant	 technology	 (Carpenter	 et	 al.,	 2008).	 It	 is	 not	 possible	 to	 express	many	
eukaryotic	 transport	proteins	 in	bacterial	 expression	 systems	due	 to	 their	 structural	 reliance	
on	 post-translational	 modifications,	 which	 do	 not	 occur	 in	 prokaryotes	 (Vinothkumar	 &	
Henderson,	 2010).	 Although	 no	 crystal	 structure	 of	 the	 extracellular	 domain	 of	 rBAT	 is	
available,	the	structural	and	sequence	similarity	to	other	related	proteins	can	be	investigated	
to	 predict	 the	 topology	 of	 the	molecule.	 Following	 the	 resolution	 of	 the	 crystal	 structure	 of	
CD98,	an	 in	silico	study	considered	the	ancestry	and	structural	relationship	of	rBAT	and	CD98	
with	the	glycoside	hydrolase	(GH)	clan	of	enzymes	(Gabrisko	&	Janecek,	2009).	In	contrast	with	
CD98,	 the	 extracellular	 domain	 of	 rBAT	 appears	 to	 share	 Domain	 B	 (Figure	 1.8B)	 and	 the	
catalytic	triad	of	the	GH-H	enzymes	(Figure	1.9)	(Gabrisko	&	Janecek,	2009).		
The	extracellular	 domain	of	 rBAT	 is	 predicted	 to	 share	many	more	of	 the	 conserved	
structural	 and	 sequential	 alpha-amylase	 features	 than	 CD98,	 potentially	 indicating	 a	 shorter	
evolutionary	distance	between	the	proteins	(Gabrisko	&	Janecek,	2009).	Consequently,	1UOK	
seems	 to	 provide	 a	 more	 accurate	 template	 for	 a	 homology	 model	 of	 rBAT.	 Despite	 the	
similarities,	rBAT	possesses	a	30	amino	acid	C-terminal	tail	that	does	not	model	to	any	known	
structure	 (Rius	 &	 Chillarón,	 2012).	 Alignment	 of	 the	 rBAT	 extracellular	 domain	 amino	 acid	
sequence	 (Asp116-Lys653)	with	 the	extracellular	domain	of	CD98	 (Gln116-Ala528)	and	oligo-
1,6-glucosidase	from	B.	cereus	demonstrates	that	the	rBAT	extracellular	domain	shares	greater	
primary	sequence	similarity	with	the	bacterial	enzyme	than	with	the	only	other	member	of	the	




























































the	GH-H	clan	of	 enzymes,	however	 it	 does	not	possess	domain	B;	B,	 Side	 view	of	 the	 rBAT	
extracellular	 domain	 model	 based	 on	 oligo-1,6-glucoside	 from	 B.	 cereus	 (PDB	 code	 1UOK;	
Watanabe	et	al.,	1997).	Red,	domain	A1;	yellow,	domain	B;	green,	domain	A2;	blue,	domain	C.	
Amino	 acid	 residue	 numbers	 that	 fall	 into	 the	 distinct	 structural	 domains	 are	 denoted	
underneath	the	domain	labels.	The	putative	location	of	the	transmembrane	domain	is	denoted	
with	an	arrow.	
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CSR 6                                                                                   
rBAT N I K T V W I T S F Y K S S L K D F R Y G V E D F R E V D P I F G T M E D F E N L V A A I H D K G L 
1uok G I D V I W L S P V Y E S P N D D N G Y D I S D Y C K I M N E F G T M E D W D E L L H E M H E R N M 
CD98 K V K G L V L G P I H K N Q K D D - - V A Q T D L L Q I D P N F G S K E D F D S L L Q S A K K K S I 
                                   
 
               
 
CSR 1                                                                                 
rBAT K L I I D F I P N H T S D K H I W F Q L S R - T R T G K Y T D Y Y I W H D C T H E N G K T I P P N N 
1uok K L M M D L V V N H T S D E H N W F I E S R K S K D N K Y R D Y Y I W R - - P G K E G K - - E P N N 
CD98 R V I L D L T P N Y R G E - N S W F S T - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 
                                                   
 
                                                      CSR 5                                     
rBAT W L S V Y G N S S W H F D E V R N Q C Y F H Q F M K E Q P D L N F R N P D V Q E E I K E I L R F W L 
1uok W G A A F S G S A W Q Y D E M T D E Y Y L H L F S K K Q P D L N W D N E K V R Q D V Y E M M K F W L 
CD98 - - - - - - - - - - - - - - - - - - - - - - - - - - - Q V D T V A T - - - - - - K V K D A L E F W L 
                                       
 
           
 
    CSR 2                                                                         
rBAT T K G V D G F S L D A V K F L L E A K H L R D E I Q V N K T Q I P D T V T Q Y S E L Y H D F T T T Q 
1uok E K G I D G F R M D V I N F I S K E E G L - - - - P T V E T E E E G Y V S G - - - - - H K H F M N G 
CD98 Q A G V D G F Q V R D I E N L K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 
                                                   
 
                                                  CSR 3                                   
rBAT V G M H D I V R S F R Q T M D Q Y S T E P G R Y R F M G T E A Y A - - - - - - - - - - - E S I D R T 
1uok P N I H K Y L H E M N E E V L S H Y - D I - - - - M T V G E M P G V T T E E A K L Y T G E E R K E L 
CD98 - D A S S F L A E W Q N I T K G F S E D R - - - - L L I A G - T N S S D L Q Q I L S L L E S N - K D 
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rBAT V M Y Y G L P F I Q E A D F P F N N Y L S M L D T V S G N S V Y E V I T S W M E N M P E G K W P N W 
1uok Q M V F Q F E H M D L D S G E G G K W D V - - K P C S L L T L K E N L T K W Q K A L E H T G W N S L 
CD98 L L L T S S Y L S D S G - - - - - - - - - - - - - S T G E H T K S L V T Q Y L N A T - G N R W C S W 
                                                   
 
CSR 4                                                             CSR 7           
rBAT M I G G P D S S R L T S R L G N - - - - - - Q Y V N V M N M L L F T L P G T P I T Y Y G E E I G M G 
1uok Y W N N H D Q P R V V S R F G N D G M Y R I E S A K M L A T V L H M M K G T P Y I Y Q G E E I G M T 
CD98 S L S Q - - - A R L L T S F L - - - - - P A Q L L R L Y Q L M L F T L P G T P V F S Y G D E I G L D 
                                                   
 
                                                                                                    
rBAT N I V A A N L N E S Y D I N T L R - - - - - - - - - - - - - - - - - - - - - - - - - - - S K S P M Q 
1uok N V R F E S I D E Y R D I E T L N M Y K E K V M E R G E D I E K V M Q S I Y I K G R D N A R T P M Q 
CD98 - - A A A L P G Q P M E A - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - P V M L 
                                                   
 
                                                                                                    
rBAT N - E L W D N S S N A G F S E A S N T W L P T N S D Y H T V N V D V Q K T Q P R S A L K L Y Q D L S 
1uok N N E I W D D Q N H A G F T T G E - P W I T V N P N Y K E I N V K Q A I Q N K D S I F Y Y Y K K L I 
CD98 K - E R W D E S S F - - - - - - - - P D I P G A V S A N - M T V K G Q S E D P G S L L S L F R R L S 
                                                   
 
                                                                                                    
rBAT L L H A L L N R G W F C H L R N D S H Y V V Y T R E L D G I D R I F I V V L N F G E S T L - - - L N 
1uok E L R K V V Y G S Y D L I L E N N P S I F A Y V R T Y - G V E K L L V I A N F T A E E C I - - - F E 
CD98 D Q R S S L L H G D F H A F S A G P G L F S Y I R H W D Q N E R - F L V V L N F G D V G L S A G L Q 
                                                   
 
                                                                                                    
rBAT L H N M I S G - - L P A K M R I R L S T N S - A D K G S K V D T S G I F L D K G E G L I F E H N T K 
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Figure	1.9:	 Sequence	 similarity	between	 the	extracellular	domains	of	 rBAT,	and	CD98	with	










The	 Aquifex	 aeolicus	 leucine	 transporter,	 LeuTAa,	 was	 crystallised	 and	 structurally	
resolved	 to	 reveal	 a	12	 transmembrane	domain	 structure,	with	an	 internal	 structural	 repeat	
(Figure	 1.10)	 (Yamashita	 et	 al.,	 2005).	 This	 5+5	 “inverse	 repeat”	 fold	 was	 previously	
unpredictable	 from	 internal	 sequence	 alignments	 of	 LeuTAa,	due	 to	 a	 low	 primary	 sequence	
similarity	between	the	domains	(Yamashita	et	al.,	2005).	Following	a	rotation	of	176.5o,	it	was	
discovered	 that	 the	 first	 five	 domains	 could	 be	 superposed	 over	 the	 following	 five	
transmembrane	domains	(Figure	1.10).	Transmembrane	domains	1	and	6	display	the	greatest	
levels	 of	 conservation,	 followed	by	domains	 3	 and	8	 (Yamashita	 et	 al.,	 2005).	 The	 structural	
organisation	of	the	crystallised	LeuTAa	in	the	occluded	conformation	revealed	an	internal	core	
of	four	helices	(transmembrane	domains	1,	3,	6,	and	8)	surrounded	by	the	additional	domains	
(2,	 4,	 5,	 7,	 9-12)	 (Yamashita	 et	 al.,	 2005).	 Transmembrane	 domains	 1	 and	 6	were	 found	 to	
possess	an	unwound	region	in	the	alpha	helix,	flanked	by	a	series	of	conserved	residues.	These	
are:	 G24,	 L25,	 G26	 in	 transmembrane	 domain	 1,	 and	 G256,	 A257,	 I258,	 I259,	 T260	 in	
transmembrane	domain	6.	The	disruption	to	the	helical	structure	is	thought	to	expose	atoms	





The	Amino	Acid-Polyamine-Organocation	 (APC)	 superfamily	 of	 transporters	 is	 one	of	
29	 distinct	 superfamilies,	 composed	 of	 600	 different	 families,	 which	 together	 include	more	
than	 5600	 transport	 proteins	 (http://tcdb.org)	 (Chang	 et	 al.,	 2004).	 The	 APC	 superfamily	
consists	of	18	distinct	transporter	families,	 including	the	Neurotransmitter:Sodium	Symporter	
(NSS)	family,	of	which	LeuTAa	is	a	member	(Chang	et	al.,	2004;	Yamashita	et	al.,	2005).	Another	
of	 the	 transporter	 families	belonging	 to	 the	APC	superfamily	 is	 the	APC	 family	 (Chang	 et	al.,	
2004).	 Included	 in	 the	 APC	 family	 of	 transporters	 are	 the	 mammalian	 L-type	 amino	 acid	
transporters	 (LATs)	 (Chang	 et	 al.,	 2004).	 The	 light	 chains	 of	 the	 heterodimeric	 amino	 acid	
transport	systems	are	members	of	the	SLC7	family	of	LATs,	along	with	homologous	membrane	
transporters	identified	in	prokaryotic	systems	(Jack	et	al.,	2000).		
Following	 the	 crystallisation	 of	 LeuTAa,	 and	 identification	 of	 the	 LeuT	 structural	 fold,	
other	prokaryotic	 transport	proteins	belonging	to	 the	APC	superfamily	have	had	their	crystal	
structures	 resolved	 (Gao	 et	 al.,	 2009;	 Shaffer	 et	 al.,	 2009).	 Through	 these	 structures,	 it	 has	















































































Although	 the	 crystal	 structures	 of	 the	 heterodimeric	 amino	 acid	 transporter	 light	
chains	 remain	unsolved,	 it	 is	predicted	 that	 they	 share	 the	LeuT	 fold	 (Chillarón	 et	al.,	 2010).	
Gasol	 et	al.	 (2004)	 identified	 the	membrane	 topology	of	 the	CD98	 light	 chain	 xCT	 through	a	
series	of	biochemical	experiments.	It	was	discovered	through	expression	of	System	xc-	in	HeLa	










has	 been	 the	 template	 most	 widely	 used	 for	 the	 creation	 of	 homology	 models	 of	 the	 slc7	
family	members	LAT1,	LAT2,	and	b0,+AT	(Chillarón	et	al.,	2010;	Rosell	et	al.,	2014;	Napolitano	et	
al.,	2015).	Additionally,	Reig	et	al.	(2007)	reported	a	prokaryotic	serine:threonine	antiporter	in	
B.	 subtilis	 (SteT)	 which	 has	 the	 highest	 identified	 primary	 sequence	 homology	 to	 the	
mammalian	 light	 chains	 (>30%).	 Despite	 the	 crystal	 structure	 of	 this	 protein	 remaining	
unknown,	 it	 has	 been	 used	 as	 a	 model	 of	 mammalian	 APC	 family	 transporters	 to	 identify	
critical	 binding	 residues	 involved	 in	 the	 transport	 of	 amino	 acids,	 namely	 in	 transmembrane	
domain	8.	The	importance	of	these	residues,	in	relation	to	the	System	b0,+	light	chain,	b0,+AT,	is	
discussed	in	Chapter	7.	
The	 structure	 of	 b0,+AT	 is	 predicted	 to	 consist	 of	 12	 transmembrane	 domains	
(Chairoungdua	 et	 al.,	 1999).	 The	 HHPRED	 algorithm	 predicts	 100%	 probability	 of	 structural	
homology	between	b0,+AT	and	 the	E.	 coli	 transport	protein	AdiC	 (PDB	 code	3L1L;	Gao	et	al.,	
2010).	 Using	 AdiC	 as	 a	 template	 structure,	 a	 homology	 model	 of	 b0,+AT	 predicts	 a	 “LeuT”	
structural	 arrangement	 of	 the	 transmembrane	 domains	 (Figure	 1.12).	 Transmembrane	
domains	1-5	and	6-8	form	the	5+5	inverse	repeat	fold	(Figures	1.11-1.12).	As	observed	in	other	
proteins	sharing	the	LeuT	fold,	transmembrane	domains	1,	3,	6,	and	8	of	b0,+AT	form	the	inner	
core	 of	 the	 protein,	 creating	 the	 substrate	 binding	 pocket	 (Figure	 1.12B),	 whilst	 the	 other	
domains	provide	 structural	 support	 (Figure	1.12A).	 The	unwound	 regions	of	 transmembrane	




























































Figure	 1.11:	 Schematic	 representation	 of	 b0,+AT	 transmembrane	 domains	 based	 upon	 the	
crystal	 structure	of	AdiC.	The	membrane	topology	of	 the	predicted	LeuT	5+5	 inverse	 repeat	
fold	 in	 the	 mammalian	 light	 chain,	 b0,+AT.	 Transmembrane	 domains	 1-5	 and	 6-10	 form	 an	
inverse	 structural	 repeat	 pattern,	 highlighted	 by	 two	 triangles.	 Transmembrane	 domains	 1	
(green)	 and	 6	 (orange)	 are	 interrupted	 by	 unwound	 regions	 of	 their	 alpha	 helices.	 Together	
with	transmembrane	domains	3	(blue)	and	8	(purple)	they	form	the	binding	pocket	for	leucine	





















































































Figure	 1.12:	 Homology	 model	 of	 b0,+AT	 based	 upon	 the	 crystal	 structure	 of	 AdiC.	 A,	 The	
predicted	 structure	 of	 b0,+AT	 based	 upon	 the	 template	 protein	 arginine:agmatine	 antiporter	
(AdiC)	from	E.coli	(PDB	code	3L1L,	Gao	et	al.,	2010).	The	light	chain	of	System	b0,+	is	predicted	
to	 have	 12	 transmembrane	 domains;	 B,	 Transmembrane	 domains	 1	 (green),	 3	 (blue),	 6	





The	 Endoplasmic	 Reticulum	 is	 a	 membrane-bound	 organelle	 found	 universally	 in	
eukaryotic	 cells.	 Comprised	 of	 a	 network	 of	 cisternae,	 it	 consists	 of	 two	 structurally	 distinct	
components	 based	 upon	 morphology:	 the	 rough	 (RER)	 and	 smooth	 (SER)	 endoplasmic	
reticulum.	When	a	ribosome	carrying	out	translation	of	the	mRNA	becomes	bound	to	the	RER,	
the	 nascent	 polypeptide	 chains	 of	 membrane	 proteins	 enter	 the	 lumen	 of	 the	 ER	 via	
translocation	 through	 the	heterotrimeric	Sec61	complex	 (Johnson	&	van	Waes,	1999).	There	
they	 are	 stabilised	 by	 the	 Binding	 immunoglobulin	 Protein	 (BiP),	 one	 member	 of	 the	 heat-
shock	protein	70	(Hsp70)	class	of	molecular	chaperones	(Figure	1.13A)	(Palade,	1975;	Johnson	
&	 van	 Waes,	 1999;	 Helenius	 &	 Aebi,	 2001).	 Molecular	 chaperones	 bind	 polypeptides	 and	
stabilise	 them	 in	 their	 unfolded	 state,	 to	 prevent	 aggregation	 of	 the	 molecule	 whilst	 the	
hydrophobic	 regions	 are	 exposed,	 facilitating	 native	 folding.	 (Flynn	 et	 al.,	 1991;	 Buck	 et	 al.,	
2010).	Following	correct	insertion	into	the	ER	membrane,	and	folding	of	the	polypeptide	chain,	
along	with	intermediate	N-linked	glycosylation,	subunit	oligomerisation,	and	the	formation	of	
disulphide	bonds,	 the	proteins	 are	 transferred	 in	 vesicles	 to	 the	Golgi	 apparatus	 (Johnson	&	








collectively	 form	the	ER-Associated	Degradation	pathway	 (ERAD),	which	mediates	 the	export	
of	mis-folded	proteins	from	the	ER	to	the	cytoplasm	for	targeting	by	the	proteasome	(Werner	
et	 al.,	 1996;	 Molinari,	 2007).	 To	 date,	 little	 is	 known	 regarding	 what	 allows	 the	 exact	
recognition	of	mis-folded	proteins	in	the	ER	lumen.	However,	it	has	been	postulated	that,	due	




been	shown	to	contribute	 to	 the	degradation	of	 the	protein	by	 the	ER	 following	mis-folding.	
Following	the	co-translational	addition	of	the	monoglucosylated	intermediate	N-linked	glycans	
to	the	newly	synthesised	proteins	(Figure	1.13B),	the	lectin	molecular	chaperones	calnexin	and	
calreticulin	 can	 bind	 (Figure	 1.13C)	 (Molinari	 &	 Helenius,	 2000).	 Whilst	 bound	 to	 the	
calnexin/calreticulin	 chaperones,	 proteins	 are	 stabilised	 in	 order	 to	 achieve	 native	 folding	
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through	transitioning	through	a	series	of	conformations	(Ruddock	&	Molinari,	2006).	In	native	
proteins,	 following	 the	 release	 of	 the	 protein	 from	 calnexin/calreticulin,	 glucosidase	 II	 trims	
the	innermost	glucose	from	the	glycan	residues	to	prevent	reassociation	of	the	lectins	(Figure	
1.13D)	 (Molinari	 &	 Helenius,	 2000;	 Helenius	 &	 Aebi,	 2001).	 These	 native	 proteins	 are	 then	
exported	 from	the	ER	to	 the	Golgi	 in	vesicles.	However,	proteins	 that	are	recognised	as	mis-





is	 by	 exposing	 N-glycans	 that	 cannot	 be	 re-glucosylated	 by	 UGT1	 (Figure	 1.13F)	 (Molinari,	





the	 ERAD	 pathway	 and	 are	 known	 as	 loss-of-function	 mutations	 that	 contribute	 to	 disease	
phenotypes.	 Perhaps	 the	 most	 well-known	 example	 of	 this	 phenomenon	 is	 the	 ΔF508	
mutation	 in	 the	Cystic	Fibrosis	Transmembrane	Conductance	Regulator	 (CFTR),	which	causes	
the	autosomal	recessive	disease	Cystic	Fibrosis	due	to	a	lack	of	trafficking	of	the	Cl-	channel	to	
the	 apical	 membrane	 of	 the	 airway	 and	 intestinal	 epithelium	 (Molinari,	 2007).	 It	 is	 also	
believed	 that	 this	 is	 the	cause	of	a	 lack	of	 trafficking	of	System	b0,+	 to	 the	membrane	of	 the	
renal	epithelium	in	Type	A	cystinuric	patients.	In	order	to	correct	the	loss	of	function	mutation	
in	CFTR	the	use	of	molecular	chaperones	has	been	suggested,	which	stabilise	the	mis-folded,	
















































































































































Figure	 1.13:	 Schematic	 representation	 of	 the	 ERAD	 pathway.	 A,	 The	 nascent	 polypeptide	
chain	enters	 the	 lumen	of	 the	ER	via	 the	Sec61	 translocon	complex;	B,	 It	 is	 stabilised	by	 the	
binding	 immunoglobulin	 protein	 (BiP,	 green)	 and,	 where	 appropriate,	 glycosylated	 by	
oligosaccharide	 transferase	 (OST,	 purple);	 C,	 Following	 the	 addition	 of	monoglucosylated	N-
glycans,	 the	polypeptide	 is	 stabilised	by	 the	calnexin/calreticulin	 chaperone	system	 (Cnx/Crt,	
grey);	D,	Proteins	that	achieve	native	folding	(orange)	are	de-glucosylated	by	glucosidase	II	and	
exported	 from	 the	 ER	 to	 the	 Golgi	 in	 vesicles;	 E,	mis-folded	 proteins	 are	 re-glucosylated	 by	
UGTI	 and	 reassociate	with	 the	 chaperone	 system	 to	 attempt	 native	 folding;	 F,	 proteins	 that	







subunits	 of	 System	 b0,+.	 Two	 glycosylated	 forms	 of	 rBAT	 are	 observed	 as	 bands	 of	 90	 and	
84kDa	 when	 electrophoretically	 resolved	 (Tate	 et	 al.,	 1992).	 The	 lower	 band	 is	
Endoglycosidase-H	 (Endo-H)	 sensitive,	 representative	 of	 immature,	 high-mannose	 N-
glycosylated	 protein	 produced	 in	 the	 ER.	 The	 upper	 band	 indicates	 the	 presence	 of	 core	







Disulphide	 bonds	 within	 the	 rBAT	 extracellular	 domain	 are	 critical	 for	 the	 native	
folding	 of	 the	 protein	 (Rius	&	 Chillarón,	 2012).	 HeLa	 cells	 were	 transfected	with	 eight	 rBAT	
single	 cysteine	mutants.	 From	 these	 studies,	 three	 disulphide	 bridges	were	 identified	 in	 the	
structure,	which	were	essential	for	function.	These	were:	Cys242-Cys273	in	Domain	A,	Cys751-
Cys666	connecting	Domain	C	with	the	30	amino	acid	tail,	and	Cys673-Cys685	in	the	C-terminal	





both	 subunits	 of	 System	 b0,+	 that	 a	 band	 representing	 the	 heterodimer	 could	 be	 observed	
following	resolution	of	proteins	under	non-reducing	conditions,	confirming	association	of	the	
two	 subunits	 via	 disulphide	 linkage.	 Through	 co-precipitation	 of	 the	 two	 proteins	 it	 was	
identified	 that	b0,+AT	was	present	 in	 the	cells	 in	great	excess	over	 rBAT,	and	almost	all	 rBAT	








al.,	 2002).	 This	 was	 detected	 by	measurement	 of	 arginine	 and	 cystine	 uptake	 in	 liposomes	
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reconstituted	from	solubilised	HeLa	cells	that	had	been	transfected	with	the	System	b0,+	 light	






not	 disrupted	 by	 the	 treatment	 of	 protein	 samples	 with	 5mM	 urea,	 and	 are	 only	 partially	
disrupted	with	 2%	 SDS	 (Fernandez	 et	 al.,	 2006).	 Pfeiffer	 et	 al.	 (1999a)	 reported	 System	 b0,+	
transport	in	HeLa	cells,	induced	by	the	expression	of	a	concatenated	cDNA.	This	cDNA	encoded	
an	rBAT-b0,+AT	fusion	protein,	linked	by	an	intracellular	sequence	of	amino	acids	between	the	
N-termini	 of	 the	 two	 proteins.	 This	 fusion	 protein,	 however,	 is	 structurally	 distinct	 to	 the	
native	heterodimer,	and	does	not	form	a	heterotetrameric	structure	when	expressed	 in	vitro	
(Fernandez	et	al.,	2006).	These	data	indicate	that	the	heterodimer	is	the	functional	unit	of	the	
transport	 system,	 despite	 a	 heterotetrameric	 structural	 assembly	 in	 vivo	 (Fernandez	 et	 al.,	







the	disulphide	bridge	 covalently	bonding	 the	 two	 subunits,	 remain	unknown.	However,	data	
has	 emerged	 regarding	 the	 interaction	 between	 CD98	 and	 its	 light	 chain	 LAT2	 and	 a	
prokaryotic	 light	chain,	SPRM1	(Pfeiffer	et	al.,	1998;	Rosell	et	al.,	2014).	Pfeiffer	et	al.	 (1998)	
demonstrated	 that	 in	 addition	 to	 the	 disulphide	 bond	 between	 heavy	 and	 light	 chains	 of	







the	 disulphide	 bond,	 the	 amount	 of	 protein	 at	 the	 membrane	 was	 reduced,	 and	 SPRM1-
mediated	amino	acid	transport	was	reduced	to	30%	of	that	seen	in	the	presence	of	wild	type	







the	 supramolecular	 architecture.	 This	 revealed	 that	 the	 large	 extracellular	 domain	 of	 CD98	
covered	 most	 of	 the	 extracellular	 face	 of	 the	 light	 chain,	 the	 site	 of	 the	 substrate	 binding	
pocket	 (Rosell	 et	 al.,	 2014).	 However,	 it	 was	 tilted	 at	 an	 angle	 forming	 a	 cleft,	 putatively	
allowing	access	of	the	substrate	to	the	binding	site,	without	the	need	for	it	to	pass	through	the	
heavy	 chain	 molecule	 (Rosell	 et	 al.,	 2014).	 From	 docking	 analyses	 of	 the	 known	 crystal	
structure	 of	 the	 CD98	 ectodomain	with	 a	 homology	model	 of	 LAT2	 from	 the	 known	 crystal	
structure	 of	 AdiC	 (PDB	 code	 3L1L;	 Gao	 et	 al.,	 2010),	 specific	 residues	 were	 identified	 that	
crosslink	the	two	proteins	(Rosell	et	al.,	2014).		These	residues	are	predicted	to	sit	far	from	the	





exist	 between	CD98	and	 the	only	other	member	of	 the	mammalian	 SLC3	 family	of	proteins,	















allow	 the	 functional	 characterisation	 of	 rBAT	 expression	 in	 Xenopus	 oocytes,	 through	 the	
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association	with	 the	endogenous	 light	 chain,	homologous	 to	b0,+AT	 (Chapter	4).	Additionally,	
techniques	 that	 would	 allow	 the	 immunodetection	 of	 rBAT	 expression	 both	 in	 total	 oocyte	
membranes,	and	specifically	at	 the	plasma	membrane	needed	to	be	developed.	Through	the	
addition	 of	 a	 series	 of	 FLAG	 epitopes	 to	 the	 exogenous	 human	 protein,	 we	 were	 able	 to	
establish	a	range	of	techniques	to	allow	the	accurate	expression	and	localisation	of	rBAT	in	the	
oocytes	(Chapter	4).		
Type	 A	 cystinuria	 is	 caused	 by	 mutations	 in	 rBAT,	 which	 are	 believed	 lead	 to	 early	
degradation	 of	 the	 mis-folded	 proteins	 in	 the	 ER,	 and	 prevent	 successful	 trafficking	 of	 the	
transport	 system	 to	 the	apical	plasma	membrane	 (Dello	 Strologo	 et	al.,	 2002;	Bartoccioni	 et	
al.,	2008).	In	turn,	this	prevents	the	reabsorption	of	cystine	and	dibasic	amino	acids	from	the	
renal	 filtrate,	 leading	 to	 the	 formation	 of	 cystine	 calculi.	 To	 date,	 of	 91	 reported	 missense	
mutations	 in	 the	 SLC3A1	 gene,	 only	 6	 have	 been	 functionally	 characterised	 (Stenson	 et	 al.,	
2014).	The	results	of	the	reported	characterisation	experiments	from	other	research	groups	is	
discussed	in	detail	in	Chapter	5.	In	Chapter	5,	the	range	of	techniques	established	in	Chapter	4		
was	used	 to	measure	of	 rBAT	mutant	 function	 in	oocytes.	Additionally,	an	 in	 silico	approach	






Xenopus	oocytes	 and	 the	mammalian	epithelial	 cell	 line,	 Caco-2.	 This	 included	 temperature-
dependent	 inhibition	 of	 the	 ERAD	 pathways,	 use	 of	 the	 proteasomal	 inhibitor	MG-132,	 and	
inhibition	of	rBAT	N-glycosylation	both	globally,	and	at	individual	Asn	residues	in	the	protein.		
Through	furthering	our	understanding	of	 the	effect	 that	 rBAT	mutations	have	on	the	
cellular	 localisation	 of	 the	 transport	 system,	 we	 could	 potentially	 predict	 novel	 therapeutic	
targets	 for	 cystinuria.	 These	 data	 are	 valuable	 in	 the	 determination	 of	 whether	 the	 use	 of	
molecular	chaperones,	such	as	those	therapeutically	implicated	in	Cystic	Fibrosis,	would	be	of	
value	 in	 cystinuria.	 Additionally,	 through	 studies	 into	 the	 biogenesis	 of	 rBAT	 and	 how	














known	 to	 be	 involved	 in	 cystinuria	 (see	 Chapter	 1).	 We	 hoped	 to	 identify	 novel,	
uncharacterised	 mutations	 in	 the	 two	 genes	 and	 investigate	 their	 effects	 on	 the	 proteins	
through	expression	in	the	Xenopus	laevis	oocyte	expression	system.		
2.2.1	Patient	DNA	sample	collection	
Patient	 genomic	 DNA	 (gDNA)	 samples	 were	 collected	 from	 44	 patients	 and	 17	
relatives.	 Samples	were	collected	 through	 the	Freeman	Hospital,	Newcastle	upon	Tyne,	with	
the	exception	of	 patients	 28	 and	29	who	were	 recruited	 remotely	 at	 the	Rare	Kidney	 Stone	
Consortium	 (RKSC)	 international	 patient	 meeting	 (London,	 December	 2012).	 The	 study	 was	
approved	by	the	National	Research	Ethics	Service	(NRES)	Committee	North	East	(11/NE/0259).	
Informed	consent	was	obtained	from	all	participants	or	their	legal	guardians	where	applicable	
by	 Dr.	 John	 Sayer.	 All	 patients	 were	 classified	 as	 cystinuric	 on	 the	 basis	 of	 at	 least	 one	
confirmed	 cystine	 stone	 through	 chemical	 analysis.	 Dr.	 John	 Sayer	 extracted	 patient	 gDNA	
samples	 from	 salival	 swabs	 or	 whole	 blood	 samples	 prior	 to,	 and	 throughout,	 this	
investigation.	Family	member	samples	were	 requested	 following	 the	 initial	genetic	 screening	
of	the	patients.	These	were	obtained	when	it	was	desirable	to	collect	further	genetic	data	to	
inform	 segregation	 analysis	 of	 mutations.	 Dr.	 John	 Sayer	 obtained	 the	 gDNA	 samples	 from	
relatives	of	patients	in	the	same	manner.		
2.2.2	Touchdown	PCR	to	amplify	patient	gDNA	samples	
The	 touchdown	 amplification	 of	 patient	 samples,	 and	 subsequent	 steps	 in	 the	












amplification	of	gDNA	 (Table	2.4).	 	Touchdown	PCR	 is	a	useful	 tool	 for	amplifying	sequences	
from	complex	genomes	as	it	increases	the	specificity	of	the	reaction	by	using	a	cycling	program	
with	varying	annealing	 temperatures	 (Don	 et	al.,	 1991).	 This	 leads	 to	a	more	 specific	duplex	
formation	between	the	primer	and	the	DNA,	and	ultimately	a	more	specific	PCR	product.	The	
annealing	 temperature	 in	 the	 initial	 reaction	must	be	5-10°C	above	the	melting	 temperature	



























































































































































































































































































































































































































































































































































































































Step	 Temperature	(°C)	 Time	 Cycles	
Activation	 95	 10min	 1	



























6x	 loading	dye	 (NEB,	UK)	 in	a	0.2ml	microfuge	tube.	The	total	volume	(6μl)	was	 then	 loaded	
onto	 the	1%	agarose-TAE	gel.	Samples	were	resolved	 for	1h	at	100V	 (Figure	2.2)	alongside	a	
100bp	 DNA	 ladder	 (NEB,	 UK)	 to	 ensure	 the	 size	 of	 the	 product	 was	 as	 predicted	 from	 the	
primer	design	(Table	2.1	and	2.2).	
	













endonuclease	 enzyme.	 This	 has	 been	 reported	 in	 the	 literature	 for	 detection	of	 single	 point	
mutations	and	small	insertions	or	deletions	(indels)	in	the	BRCA1	gene	and	will	be	explained	in	
detail	in	section	2.2.6	(Oleykowski	et	al.,	1998).		
The	 CEL-I	 endonuclease	 enzyme	 can	 be	 easily	 and	 cheaply	 extracted	 from	
homogenised	raw	celery.	This	protocol	was	taken	from	Oleykowski	et	al.	(1998).	The	following	
steps	were	carried	out	at	4°C.	Fresh	celery	(1kg)	was	rinsed	in	clean	water	and	dried	before	the	
leaves	were	 removed	 and	 the	 stalks	 trimmed.	 The	 celery	was	 homogenised	with	 an	 electric	
hand	blender	(Breville,	UK)	until	no	visible	 lumps	remained.	The	subsequent	mixture	(900ml)	
was	 adjusted	 to	 pH	 7.7	 using	 Buffer	 A	 (stock	 concentration	 0.1M	




The	 pellet	 was	 discarded	 and	 the	 supernatant	 containing	 soluble	 proteins	 was	
adjusted	 to	 25%	 (w/v)	 (NH4)2SO4	by	 direct	 addition	 of	 the	 salt	 in	 solid	 form,	 and	mixed	 for	
30min.	 (NH4)2SO4	was	used	 to	 induce	a	“salting	out”	effect.	This	 is	a	phenomenon	where,	at	
high	 salt	 concentrations,	 proteins	 will	 precipitate	 from	 the	 solution.	 (NH4)2SO4	 is	 commonly	
used	to	achieve	this	salting	out	effect	as	it	is	highly-soluble,	yet	does	not	interfere	with	enzyme	
activity.	 Thus,	 it	 can	 be	 used	 to	 quickly	 remove	 high	 levels	 of	 contaminant	 proteins.	 The	
concentration	of	(NH4)2SO4	required	to	cause	precipitation	of	the	contaminant	proteins,	whilst	
retaining	 the	 more	 hydrophilic	 enzyme	 in	 solution,	 had	 been	 established	 previously	
(Oleykowski		et	al.,	1998).	Following	this	adjustment,	the	solution	was	centrifuged	at	16,000g	
for	 40min,	 4°C.	 The	 pellet,	 containing	 the	 undesirable,	 precipitated	 proteins,	was	 discarded.	
The	 supernatant	 volume	 was	 recorded	 (450ml),	 and	 adjusted	 to	 80%	 (w/v)	 (NH4)2SO4,	 and	
mixed	 overnight	 (16h).	 This	 higher	 salt	 concentration	 was	 used	 to	 salt	 out	 the	 remaining	
proteins	in	the	solution,	including	the	CEL-I	endonuclease.	The	following	day	the	mixture	was	
pelleted	 by	 centrifugation	 at	 16,000g,	4°C	 for	 90min.	 The	 pellet	 containing	 the	 enzyme	was	











of	 the	 enzyme	 it	 was	 tested	 against	 a	 commercially	 available	 kit.	 The	 SURVEYOR	 mutation	
detection	kit	 (Transgenomic,	Nebraska,	USA)	 contains	 two	 samples	of	double-stranded	DNA,	
both	600bp	in	length	(Control	C	and	Control	G).	One	of	the	two	samples	has	a	single	C>G	base	
change	(Control	G).		
Two	 separate	 reactions	 were	 prepared,	 one	 for	 treatment	 with	 the	 SURVEYOR	 kit	
enzyme,	 the	 second	 for	 treatment	 with	 the	 celery	 extract.	 To	 prepare	 the	 reaction,	 5μl	 of	
Control	 C	was	mixed	with	5μl	 Control	G	 from	 the	 SURVEYOR	kit	 in	 two	 separate	PCR	 tubes.	
Using	 a	 thermal	 cycler	 (BIORAD	DNA	Engine	Dyad	Peltier	 Thermal	 cycler)	 the	mixtures	were	
heated	 to	 95°C	 for	 2min	 after	 which	 the	 temperature	 was	 reduced	 to	 85°C	 over	 5s.	 The	
temperature	was	then	further	reduced	to	25°C	at	a	rate	of	-0.1°C.s-1	over	10min.	This	heating	
and	cooling	process	caused	the	separation	of	the	double	stranded	Control	C	and	G	cDNA,	and	
subsequent	 formation	of	heteroduplexes,	 in	which	one	 strand	of	 control	C	DNA	 re-annealed	
with	 the	 opposite	 strand	of	 Control	G	DNA.	Where	 heteroduplexes	 had	been	 formed,	 there	
would	be	a	single	base	pair	mismatch	at	the	site	of	the	C>G	base	change.	
One	of	the	tubes	was	treated	with	the	SURVEYOR	nuclease	(0.5μl	SURVEYOR	enhancer	




















Figure	 2.3:	 Resolution	 of	 DNA	 samples	 enzymatically	 digested	 by	 two	 different	 enzyme	
solutions.	 Heteroduplex	 DNA	 formed	 from	 the	 SURVEYOR	 kit	 Control	 C	 and	 Control	 cDNA	
samples	 resolved	 on	 a	 2%	 (w/v)	 agarose-TAE	 gel	 following	 incubation	 with	 the	 SURVEYOR	
enzyme	 or	 the	 celery	 extract.	 	 Both	 enzymes	 digested	 the	 600bp	 control	 DNA,	 designed	 to	
form	fragments	400	and	200bp	in	length.	a,	1kb	DNA	ladder,	the	sizes	of	markers	are	listed	on	
























and	 used	 5μl	 of	 this	mixture	 to	 confirm	 PCR	 success	 (Figure	 2.2).	We	 then	 used	 5μl	 of	 the	





heteroduplexes	 through	 cooling	 and	 re-annealing	 of	 the	 single	 stranded	 DNA	 (BIORAD	 DNA	
Engine	Dyad	Peltier	Thermal	cycler)	(Figure	2.4	b	and	c).	
The	 10μl	 mixtures	 were	 kept	 on	 ice	 as	 6µl	 celery	 extract	 was	 added,	 and	 then	
incubated	at	 42°C	 for	 20min	 (Figure	2.4	d).	 This	 incubation	allowed	 the	CEL-I	 enzyme	 in	 the	
celery	 extract	 to	 cleave	 the	heteroduplexes	 at	 the	point	 of	 any	 single	 base	pair	mismatches	
caused	by	mutations	in	the	DNA	of	either	patient.	To	terminate	the	reaction,	3μl	stop	solution	
(30%	glycerol,	250mM	EDTA,	6x	loading	dye)	was	added	to	each	sample.		
The	 samples	 were	 loaded	 onto	 a	 2%	 agarose-TAE	 gel	 and	 were	 resolved	 by	
electrophoresis	 (100mV,	 1.5h).	 The	 separated	 digestion	 products	 were	 visualised	 under	 UV	




























































Figure	2.4:	A	schematic	diagram	of	 the	key	steps	used	 to	 identify	mutations	 in	 the	SLC3A1	
and	SLC7A9	genes	using	CEL-I	endonuclease.	The	CEL-I	endonuclease	method	for	detection	of	




DNA;	 c,	 as	 the	 samples	 were	 cooled,	 the	 single	 strands	 re-annealed,	 forming	 a	 mixture	 of	
homoduplexes	(both	DNA	strands	from	the	same	patient)	and	heteroduplexes	(one	strand	of	
DNA	from	patient	1	and	the	second	strand	from	patient	2).	When	heteroduplexes	were	formed	
in	 the	presence	of	small	mutations,	 there	was	a	mis-match	 in	base	pairing,	 forming	a	nick	 in	
the	DNA	strands;	d,	the	re-annealed	DNA	was	incubated	with	the	celery	extract	containing	the	
CEL-I	 endonuclease,	 which	 detects	 single	 base-pair	 mismatches	 and	 can	 cleave	 both	 DNA	
strands	3’	 of	 the	nick.	 This	 created	 small	 fragments	of	DNA.	 In	 this	 cartoon	example,	 600bp	












Each	 lane	 in	 which	 a	 fragment	 band	 was	 identified	 contained	 the	 DNA	 amplicons	 of	 two	
patients	 used	 to	 create	 the	 heteroduplex.	 The	 remaining	 15μl	 of	 the	 original	 PCR	 reaction	
mixture	 belonging	 to	 these	 two	 patients	 was	 purified	 using	 QIAquick	 PCR	 Purification	 Kit	
(Qiagen,	Manchester,	 UK)	 according	 to	 the	manufacturer’s	 protocol.	 	 To	 each	 15µl	 sample,	
75µl	Buffer	PB	was	added	(5	volumes).	This	allowed	efficient	binding	of	DNA	fragments	to	the	
spin	 column	 silica	 membrane	 and	 contained	 a	 pH	 indicator.	 This	 is	 to	 ensure	 that	 pH	 is	
optimum	for	DNA	binding	(<7.5).	The	sample	was	applied	to	the	spin	column	and	centrifuged	






Sequencing	 files	 were	 returned	 from	 GATC	 in	 ab1	 format	 containing	 the	 DNA	 base	
sequence.	 These	 files	 were	 loaded	 in	 Mutation	 Surveyor	 software	 (Softgenetics,	 USA).	 This	
software	 reads	 ab1	 files	 and	 matches	 them	 to	 reference	 sequences	 from	 GenBank	
(http://www.ncbi.nlm.nih.gov/genbank/),	 identifying	variants	from	the	wild-type	sequence.	 It	
is	 able	 to	 identify	 bases	 changes	 including	 known	and	novel	mutations,	 along	with	 common	
single	nucleotide	polymorphisms	(SNPs)	and	provide	the	reference	sequence	(rs)	code.		
Patients	 in	whom	no	causative	mutations	were	 found	 in	SLC3A1	or	SLC7A9	using	the	
CEL-I	detection	protocol	had	all	PCR	amplicons	of	both	genes	sent	for	full	Sanger	sequencing	
(GATC,	 Cologne,	 Germany).	 End-point	 touchdown	 PCR	 used	 for	 exon	 amplification	 is	 a	 non-
quantitative	 technique.	 Whilst	 treatment	 of	 DNA	 samples	 amplified	 in	 this	 manner	 can	 be	







were	 sent	 to	 Southmead	 Hospital,	 Bristol	 for	 Multiplex	 Ligation-dependent	 Probe	
Amplification	(MLPA).	These	samples	were	included	in	a	collaborative	study	with	the	research	
	 69 
group	of	Dr.	Richard	Coward,	Bristol	University	 (Rhodes	 et	al.,	 2015).	 First	 reported	 in	2002,	
MLPA	 provides	 a	 simple,	 multiplex	 PCR	 technique	 to	 quantify	 deletions	 or	 duplications	 of	
whole	 genes	 or	 exons,	 such	 as	 those	 commonly	 seen	 in	 Down’s	 syndrome	 and	 Duchenne	
muscular	dystrophy	(Schouten	et	al.,	2002).	MLPA	has	replaced	older	quantitative	techniques,	




DNA.	 Secondly,	 they	 contain	universal	PCR	primer	 sequences	 for	amplification	of	 the	 ligated	
probe.	 Finally,	 there	 is	 a	 “stuffer	 sequence”,	 unique	 in	 length	 to	 each	 pair	 of	 half-probes	
(Figure	2.5	b).		
When	the	adjacent	hybridisation	sequences	of	the	two	half-probes	anneal	to	the	DNA	
they	 are	 ligated	 to	 form	 a	 single	 probe	 (Figure	 2.5	 c).	 Following	 ligation,	 the	 probes	 are	
amplified	by	PCR	using	the	universal	primers.	The	unique	stuffer	sequence	allows	each	probe	
to	 create	 a	 PCR	 product	 of	 a	 distinct	 length	 (Figure	 2.5	 d).	 The	 products	 are	 separated	 by	
capillary	electrophoresis	and	the	peak	intensities	can	be	analysed	and	normalised	to	a	control	
probe.	 This	 can	 interpreted	 to	 provide	 the	 relative	 copy	 number	 of	 each	 exon	 in	 the	 gene	
(Schouten	et	al.,	2002).		
	 Samples	were	prepared	and	sent	to	the	NHS	UK	Genetic	Testing	Network	(UKGTN)	at	
Southmead	Hospital	 in	Bristol	by	Dr.	 John	Sayer,	Newcastle	University	 (Rhodes	 et	al.,	 2015).	
Probe	sequences	for	SLC3A1	and	SLC7A9	were	taken	from	Bisceglia	et	al.	(2010)	and	are	listed	
in	Table	2.5	and	2.6.	The	universal	PCR	primer	sequences	used	for	probe	amplification	were	as	
































































































































techniques	 to	 screen	 for	 mutations	 in	 the	 cohort	 allowed	 the	 identification	 of	 causative	
cystinuria	mutations	in	the	majority	of	the	patients	(see	Chapter	3).	The	employment	of	these	
techniques	 in	 this	 study	 is	 critically	 considered	 in	 section	3.4.	Despite	 the	 inability	 to	detect	
causative	mutations	 in	 the	DNA	sequence	of	all	patients	 in	 the	 two	genes	 considered,	many	
mutations	of	interest	were	identified.	Following	the	identification	of	mutations	in	SLC3A1	and	
SLC7A9,	 the	use	of	 the	Xenopus	 laevis	oocyte	expression	 system	was	utilised	 to	characterise	
the	proteins	encoded	by	these	two	genes:	rBAT,	and	b0,+AT,	respectively.	From	this	we	could	




b0,+	 and	 the	 effect	 of	 the	 mutations	 identified	 in	 our	 cohort.	 To	 achieve	 this,	 membrane	
transport	proteins	were	expressed	 in	Xenopus	 laevis	oocytes	 and	Caco-2	 intestinal	 epithelial	
cells.	Xenopus	laevis	oocytes	are	a	useful	tool	for	studying	the	function	of	rBAT,	the	protein	in	
which	 all	 novel	mutations	were	 identified	 in	 this	 study.	 This	 is	 because	 the	oocytes	have	an	
endogenous	light	chain,	homologous	to	human	b0,+AT	(Bertran	et	al.,	1992).		
Bacterial	 plasmid	 vectors	 containing	 the	 open	 reading	 frame	 (ORF)	 of	 the	 gene	 of	
interest	are	able	to	self-replicate	under	the	correct	culture	conditions	and	were	used	to	yield	






the	 appropriate	 antibiotic	 for	 selective	 growth	 (Table	 2.7).	 The	 inoculated	 broths	 were	
cultured	overnight	(37°C,	200rpm).		
	 Plasmid	cDNA	was	isolated	from	bacterial	cultures	using	QIAprep	Miniprep	kit	(Qiagen)	
according	 to	 the	manufacturer’s	 protocol.	 Bacterial	 cultures	were	 pelleted	 by	 centrifugation	
(10,000rpm,	 3min,	 at	 room	 temperature).	 The	 pellets	were	 re-suspended	 and	bacterial	 cells	
lysed	 to	 isolate	 plasmid	 DNA.	 	 Sodium	 acetate	 was	 added	 to	 precipitate	 proteins	 and	
chromosomal	 DNA.	 The	 solution	 was	 then	 centrifuged	 (13,000rpm,	 10min,	 at	 room	
temperature)	 to	pellet	 the	precipitate.	The	supernatant	containing	plasmid	DNA	was	 filtered	
and	through	a	column	containing	a	silica-gel	membrane.	The	membrane	binds	DNA	under	high	
salt	 conditions.	 The	 salt	was	 removed	by	 a	wash	 step.	 The	plasmid	DNA	was	 then	 eluted	 in	
	 74 
30μl	 room	 temperature	 molecular	 grade	 water	 (m.H2O)	 under	 low	 salt	 conditions	 (VWR,	
Lutterworth).	The	eluted	cDNA	was	quantified	using	NanoDrop	2000	(Thermo	Scientific).	cDNA	






































rBAT	 SLC3A1	 Human	 pSPORT1	 T7	 Ampicillin	 Hind-III	 A.	Werner	(gift)	
Xenopus	
oocyte	
NaPi-IIa	 SLC34A1	 Flounder	 pSPORT1	 T7	 Ampicillin	 Hind-III	 A.	Werner	(gift)	
Xenopus	
oocyte	































































































Site	 directed	mutagenesis	 was	 carried	 out	 on	 human	 rBAT	 cDNA	 for	 two	 purposes.	
Firstly,	it	was	used	for	the	addition	of	FLAG	(DYKDDDDK)	motifs	to	the	rBAT	cDNA	sequence	to	
aid	immunodetection	of	rBAT	protein.	Secondly,	mutagenesis	was	used	to	introduce	the	same	
point	mutants	 into	 the	 rBAT	 cDNA	 sequence	 that	 had	been	 identified	 in	 the	patient	 cohort.	




and	Caco-2	 cells,	 a	 series	of	 site-directed	mutagenesis	 reactions	were	performed	 to	add	 the	
FLAG	 (DYKDDDDK)	 epitope	 to	 the	 N-	 and	 C-	 termini	 of	 the	 protein.	 The	 different	 FLAG	
constructs	manufactured	and	used	as	part	of	this	study	are	shown	in	Figure	2.7.	
Mutagenesis	primers	were	designed	using	 the	online	QuikChange	primer	design	 tool	
(https://genomics.aglinet.com/)	 and	 purchased	 from	 Integrated	 DNA	 Technologies	 (IDT,	
Leuven,	Belgium).	The	mutagenesis	primers	used	in	this	study	are	listed	in	Tables	2.10	and	2.11	
and	 were	 based	 on	 the	 recommendations	 of	 Qi	 and	 Scholthof	 (2008).	 	 Mutagenesis	 was	





designed	 and	made	 by	 Dr.	 Noel	 Edwards.	 However,	 the	 primers	 synthesised	 to	 add	 a	 FLAG	
epitope	to	the	N-terminal	of	rBAT	were	incorrectly	designed	and	resulted	in	the	tag	sequence	
DYKDDDK,	 with	 a	 missing	 aspartate	 residue.	 To	 correct	 this,	 a	 further	 set	 of	 mutagenesis	
correctors	were	designed	to	add	in	the	missing	residue	(Table	2.10).		
The	 insertion	of	sequences	of	more	than	6	nucleotides	 in	 length	 is	classed	as	a	 large	
insertion	and	 in	 this	case	 the	 inverse	PCR	primers	are	designed	to	anneal	back	 to	back,	with	
each	primer	containing	half	of	the	desired	insertion	sequence	at	the	5’	end	(Figure	2.8	A	and	









	 Forward	 and	 reverse	 mutagenic	 primer	 pairs	 (Table	 2.11)	 were	 designed	 using	 the	
online	 Quikchange	 primer	 design	 tool	 (https://www.genomics.agilent.com).	 This	 technique	
uses	 a	 single	 pair	 of	 complementary	 primers	 that	 contain	 the	 required	 base	 changes	 in	 the	
middle	of	 the	sequence	 (Figure	2.8	d).	The	 recommendations	 for	primer	design	 to	 introduce	
base	substitutions	is	that	the	oligonucleotides	should	be	25-45	bases	in	length	and	have	a	GC	
content	 of	 40%.	 The	 design	 incorporates	 the	 desired	 base	 changes	 in	 the	 middle	 of	 the	












































































































































































































































































Primer	Name	 Sequence	(5'	to	3')	 Tm	(°C)	 Purification	
FLAG-rBAT	FWD*	 TAC	AAG	GAT	GAC	GAT	AAG	GCT	GAA	GAT	AAA	AGC	AAG	AGA	GAC	TCC	ATC	 65.0	 Desalting	
FLAG-rBAT	REV*	 ATC	GTC	GTC	ATC	CTT	GTA	ATC	CAT	GTC	TCA	CCG	ACT	TAT	GTC	TTC	GGA	GTG	 67.6	 Desalting	
FLAG-rBAT	corrector	FWD	 GTG	AGA	CAT	GGA	TTA	CAA	GGA	CGA	TGA	CGA	TGA	CGA	TAA	GGC	TGA	AG	 64.6	 Desalting	
FLAG-rBAT	corrector	REV	 GTG	AGA	CAT	GGA	TTA	CAA	GGA	CGA	TGA	CGA	TAA	GGC	TGA	AG	 64.6	 Desalting	
rBAT-FLAG	FWD*	 TAC	AAG	GAT	GAC	GAC	GAT	AAG	TAG	GCA	CCT	TTA	TGA	AGA	GAT	GAA	GAC	 64.8	 Desalting	
rBAT-FLAG	REV*	 ATC	GTC	GTC	ATC	CTT	GTA	ATC	ACA	CGA	GGT	ATA	CAG	TAT	GTT	CAG	TAC	AC	 65.3	 Desalting	
rBAT-2xFLAG	FWD	 ACT	GTA	TAC	CTC	GTG	TGA	TTA	TAA	AGA	TCA	TGA	CAT	CGA	TTA	CAA	GGA	TGA	CG	 64.4	 PAGE	
rBAT-2xFLAG	REV	 CGT	CAT	CCT	TGT	AAT	CGA	TGT	CAT	GAT	CTT	TAT	AAT	CAC	ACG	AGG	TAT	ACA	GT	 64.4	 PAGE	
rBAT-3xFLAG	FWD	 CTG	AAC	ATA	CGT	TAT	ACC	TCG	TGT	GAC	TAC	AAA	GAC	CAT	GGT	GAT	TAT	AAA	GAT	CAT	GAC	ATC	GAT	 67.1	 PAGE	

















































Step	 Temperature	(°C)	 Time	 Cycles	


























































































Figure	 2.8:	 A	 schematic	 diagram	 showing	 the	 outline	 of	 the	 site-directed	 mutagenesis	
concept.	A,	The	mutagenic	primers	each	carrying	half	of	the	FLAG	sequence	(red)	to	be	added	
anneal	 to	 the	 template	 DNA	 (black,	 dashed)	 adjacent	 on	 opposite	 strands;	 B,	 During	 the	
temperature	cycling	the	template	DNA	is	replicated	(grey)	by	Pfu	polymerase.	Incorporation	of	
the	 FLAG	 sequence	 produces	 nicked	 DNA;	 C,	 The	 methylated	 template	 DNA	 is	 selectively	
digested	 using	 DpnI	 enzyme.	 The	 remaining	 DNA	 is	 transformed	 into	 E.	 coli	 cells	 and	
recombined;	d,	mutagenic	primers	that	inversely	overlap	and	contain	the	desired	base	changes	
in	 the	 centre	 of	 the	 sequence	 (star)	 anneal	 to	 the	 DNA	 (black,	 dashed);	 E,	 During	 the	
temperature	cycling	the	template	DNA	is	replicated	(grey)	by	Pfu	polymerase.	Incorporation	of	
the	 base	 changes	 produces	 nicked	 DNA;	 F,	 The	 methylated	 template	 DNA	 is	 selectively	





	 Molecular	modification	 of	 human	 rBAT	 at	 the	 cDNA	 level	was	 performed	by	 inverse	
overlapping	PCR	using	 the	Quikchange	Lightning	kit	 (Agilent	Technologies).	The	PCR	 reaction	
mix	is	listed	in	Table	2.12	and	the	PCR	cycling	parameters	used	are	displayed	in	Table	2.13.	The	









2.14)	 was	 added	 and	 the	 culture	 was	 incubated	 at	 37°C,	 200rpm	 for	 1h.	 After	 1h,	 50μl	 of	
culture	 medium	 was	 removed	 and	 spread	 aseptically	 onto	 an	 LB-ampicillin	 agar	 plate	 and	























	 To	enable	characterisation	of	 the	wild-type	and	mutant	proteins	of	System	b0,+,	 rBAT	
was	heterologously	expressed	in	in	Xenopus	laevis	oocytes.	Protein	expression	in	the	oocytes	
was	achieved	following	micro-injection	of	cRNA.	In	vitro	transcription	of	cRNA	was	performed	




	 To	 select	 a	 restriction	 enzyme	 that	 would	 produce	 a	 single	 cut	 in	 the	 plasmid,	 the	







	 Following	 linearisation,	 cDNA	 was	 recovered	 by	 ethanol	 precipitation.	 To	 the	 100μl	
reaction,	 10μl	 of	 3M	 sodium	acetate	 and	 250μl	 100%	ethanol	were	 added	 and	 the	 reaction	
mixture	 was	 incubated	 at	 -20°C	 overnight	 or	 -80°C	 for	 2h.	 The	 DNA	 was	 then	 pelleted	 by	
centrifugation	 at	 18,000rpm	 (30min,	 4°C).	 The	 supernatant	 was	 removed	 and	 the	 pellet	
washed	with	1ml	100%	ethanol.	The	sample	was	centrifuged	at	18,000rpm	for	15min	at	4°C.	
The	supernatant	was	removed	and	the	pellet	air-dried	for	10min	before	being	re-suspended	in	



















































components	 of	 this	 reaction	 mixture	 are	 listed	 in	 Table	 2.15.	 5’-7-methylguanosine	 cap	




	 The	 recovery	 of	 cRNA	 from	 the	 reaction	mix	was	 achieved	 by	 addition	 of	 100μl	 5:1	
phenol:chloroform.	The	mixture	was	vortexed	and	centrifuged	 (16,000rpm,	10min,	4°C).	 The	
upper	 aqueous	 phase	 containing	 the	 cRNA	 was	 removed	 and	 transferred	 to	 a	 fresh	 1.5ml	
centrifuge	 tube	containing	10μl	 sodium	acetate	 (3M)	and	250μl	ethanol	 (100%).	 The	 sample	
was	 vortexed	 and	 stored	 at	 -80°C	 overnight.	 	 The	 following	 day,	 the	 cRNA	was	 pelleted	 by	
centrifugation	(18,000rpm,	30min,	4°C).	The	supernatant	was	removed	and	the	pellet	air-dried	
for	 10min	 before	 being	 re-suspended	 in	 15μl	 Buffer	 EB	 (Qiagen).	 cRNA	 was	 quantified	 as	
described	in	section	2.5.1	and	stored	at	-80°C	until	use.		
2.6	Functional	expression	in	Xenopus	laevis	oocytes	
	 In	 this	 investigation,	human	 rBAT	 cRNA	was	 injected	 into	Xenopus	 laevis	 oocytes	 for	






were	 sacrificed	 by	 destruction	 of	 the	 cranium	 in	 accordance	 with	 Home	 Office	 Schedule	 1	
methods.	Ovaries	were	surgically	removed,	dissected	manually	and	incubated	in	ORII	solution	
(82.5mM	 NaCl,	 2mM	 KCl,	 1mM	MgCl2,	 10mM	 HEPES,	 pH	 7.5)	 containing	 collagenase	 A	 	 at	
2.5mg.ml-1,	 for	 60-90min	 (lyophilised	 from	 Clostridium	 histolyticum,	 Roche,	 Germany).	
Collagenase-treated	 oocytes	 were	 washed	 6	 times	 with	 50ml	 ORII	 solution	 followed	 by	 6	
washes	with	 50ml	modified	 Barth’s	 solution	 (MBS)	 (88mM	NaCl,	 1mM	KCl,	 0.82mM	MgSO4,	
0.41mM	CaCl2,	 0.33mM	Ca(NO3)2,	 10mM	HEPES,	 2.4mM	Na2(HCO3),	 adjusted	 to	pH	7.5	with	
Tris)	supplemented	with	gentamycin	(0.02mg.ml-1)	(Gurdon,	1977).	Healthy-looking	stage	V-VI	







































































































































































































































































































Oocytes	 (n=10)	were	washed	 for	2min	at	 room	temperature	 in	Na+-free	wash	buffer	
(100mM	choline	chloride,	2mM	KCl,	1mM	CaCl2,	1mM	MgCl2,	10mM	HEPES,	adjusted	to	pH	7.4	
with	 Tris)	 and	 then	 placed	 in	 a	 10ml	 test	 tube.	 Excess	 buffer	 was	 removed	 and	 200µl	
radiolabelled	 uptake	 solution	 (wash	 buffer	 containing	 2.5-5µCi.ml-1	 [3H]amino	 acid	 (10µM))	
was	added	immediately.	A	list	of	all	radiolabelled	compounds	used	in	this	study	can	be	found	
in	Table	2.16.	
Following	 incubation	 for	 up	 to	 3h	 at	 21-24°C,	 the	 radiolabelled	 uptake	 solution	was	
removed	and	the	oocytes	washed	three	times	in	5ml	ice-cold	wash	buffer	to	stop	the	reaction.	
Single	 oocytes	 were	 placed	 in	 individual	 scintillation	 vials	 (7ml,	 Meridian	 Biotech,	 UK)	 and	
200µl	of	10%	SDS	was	added	to	each	vial.	Cells	were	left	overnight	to	lyse,	following	which	1ml	
scintillation	fluid	(Gold	Star	Quanta,	Meridian	Biotech,	UK)	was	added	to	each	vial.	[3H]Amino	
acid	 uptake	 was	 detected	 by	 liquid	 scintillation	 counting	 using	 an	 LS	 6500	 multi-purpose	
scintillation	 counter	 (Beckman-Coulter,	 High	Wycombe,	 UK).	 Disintegrations	 per	 min	 (DPM)	
were	measured	and	used	to	determine	amino	acid	uptake	(Equation	2.1).		
	





of	 amino	 acid	 in	 the	 solution,	 in	 moles,	 available	 for	 uptake.	 Results	 are	 expressed	 as	 the	
amount	of	amino	acid	taken	into	the	oocyte	over	time	(pmol.oocyte-1.(60min)-1).	
	 For	example,	in	an	rBAT-expressing	oocyte	incubated	in	200μl	uptake	solution	(pH	7.4,	





Alanine	 3H	 1	 0.132	 Perkin	Elmer	
Arginine	 3H	 1	 54.6	 Perkin	Elmer	
Cystine	 14C	 0.02	 0.11	 Perkin	Elmer	
Glutamic	acid	 3H	 1	 51.9	 American	Radiolabelled	Chemicals	
Leucine	 3H	 1	 115.4	 Perkin	Elmer	
Lysine	 3H	 1	 92	 Perkin	Elmer	





A	 range	 of	 immunodetection	 techniques	was	 employed	 in	 this	 study	 to	 support	 the	
data	from	the	functional	uptake	experiments.	These	detection	techniques	were	carried	out	to	





rBAT-3xFLAG	 cRNA,	 as	 previously	 described	 (Geering	 et	 al.,	 1989).	 Oocytes	 (n=25-50)	 were	
homogenised	 on	 ice	 in	 500μl	 lysis	 buffer	 (83mM	 NaCl,	 10mM	 HEPES,	 pH	 7.8,	 plus	 one	
Complete	Mini	protease	inhibitor	cocktail	tablet	(Roche)	per	10ml	buffer)	by	repeated	passage	
through	a	P200	pipette	tip.	Samples	were	vortexed	to	remove	remaining	visible	granules	and	
pelleted	 by	 centrifugation	 (2000rpm,	 5min,	 4°C).	 The	 supernatant	 was	 removed	 and	




the	 resultant	 supernatant	were	absorbed	onto	 filter	paper	and	discarded	and	 the	 remaining	
solution	was	removed	by	pipetting.		
The	pelleted	membranes	were	 re-suspended	 in	50μl	 lysis	 buffer	 and	 stored	at	 -80°C	
until	use.	Protein	concentration	was	established	by	Bradford’s	method	(Bradford,	1976)	using		
Quick	Start	protein	assay	(Bio-Rad,	UK)	according	to	the	manufacturer’s	protocol.	Absorbance	
at	 592nm	 was	 measured	 in	 triplicate	 using	 a	 FLUOstar	 Omega	 microplate	 reader	 (BMG	
LabTech,	Germany).	A	standard	curve	was	measured	using	concentrations	of	BSA	ranging	from	
0.0625mg.ml-1-2mg.ml-1	and	absorbance	values	were	fitted	to	a	standard	curve	using	a	second	








curve	 was	 produced	 using	 solutions	 of	 BSA	 of	 known	 concentration.	 This	 was	 used	 for	
calculation	of	 protein	 concentrations	 of	 samples	 using	 linear	 regression	 analysis.	 Samples	 of	
unknown	concentration	were	diluted	to	<5µg.10µl-1.		
	 	






















of	 the	 rate	of	protein	 translation	versus	 the	 rate	of	degradation.	Additionally,	 this	 technique	
will	allow	the	detection	of	the	different	glycosylated	forms	of	the	protein,	providing	an	insight	
into	the	cellular	processing	of	the	wild-type	and	mutant	heavy	chains.	Total	membrane	protein	
fractions	 (25μg)	 from	 Xenopus	 oocytes	 were	 resolved	 by	 sodium	 dodecyl	 sulphate-
polyacrylamide	gel	 electrophoresis	 (SDS-PAGE)	using	 the	Criterion	Cell	 system	 (Bio-Rad,	UK).	





	 The	 separated	 protein	 was	 transferred	 to	 an	 Immobilon-P	 polyvinylidene	 fluoride	
(PVDF)	membrane	 for	 1h	 at	 50V	 (Criterion	 Blotter,	 Bio-Rad,	 UK).	 The	 PVDF	membrane	 was	





the	 membrane	 was	 incubated	 in	 5ml	 of	 enhanced	 chemiluminescent	 (ECL)	 substrate	







antibody	 Supplier	 Raised	in	 Dilution	 Secondary	antibody	 Supplier	 Raised	in	 Dilution	















antibody	 Supplier	 Raised	in	 Dilution	 Secondary	antibody	 Supplier	 Raised	in	 Dilution	
Anti-FLAG	 Sigma	(F3165)	 Mouse,	monoclonal	 1:50	 Anti-mouse	FITC	
Life	Technologies	(A-
11029)	 Goat,	polyclonal	 1:50	
Anti-FLAG	 Proteintech	(60,002-1)	 Mouse,	monoclonal	 1:50	 Anti-mouse	FITC	
Life	Technologies	(A-
11029)	 Goat,	polyclonal	 1:50	
Anti-SLC7A9	 Bioss	(bs-10085R)	 Rabbit,	polyclonal	 1:100	 Anti-rabbit	TRITC	 Life	Technologies	(A-11037)	 Goat,	polyclonal	 1:50	
Anti-CD98	 BD	Pharmingen	(556074)	 Mouse,	monoclonal	 1:50	 Anti-mouse	FITC	
Life	Technologies	(A-
11029)	 Goat,	polyclonal	 1:50	







Plasma	membranes	were	 isolated,	 as	described	previously	 (Kamsteeg	&	Deen,	2001;	
Leduc-Nadeau	 et	 al.,	 2007)	 to	 detect	 the	 amount	 of	 rBAT	 protein	 present	 in	 the	 plasma	
membrane	 of	 the	 oocyte.	 This	 technique	 would	 allow	 comparison	 of	 the	 quatity	 of	 rBAT	
subunits	 successfully	 trafficked	 to	 the	 outer	 oocyte	membrane	 in	 the	wild-type	 and	mutant	
proteins.	 Oocytes	 were	 washed	 in	 MES-buffered	 saline	 solution	 (MBSS)	 (NaCl	 80mM,	 MES	
20mM,	pH	6)	prior	to	incubation	over	5-10min	with	0.005%	Subtilisin	A	(P4560,	Sigma,	UK)	to	
partially	 digest	 vitelline	 membranes.	 Following	 removal	 of	 the	 enzyme	 by	 three	 washes	 in	
MBSS,	 oocytes	 were	 incubated	 with	 1%	 Ludox	 Cl	 colloidal	 silica	 (Sigma,	 UK)	 for	 1h	 at	 4°C.	
Oocytes	were	washed	three	times	in	MBSS	(5min,	4oC)	to	remove	the	silica	and	then	incubated	
for	1h	in	0.1%	poly(acrylic)	acid	(Sigma,	UK)	(1h,	4oC)	with	gentle	agitation.		
The	wash	 step	was	 repeated	 and	 oocytes	were	 homogenised	 by	 passage	 through	 a	





was	 removed,	 and	 the	 pellet	 was	 re-suspended	 in	 the	 same	 volume.	 Following	 the	 final	
centrifugation	 step,	 pellets	 were	 re-suspended	 in	 homogenisation	 buffer	 containing	 0.1%	
Triton	 X	 to	 dissociate	 protein	 leaflets	 and	 allow	 quantification	 through	 Bradford	 Assay	
(Bradford,	1976).	
2.7.4	Immunocytochemical	detection	of	membrane	protein	in	whole	oocytes	
	 Whole	 oocytes	 were	 used	 for	 the	 immunocytochemical	 detection	 of	 FLAG-tagged	
rBAT.	 The	 use	 of	 whole	 oocytes	 allowed	 the	 detection	 of	 wild-type	 rBAT	 protein,	 a	mutant	
rBAT	 proteins	 in	 the	 plasma	 membrane	 of	 the	 oocytes.	 Only	 protein	 that	 was	 successfully	
targeted	 to	 the	 plasma	 membrane	 could	 be	 detected	 using	 this	 technique.	 Following	




(v/v)	 horse	 serum-PBS	 at	 the	 appropriate	 concentration	 (Table	 2.17)	 for	 16h	 at	 4°C	on	 a	 tilt	
table.	The	primary	antibody	was	 removed	by	 three	washes	 in	PBS	at	 room	temperature	and	
the	 oocytes	 were	 blocked	 in	 5%	 (v/v)	 goat	 serum-PBS	 for	 30min.	 Following	 removal	 of	 the	
secondary	 block,	 the	 fluorophore-conjugated	 secondary	 antibody	 was	 applied	 at	 the	
	 100	
appropriate	 dilution	 in	 50μl	 5%	 (v/v)	 goat	 serum-PBS	 (Table	 2.17)	 in	 the	 dark	 (1h,	 RT).	 The	
secondary	antibody	was	removed	and	the	oocytes	were	washed	three	times	in	PBS.		
Oocytes	were	transferred	immediately	to	individual	wells	of	a	96-well	Nunc	micro-well	
plate.	 The	 dish	 was	 carefully	 filled	 with	 PBS	 and	 oocytes	 were	 imaged	 using	 a	 20x	 water-
dipping	 lens	 on	 a	 Leica	 TCS	 SP2	 AOBS	 MP	 point	 scanning	 confocal	 microscope	 (Leica	
Microsystems,	 Germany)	 with	 the	 help	 of	 Dr.	 Trevor	 Booth	 (Bioimaging	 Facility,	 Newcastle	
University).	 The	 secondary	 antibody-conjugated	 fluorophores	 used	 in	 this	 study	 were	 FITC	
(peak	excitation/emission	495/519nm)	and	TRITC	(peak	excitation/emission	547/572nm).		
	 Each	 water-injected	 control	 oocyte	 (n=6-10)	 was	 imaged	 to	 establish	 the	 level	 of	
background	 fluorescence.	 For	 each	 control	 oocyte	 the	 gain	was	 reduced	 to	 display	minimal	
fluorescence.	The	mean	value	for	all	control	oocytes	was	calculated	and	all	control	and	RNA-
injected	oocytes	 from	the	same	experiment	were	 imaged	at	 the	same	settings.	 Images	were	
taken	at	the	equator	of	the	oocyte,	identified	by	the	widest	point	of	the	membrane	arc.		
2.7.5	Immunocytochemical	detection	of	membrane	protein	in	oocyte	sections	
	 Oocyte	 sections	 were	 used	 for	 the	 immunocytochemical	 detection	 of	 FLAG-tagged	
rBAT.	 The	 use	 of	 oocyte	 sections	 allowed	 the	 detection	 of	 rBAT	 protein	 in	 the	 plasma	




60°C	 in	 a	 Shandon	 cryotome	 E	 (Thermo	 Scientific).	 Thin	 slices	 (15μM)	were	 taken	 from	 the	
frozen	medium	and	mounted	onto	HistoBond	glass	slides	(Marienfeld	GmbH,	Germany).	Slides	
were	kept	on	 ice	and	 flooded	with	PBS	 to	 remove	 the	OCT	and	prevent	 the	oocyte	 sections	
from	dehydrating	whilst	further	sections	were	being	taken.	
	 Immunocytochemical	 detection	 was	 carried	 out	 on	 the	 glass	 slides	 as	 described	 in	
section	2.9.4,	but	without	agitation.	Slides	were	 incubated	overnight	 in	the	primary	antibody	
at	4°C	in	a	moist,	airtight	container	to	prevent	evaporation	of	the	antibody	solution	from	the	
slide	 surface.	 Following	 completion	 of	 the	 immunocytochemistry,	 slides	 were	mounted	 in	 a	
small	drop	of	Vectashield	(Vector	Laboratories,	Peterborough,	UK)	under	a	13mm	round	glass	
coverslip.		










	 The	 immortalised	 human	 intestinal	 epithelial	 cell	 line,	 Caco-2	 was	 cultured,	 as	
described	 previously	 (passage	 106-115)	 (Thwaites	 et	 al.,	 1996)	 in	 high	 glucose	 (4.5g.l-1)	
Dulbecco’s	modified	Eagle’s	medium	(DMEM)	with	supplements	(Table	2.18).	
	 Cells	were	seeded	at	a	density	of	67,000.cm-2	in	a	150cm2	flask	 (Corning	Life	Science,	
The	 Netherlands)	 containing	 75ml	 of	 Caco-2	 growth	 medium	 (Table	 2.18),	 changed	 twice	
weekly.	Cells	were	routinely	incubated	at	37°C	at	an	atmosphere	of	5%	CO2	in	air	and	passaged	
every	10-14	days.	For	passaging,	growth	medium	was	removed	and	cells	were	washed	three	
times	 in	phosphate	buffered	saline	 (PBS).	Cells	were	 incubated	(20	min,	37°C)	 in	10ml	0.05%	
trypsin,	0.02%	EDTA	with	agitation	every	5min	 to	aid	detachment	 from	the	 flask	wall.	When	
around	half	of	the	cells	had	visibly	detached,	trypsinisation	was	inhibited	by	addition	of	30ml	
growth	 medium.	 Cells	 were	 isolated	 and	 re-suspended	 by	 passage	 through	 a	 large	 bore	
needle.	 Cell	 numbers	 were	 established	 using	 a	 Cellometer	 Auto	 T4	 (Nexcelom	 Bioscience,	
Lawrence,	 MA)	 and	 cells	 were	 seeded	 in	 new	 flasks	 or	 onto	 0.4μm	 pore	 polycarbonate	
membrane	 Transwell	 permeable	 supports	 in	 (5x105	cells.cm-2)	 for	 functional	 uptake	 studies.	
Cells	 grown	 on	 Transwell	membranes	were	 supplied	with	 1ml	 growth	medium	 in	 the	 apical	
































and	 had	 the	 growth	 medium	 changed	 one	 day	 prior	 to	 experimental	 use.	 Monolayer	
confluence	 was	 established	 by	 measurement	 of	 trans-epithelial	 resistance	 (RT)	 using	 EVOM	
voltohmmeter	 (WPI,	 Stevenage,	UK).	 Resistance	 values	measured	 in	 growth	medium	 from	a	
typical	 experiment,	 11	 days	 post-seeding,	 were	 362±8Ω.cm2	 (n=60).	 Monolayers	 were	
arranged	to	create	an	equal	average	RT	value	between	treatment	groups	(n=4-5).	
	 Cell	growth	medium	was	removed	by	four	washes	 in	500ml	Na+-free	modified	Krebs’	
solution	 (Table	 2.19).	 Monolayers	 were	 placed	 in	 a	 clean	 12-well	 plate	 and	 incubated	 in	
modified	 Krebs’	 solution	 (0.5ml	 apical,	 1ml	 basolateral)	 for	 30min	 at	 37°C.	 Where	 no	 pre-
incubation	 had	 occurred	 prior	 to	 the	 experiment,	 trans-epithelial	 resistance	 was	 measured	
once	more	to	ensure	approximately	equal	distribution	of	resistance	was	achieved	between	the	
different	treatment	groups.	
	 The	 apical	 Krebs’	 solution	was	 removed	and	 immediately	 replaced	with	0.5ml	10μM	
[3H]arginine		(0.5μCi.ml-1).	For	competition	experiments	where	arginine	uptake	was	measured	
in	 the	 presence	 of	 5mM	 of	 amino	 acid	 competitors,	 the	 control	 also	 contained	 5mM	 D-
mannitol	to	exclude	effects	due	to	osmotic	changes.	Uptake	of	arginine	was	carried	out	over	
5min	 after	which	 the	 radiolabel	was	 removed	 by	 aspiration	 and	 the	 reaction	 terminated	 by	
three	washes	in	500ml	ice-cold	Krebs’	solution.		
The	 polycarbonate	 membrane-attached	 cell	 monolayers	 were	 removed	 from	 the	
plastic	supports	using	a	scalpel	and	placed	in	individual	7ml	scintillation	vials.	To	each	vial,	1ml	
scintillation	fluid	was	added	(Gold	Star	Quanta,	Meridian,	UK).	Disintegrations	per	min	(DPM)	
were	 measured	 as	 described	 in	 Section	 2.4.2	 and	 used	 to	 determine	 amino	 acid	 uptake	
(Equation	2.2).		
	
Equation	2.2:		 Apical uptake = Monolayer DPM(Standard DPM x 50)  x M  ÷ 1.13 	
	



















lysis	 buffer	 was	 added	 to	 the	 flask.	 Cells	 were	 removed	 from	 the	 wall	 of	 the	 flask	 using	 a	







	 In	order	to	express	a	FLAG-tagged	rBAT	construct	 in	Caco-2	cells,	 it	was	necessary	to	
sub-clone	the	open	reading	frame	of	rBAT-3xFLAG	into	a	vector	containing	a	cytomegalovirus	
(CMV)	 promoter.	 The	 early	 CMV	 promoter	 region	 has	 been	 shown	 to	 drive	 high	 levels	 of	
constitutive	 protein	 expression	 in	mammalian	 cells,	 unlike	 the	 T7	 promoter	 region	which	 is	
present	in	the	pSPORT1	vector.	Expression	vectors	pSPORT1	and	pCMV-SPORT6		have	different	
promoter	 regions	 (T7	 and	 CMV,	 respectively).	 Despite	 this,	 both	 have	 very	 similar	 multiple	
cloning	sites	within	their	sequences.	The	rBAT-3xFLAG	construct	used	for	in	vitro	transcription	
of	cRNA	is	contained	in	the	pSPORT1	vector	(Table	2.7),	with	a	T7	promoter	upstream	of	the	
start	 codon	 (Figure	 2.12	 a).	 pCMV-SPORT6	 already	 contained	 an	 insert	 within	 its	 multiple	
cloning	site,	the	open	reading	frame	of	the	IKEPP	gene	(Figure	2.12	b).	Both	bacterial	plasmids	
had	the	EcoRI	restriction	site	upstream	of	the	start	codon	(ATG)	and	HindIII	downstream	of	the	
stop	 codon	 (TAG)	 (Figure	 2.12	 a	 and	 b).	 Neither	 of	 the	 open	 reading	 frames	were	 cut	with	
HindIII	or	EcoRI.	
	 105	
	 Both	bacterial	plasmids	were	grown	from	glycerol	 stocks	and	cDNA	was	 isolated	and	
purified	as	described	in	section	2.5.1.	
	 A	 double	 digest	 was	 carried	 out	 on	 the	 plasmid	 cDNA	 to	 cut	 both	 restriction	 sites	
simultaneously,	isolating	both	required	cDNA	sequences:	rBAT	and	pCMV-SPORT6	(Figure	2.12	
c,d).	 The	 enzymes	 used	 were	 HindIII-HF	 and	 EcoRI-HF	 (NEB),	 which	 have	 100%	 activity	 in	
CutSmart	 buffer.	 The	 reaction	 mixture	 was	 comprised	 as	 follows:	 2μg	 cDNA,	 5μl	 CutSmart	








	 Plasmid	 and	 insert	 cDNA	 were	 ligated	 for	 1h	 at	 room	 temperature	 at	 a	 3:1	









































































SPORT6.	 a,	 The	 rBAT	 coding	 sequence	 in	 pSPORT1	 with	 a	 T7	 promoter	 used	 for	 in	 vitro	
transcription	of	cRNA.	EcoRI	and	HindIII	restriction	sites	sit	upstream	of	the	start	codon	(ATG)	
and	downstream	of	 the	 stop	 codon	 (TAG),	 respectively;	 b,	 IKEPP	 coding	 sequence	 in	 pCMV-
SPORT-6.	 Both	 restriction	 sites	 are	 present	 in	 the	MCS	 and	 are	 in	 the	 correct	 orientation	 to	
insert	 rBAT	 downstream	 of	 the	 CMV	 promoter	 for	 expression	 in	mammalian	 cells;	 c	 and	 d,		
Double	enzyme	digest	using	EcoRI-HF	and	HindIII-HF	is	carried	out	to	produce	linear	insert	and	
plasmid	 DNA;	 e,	 digest	 products	 are	 resolved	 on	 a	 0.8%	 agarose-TAE	 gel	 and	 the	 bands	 of	
linear	rBAT	DNA	(lanes	a	and	b,	red	box,	2.1kb)	and	linear	pCMV-SPORT6	(lanes	c	and	d,	grey	








cells.well-1)	 for	 24h	 (37°C,	 5%	 CO2)	 in	 normal	 growth	medium	 (Table	 2.18).	 Cells	 were	 then	
washed	 three	 times	 in	 PBS	 and	 the	 medium	 was	 replaced	 with	 0.5ml	 Opti-MEM	 (Life	
Technologies,	Paisley,	UK)	supplemented	with	5%	FBS	and	1%	non-essential	amino	acids.		
	 Cell	 transfection	 was	 carried	 out	 using	 Lipofectamine	 2000	 (Life	 Technologies,	 UK)	
according	 to	 the	manufacturer’s	protocol.	Reagents	were	brought	 to	 room	 temperature	and	
gently	 vortexed	prior	 to	use.	 cDNA:lipid	 complexes	were	 formed	 in	non-supplemented	Opti-
MEM	through	 incubation	at	room	temperature	for	20min	at	a	ratio	of	1:3	 (0.5μg	cDNA:1.5μl	
lipofectamine).	 cDNA:lipid	 complex	 mixture	 (100μl)	 was	 added	 to	 the	 500μl	 Opti-MEM	
contained	 in	each	well.	The	plate	was	 rocked	gently	 for	30s	before	 incubation	at	37°C.	After	









the	 wells	 and	 placed	 on	 a	 parafilm-covered	 surface.	 Immunocytochemical	 detection	 was	
carried	out	on	the	glass	coverslips	as	described	 in	section	2.9.4,	but	without	agitation.	Slides	
were	 incubated	 overnight	 in	 the	 primary	 antibody	 at	 4°C	 in	 a	 moist,	 airtight	 container	 to	
prevent	 evaporation	 of	 the	 solution	 from	 the	 slide	 surface.	 Following	 completion	 of	
immunocytochemistry,	slides	were	mounted	face	down	in	a	small	drop	of	Vectashield	(Vector	
Laboratories,	Peterborough,	UK)	on	glass	slides.		
	 The	transfected	cells	were	 imaged	using	a	Leica	TCS	NT	krypton-argon	 laser-scanning	
confocal	 microscope	 (Leica	 Microscope	 and	 Systems,	 Germany)	 connected	 to	 a	 computer	
running	 the	 Leica	 TCS	 NT	 software.	 Excitation	 and	 emission	 spectra	 were	 as	 described	 in	
section	2.9.4.	Images	were	taken	at	a	range	of	magnifications	(20-63x).	
2.10	Prediction	of	3D	protein	structure	by	homology	modelling	
	 Due	 to	 the	difficulties	 in	 crystallising	hydrophobic	membrane	 transport	proteins,	 the	
tertiary	 structure	 of	 many	 of	 these	 molecules	 is	 unknown.	 For	 this	 reason,	 it	 has	 become	
common	 practice	 to	 use	 computational	 methods	 to	 predict	 the	 topology	 of	 proteins	 with	
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downloaded	 in	 FASTA	 format	 from	 the	 NCBI	 nucleotide	 database	
(http://www.ncbi.nlm.nih.gov).	The	amino	acid	sequence	for	each	protein	was	individually	put	





Once	 the	most	probable	 related	structures	have	been	 identified	 from	the	Protein	Data	Bank	
(PDB)	 database	 (https://www.rcsb.org/pdb/home),	 the	 most	 appropriate	 template	 can	 be	
selected	manually.		
	 Once	 selected,	 the	 alignment	with	 the	 template	 sequence	 is	 automatically	 uploaded	
into	 MODELLER	 (http//www.toolkit.tuebingen.mpg.de/modeller)	 and	 a	 PDB	 file	 is	 created	
containing	 the	 predicted	 3D	 model.	 MODELLER	 uses	 both	 Ramachandran	 analysis	 and	
MolProbity	to	assess	the	quality	of	the	model	and	validate	the	structure.	A	Ramachandran	plot	
considers	the	dihedral	backbone	angles	of	amino	acids	in	a	protein	structure	against	their	side	
chains	 and	 the	 side	 chains	of	other	 amino	acids	 in	 the	protein	 (Ramachandran	 et	 al.,	 1963).	
MolProbity	(http://molporbity.biochem.duke.edu)	 is	an	online	web	service	used	for	structure	




automatically	 tries	 the	 residues	 in	 both	 conformations	 to	 provide	 the	 best	 steric	 fit	 and	
optimise	the	position	of	H	residues	for	hydrogen	bonding	Davis	et	al.	(2007).	
	 The	final	homology	models	were	viewed	in	PyMol	(http//www.pymol.org)	from	which	
the	 predicted	 location	 of	 functionally-important	 residues	 in	 both	 rBAT	 and	 b0,+AT	 could	 be	
identified	and	the	effects	of	the	mutations	predicted	using	the	in-built	mutagenesis	tool.		
2.11	Statistical	analysis	
Data	 are	 expressed	 as	 mean	 ±	 standard	 error	 of	 the	 mean	 (SEM),	 where	 n	 is	 the	
number	of	oocytes	or	Caco-2	monolayers	used	per	condition.	GraphPad	Prism	version	6	was	


















lack	 of	 reabsorption	 of	 dibasic	 amino	 acids	 and	 the	 cysteine	 dimer,	 cystine,	 from	 the	 renal	
proximal	 tubule	 (Font	 et	 al.,	 2001).	 	 Cystinuria	 is	 traditionally	 believed	 to	 be	 an	 autosomal	
recessive	 disease,	 with	 the	 majority	 of	 patients	 presenting	 with	 a	 compound	 heterozygous	
genotype	(Dello	Strologo	et	al.,	2002).	The	current	classification	system	for	cystinuric	patients	
was	 discussed	 in	 Chapter	 1.	 Patients	 carrying	mutations	 in	SLC3A1,	 are	 “Type	A”,	 and	 those	
with	mutations	in	SLC7A9	are	“Type	B”.	Thus,	a	patient	who	had	one	mutation	in	SLC3A1	and	
one	in	SLC7A9	would	be	“Type	AB”	(Dello	Strologo	et	al.,	2002).		
To	 date,	 there	 have	 been	 many	 investigations	 reported	 in	 the	 literature	 on	 the	
identification	 of	 pathogenic	mutations	 in	 cohorts	 of	 cystinuric	 patients.	 These	 cohorts	 have	
ranged	in	size	from	fewer	than	10	patients	(Calonge	et	al.,	1994;	Miyamoto	et	al.,	1995;	Yuen	
et	 al.,	 2006)	 to	 over	 150	 Spanish	 and	 Italian	 patients	 recruited	 through	 the	 International	
Cystinuria	Consortium	(ICC)	(Font-Llitjos	et	al.,	2005;	Bisceglia	et	al.,	2010).	Amongst	24	reports	
of	 mutation	 detection	 in	 these	 cohorts,	 published	 between	 1994	 and	 2015,	 the	 mutation	





al.,	 2008;	 Popovska-Jankovic	 et	 al.,	 2009;	 Bisceglia	 et	 al.,	 2010;	 Eggermann	 et	 al.,	 2011;	
Barbosa	et	al.,	2012;	Rhodes	et	al.,	2015;	Wong	et	al.,	2015).		
The	presence	of	a	dibasic	aminoaciduria	in	heterozygote	carriers	of	SLC7A9	mutations,	
along	 with	 the	 failure	 to	 detect	 two	 causal	 variants	 in	 the	 genes	 known	 to	 be	 involved	 in	
cystinuria,	 has	 raised	 questions	 of	 the	 penetrance	 of	 phenotype.	 Genotype-phenotype	
correlation	 studies	 have	 shown	 that	 the	 penetrance	 of	 the	 cystinuria	 phenotype	 can	 vary	
between	 mutations	 and	 individuals.	 Mutations	 in	 SLC7A9	 are	 inherited	 in	 an	 autosomal	
dominant	 manner	 with	 variable	 penetrance	 of	 phenotype	 (Font-Llitjos	 et	 al.,	 2005).	 This	
variable	penetrance	of	SLC7A9	mutations	suggests	the	presence	of	other	modifying	factors	on	






et	 al.,	 2005).	 Conversely,	 whilst	 the	 vast	 majority	 of	 SLC3A1	 mutations	 are	 considered	
autosomal	 recessive	 mutations,	 one	 SLC3A1	 variant	 has	 been	 shown	 to	 have	 a	 largely	
dominant	inheritance	pattern	(Font-Llitjos	et	al.,	2005).	A	complete	duplication	of	exons	5	to	9	




Oleykowski	 et	 al.	 (1998).	 This	 enzymatic	 approach	 to	 mutation	 detection	 was	 employed	 to	
identify	 single	 base	 changes	 in	 the	 BRCA1	 gene	 (Oleykowski	 et	 al.,	 1998).	 The	 use	 of	 an	
endonuclease	 to	 detect	 the	 causal	 variants	 in	 cohorts	 of	 patients	 with	 genetic	 disease	 has	
subsequently	been	widely-reported	 (Qiu	 et	al.,	 2004;	 Scaffino	 et	al.,	 2004;	Otto	 et	al.,	 2008;	
Voskarides	&	Deltas,	2009).	Although	the	commercial	Surveyor™	kit	is	available,	the	extraction	
of	 the	 enzyme	 from	 celery	 has	 proved	 a	 valuable	 source	 of	 a	 functional	 endonuclease	
(Oleykowski	et	al.,	1998;	Scaffino	et	al.,	2004;	Otto	et	al.,	2008).	The	CEL-I	enzyme	is	present	in	
a	wide	variety	of	vegetable	extracts,	but	celery	is	the	preferred	crude	source	of	plant	material	
due	 to	 its	 lack	 of	 chlorophyll	 pigment,	 which	 can	 interfere	 with	 activity	 (Oleykowski	 et	 al.,	
1998).	 The	 CEL-I	 endonuclease	 remains	 stable	 through	 extraction,	 storage	 and	 use,	 and	 is	
functional	at	pH	5-9.5.	The	use	of	the	heteroduplex-endonuclease	assay,	described	in	detail	in	
Chapter	 2,	 allows	 an	 increased	 throughput	 in	 the	 screening	 of	DNA	 samples.	 Additionally,	 it	
shows	 a	 high	 specificity	 for	 unique	 double-strand	 mismatches,	 and	 a	 greater	 sensitivity	 of	
detection	 than	 other	 common	 mutation	 detection	 protocols	 such	 as	 single	 strand	
conformation	 polymorphism	 (SSCP)	 analysis,	 used	 widely	 in	 other	 analyses	 of	 cystinuric	
cohorts	 (Michaud	 et	 al.,	 1992;	 Scaffino	 et	 al.,	 2004;	 Otto	 et	 al.,	 2008;	 Voskarides	 &	 Deltas,	
2009).	
In	 the	 current	 Chapter,	 we	 report	 the	 use	 a	 combination	 of	 non-quantitative	
techniques	 to	 detect	 causal	 variants	 in	 a	 cohort	 of	 cystinuria	 patients.	 Multiplex	 Ligation-
dependent	 Probe	 Amplification	 (MLPA)	 was	 also	 employed	 to	 quantify	 whole	 exon	 copy	
numbers,	 and	 identify	 gross	 deletions	 or	 duplications.	 To	 date,	 17	 distinct	 whole-exon	
mutations	have	been	identified	in	SLC3A1	(Stenson	et	al.,	2014).	Following	the	identification	of	






SLC7A9	 using	 the	 CEL-I	 endonuclease	 detection	 protocol	 described	 in	 Chapter	 2.	 Sanger	
sequencing	of	all	exons	of	the	two	genes	was	employed	to	determine	the	genotype	of	Patients	
28-31.	Patients	32-44	were	recruited	to	the	study	by	Dr.	John	Sayer	at	the	Freeman	Hospital,	












clinical	 diagnosis	 of	 cystinuria.	 Therefore,	 retrospectively,	 they	 did	 not	 meet	 the	 inclusion	
criteria.	 Thus,	 for	 the	 purposes	 of	 this	 report	 they	 have	 been	 excluded.	 All	 of	 the	 patients	
included	 in	 this	 report	 had	 a	 clinical	 diagnosis	 of	 cystinuria	 confirmed	 through	 chemical	




49y,	 respectively).	 These	 data	 are	 also	 displayed	 in	 Figure	 3.1A	 and	 B.	 The	 calculated	mean	
ages	of	presentation	and	clinical	diagnosis	in	cystinuria	are	24.3y	and	22.8y,	respectively.	This	
is	 in	 agreement	with	 the	 findings	 of	Wong	 et	 al.	 (2015)	who	 showed	 that	 the	mean	 age	 of	
clinical	 presentation	 in	 a	 cohort	 of	 74	 patients	 in	 the	 UK	 was	 23y.	 Rhodes	 et	 al.	 (2015)	
identified	the	median	age	at	first	stone	event	in	a	cohort	of	72	patients	to	be	23y.	The	mean	
number	of	stones	requiring	surgical	intervention	in	the	cohort	was	5.6	(Figure	3.1D),	although	
from	 the	data	 presented	 in	 Table	 3.1	 it	 is	 clear	 that	many	patients	 pass	 stones	 through	 the	








cohort	was	0.92mM	(Figure	3.1C).	However,	 these	were	spot	urine	 tests	 taken	 following	 the	
commencement	of	various	cystinuria	therapies.	They	may	not	be	reflective	of	the	patients’	24h	
urinary	 cystine	 levels,	 or	 those	 that	 would	 be	 measured	 in	 the	 absence	 of	 therapeutic	
intervention.	Additionally,	it	can	be	noted	from	the	data	that	despite	the	apparently	low	levels	
of	cystine	in	the	urine,	patients	continue	to	form	cystine	stones	(Table	3.1).	Additionally,	it	has	
been	 reported	 that	 urinary	 cystine	 is	 a	 poor	 marker	 of	 disease	 activity	 due	 to	 the	 rapid	
precipitation	 of	 cystine	 at	 pathophysiological	 concentrations	 (Wong	 et	 al.,	 2015).	 For	 this	
reason,	 it	 may	 be	 more	 reliable	 to	 assess	 urinary	 arginine	 or	 lysine	 concentrations	 as	 a	
measure	of	phenotype	severity	(Pardy	et	al.,	2011;	Thomas	et	al.,	2014;	Wong	et	al.,	2015)	
Of	the	20	patients	presented	in	Table	3.1,	17	were	receiving	treatment	for	cystinuria.	





	 Of	 the	 20	 patients	 for	 which	 clinical	 data	 was	 collected,	 12	 had	 been	 prescribed	 at	
least	one	 cystine	binding	 thiol	drug	 (CBTD)	 following	 their	diagnosis.	Of	 these	12	patients,	 6	
had	discontinued	treatment	with	at	least	one	CTBD	due	to	intolerable	side	effects	(Table	3.1).	
This	 is	 in	 accordance	 with	 the	 statistics	 reported	 in	 the	 literature	 on	 the	 high	 incidence	 of	
adverse	reactions,	which	include	renal	or	hepatic	failure,	rashes	and	SLE	(Thomas	et	al.,	2014).	
The	 poor	 tolerance	 of	 CBTD	 highlights	 the	 importance	 of	 the	 discovery	 of	 novel	 therapies,	
which	 are	 targeted	 to	 correcting	 the	 function	 of	 the	 transport	 system,	 and	 have	 a	 lower	
















































































































































































































































































































































































































































































































































































































































































the	 box.	 OD,	 once	 daily;	 BD,	 twice	 daily;	 TDS,	 three	 times	 daily;	 QDS,	 four	 times	 daily;	 SLE,	
systemic	 lupus	 erythematosus.	 The	 three	 patients	 who	 have	 never	 presented	 with	 kidney	
stones	but	were	diagnosed	with	cystinuria	based	upon	a	dibasic	aminoaciduria	and	renal	colic	











































































patients	 of	 the	 cohort	 (1-15,	 17-26)	 were	 investigated	 through	 the	 employment	 of	 a	 CEL-I	
endonuclease	detection	protocol	 (Oleykowski	 et	al.,	 1998).	 This	mutation	detection	protocol	
was	 outlined	 in	 detail	 in	 Chapter	 2.	 The	 reason	 for	 the	 use	 of	 this	method	 in	 our	 cystinuria	
cohort	was	to	rapidly	screen	through	the	exons	of	SLC3A1	and	SLC7A9	in	a	pair-wise	fashion	to	
detect	 pathogenic	mutations.	 Additionally,	 this	was	 proposed	 to	 be	 a	 technique	 that	would	
allow	 expansion	 to	 high-throughput	 screening	 in	 a	 larger	 cohort,	 where	 larger	 numbers	 of	
patient	 samples	would	be	combined	 to	 form	heteroduplexes.	As	described	 in	Chapter	2,	 the	
detection	 of	 a	 DNA	 fragment	 band	 following	 endonuclease	 treatment	 of	 patient-pair	
heteroduplexes	 led	 to	 both	 samples	 being	 sent	 for	 Sanger	 sequencing.	 This	 allowed	 the	
identification	 of	 the	 sequence	 variant	 that	 led	 to	 a	 heteroduplex	 mismatch,	 and	 ultimately	
cleavage	of	the	double-stranded	DNA.	Patients	1-15	and	17-21	were	investigated	by	Dr.	Noel	
Edwards	 in	 the	 preliminary	 investigations	 of	 this	 study.	 The	 remaining	 patients	 (22-26),	 I	
investigated	personally.		
Using	 this	 method	 we	 “solved”	 the	 genotype	 of	 14/25	 patients	 (56%)	 (Table	 3.2).	
Patients	 were	 classed	 as	 “solved”	 following	 the	 identification	 of	 two	 pathogenic	 SLC3A1	
mutations	 (Type	AA),	 at	 least	 one	 variant	 in	SLC7A9	 (Type	B	 or	 BB),	 or	 one	mutant	 allele	 in	
each	gene	 (Type	AB).	No	patients	 in	 this	 cohort	were	discovered	 to	have	Type	AB	cystinuria	
(Table	3.2).	Five	of	the	patients	had	two	causative	mutations	in	SLC3A1	(Type	AA),	and	six	had	
a	single	mutated	allele	in	SLC7A9	(Table	3.2).	Additionally,	three	patients	had	two	mutations	in	




reported	 cystinuria	mutations.	 Repeated	 Sanger	 sequencing	 of	 the	 single	 exon	 in	which	 the	
mutation	 fell	 confirmed	 the	 identification	 of	 novel,	 potentially	 causal,	 variants.	 These	
potentially	 pathogenic	 variants	 were	 confirmed	 as	 being	 absent	 in	 the	 general	 population	
through	 consultation	 with	 the	 Exome	 Aggregation	 Consortium	 (ExAC)	 database.	 This	 online	
resource	holds	the	genetic	data	of	121,142	sequenced	alleles	taken	from	disease-specific	and	
population	 genetic	 studies	 	(Exome	 Aggregation	 Consortium	 (ExAC),	 Cambridge,	 MA	 (URL:	
http://exac.broadinstitute.org),	August,	2015).	To	date,	this	is	the	largest	available	resource	of	
population	genetic	data.			
In	 SLC3A1,	 the	 gene	 encoding	 rBAT,	 most	 mutations	 are	 inherited	 in	 an	 autosomal	
recessive	 pattern	 (Dello	 Strologo	 et	 al.,	 2002).	 In	 this	 gene,	 6	 rare	 sequence	 variants	 were	
	 119	
discovered	 (Table	 3.2).	 Two	 of	 these	 mutations,	 M467T	 and	 R452W,	 had	 previously	 been	
reported	in	the	literature	as	causal	cystinuria	mutations	(de	Sanctis	et	al.,	1996;	Endsley	et	al.,	





band	 of	 lower	 molecular	 weight	 than	 the	 262bp	 exon	 band	 was	 identified	 following	
electrophoretic	 resolution	 of	 CEL-I	 treated	 heteroduplexes	 formed	 between	 SLC3A1	 exon	 3	
amplicons	of	Patients	1	and	2	(Figure	3.2A).	Following	Sanger	sequencing,	the	chromatograph	
revealed	a	heterozygous	Asn>Thr	missense	mutation	caused	by	a>c	base	change	in	exon	3	of	
SLC3A1	 (Figure	3.2A).	This	base	change	was	absent	 in	Patient	1,	who	had	 the	wild-type	DNA	
sequence	in	this	region	of	exon	3	(Figure	3.2A).	The	N254T	variant	was	not	identified	in	any	of	
the	alleles	recorded	 in	the	ExAC	database	and	was,	therefore,	proposed	to	be	a	novel	casual	
variant	 of	 cystinuria.	 A	 missense	 mutation,	 N253S,	 was	 recorded	 as	 a	 rare	 variant	 in	 the	
flanking	 residue	 in	 1/121168	 alleles	 of	 the	 ExAC	 database	 (http://exac.broadinstitute.org,	
August,	2015).		
A	 second	 novel	 variant	 was	 identified	 in	 exon	 7	 of	 SLC3A1	 (Table	 3.2).	 The	
heterozygous	leucine	to	proline	amino	acid	substitution	at	position	416	in	the	protein	(L416P)	
was	 identified	 in	 Patient	 26	 of	 the	 cohort	 in	 combination	 with	 known	 cystinuria	 mutation	
M467T	(Table	3.2).	The	amplicon	of	exon	7	was	303	bases	in	size,	yet	following	CEL-I	treatment	
of	 the	 Patient	 25/26	 heteroduplex,	 a	 fragment	 band	 of	 around	 150bp	 in	 size	was	 identified	
(Figure	3.2B).	This	led	to	the	Sanger	sequencing	of	both	of	these	patients	in	exon	7	of	SLC3A1.	
The	 sequencing	 results	 revealed	 a	 heterozygous	 t>c	 base	 change	 in	 Patient	 26,	 causing	 the	
mutation	L416P	at	the	protein	level	(Figure	3.2B).	Patient	25	carried	the	wild-type	allele	in	the	
region	of	this	mutation	(Figure	3.2B).	This	mutation	has	not	been	reported	in	the	literature	as	a	







3.3A).	 Following	Sanger	 sequencing,	 a	homozygous	 t>a	base	 change	was	detected	 in	Patient	
25,	which	was	absent	in	Patient	26	(Figure	3.3A).	The	missense	mutation	M465K	has	not	been	




The	 final	 novel	 missense	 variant	 detected	 in	 SLC3A1	 of	 our	 cohort	 by	 the	 CEL-I	
endonuclease	detection	method	was	Y579D.	This	mutation	was	 identified	 in	exon	10	of	 two	
unrelated	 patients,	 6	 and	 20	 (Table	 3.2).	 Fragment	 bands	 were	 detected	 following	
endonuclease	treatment	of	Patient	5/6	and	19/20	exon	10	heteroduplexes	(Figure	3.3B,	lanes	c	
and	d,	respectively).	Sanger	sequencing	revealed	a	heterozygous	t>g	base	change	in	exon	10	of	
both	 of	 these	 patients,	which	 led	 to	 a	 Tyr	 to	 Asp	 amino	 acid	 change	 at	 position	 579	 in	 the	
protein	 (Figure	 3.3B).	 This	mutation	 has	 not	 been	 reported	 previously	 as	 a	 causal	 variant	 in	
cystinuria,	 nor	 is	 it	 recorded	 in	 the	 ExAC	 database	 (http://exac.broadinstitute.org,	 August,	
2015).	 The	 mutation	 was	 present	 in	 the	 genotype	 of	 Patients	 6	 and	 20,	 along	 with	 known	
pathogenic	SLC3A1	variants	R452W	and	M467T	(Table	3.2).		
A	 rare	 variant	was	also	detected	 in	SLC7A9	 (Table	3.2).	 The	 intronic	deletion	of	 four	


















Gene	 SLC3A1	 SLC7A9	 Mutated	
alleles	 Type	 Solved	Patient	 Allele	1	 Allele	2	 Allele	1	 Allele	2	
1	 	 	 A224A/V	 	 1	 B	 Y	
2	 N254N/T	 	 	 	 1	 A	 N	
3	 	 	 	 	 0	 --	 N	
4	 	 	 	 	 0	 --	 N	
5	 M467M/T	 	 	 	 1	 A	 N	
6	 R452R/W	 Y579Y/D	 	 	 2	 AA	 Y	
7	 	 	 G105G/R	 	 1	 B	 Y	
8	 	 	 	 	 0	 --	 N	
9	 	 	
	Heterozygous	
c.1586+3_delAGTA	  1	 B	 Y	
10	 	 	 A224A/V	 	 1	 B	 Y	
11	 	 	 	 	 0	 --	 N	
12	 	 	 A224A/V	 	 1	 B	 Y	
13	 	 	 	 	 0	 --	 N	
14	 M467M/T	 	 	 	 1	 A	 N	
15	 	 	 A182A/T	 A354A/T	 2	 BB	 Y	
17	 R452R/W	 M467M/T	 	 	 2	 AA	 Y	
18	 M467M/T	 	 	 	 1	 A	 N	
19	 	 	 T132T/M	 A224A/V	 2	 BB	 Y	
20	 M467M/T	 Y579Y/D	 	 	 2	 AA	 Y	
21	 	 	
Homozygous	
c.1586+3_delAGTA	 	 2	 BB	 Y	
22	 	 	 	 	 0	 --	 N	
23	 	 	 	 	 0	 --	 N	
24	 	 	 A224A/V	 	 1	 B	 Y	
25	 M465K	 	 	 	 2	 AA	 Y	


















































































had	 a	 heterozygous	 A>C	 base	 change	 leading	 to	 the	 missense	 mutation	 N254T	 (*).	 This	
mutation	was	 detected	 following	 identification	 of	 a	 DNA	 fragment	 band	 of	 lower	molecular	
weight	 than	the	262bp	amplicon	of	exon	3.	A,	100bp	DNA	 ladder;	b,	Surveyor™	control	DNA	
heteroduplex	 (600bp)	with	 a	 single	 base	mismatch	 leading	 to	 cleavage	 products	 400bp	 and	
200bp	 in	 size	 following	CEL-I	 treatment;	 c,	P1/2	SLC3A1	exon	3	amplicon	heteroduplex	band	




DNA	 ladder;	 b,	 Surveyor™	 control	 DNA	 heteroduplex	 (600bp)	 with	 a	 single	 base	 mismatch	

































































































25	 had	 a	 homozygous	 T>A	 base	 change	 leading	 to	 the	 missense	 mutation	M465K	 (*).	 This	
mutation	was	 detected	 following	 identification	 of	 a	 DNA	 fragment	 band	 of	 lower	molecular	
weight	 than	the	379bp	amplicon	of	exon	8.	A,	100bp	DNA	 ladder;	b,	Surveyor™	control	DNA	
heteroduplex	 (600bp)	with	 a	 single	 base	mismatch	 leading	 to	 cleavage	 products	 400bp	 and	
200bp	in	size	following	CEL-I	treatment;	c,	P25/26	SLC3A1	exon	8	amplicon	heteroduplex	band	
(379bp)	 and	 2	 fragment	 bands	 of	 lower	 molecular	 weight.	 B,	 Sanger	 sequencing	 results	 of	
SLC3A1	 exon	 10a	 in	 Patients	 5,	 6	 and	 20.	 Patients	 6	 and	 20	 had	 a	 heterozygous	 T>G	 base	
change	 leading	 to	 the	 missense	 mutation	 Y579D	 (*).	 This	 mutation	 was	 detected	 following	
identification	of	a	DNA	fragment	band	of	lower	molecular	weight	than	the	364bp	amplicon	of	
exon	10a.	A,	100bp	DNA	ladder;	b,	Surveyor™	control	DNA	heteroduplex	(600bp)	with	a	single	
base	 mismatch	 leading	 to	 cleavage	 products	 400bp	 and	 200bp	 in	 size	 following	 CEL-I	
treatment;	 c,	 P5/6	 SLC3A1	 exon	 10a	 amplicon	 heteroduplex	 band	 (364bp)	 and	 a	 fragment	















































type	 reference	 sequence.	 Patient	 9	 had	 a	 heterozygous	 deletion	 of	 AGTA,	 3	 bases	 down	
stream	 of	 the	 end	 of	 exon	 12,	 in	 the	 splicing	 region.	 This	mutation	was	 detected	 following	
identification	of	a	DNA	fragment	band	of	lower	molecular	weight	than	the	370bp	amplicon	of	
exon	12.	The	same	mutation	was	identified	homozygously	in	Patient	22.	B,	Image	of	the	gel	on	
which	 the	 fragment	 band	 was	 identified	 following	 CEL-I	 endonuclease	 treatment	 of	
heteroduplexes;	a,	100bp	DNA	ladder;	b,	Surveyor™	control	DNA	heteroduplex	(600bp)	with	a	
single	 base	mismatch	 leading	 to	 cleavage	 products	 400bp	 and	 200bp	 in	 size	 following	 CEL-I	
treatment;	 c,	 P9/10	 SLC7A9	 exon	 12	 amplicon	 heteroduplex	 band	 (370bp)	 and	 a	 fragment	





Not	 all	 patients	 had	 their	 phenotype	 explained	 by	 causal	 mutations	 following	
investigation	 with	 the	 CEL-I	 endonuclease	 protocol.	 Therefore,	 patients	 who	 remained	
unsolved	had	all	exons	of	SLC3A1	and	SLC7A9	sequenced	by	Sanger	sequencing	following	PCR	
amplification.	 Four	 additional	 patients	 had	 also	 been	 recruited	 to	 this	 study,	 and	 were	
investigated	by	Sanger	sequencing	of	all	SLC3A1	and	SLC7A9	amplicons.		








Sanger	 sequencing	of	all	exonic	 regions	of	SLC3A1	 and	 SLC7A9.	Patients	28	and	29	were	not	
recruited	through	the	Freeman	Hospital,	but	were	siblings	recruited	to	the	study	at	 the	Rare	
Kidney	 Stone	 Consortium	 (RKSC)	 patient	 information	 day.	 They	 are	 the	 only	 two	 patients	
recruited	remotely,	and	the	only	two	related	patients	in	the	cohort.	They	were	discovered	to	
have	 homozygous	 R452W	 mutations	 in	 SLC3A1,	 solving	 their	 genotype	 (Table	 3.3).	 The	
segregation	analysis	of	this	mutation	was	investigated	and	is	reported	in	section	3.3.7.	Patients	













Patient	 Allele	1	 Allele	2	 Allele	1	 Allele	2	
28	 R452W	 		 	 	 2	 AA	 Y	
29	 R452W	 		 	 	 2	 AA	 Y	
30	 	 	 G105G/R	
c.614dup	
p.N206Efs*3	 2	 BB	 Y	
31	 	
	
	 G105G/R	 	 1	 B	 Y	
	
Table	 3.3:	 Pathogenic	 variants	 identified	 in	 Patients	 28-31	 of	 the	 cohort	 by	 Sanger	
Sequencing.	Heterozygous	missense	mutations	are	listed	with	both	the	wild-type	and	mutant	









Figure	 3.5:	 A	 novel	 SLC7A9	 base	 duplication	 identified	 in	 Patient	 31	 of	 the	 cohort.	 Sanger	
sequencing	results	of	SLC7A9	exon	5	in	Patient	31,	plus	the	wild-type	reference	sequence	from	
Patient	2,	shown	as	an	example.	Patient	31	had	a	heterozygous	insertion	of	an	adenosine	base,	























Boston,	MA.	This	was	because	they	were	 included	 in	the	report	by	Halbritter	et	al.	 (2014)	as	
part	of	a	cohort	of	272	genetically	unresolved	individuals	with	nephrolithiasis.	Once	identified,	
the	 detection	 of	mutations	 by	 the	 high-throughput	 NGS	 platform	was	 confirmed	 by	 Sanger	
sequencing.	 In	 the	published	study,	 the	 individuals	were	screened	 for	mutations	 in	30	genes	
known	 to	 be	 involved	 in	 nephrolithiasis.	 This	 included	 SLC3A1	 and	 SLC7A9	 (Table	 3.4)	







across	 30	 genes	 known	 to	 be	 involved	 in	 monogenic	 causes	 of	 nephrolithiasis	 (Table	 3.5).	
Through	NGS	of	Patients	32-44,	85%	had	 their	genotype	solved	 through	 the	 identification	of	
mutations	 in	 SLC3A1	 and	 SLC7A9	 (Table	 3.5).	 In	 the	 two	 unsolved	 patients,	 one	 was	
heterozygous	 for	 M467T	 in	 SLC3A1	 (Patient	 38)	 and	 in	 the	 second,	 no	 mutations	 were	
discovered	(Patient	35).	It	is	possible	that	these	patients	had	large	deletions	or	duplications	of	
whole	or	multiple	exons,	which	would	only	be	identified	through	a	quantitative	technique	such	
as	 MLPA.	 No	 pathogenic	 mutations	 were	 identified	 in	 the	 28	 other	 genes	 included	 in	 the	
investigation,	 supporting	 the	 hypothesis	 that	 only	 SLC3A1	 and	 SLC7A9	 are	 involved	 in	
cystinuria.	 However,	 SLC7A9	 mutations	 were	 identified	 in	 calcium	 phosphate	 and	 calcium	
oxalate-stone	forming	patients,	who	were	not	previously	thought	to	be	cystinuric	(Halbritter	et	
al.,	2014).	This	supports	the	hypothesis	that	a	cystine	nidus	in	the	filtrate	of	a	cystinuric	patient	






Gene	Symbol	 Accession	Number	 Disease	 Mode	
ADCY10/SAC	 NM_018417.4	 Idiopathic	hypercalciuria	 AD	
AGXT	 NM_000030.2	 Primary	hyperoxaluria	 AR	
APRT	 NM_000485.2	 APRT	deficiency	 AR	
ATP6V0A4	 NM_020632.2	 dRTA	 AR	
ATP6V1B1	 NM_001692.3	 dRTA	with	deafness	 AR	
CA2	 NM_000067.2	 Osteopetrosis	+dRTA	 AR	
CASR	 NM_001178065.1	 Hypocalcaemia	with	Bartter	Syndrome	 AD	
CLCN5	 NM_001127898.3	 Dent	disease	 XR	
CLCNKM	 NM_000085.4	 Bartter	Syndrome	 AR	
CLDN16	 NM_006580.3	 FHHNC	 AR	
CLDN19	 NM_001123395.1	 FHHNC	and	ocular	abnormalities	 AR	
CYP24A1	 NM_000782.4	 Infantile	hypercalcaemia	 AR	
FAM20A	 NM_017565.3	 Enamel-Renal	syndrome	 AR	
GRHPR	 NM_012203.1	 Primary	hyperoxaluria	 AR	
HNF4A	 NM_000457.4	 MODY	and	Fanconi	Syndrome	 AD	
HOGA1	 NM_138413.3	 Primary	hyperoxaluria	 AR	
HPRT1	 NM_000194.2	 Kelley-Seegmiller	syndrome	 XR	
KCNJ1	 NM_000220.4	 Bartter	syndrome	 AR	
OCRL	 NM_000276.3	 Lowe	syndrome	 XR	
SLC12A1	 NM_000338.2	 Bartter	syndrome	 AR	
SLC22A12	 NM_144585.3	 Renal	hypouricemia	(RHUC1)	 AD/AR	
SLC2A9	 NM_001001290.1	 Reanl	hypouricemia	(RHUC2)	 AD/AR	
SLC34A1	 NM_003052.4	 NPHLOP1	 AD/AR	
SLC34A3	 NM_001177316.1	 Hypophosphatemic	rickets	 AR	
SLC3A1	 NM_000341.3	 Cystinuria,	Type	A	 AR	
SLC4A1	 NM_000342.3	 dRTA	 AD/AR	
SLC7A9	 NM_014270.4	 Cystinuria,	Type	B	 AD/AR	
SLC9A3R1	 NM_004252.4	 NPHLOP2	 AD	
VDR	 NM_000376.2	 Idiopathic	hypercalciuria	 AD	
XDH	 NM_000379.3	 Xanthinuria	 AR	
Table	 3.4:	 The	 30	 genes	 involved	 in	 nephrolithiasis	 investigated	 by	 Next-Generation	
Sequencing	 in	 Patients	 32-44	 of	 the	 cohort.	 APRT,	 adenine	 phosphoribosyltransfease	
deficiency;	 dRTA,	 distal	 renal	 tubular	 acidosis;	 FHHNC,	 familial	 hypomagnesemia	 with	
hypercalciuria	 and	 nephrocalcinosis;	MODY,	maturity	 onset	 diabetes	 of	 the	 young;	NPHLOP,	





























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table	 3.6	 Summary	 of	 mutations	 identified	 in	 the	 current	 cohort	 through	 endonuclease	
analysis,	 Sanger	 sequencing	 and	 NGS.	 Exons	 of	 both	 SLC3A1	 and	 SLC7A9	 genes	 in	 which	
variants	 were	 identified	 are	 displayed	 in	 this	 table.	 Other	 exons	 have	 been	 omitted.	
Heterozygous	missense	mutations	 are	 indicted	 by	 the	 denotation	 of	 both	 alleles,	 or,	 in	 the	
case	 of	 synonymous	 coding	 SNPs,	 (het).	 Yellow,	 common	 SNPs;	 green,	 missense	 mutations	





To	 identify	 whether	 large	 deletions	 or	 duplications	 of	 whole	 exons	 in	 SLC3A1	 or	
SLC7A9	were	responsible	for	the	cystinuria	phenotype	in	the	unsolved	patients	of	the	current	





Of	 the	10	patient	samples	sent	 for	MLPA	sequencing,	6	patients	were	 found	to	have	







20%	were	genetically	“solved”	prior	 to	 this	protocol	 (Table	3.6).	Following	MLPA,	a	 further	6	
patients	were	solved	(80%).	Of	the	remaining	unsolved	patients,	1	had	one	identified	mutation	
















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































was	 desirable	 to	 perform	 segregation	 analysis	 on	 the	 mutations	 detected	 in	 our	 cohort.	






3.7).	 The	 patient	 was	 found	 to	 have	 M467M/T	 in	 exon	 8	 of	 SLC3A1	 and	 a	 heterozygous	
duplication	 of	 exons	 5-9	 in	 SLC3A1	 (Table	 3.6).	 Analysis	 of	 SLC3A1	 exon	 8	 in	 the	 samples	
obtained	from	the	relatives	of	this	patient	revealed	that	the	father	(Figure	3.6,	I.2)	and	sister	
(Figure	3.6,	 II.1)	 of	 Patient	 5	 (Figure	3.6,	 II.2)	were	both	heterozygous	 carriers	 of	M467M/T.	
The	mother	 carried	 the	 wild-type	 allele	 of	 exon	 8	 (Figure	 3.6,	 I.1).	 Unfortunately,	 we	 were	
unable	 to	 perform	MLPA	 analysis	 of	 SLC3A1	 in	 the	mother	 of	 Patient	 5.	 However,	we	must	
assume	that	the	patient	has	inherited	this	mutation	from	his	mother.	The	relatives	of	Patient	5	






genotype	 for	mutations	 R452W	 and	 the	 novel	 variant	 Y579D	 in	 exons	 8	 and	 10	 of	 SLC3A1,	
respectively	 (Figure	 3.7,	 II.2).	 It	 was	 discovered	 that	 the	 mother	 of	 Patient	 6	 was	 a	












Number	 Mutation	1	 Mutation	2	 Fig.	 ID	 Relationship	 SLC3A1	 SLC7A9	
5	 M467M/T	 Het	dup	5-9	 3.5	
I.1	 Mother	 --	 --	
I.2	 Father	 M467M/T	 --	
II.1	 Sister	 M465M/T	 --	
6	 R452R/W	 Y579Y/D	 3.6	
I.1	 Mother	 R452R/W	 --	
II.1	 Sister	 Y579Y/D	 --	
14	 M467M/T	 Het	dup	5-9		 3.7	
I.1	 Mother	 --	 --	
III.1	 Son	 --	 --	
25	 M465K	 		 3.8	
I.1	 Mother	 M465M/K	 --	
I.2	 Father	 M465M/K	 --	
II.3	 Sister	 M465K	 --	
III.1	 Daughter	 M465M/K	 --	
26	 M467M/T	 L416L/P	 3.9	 I.1	 Mother		 M467M/T	 --	
28,29	 R452W	 		 3.9	
I.1	 Mother	 R452R/W	 --	
I.2	 Father	 --	 --	
II.3	 Cousin	 M467M/T	 --	
	



















































































































































































Figure	 3.6:	 Segregation	 analysis	 of	 a	 mutation	 identified	 in	 Patient	 5.	 A,	 Pedigree	 of	 the	
obligate	heterozygote	 relatives	of	Patient	5	who	had	a	compound	heterozygous	genotype	of	
M467M/T	 and	 dup5-9	 in	 SLC3A1.	 The	 father	 (I.2)	 and	 sister	 (II.1)	 of	 Patient	 5	 were	
heterozygote	carriers	of	M467M/T;	B,	chromatographs	of	Sanger	sequencing	of	SLC3A1	exon	
8.	The	encoded	amino	acid	residues	are	indicated	above	their	respective	codons,	with	residue	





































































































































































































































































(Figure	 3.8).	 However,	 as	 the	 exon	 5-9	 duplication	 would	 be	 undetectable	 by	 Sanger	
sequencing,	 we	 must	 assume	 that	 both	 of	 the	 relatives	 carry	 this	 mutation,	 as	 obligate	
heterozygotes.	Further	investigation	by	MLPA	would	be	required	to	confirm	this.		
In	Patient	25	of	the	cohort	we	identified	a	homozygous	novel	SLC3A1	variant,	M465K	
(Figure	 3.9,	 II.2).	 We	 identified	 the	 same	 homozygous	 change	 in	 the	 sister	 of	 the	 proband	
(Figure	3.9,	II.3),	who	was	also	discovered	to	have	a	cystinuric	phenotype.	Upon	investigation,	
it	was	discovered	that	the	parents	of	the	siblings	were	third	cousins,	and	both	carried	M465K	
in	exon	8	of	SLC3A1	 	 (Figure	3.9).	The	daughter	of	Patient	25	 (Figure	3.9,	 III.1)	 inherited	one	





26,	 along	 with	 the	 heterozygous	 causal	 variant	 M467T	 (Figure	 3.10,	 II.1).	 We	 were	 able	 to	
obtain	 a	 gDNA	 sample	 from	 the	 mother	 of	 the	 patient	 who	 was	 a	 heterozygous	 carrier	 of	
M467T	(Figure	3.10,	I.1).	Neither	parent	has	a	history	of	cystinuria.	We	must	assume	that	the	
father	would	have	been	a	heterozygous	carrier	of	L416L/P.	These	data	support	the	hypothesis	
that	 L416P	 is	 a	 pathogenic	 mutation	 in	 SLC3A1,	 with	 an	 autosomal	 recessive	 inheritance	
pattern.		
Patients	 28	 and	29	 are	 a	 pair	 of	 siblings,	 recruited	 to	 this	 study	 at	 the	RKSC	patient	
information	day	at	 the	Royal	Free	Hospital,	 London	 in	December	2012.	Upon	 investigation	 it	
was	discovered	that	both	patients	were	homozygous	for	the	known	cystinuria	variant	R452W,	
in	exon	8	of	SLC3A1	 (Figure	311,	 II.1	and	 II.2).	 It	was	anticipated	that	both	parents	would	be	
carriers	 of	 the	 mutation.	 However	 it	 was	 discovered	 that	 only	 the	 mother	 (I.1)	 was	






I.2).	 Although	 the	 results	 of	 this	 segregation	 analysis	 are	 unclear,	 these	 data	 support	 the	
	 147	













































































































































heterozygote	 relatives	 of	 Patient	 14	 who	 had	 a	 compound	 heterozygous	 genotype	 of	
M467M/T	 and	 dup5-9	 in	 SLC3A1.	 The	mother	 (I.1)	 and	 sister	 (II.1)	 of	 Patient	 14	 carried	 the	
wild-type	allele	 in	exon	8;	B,	 chromatographs	of	Sanger	 sequencing	of	SLC3A1	 exon	8	 in	 the	
region	of	the	M467T	missense	mutation.	The	encoded	amino	acid	residues	are	indicated	above	
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heterozygote	 relatives	 of	 Patient	 25	 who	 had	 the	 novel	 homozygous	 mutation	 M465K	 in	
SLC3A1.	 The	mother	 (I.1)	 and	 father	 (II.2)	 of	 Patient	 25	were	 both	 heterozygous	 carriers	 of	
M465M/K,	 as	 was	 the	 daughter	 of	 the	 proband	 (III.1).	 The	 sister	 of	 Patient	 25	 had	 also	
inherited	both	mutant	alleles	and	had	a	homozygous	genotype	of	M465K;	B,	chromatographs	
of	 Sanger	 sequencing	of	 SLC3A1	exon	8	 in	 the	 region	of	 the	M465K	missense	mutation.	The	
encoded	 amino	 acid	 residues	 are	 indicated	 above	 their	 respective	 codons,	 with	 residue	
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the	 obligate	 heterozygote	 relatives	 of	 Patients	 28	 and	 29	 had	 the	 homozygous	 R452W	
mutation	in	SLC3A1.	The	mother	(I.1)	of	the	siblings	was	a	heterozygous	carrier	of	R452W.	The	
paternal	 cousin	 of	 the	 siblings	 was	 a	 carrier	 of	 the	 heterozygous	 mutation	 M467M/T;	 B,	
chromatographs	 of	 Sanger	 sequencing	 of	 SLC3A1	 exon	 8	 in	 the	 region	 of	 the	 R452W	 and	
M467T	 missense	 mutations.	 The	 encoded	 amino	 acid	 residues	 are	 indicated	 above	 their	









	 In	 the	 current	 study,	 single	 nucleotide	 polymorphisms	 (SNPs)	 were	 detected	 in	 our	





homozygous	 for	 the	 same	 SNP,	 this	 would	 not	 lead	 to	 the	 cleavage	 of	 DNA	 following	 the	
endonuclease	treatment.	Due	to	this,	it	is	possible	that	not	all	SNPs	in	Patients	1-16	and	17-26	
were	 recorded	 (Table	 3.2).	 However,	 as	 not	 all	 patients	 in	 the	 cohort	 were	 genotypically	





as	modifying	 factors	 on	 the	 penetrance	 of	 disease	 (Albers	 et	 al.,	 1999).	 The	 involvement	 of	




sequence,	 they	 were	 considered	 non-pathogenic	 and	 unable	 to	 confer	 a	 phenotype	 to	 the	
folding	 or	 function	 of	 the	 gene	 product	 (Sauna	 &	 Kimchi-Sarfaty,	 2011).	 However,	 recent	
advances	in	our	understanding	of	protein	translation	have	discovered	several	mechanisms	by	
which	 sSNPs	 can	 confer	 a	 disease	 phenotype	 (Sauna	 &	 Kimchi-Sarfaty,	 2011).	 The	
phenomenon	of	codon	usage	bias	 is	widely	accepted.	However,	 the	reasons	 for	evolutionary	
pressure	upon	synonymous	codons	have	remained	poorly	understood	(Plotkin	&	Kudla,	2011).	
The	 advent	 of	 Genome-Wide	 Association	 Studies	 (GWAS),	 which	 identify	 causal	 variants	 in	















rs3738985	 G38G	 SLC3A1	 35.17%	 41%	
rs146630359	 S77S	 SLC3A1	 0.27%	 9%	
rs556841667	 c.1137+1T>C	 SLC3A1	 11.18%	 6%	
rs61179824	 c.1137+2_delT	 SLC3A1	 --	 6%	
rs3738984	 c.1331+7C>T	 SLC3A1	 27.10%	 35%	
rs140821819	 N466N	 SLC3A1	 0.23%	 1%	
rs698761	 M618I	 SLC3A1	 59.60%	 46%	
rs8886	 c.*132T>C	 SLC3A1	 57.55%	 22%	
rs12150904	 c.236+21T>G	 SLC7A9	 30.48%	 7%	
rs35170371	 S133S	 SLC7A9	 19.40%	 6%	
rs12150889	 V142A	 SLC7A9	 30.98%	 15%	
rs12150890	 C137C	 SLC7A9	 10.60%	 7%	
rs6510300	 c.478+9T>C	 SLC7A9	 11.30%	 7%	
rs1007160	 L233M	 SLC7A9	 29.71%	 17%	
rs1007161	 L229L	 SLC7A9	 29.73%	 15%	
rs11084673	 S169S	 SLC7A9	 30.05%	 24%	
rs11084671	 c.603+25T>C	 SLC7A9	 30.04%	 17%	
rs11084672	 c.603+11G>A	 SLC7A9	 10.60%	 13%	
rs2287880	 c.977+50A>G	 SLC7A9	 12.70%	 9%	
rs34347941	 V455V	 SLC7A9	 2.30%	 6%	
rs61730903	 A324A	 SLC7A9	 1.20%	 2%	

















of	domain	C	 (Figure	3.12).	 The	putative	effect	of	 these	amino	acid	 substitutions	based	upon	
their	location	in	the	protein	structure	is	discussed	in	section	5.4.		




capacity	 of	 the	 transport	 system	 to	bind	 amino	acid	 substrates	 and	 translocate	 them	across	
the	apical	membrane	of	the	epithelium	(Font	et	al.,	2001).	From	the	homology	model,	it	can	be	
seen	 than	 3/5	 of	 the	 mutations	 are	 predicted	 to	 be	 located	 in	 the	 “core”	 transmembrane	
domains:	 1,	 3,	 6,	 and	 8	 (Figure	 3.13).	 The	 functional	 characterisation	 of	 these	mutations	 on	
System	b0,+	is	outside	of	 the	scope	of	 this	 investigation	due	 to	 the	difficulties	 in	expressing	a	
functional	 light	 chain	 in	 Xenopus	 oocytes,	 discussed	 in	 Chapter	 4	 (Pfeiffer	 et	 al.,	 1999a).	
However,	we	can	predict	the	effects	of	these	mutations	based	upon	our	knowledge	of	critical	







cystinuria	 mutations.	 Top	 view	 of	 the	 rBAT	 extracellular	 domain	model	 based	 on	 oligo-1,6-
glucoside	 from	B.	 cereus	 (PDB	 code	 1UOK)	 to	 show	 the	 putative	 location	 of	 the	mutations,	
denoted	by	black	arrows.	The	mutations	highlighted	are	those	investigated	in	this	study.	This	
includes	the	common	SNP,	M618I;	pathogenic	mutation,	M467T;	and	the	four	novel	mutations	































































































E.	 coli	 arginine:agmatine	 antiporter	 (AdiC,	 PDB	 code	 3L1L;	 Gao	 et	 al.,	 2010).	 A,	 Homology	
model	of	all	12	transmembrane	domains	(TMD)	of	b0,+AT;	B,	homology	model	of	the	core	TMD	











cohorts	 of	 cystinuria	 patients.	 The	 first	 reason	 accounting	 for	 the	 low	 detection	 rate	 in	 the	
early	literature	is	that	whilst	SLC3A1	was	identified	as	a	gene	involved	in	the	pathogenesis	of	
cystinuria	in	1994,	it	was	1999	before	the	involvement	of	SLC7A9	was	confirmed	(Feliubadalo	
et	 al.,	 1999).	 Of	 the	 24	 reports	 of	 cystinuria	 cohort	 data	 listed	 in	 the	 introduction	 to	 this	
chapter,	the	mean	detection	rate	of	mutations	in	those	published	prior	to	1999	was	54%,	rising	
to	79.5%	in	those	published	post-identification	of	SLC7A9.	Additionally,	the	methods	employed	
in	 the	 detection	 of	 mutations	 have	 likely	 played	 a	 major	 role	 in	 the	 inability	 to	 solve	 the	
genotype	of	all	patients.		
Of	 24	 reports	 of	 cohort	 data	 in	 cystinuria	 patients,	 18	 employed	 single	 strand	
conformation	polymorphism	(SSCP)	analysis	to	detect	mutations	in	SLC3A1	and	SLC7A9.	SSCP	
was	first	reported	by	Orita	et	al.	(1989)	as	a	way	of	rapidly	screening	for	novel	point	mutations	
in	 a	DNA	 sequence.	 The	 SSCP	 technique	 relies	 on	 differences	 in	 the	 conformation	of	 single-
stranded	DNA	or	RNA,	which	occur	upon	the	introduction	of	a	sequence	variant.	Following	PCR	
amplification	 of	 wild-type	 DNA,	 the	 strands	 are	 separated	 and	 denatured,	 forming	 a	
characteristic	 single-stranded	 conformation.	 When	 mutated	 samples	 are	 resolved	 by	
electrophoresis	against	wild-type	control	strands,	a	shift	 in	band	size	can	be	detected	due	to	
the	 different	 migration	 distances	 of	 mutated	 strands	 (Orita	 et	 al.,	 1989;	 Grompe,	 1993).	
Following	the	identification	of	a	shift	in	band	size,	samples	can	be	sent	for	Sanger	sequencing	
to	identify	the	causal	mutation.	This	technique	became	the	most	widely-employed	method	of	
mutation	detection	 in	 cystinuric	 cohorts	 for	 over	 a	 decade,	 due,	 in	 part,	 to	 the	 high	 cost	 of	
Sanger	sequencing	 (Grompe,	1993).	 	Through	the	 identification	of	mutated	DNA	by	SSCP	the	
need	for	full	Sanger	sequencing	of	the	entire	gene	in	each	patient	was	eliminated.	The	method	
was	 also	 deemed	 to	 be	 simple	 and	 sensitive,	 whilst	 allowing	 the	 simultaneous	 analysis	 of	
multiple	 samples.	 Michaud	 et	 al.	 (1992)	 measured	 a	 70%	 detection	 rate	 of	 known	 point	
mutations	in	200bp	fragments	of	the	ornithine	amino-transferase	gene	by	SSCP.	The	efficacy	of	
SSCP	on	detecting	 known	SLC3A1	 variants	was	 investigated	by	Giannattasio	 et	 al.	 (1995).	Of	
the	 mutations	 investigated	 (M467T,	 M467K,	 T652R,	 P615T	 and	 L678P),	 4	 out	 of	 5	 were	
identified	 through	 SSCP.	 However,	 it	 was	 not	 possible	 to	 detect	 missense	 mutation	 L678P	
	 163	
using	 this	 technique	 (Giannattasio	 et	 al.,	 1995).	 The	 failure	 to	 detect	 all	 SLC3A1	 mutations	
using	the	SSCP	technique	could	account	for	some	of	the	missing	heredity	in	cystinuria	cohorts.		
Around	the	same	time	of	the	development	of	this	technique,	the	use	of	heteroduplex	
analysis	 to	 detect	 DNA	 mutations	 also	 emerged.	 This	 technique	 initially	 relied	 upon	 the	
formation	 of	 heteroduplexes	 between	 radiolabelled	 wild-type	 RNA	 “riboprobe”	 and	 the	
sample	 mutant	 DNA	 being	 investigated	 (Grompe,	 1993).	 Following	 DNA-RNA	 heteroduplex	
formation,	 samples	 are	 treated	with	RNase	A,	which	 cleaves	 the	 single-stranded	RNA	at	 the	
point	 of	 heteroduplex	 base	 mismatching	 (Gibbs	 &	 Caskey,	 1987).	 A	 mutation	 detection	
sensitivity	 of	 80-90%	was	 reported	 through	 the	 use	 of	 the	 heteroduplex	mismatch	 protocol	
(White	 et	 al.,	 1992).	 In	 the	 current	 study,	 we	 used	 a	 CEL-I	 endonuclease	 isolated	 from	 raw	
















large	 genomic	 rearrangements	 such	 as	whole	 exon	 duplications,	which	 are	 undetectable	 by	
this	technique.		
Chillarón	et	al.	 (2010)	employed	a	cohort	of	175	cystinuric	patients	and	 their	known	
heterozygous	 relatives	 in	 order	 to	 attempt	 to	 establish	 the	 inheritance	 pattern	 of	 SLC7A9	




	 Due	to	this	missing	heredity	 in	cystinuria,	 the	search	for	other	gene	 involvement	has	
been	 attempted.	 Linkage	 analysis	 in	 cystinuric	 patients	 only	 maps	 the	 locations	 of	 gene	
	 164	
involvement	 to	 2p21	 and	 19q13.11,	 the	 locations	 of	 SLC3A1	 and	 SLC7A9,	 respectively.	 This	
ignited	 the	 search	 for	 other	 solute	 carrier	 genes	 at	 these	 locations.	 Two	 were	 identified:	
SLC7A10,	 encoding	 Asc-1,	 a	 high-affinity	 serine	 transporter;	 and	 SLC1A5,	 encoding	 ASCT2,	









mutations	 in	 SLC3A1	 and	 SLC7A9	 (Table	 3.5).	 Of	 these	 13	 patients,	 11	 had	 their	 genotype	
“solved”	 using	 this	 protocol	 (Table	 3.5).	 Additionally,	 using	 the	 high	 throughput	 assay,	 they	
were	 investigated	 in	 28	 other	 genes	 known	 to	 be	 involved	 in	 nephrolithiasis	 or	
nephrocalcinosis	(Halbritter	et	al.,	2014).	No	causal	variants	were	identified	in	any	of	the	other	






2010).	 Bisceglia	 et	 al.	 (2010)	 identified	 large	 deletions	 or	 duplications	 accounted	 for	 11%	of	
causal	 alleles	 in	 their	 cohort.	 Using	 a	 combination	 of	 Sanger	 sequencing	 and	 MLPA,	 the	
cystinuria	 phenotype	 of	 88%	 of	 patients	 was	 genetically	 solved.	 However,	 7/172	 (4%)	 of	
patients	still	had	no	mutant	alleles	identified	(Bisceglia	et	al.,	2010).	Subsequent	studies	have	
emerged	 that	 have	 used	 MLPA	 to	 detect	 these	 large	 genomic	 rearrangements	 in	 patient	
cohorts	(Rhodes	et	al.,	2015;	Wong	et	al.,	2015).	In	the	current	study,	patients	were	classified	
as	 “solved”	 following	 the	 identification	 of	 two	 SLC3A1	 mutations	 (Type	 AA),	 or	 one	 SLC7A9	
mutation	(Type	B).	It	has	been	identified	previously	that	the	duplication	of	exons	5-9	in	SLC3A1	
can	 have	 a	 variable	 penetrance	 (Font-Llitjos	 et	 al.,	 2005).	 If	 we	 assume	 that	 heterozygote	
carriers	 of	 this	 mutation	 are,	 therefore,	 genetically	 solved,	 83%	 of	 causal	 mutations	 were	




	 To	 date,	 280	 causal	 cystinuria	 variants	 have	 been	 reported	 in	 SLC3A1	 and	 SLC7A9	
(Stenson	 et	 al.,	 2014).	 This	 includes	 missense/nonsense	 mutations,	 splicing	 variants,	 small	












found	 the	 most	 common	 SLC3A1	 mutations	 in	 their	 UK	 cohort	 to	 be	 M467T	 (25%)	 and	 a	
duplication	of	exons	5-9	 (27%).	The	 same	 result	was	 identified	by	Rhodes	et	al.	 (2015),	with	
mutant	allele	frequencies	of	23%	and	24%,	respectively.	The	duplication	of	exons	5-9	in	SLC3A1	
has	 a	 lower	 frequency	 worldwide	 (5%),	 with	 German	 patients	 carrying	 the	 duplication	 at	 a	
similar	 rate	 to	 that	 detected	 in	 the	UK	 cohorts	 (28%)	 (Chillarón	 et	 al.,	 2010).	 In	 the	 current	
study,	the	most	common	causal	SLC3A1	variant	was	M467T	(33%),	followed	by	the	duplication	
of	 exons	 5-9	 (19%).	 However,	 not	 all	 patients	 were	 investigated	 using	 MLPA	 (Table	 3.6).	
Amongst	 the	11	patients	 that	were	 analysed	by	 the	quantitative	method,	 the	duplication	of	




c.614dupA	 (20%),	 which	 leads	 to	 a	 frame	 shift,	 causing	 the	 N260E	missense	mutation,	 and	





















507	 to	 be	 encoded	 by	 ATT,	 rather	 than	 the	 wild-type	 ATC	 (Bartoszewski	 et	 al.,	 2010).	
Bartoszewski	 et	 al.	 (2010)	 used	 a	 biochemical	mRNA	 folding	 assay	 to	 demonstrate	 that	 the	





these	 mRNAs	 in	 HeLa	 cells,	 it	 was	 determined	 that	 the	 alteration	 in	 folding	 significantly	
reduced	 (p<0.05)	 the	 rate	 of	 translation	 of	 ΔF508-CFTR,	measured	 through	 incorporation	 of	
[35S]methionine	 into	 the	 translated	 protein,	 compared	 to	 the	wild-type	 channel.	 The	 rate	 of	
translation	 of	 ΔF508-Ile507ATC-CFTR	 was	 not	 significantly	 different	 from	 the	 wild-type	
(p>0.05)	 (Bartoszewski	 et	 al.,	 2010).	 Previous	 studies	 had	 shown	 that	 levels	 of	 ΔF508-CFTR	
expression	increases	significantly	when	expressed	in	HeLa	cells	incubated	at	low	temperatures	
(27°C)	 due	 to	 a	 proposed	 inhibition	 of	 the	 ERAD	 pathway	 (Jurkuvenaite	 et	 al.,	 2010).	
Interestingly,	 when	 the	 temperature-dependent	 release	 of	 ΔF508-Ile507ATC-CFTR	 was	






Another	 transport	 protein	 in	which	 a	 sSNP	has	been	 shown	 to	 affect	 function	 is	 the	
ATP-Binding	Cassette	(ABC)	transporter,	ABCB1.	A	sSNP	in	the	MDR1	gene	has	been	shown	to	
affect	 substrate	 specificity	 of	 the	 P-glycoprotein	 (ABCB1)	 transporter	 (Kimchi-Sarfaty	 et	 al.,	
	 167	
2007).	It	was	hypothesised	that	the	C>T	base	change	led	to	the	presence	of	a	rare	codon,	and	
increased	the	time	taken	for	 translation,	affecting	the	co-translational	 folding	of	 the	protein,	
and	the	extent	of	stabilisation	between	non-sequential	areas	of	the	polypeptide	chain	(Kimchi-
Sarfaty	et	al.,	2007;	Tsai	et	al.,	2008).		
Although	 the	 detection	 of	 common	 SNPs	 was	 not	 a	 primary	 aim	 of	 this	 study,	 the	









cystinuric	 cohort	 data	 considers	 the	 frequency	 of	 SNP	 detection.	 Schmidt	 et	 al.	 (2002)	
identified	 a	 statistical	 association	 of	 SLC7A9	 SNPs	 L233M	 and	 L229L	 with	 cystine	 stone	
formation.	These	SNPs	were	both	identified	in	patients	of	the	current	cohort,	at	frequencies	of	
17%,	and	15%,	respectively	(Table	3.9).	This	was	lower	than	the	rates	of	these	SNP	reported	in	
the	 ExAC	 database	 (29.7%).	 However,	 they	 showed	 that	 these	 two	 SNP	 are	 in	 linkage	
disequilibrium	with	each	other,	and	may	also	be	in	disequilibrium	with	causal	variants,	which	
would	 explain	 the	 statistical	 association	 (Schmidt	 et	 al.,	 2002).	 Despite	 this,	 the	 failure	 to	





cystinuria	 cohorts	 (Font	 et	 al.,	 2001;	 Dello	 Strologo	 et	 al.,	 2002;	 Font-Llitjos	 et	 al.,	 2005;	
Rhodes	 et	 al.,	 2015;	Wong	 et	 al.,	 2015).	 The	 traditional	 classifications	 of	 “Type-I”	 and	 “non	
Type-I”	 cystinuria	 was	 based	 upon	 the	 finding	 that	 some	 heterozygote	 carriers	 of	 SLC7A9	
mutations	presented	with	a	dibasic	aminoaciduria	(Rosenberg	et	al.,	1966).	Harris	et	al.	(1955)	
screened	the	relatives	of	cystinuric	patients	and	detected	that	some	heterozygotes,	although	







based	 upon	 the	 genotype	 of	 the	 patient	 (Dello	 Strologo	 et	 al.,	 2002).	 In	 the	 modern	
classification	 system,	 type	 “A”	 patients	 carry	 mutations	 in	 SLC3A1,	 and	 type	 “B”	 have	
mutations	 in	 SLC7A9.	 An	 individual	 can,	 therefore,	 be	 type	 AA,	 AB,	 BB,	 or	 B	 (Gucev	 et	 al.,	
2011).	 It	 was	 initially	 thought	 that	 Type	 A	 mutations	 led	 to	 a	 “type-I”	 phenotype,	 being	
inherited	 in	 an	 autosomal	 recessive	 manner,	 with	 Type	 B	 mutations	 being	 dominant	 with	
variable	penetrance	(Dello	Strologo	et	al.,	2002).	 In	a	cohort	of	162	cystinuric	patients,	Font-
Llitjos	 et	 al.	 (2005)	 discovered	 that	 the	 majority	 of	 “type	 A”	 alleles	 segregated	 with	 the	
traditional	 “type-I”	 phenotype	 (recessive)	 and	 “type	 B”	 with	mainly	 “non	 type-I”	 (dominant	
inheritance).	However,	Dello	Strologo	et	al.	(2002)	found	that	14%	of	patients	with	a	mutation	
in	SLC7A9,	had	an	amino	acid	excretion	profile	identical	to	that	of	the	“type-I”	individuals,	with	






of	 a	 UK	 cohort	 by	 Rhodes	 et	 al.	 (2015)	 identified	 that	 subgroups	 of	 patients	 who	 have	 the	
same	 genotype,	 including	 pairs	 of	 siblings,	 show	 great	 diversity	 in	 clinical	 presentation,	 and	
progression	of	the	disease.	
	 Attempts	to	relate	genotype	to	phenotype	in	cystinuria	have	been	inconclusive.	Dello	




study	 by	Wong	et	 al.	 (2015),	 supported	 the	 findings	 that	 there	was	 no	 difference	 in	 clinical	
presentation	 between	 Type	 A	 or	 Type	 B	 patients.	 However,	 it	 was	 indicated	 that	 Type	 AB	
patients	presented	with	 later	onset	of	disease	 (mean	47y)	compared	to	Type	AA	 (21y)	or	BB	
(23.5y).	 However,	 Type	 AB	 cystinuria	 is	 rarely	 reported	 in	 the	 literature.	 This	 genotype	 has	
been	reported	with	an	average	rate	of	2.7%	in	cohort	studies	(Font-Llitjos	et	al.,	2005;	Rhodes	
et	al.,	2015;	Wong	et	al.,	2015).	Despite	this,	 the	frequency	of	Type	A	and	Type	B	patients	 is	
equally	 distributed	 (Dello	 Strologo	 et	 al.,	 2002).	 In	 the	 current	 study,	 no	 patients	 were	
identified	 as	 being	 Type	 AB	 (Table	 3.6).	 Wong	 et	 al.	 (2015)	 divided	 Type	 A	 patients	 into	





and	ornithine	were	significantly	greater	 than	 the	control	group,	and	 those	carrying	missense	
mutations	 (p<0.0001)	 (Wong	 et	 al.,	 2015).	Due	 to	 the	diversity	 in	 the	 clinical	 progression	of	
cystinuria,	even	within	 relatives	 carrying	 the	 same	genotype,	 the	consideration	of	genotype-
phenotype	correlation	was	outside	of	the	scope	of	this	report.		
In	 this	Chapter	we	have	 investigated	a	 cohort	of	 cystinuria	patients	 for	mutations	 in	




scale	 investigations	 using	 a	 combination	 of	 Sanger	 sequencing	 and	 MLPA	 (Bisceglia	 et	 al.,	
2010).	We	have	shown	through	analysis	of	obligate	heterozygote	 relatives	of	 the	patients	of	
our	 cohort,	 that	 the	SLC3A1	mutations	 show	autosomal	 recessive	penetrance	of	 phenotype.	
Moreover,	 we	 have	 identified	 4	 novel	 missense	 mutations	 in	 SLC3A1.	 The	 aims	 of	 this	
investigation	will	focus	upon	the	expression	of	rBAT	and	our	novel	mutant	proteins	in	Xenopus	
laevis	 oocytes	 to	 try	 and	 identify	 the	 effect	 that	 these	 mutations	 have	 on	 the	 proteins	 of	
System	b0,+.	We	have	shown	from	the	clinical	data	in	our	cohort,	that	despite	treatment	with	a	
range	of	CBTD,	with	a	spectrum	of	severe	adverse	effects,	many	cystinuric	patients	have	poor	
control	 over	 their	 disease.	 The	 identification	 of	 novel	 therapeutic	 targets	 through	 further	




• Mutations	 identified	 in	 SLC3A1	 appear	 to	 have	 a	 recessive	 mode	 of	
inheritance.	









For	 successful	 reabsorption	of	hydrophilic	molecules	 from	the	 renal	proximal	 tubule,	
the	 presence	 of	 a	wide	 range	 of	 transport	 proteins	 in	 the	 apical	 phospholipid	membrane	 is	
required	(see	Chapter	1).	These	transport	systems	have	distinct	substrate	specificities	and	ion-
coupling	 mechanisms	 that	 permit	 selective	 reabsorption	 of	 molecules	 into	 the	 renal	
epithelium,	and,	ultimately,	the	blood.		
One	 proximal	 tubular	 transport	 system,	 System	 b0,+,	 is	 an	 obligatory	 exchanger	 of	




β-carbon,	 thus	 displaying	 greater	 substrate	 selectivity	 than	 the	Na+-dependent	 transport	 via	
System	B0,+.		
	 The	 identification	 of	 System	 b0,+	 and	 its	 proposed	 involvement	 in	 the	 renal	 stone	
disease,	 cystinuria	 (see	 Chapter	 1),	 led	 to	 a	 breakthrough	 in	 the	 early	 1990s,	 when	 three	
groups	 independently	 identified	 cDNA	 clones	 that	 induced	 System	 b0,+-like	 transport	 by	
functional	 expression	 cloning	 in	 Xenopus	 oocytes	 (Gurdon	 et	 al.,	 1971).	 The	 cloned	 cDNAs	
were	 isolated	 from	 tissues	 of	 rabbit	 (Bertran	 et	 al.,	 1992b),	 rat	 (Tate	 et	 al.,	 1992;	Wells	 &	
Hediger,	1992),	and	human	(Bertran	et	al.,	1993;	Lee	et	al.,	1993)	kidney	and	small	 intestine.	
All	 three	 research	 groups	 identified	 that	 expression	 of	 these	 proteins	 in	 oocytes	 induced	
transport	 function	 with	 the	 same	 selectivity	 profile	 as	 that	 reported	 by	 Van	 Winkle	 (Van	
Winkle	 et	 al.,	 1988).	 The	 hypothesis	 that	 the	 isolated	 cDNAs	 encoded	 a	 Type-II	 membrane	
glycoprotein	with	only	one	membrane-spanning	domain	(see	Chapter	1)	led	to	the	belief	that	
this	protein	served	as	a	“modulator”	of	transport,	rather	than	a	transport	pore	(Bertran	et	al.,	
1992b;	 Wells	 &	 Hediger,	 1992;	 Lee	 et	 al.,	 1993).	 The	 protein,	 named	 D2,	 NBAT,	 or	 rBAT	
(related	 to	 b0,+AT	 amino	 acid	 transporter)	 was	 predicted	 to	 induce	 transport	 through	
association	 with	 an	 endogenous	 protein.	 Hence,	 the	 measured	 transport	 activity,	 and	
conferred	substrate	specificity,	was	that	of	the	Xenopus	protein	(Wells	&	Hediger,	1992;	Wang	
&	Tate,	1995).		
All	 three	 research	 groups	 reported	 high-affinity	 transport	 of	 cystine,	 dibasic,	 and	
neutral	 amino	 acids	with	measured	 Km	 values	 in	 the	 1-100μM	 range	 (Bertran	 et	 al.,	 1992b;	
Tate	 et	 al.,	 1992;	Wells	 &	 Hediger,	 1992).	 The	 uptake	 of	 5μM	 cystine,	 leucine,	 alanine	 and	
arginine	was	 inhibited	by	 the	presence	of	 5mM	unlabelled	 competitors	 in	 the	order:	 dibasic	
amino	acids	>	leucine	>	phenylalanine	>	histidine	>	unbulky	amino	acids	or	those	branched	at	
	 171	
the	 β-carbon	 >	 α-AIB	 >	 proline	 >	 MeAIB	 (Bertran	 et	 al.,	 1992b).	 No	 measurable	 transport	
activity	was	observed	for	small	or	acidic	amino	acids,	proline	or	α-AIB	(Bertran	et	al.,	1992b).	




b0,+	 substrate	 specificity	 have	 also	 been	 made	 in	 human	 Caco-2	 cells,	 which	 endogenously	
express	both	subunits,	and	COS-7	cells	stably	transfected	with	human	rBAT	and	rat	b0,+AT	(Van	




interest.	 The	polypeptide	 serves	 as	 an	 antigen	 to	 an	 antibody	 raised	 against	 the	 amino	 acid	
sequence.	 This	 can	 allow	 the	 determination	 of	 protein	 size	 and	 abundance,	 trafficking	 and	
cellular	 localisation,	 and	 the	 post-translational	modification	 state	 of	 proteins	 expressed	 in	 a	
wide	 range	 of	 biological	 systems	 (Maue,	 2007).	 The	 FLAG	 epitope	 (DYKDDDDK)	 was	 first	
designed	by	Hopp	et	al.	(1988).	The	polypeptide	sequence	was	designed	so	as	not	to	interfere	
with	 folding	 of	 the	 native	 protein,	 and	 to	 have	 a	 high	 degree	 of	 hydrophilicity	 for	maximal	
exposure	 of	 the	 surface	 and	 ligand	 interaction	 (Hopp	 et	 al.,	 1988;	 Einhauer	 &	 Jungbauer,	
2001).	 In	 1960	 it	 was	 reported	 that	 the	 major	 factor	 in	 antibody-antigen	 interaction	 is	 the	






The	 objectives	 of	 the	 work	 described	 in	 this	 chapter	 were	 to	 induce	 System	 b0,+	
transport	activity	 in	Xenopus	oocytes	by	heterologous	expression	of	 the	human	rBAT	protein	
and	 its	 association	 with	 the	 endogenous	 Xenopus	 light	 chain;	 and	 to	 optimise	 a	 range	 of	





Radiolabelled	 amino	 acid	 uptake	 was	 performed	 in	 Xenopus	 laevis	 oocytes	 as	
described	 in	 Chapter	 2.	 Substrate	 specificity	 and	 affinity	 were	 determined	 by	 uptake	 and	
competition	experiments.	
A	multiple	 sequence	alignment	of	 the	human	and	Xenopus	 b0,+AT	protein	 sequences	
was	 created	 using	 ClustalW	 (http://www.ebi.ac.uk/Tools/msa/clustalw2/).	 Nucleotide	
sequences	 were	 taken	 from	 the	 National	 Centre	 for	 Biotechnology	 Information	 website	
(http://www.ncbi.nlm.nih.gov/).	
4.3	Results	
The	 aim	 of	 the	 investigations	 reported	 in	 this	 chapter	 was	 to	 establish	 a	 range	 of	
techniques	 to	 accurately	 measure	 the	 expression	 of	 rBAT	 protein.	 This	 would	 enable	
subsequent	 characterisation	 of	 mutant	 rBAT	 expression,	 informed	 by	 the	 data	 reported	 in	
Chapter	 3.	 Throughout	 this	 study,	 the	 functional	 expression	 of	 rBAT	 is	 measured	 indirectly	






the	protein	 (see	Chapter	2).	 It	was	 important	 to	establish	 that	 the	epitope	did	not	 interfere	
with	protein	folding	and	subsequent	function	or	expression.	In	a	single	experiment,	uptake	of	a	
prototypical	 System	 b0,+	 substrate,	 [3H]arginine	 (10μM,	 pH	 7.4,	 Na+-free),	 was	 increased	 by	
approximately	20-fold	in	oocytes	expressing	human	rBAT	compared	to	water-injected	control	
oocytes	 (Figure	 4.1).	 No	 significant	 difference	 in	 uptake	 levels	 (p>0.05)	 was	 observed	 in	
oocytes	expressing	rBATF	compared	to	untagged	rBAT.	Uptake	of	 [3H]arginine	via	System	b0,+	







Figure	 4.1:	Uptake	 of	 [3H]arginine	 into	Xenopus	oocytes	 expressing	 untagged	 rBAT	 and	 C-
terminally	FLAG-tagged	rBAT	(rBATF).	[3H]Arginine	(10μM)	uptake	into	water-injected	(control,	





























































uptake	 was	 measured	 via	 the	 induced	 b0,+	 transport	 over	 40min	 (Figure	 4.2).	 In	 this	 single	
experiment	(n=8-10),	the	fold	uptake	into	cRNA-injected	oocytes	above	water-injected	control	
oocytes	was	 low	 (1.6-3.7).	 The	measured	 levels	of	background	 [3H]arginine	uptake	 (14.1±0.5	
pmol.oocyte-1.(40min)-1)	 were	 more	 than	 double	 the	 mean	 control	 values	 observed	 in	 10	
different	batches	of	oocytes	over	 a	 10-month	period	 (6.1±0.4	pmol.oocyte-1.(40min)-1,	 n=97)	
(Figure	4.3).	This	is	indicative	of	poor	oocyte	quality	in	this	single	experiment	and	reflects	the	
variability	 in	 results	 sometimes	 observed	 during	 the	 course	 of	 this	 study.	 Despite	 this,	 an	
increase	in	uptake	of	[3H]arginine	was	observed	with	an	increase	in	the	quantity	of	rBAT	cRNA	
injected.	There	was	no	 further	 increase	 in	uptake	when	amounts	of	cRNA	greater	 than	10ng	
(0.2μg.μl-1)	 were	 injected	 (Figure	 4.2).	 As	 a	 result	 of	 this	 experiment,	 10ng	 rBAT	 cRNA	 was	
routinely	injected	into	oocytes	to	provide	maximal	uptake	of	[3H]arginine	via	System	b0,+.	
To	 determine	 the	 extent	 of	 the	 inter-experiment	 variability	 in	 protein	 expression,	
uptake	of	 [3H]arginine	 in	oocytes	 injected	with	 rBATF	 cRNA	 (10ng)	was	measured	over	 a	10-
month	 period,	 2-3	 days	 post-injection	 (May	 2012	 -	 February	 2013).	 The	 mean	 uptake	 of	
[3H]arginine	 (33.6±3.1	 pmol.oocyte-1(40min)-1)	 was	 5-fold	 greater	 than	 in	 water-injected	
control	oocytes	(Figure	4.3).	Over	this	period,	uptake	in	water-injected	control	oocytes	ranged	
from	2.5±0.5	–	14.1±0.5	pmol.oocyte-1.(40min)-1	 and	 	 from	20.3±3.3	–	41.8±4.4	pmol.oocyte-
1.(40min)-1	 in	 oocytes	 injected	 with	 10ng	 rBATF	 cRNA.	 These	 data	 indicate	 that	 through	
injection	of	10ng	rBATF	cRNA,	it	is	possible	to	consistently	induce	significant	(p<0.05)	uptake	of	






Figure	 4.2:	 An	 increase	 in	 [3H]arginine	 uptake	 into	Xenopus	oocytes	 is	 observed	 upon	
injection	 of	 increasing	 amounts	 of	 rBAT	 cRNA.	 [3H]Arginine	 (10μM)	 uptake	 into	 water-
injected	 (control,	 open	 bar),	 or	 rBAT-expressing	 (1-50ng,	 black	 bars)	 Xenopus	 oocytes	
measured	 over	 40min	 (pH	 7.4,	 Na+-free).	 Data	 are	 mean±SEM	 (n=8-10).	 ***,	 p<0.001;	 **,	
p<0.01;	ns,	p<0.05	vs.	water-injected	oocytes.	
	 	

































































































































was	 to	 determine	 whether	 increased	 levels	 of	 rBATF	 expression	 were	 observed	 at	 different	
days	post-injection	 (Figure	4.4).	Any	 significant	difference	 (p<0.05)	 in	uptake	 levels	 between	
experiments	conducted	on	different	days	post-injection	of	cRNA	would	mean	that	this	 factor	
would	have	to	be	controlled	for	to	minimise	the	variability	observed	between	experiments.		
Oocytes	 were	 injected	 with	 0.5,	 5,	 or	 20ng	 of	 rBATF	 cRNA	 and	 uptake	 experiments	
performed	over	60min.	[3H]Arginine	uptake	levels	increased	over	1-6	days	post-injection,	with	
maximal	uptake	observed	by	day	3	 (Figure	4.4A).	 In	oocytes	 injected	with	20ng	 rBATF	 cRNA,	
the	 fold-increase	 over	water-injected	 oocytes	 ranged	 from	 27-43	 fold	 over	 days	 1-6	 (Figure	
4.4B).	This	high	 fold	 increase	 in	 [3H]arginine	uptake	was	due	to	 low	uptake	 in	water-injected	
control	 oocytes	 over	 days	 1-3	 in	 this	 single	 experiment	 (0.5±0.1	 -	 1.9±1.1	 	 pmol.oocyte-
1(60min)-1).	 Again,	 this	 reflects	 the	 variability	 in	 oocyte	 quality	 between	 batches,	 as	 this	
background	uptake	value	was	12-fold	lower	than	the	mean	value	between	10	oocyte	batches	
reported	 in	Figure	4.3.	A	decline	 in	oocyte	quality	by	day	6	 led	to	an	 increase	 in	 [3H]arginine	
uptake	 in	 	water-injected	 control	 oocytes	 (10.7±1.6	pmol.oocyte-1.(60min-1),	 and	 subsequent	
decrease	 in	 the	 calculated	 fold	uptake	 (Figure	4.4B).	 In	oocytes	 injected	with	all	 amounts	of	
rBATF	 cRNA,	 no	 significant	 increase	 (p>0.05)	 in	 [3H]arginine	 uptake	 is	 observed	 after	 2	 days	
post-injection,	with	maximal	uptake	values	observed	by	day	3	(Figure	4.4).		
These	 data	 indicate	 that	 the	 level	 of	 uptake	 observed	 in	 oocytes	 via	 System	 b0,+	 is	
dependent	on	the	amount	of	cRNA	injected	(Figure	4.4).	This	likely	affects	the	extent	of	rBATF	








Figure	4.4:	An	 increase	 in	 [3H]arginine	uptake	 is	observed	over	a	number	of	days	 following	
injection	 of	 rBATF	 cRNA.	 [3H]Arginine	 (10μM)	uptake	 into	 rBATF-expressing	Xenopus	oocytes	
measured	over	40min	(pH	7.4,	Na+-free).	A,	[3H]Arginine	uptake	following	subtraction	of	water-
injected	control	values;	!,	0.5ng;	",	5ng;	#,	20ng	rBAT	cRNA;	B,	Data	are	as	in	panel	A	prior	to	
subtraction	 of	water-injected	 control	 values;	 ns;	 p>0.05;	 **,	 p<0.01;	 ***,	 p<0.001	 vs.	 day	 6	
uptake	value.	Data	are	mean±SEM	(n=9-10).	










































































































































1min,	 2min,	 5min,	 10min,	 20min,	 40min,	 120min,	 150min,	 and	 180min	 at	 the	 three	
temperatures	 (Figure	 4.5).	 Due	 to	 a	 rapid	 deterioration	 in	 oocyte	 quality	 at	 higher	
temperatures,	 the	 uptake	 at	 32°C	 was	 terminated	 after	 10min.	 From	 the	 time-dependent	
uptake	 results,	 it	 appears	 as	 though	 the	 linear	 phase	 of	 transport	 is	 up	 to	 2h.	 Subsequent	
uptake	experiments	were	carried	out	at	a	maximum	length	of	60min	(Figure	4.5).		
These	data	support	the	experimental	conditions	reported	 in	the	 literature.	Uptake	of	
amino	 acids	 via	 System	b0,+	 in	Xenopus	oocytes	 has	 been	 carried	 out	 between	 5min	 and	 1h	
(Bertran	et	al.,	1992b;	Bertran	et	al.,	1992c;	Tate	et	al.,	1992;	Wells	&	Hediger,	1992;	Bertran	
et	 al.,	 1993;	 Lee	 et	 al.,	 1993;	Markovich	 et	 al.,	 1993;	 Calonge	 et	 al.,	 1994;	 Chillarón	 et	 al.,	
1997).	Tate	et	al.,	and	Chillarón	et	al.,	reported	that	their	uptake	measurements	were	carried	
out	at	20°C	and	25°C,	 respectively	 (Tate	et	al.,	1992;	Chillarón	et	al.,	1997).	Most	 reports	do	













































































































It	was	 important	 to	 ensure	 that	 uptake	 studies	were	 a	 reliable	measurement	 of	 the	
functional	 expression	 of	 rBATF.	 Therefore,	 a	 series	 of	 experiments	 was	 carried	 out	 to	
determine	 the	 substrate	 selectivity	 of	 the	 rBATF-induced	 transport	 (Figures	 4.6-4.7).	
[3H]Arginine,	[3H]lysine,	and	[3H]leucine	all	demonstrated	significantly	higher	uptake	in	rBATF-
expressing	 oocytes	 versus	 water-injected	 controls	 (Figures	 4.6-4.7).	 Although	 [3H]Alanine	





et	 al.,	 1992;	 Wells	 &	 Hediger,	 1992;	 Bertran	 et	 al.,	 1993;	 Lee	 et	 al.,	 1993).	 Competition	
experiments	confirmed	and	extended	these	observations	(Figure	4.8).	Unlabelled	amino	acids	




Figure	 4.6:	 Expression	 of	 rBATF	 in	 Xenopus	 oocytes	 induces	 transport	 with	 b0,+-like	
substrate	 selectivity.	 Uptake	 of	 [3H]amino	 acids	 (10μM,	 2.5-5μCi.ml-1)	 into	 water-injected	





















































































































































































































































Figure	 4.7:	 Substrate	 selectivity	 of	 System	 b0,+.	 Uptake	 of	 [3H]amino	 acids	 (10μM)	 into	
water-injected	 controls	 (open	 bars)	 and	 rBATF-expressing	Xenopus	oocytes	 (black	 bars)	 over	
40min	(pH	7.4,	Na+-free).	A,	Arginine	(2.5μCi.ml-1,	n=39-40)	vs.	 lysine	(5μCi.	ml-1,	n=35-38);	B,	
arginine	(2.5μCi.ml-1,	n=38-39)	vs.	leucine	(5μCi.ml-1,	n=37-40);	C,	arginine	(2.5μCi.ml-1,	n=9-10)	






















































































































Figure	 4.8:	 System	 b0,+
	
substrate	 specificity	 determined	 by	 competitive	 inhibition	 of	
[3H]arginine	uptake.	[3H]Arginine	uptake	(10μM,	pH	7.4,	Na+-free)	in	the	absence	(control)	or	
presence	of	5mM	competitor	compounds	measured	over	40min.	Arginine	(+Arg);	lysine	(+Lys);	
leucine	 (+Leu);	 alanine	 (+Ala);	 histidine	 (+His);	 glycine	 (+Gly),	 proline	 (+Pro).	 A,	 Uptake	 of	
[3H]arginine	 in	 water-injected	 control	 (open	 bars,	 n=18-20)	 and	 rBATF-expressing	 oocytes	
(black	bars,	n=19-20);	B,	data	 (as	shown	 in	panel	A)	are	expressed	as	 the	percentage	uptake	
relative	to	uptake	in	the	absence	of	competitor	compound	following	the	subtraction	of	water-

















rBAT3F	 to	 calculate	 the	 kinetic	 parameters	 of	 System	 b0,+.	 In	 a	 single	 experiment,	 uptake	 of	
[3H]arginine	was	performed	at	0.01-20mM	(Figure	4.10A).	When	the	data	were	plotted	up	to	
1mM,	the	measured	affinity	(Km)	of	the	transport	system	was	70±17μM	with	a	capacity	(Vmax)	


















































































































































































































































Figure	 4.10:	 Concentration-dependent	 [3H]arginine	 uptake	 via	 rBAT3F-induced	 transport	 in	
oocytes.	 	[3H]Arginine	uptake	(0.01-20mM,	pH	7.4,	Na+-free)	in	Xenopus	oocytes	injected	with	
rBAT3F	cRNA	 (50ng).	Uptake	was	carried	out	3	days	post-injection	of	oocytes.	Water-injected	
control	 values	 have	 been	 subtracted.	Data	 are	mean±SEM	of	 a	 single	 experiment	 (n=10).	 A,	
Data	 for	 rBAT3F-mediated	uptake	 from	0.01-20mM	were	 fitted	 to	Michaelis-Menten	one-site	
binding	kinetics	 (r2=0.46);	B,	Data	 for	 rBAT3F-mediated	uptake	 from	0.01-1mM	were	 fitted	to	
Michaelis-Menten	one-site	binding	kinetics	(r2=0.64);	C,	Data	for	rBAT3F-mediated	uptake	from	






Further	uptake	and	 competition	 studies	were	 carried	out	with	 rBAT3F	 to	 confirm	 the	




rBAT3F	 expressing	 oocytes	 above	 water-injected	 control	 oocytes	 (Figure	 4.11A).	 The	
[14C]cystine	 uptake	 was	 carried	 out	 in	 the	 presence	 of	 0.1mM	 diamide	 to	 prevent	 the	
reduction	 of	 cystine	 to	 the	 thiol	 amino	 acid	 cysteine	 (Bertran	 et	 al.,	 1992b;	 Thwaites	 et	 al.,	
1996).	
Competition	experiments	showed	inhibition	of	[3H]arginine	uptake	in	the	presence	of	
5mM	 arginine	 (99%	 inhibition),	 ornithine	 (95%	 inhibition),	 and	 cysteine	 (80%	 inhibition).	
Cysteine	 competition	was	measured	 in	 the	 presence	 of	 0.1mM	DTT	 to	 prevent	 oxidation	 of	
cysteine	to	the	dimer	cystine	(Bertran	et	al.,	1992b;	Thwaites	et	al.,	1996).	In	Figure	4.11C	the	
same	data	are	shown	as	in	panel	B,	expressed	as	percentage	control	of	arginine	uptake	in	the	
absence	of	 any	 competitor.	Water-injected	 control	 values	have	been	 subtracted.	 These	data	
further	 confirm	 that	 the	 substrate	 selectivity	 measured	 in	 this	 investigation	 correlate	 with	
those	reported	in	the	literature,	along	with	the	results	reported	in	section	4.3.5.	No	change	in	
function	is	measurable	in	rBAT	with	a	3xFLAG	epitope	on	the	C	terminal	of	the	protein	(rBAT3F).		
The	 data	 reported	 thus	 far	 in	 this	 chapter	 indicate	 successful	 optimisation	 of	
conditions	 for	 System	 b0,+	 transport	 in	 oocytes	 following	 injection	 of	 untagged	 and	 FLAG-
tagged	rBAT	cRNA.	This	function	was	mediated	through	an	associated	of	human	rBAT	with	an	
endogenous	 light	 chain	 in	 the	 oocyte.	 The	 secondary	 aim	 of	 these	 studies	 was	 to	


























































































































ornithine,	 +Orn;	 cysteine,	 +Cys.	 Data	 are	 mean±SEM	 (n=18-20).	 ns,	 p>0.05;	 ***,	 p<0.01	 vs.	
water-injected	control	oocytes;	C,	Data	(as	shown	in	Figure	4.11B)	expressed	as	the	percentage	
uptake	 relative	 to	 uptake	 in	 the	 absence	 of	 competitor	 compound	 following	 subtraction	 of	








in	 Xenopus	 oocytes.	 This	 would	 allow	 site-directed	 mutagenesis	 to	 be	 performed	 on	 the	
exogenous	 cDNA	 sequence.	 Thus,	 it	 was	 important	 to	 determine	 whether	 rBAT	 would	
selectively	associate	with	a	heterologously-expressed	human	or	mouse	b0,+AT,	rather	than	the	
Xenopus	light	chain,	when	the	cRNAs	for	both	subunits	were	co-injected	into	oocytes.	
Firstly,	 it	 was	 established	 whether	 injection	 of	 the	 two	 subunits	 in	 isolation	 would	
induce	uptake	of	arginine	above	that	observed	in	water-injected	control	oocytes	(Figure	4.12).	
The	 expression	 of	 rBATF	 in	 the	 oocytes	 following	 injection	 of	 10ng	 cRNA	 led	 to	 a	 significant	
increase	 in	uptake	 (p<0.01)	 above	water-injected	oocytes	 (Figure	4.12A).	 In	oocytes	 injected	
with	25ng	of	human	or	mouse	b0,+AT	cRNA,	no	uptake	of	arginine	was	measured	above	that	in	
water-injected	 control	 oocytes	 (Figure	 4.12B).	 In	 fact,	 the	 uptake	 values	 for	 the	 oocytes	
injected	 with	 the	 light	 chain	 cRNAs	 were	 lower	 than	 the	 water-injected	 control	 values,	
although	 these	differences	were	not	 significant	 (p>0.05).	 In	 the	absence	of	 rBATF,	 the	b0,+AT	
protein	 is	 not	 trafficked	 to	 the	 plasma	membrane	 (Chairoungdua	 et	 al.,	 1999).	 However,	 as	
shown	 previously	 in	 this	 study,	 the	 introduction	 of	 rBATF	 protein	 allows	 association	with	 an	
endogenous	light	chain	in	the	oocyte.		
Human	 rBATF	 cRNA	 (1-10ng)	 was	 injected	 into	 Xenopus	 oocytes	 in	 the	 absence	 or	
presence	of	human	b0,+AT	cRNA	(1-50ng)	 (Figure	4.13A-C).	At	all	 three	rBATF	cRNA	quantities	
tested,	 [3H]arginine	 uptake	 was	 significantly	 greater	 (<0.001)	 than	 water-injected	 controls	
(Figure	4.13A-C).	No	 further	 stimulation	of	uptake	was	measured	upon	co-injection	of	b0,+AT	
cRNA	 (1-50ng).	 In	 fact,	 in	 some	 instances	 an	 apparent	 reduction	 in	 uptake	 was	 observed	
(Figure	 4.13B).	 The	 same	 measurements	 were	 carried	 out	 in	 oocytes	 injected	 with	 mouse	
b0,+AT	cRNA,	and	broadly	similar	observations	were	made	(Figure	4.14).		
These	 data	 are	 consistent	 with	 results	 reported	 in	 the	 literature,	 where	 oocyte	
injection	 of	 human	 rBAT	 and	mouse	 b0,+AT	 cRNA	 did	 not	 stimulate	 [3H]arginine	 above	 that	
observed	when	rBAT	cRNA	was	 injected	alone	(Pfeiffer	et	al.,	1999a;	Fernandez	et	al.,	2006).	










(see	 section	 4.4).	 Uptake	 of	 arginine,	 lysine,	 leucine,	 alanine	 and	 proline	 was	 carried	 out	
(10μM,	pH	7.4,	Na+-free)	in	oocytes	injected	with	water	(control),	rBATF	cRNA	(10ng),	or	rBATF-
b0,+AT	 concatenated	 cRNA	 (10ng)	 (Figure	 4.15).	 Significant	 uptake	 (p<0.001)	 of	 System	 b0,+	
substrates	 arginine	 (16-fold),	 lysine	 (8.5-fold),	 and	 leucine	 (4-fold)	was	measured	 in	 oocytes	
expressing	rBATF	 in	association	with	Xenopus	b0,+AT	compared	to	water-injected	controls.	No	
significant	uptake	was	measured	in	oocytes	expressing	the	fusion	protein	compared	to	water-
injected	controls,	with	 the	exception	of	arginine.	However,	 this	 is	 likely	within	 the	margin	of	
error	 and	 to	 produce	 reliable	 uptake	 via	 the	 fusion	 protein,	 significant	 uptake	 of	 all	 b0,+	
substrates	 would	 need	 to	 be	 identified.	 These	 data	 are	 the	 mean	 of	 two	 individual	
experiments	(n=20)	and	are	consistent	with	the	results	achieved	by	Dr.	Noel	Edwards.		
The	 failure	 to	measure	uptake	of	b0,+	 substrates	via	 the	human	or	mouse	 light	 chain	
was	disappointing.	However,	all	novel	mutants	reported	in	this	study	were	located	in	the	gene	
encoding	the	rBAT	protein	(SLC3A1)	(Chapter	3).	Therefore,	for	characterisation	of	the	SLC3A1	
mutations	 identified	 in	 the	 current	 cohort	 of	 patients,	 the	 association	 of	 rBAT	 with	 the	
endogenous	light	chain	in	Xenopus	oocytes	is	a	valuable	tool.	This	will	allow	the	measurement	
of	 rBAT	 protein	 expression	 and	 trafficking	 to	 the	 plasma	 membrane.	 Following	 the	




























































































Figure	4.12:	 System	b0,+-like	 activity	 is	 not	observed	 following	 injection	of	b0,+AT	 cRNA	
alone.	 [3H]Arginine	uptake	 (10μM,	pH	7.4,	Na+-free,	 60min)	via	oocytes	 injected	with	water	
(controls),	 rBATF	 cRNA	 (10ng),	 human	 b0,+AT	 cRNA	 (25ng),	 or	mouse	 b0,+AT	 cRNA	 (25ng).	 A,	
[3H]Arginine	 uptake	 in	 water-injected	 control	 (open	 bar,	 n=8)	 and	 rBATF-injected	 oocytes	
(black	bars,	1-10ng	cRNA,	n=8-10);	B,	[3H]Arginine	uptake	in	water-injected	controls	(open	bar,	
n=8),	human	b0,+AT-expressing	 (black	bar,	n=10),	and	mouse	b0,+AT-expressing	oocytes	 (black	

































































































































Figure	 4.13:	 Co-injection	 of	 Xenopus	 oocytes	 with	 rBATF	 and	 human	 b0,+AT	 cRNA.	
[3H]Arginine	uptake	(pH	7.4,	Na+-free)	via	oocytes	 injected	with	water	 (controls),	 rBATF	cRNA	






























































































































Figure	 4.14:	 Co-injection	 of	 Xenopus	 oocytes	 with	 rBATF	 and	 mouse	 b0,+AT	 cRNA.	
[3H]Arginine	uptake	(10μM,	pH	7.4,	Na+-free,	60min)	via	oocytes	injected	with	water	(controls),	
rBATF	 cRNA	 (1-10ng),	 and/or	 mouse	 b0,+AT	 cRNA	 (1-50ng).	 [3H]Arginine	 uptake	 (10μM)	 in	
water-injected	control	oocytes,	with	or	without	co-injection	of	1-50ng	b0,+AT	cRNA	(open	bars,	







an	 rBATF-b0,+AT	 fusion	 protein.	 [3H]Amino	 acid	 uptake	 (10μM,	 2.5-5μCi.ml-1)	 into	 water-


























































by	 isolating	 total	 membrane	 proteins	 from	 homogenised	 oocytes	 (see	 section	 2.9.1).	 The	
second	 technique	 isolated	 oocyte	 plasma	 membrane	 proteins	 to	 detect	 rBAT	 at	 the	 outer	
membrane	of	the	cells.	This	was	achieved	through	incubation	of	whole	oocytes	with	positively-
charged	 silica	 and	 coating	 them	 in	 high	 molecular	 weight	 poly(acrylic)acid,	 before	
centrifugation,	as	described	in	section	2.9.3.		
	 Water,	 or	 rBATF	cRNA	 (50ng)	 (Figure	 4.16A)	was	 injected	 into	Xenopus	 oocytes	 and,	
following	 incubation	 (3	 days),	 membranes	 were	 separately	 prepared	 by	 ultracentrifugation	
(total	 membranes)	 and	 silica	 isolation	 (plasma	 membranes).	 The	 protein	 samples	 were	
separated	by	SDS-PAGE	and	transferred	onto	PVDF	membranes	prior	to	 immunodetection	as	
described	 in	 Chapter	 2.	 The	 mouse	 M2	 anti-FLAG	 primary	 antibody	 (Sigma,	 UK)	 was	 used,	
along	 with	 a	 HRP-conjugated	 anti-mouse	 secondary	 antibody	 (see	 Chapter	 2).	 As	 a	 positive	
control	 for	antibody	application,	protein	samples	using	both	 techniques	were	prepared	 from	
oocytes	 injected	with	 50ng	 cRNA	of	 flounder	 sodium-phosphate	 transporter,	NaPi-IIa,	which	
had	FLAG-tags	on	both	the	N-	and	C-termini	(Figure	4.16B).		
When	 detected	 through	 western	 blotting,	 rBAT	 protein	 appears	 as	 a	 double	 band	
between	 85	 and	 90	 kDa	 in	 size.	 These	 “doublets”	 correspond	 to	 the	 core	 glycosylated,	
immature	 protein	 (lower	 band,	 85kDa)	 and	 the	 mature	 glycosylated	 protein	 (upper	 band,	
90kDa)	processed	by	the	Golgi	apparatus	(Chillarón	et	al.,	1997).	No	rBAT-specific	bands	were	
















in	vitro	 transcribed.	Start,	 start	codon	 (atg);	 rBAT,	 rBAT	open	reading	 frame	(ORF)	sequence;	
FLAG,	 position	 of	 DYKDDDDK	 epitope;	 Stop,	 stop	 codon	 (tag);	 C,	Western	 blot	 detection	 of	
rBATF	and	NaPi-IIa	in	oocyte	total	membrane	and	plasma	membrane	fractions	using	the	Sigma	
M2	anti-FLAG	primary	 antibody	 (1:200).	 The	 lanes	 represent	 oocytes	 injected	with:	 a,	water	
(control,	total	membranes);	b,	50ng	rBATF	cRNA	(total	membranes);	c,	water	(control,	plasma	





























the	M2	 primary	 antibody	 (not	 shown).	 However,	 the	 use	 of	 a	 Proteintech	mouse	 anti-FLAG	
primary	 antibody	 led	 to	 the	 detection	 of	 FrBATF-specific	 bands	 in	 total	 membrane	 proteins	
(Figure	4.17C	 lanes	e	and	 f).	No	bands	were	detected	 in	 lanes	 representing	 total	membrane	
proteins	from	oocytes	injected	with	rBATF	cRNA	(Figure	4.17C	lanes	c	and	d),	or	water	(Figure	
4.17,C,	 lanes	 a	 and	 b).	 Increasing	 the	 amount	 of	 protein	 used	 in	 the	 blot	 from	 50-100μg	




4.18).	However	 the	experimental	 conditions	 led	 to	 the	presence	of	many	non-specific	bands	
(Figure	4.18D,	lanes	b,	c,	and	d).		
To	 increase	 the	 sensitivity	 of	 rBAT	 detection,	 and	 enable	 a	 lower	 antibody	





Chapter	 2).	 Using	 the	 Proteintech	 anti-FLAG	 primary	 antibody,	 rBAT2F	 (Figure	 4.18C,	 lane	 e)	
and	 rBAT3F	 (Figure	 4.18C,	 lanes	 f-h)	 were	 detected	 with	 less	 sensitivity	 than	 FrBATF	 (Figure	
4.18C,	 lanes	 b-d).	 In	 the	 literature	 differences	 in	 critical	 binding	 residues	 for	 different	 anti-
FLAG	antibodies	are	 reported	 (Hernan	et	al.,	2000).	The	Sigma	M2	anti-FLAG	antibody	had	a	
markedly	 increased	 sensitivity	 of	 detection	 of	 the	 3xFLAG	 epitope	 compared	 to	 other	
antibodies	 (Hernan	 et	 al.,	 2000).	 Consequently,	 the	 western	 blot	 detection	 of	 rBAT3F	 was	
repeated	 with	 the	 M2	 anti-FLAG	 primary	 antibody	 (Figure	 4.19F).	 This	 was	 carried	 out	 to	
determine	 whether	 the	 M2	 anti-FLAG	 antibody	 measured	 detection	 of	 rBAT-3xFLAG	 with	
greater	sensitivity	than	the	Proteintech	anti-FLAG	antibody.	Total	membrane	protein	samples	
from	 oocytes	 injected	with	 1,	 2,	 5,	 10,	 20	 and	 50ng	 rBAT3F	 cRNA	were	 used	 (Figure	 4.19F).	
Doublet	 bands	 80-90kDa	 in	 size	were	 detected	with	 increasing	 intensity	 in	 lanes	 containing	
total	membrane	protein	from	oocytes	injected	with	1-50ng	rBAT3F	cRNA	(Figure	4.19F,	lanes	b-
g,	 respectively).	No	bands	were	detected	 in	the	water-injected	control	oocyte	 lysates	 (Figure	
4.19F,	lane	a).			
To	 illustrate	 the	 sensitivity	 in	detection	of	 the	different	 tagged	constructs	by	 the	
M2	antibody,	Figure	4.19F	lanes	h-m	represent	25μg	total	membrane	protein	from	oocytes	
injected	with	water	 (h),	or	50ng	of	 rBAT	 (i),	 rBATF	 (j),	 FrBATF	 (k),	 rBAT2F	 (l),	or	 rBAT3F	 (m)	





two	 single	 FLAG	 tags.	 This	 was	 not	 observed	 using	 the	 Proteintech	 anti-FLAG	 antibody	
(Figure	4.18).		
The	optimised	detection	system	also	worked	successfully	with	plasma	membrane	
proteins	 isolated	using	 the	silica-based	preparation	method	 (Figure	4.19F,	 lanes	n-q).	No	
bands	were	detected	in	lanes	containing	water-injected	oocyte	protein	(n,	2μg;	p,	1μg)	but	
strong	 bands	 of	 around	 80kDa	were	 detected	 in	 rBAT3F	 protein	 preparations	 (o,	 2μg;	 q,	
1μg).	However,	the	successful	optimisation	of	the	plasma	membrane	preparation	was	only	
achieved	 as	 this	 study	 was	 nearing	 the	 end.	 The	 preparation	 of	 oocytes	 using	 this	
technique	 was	 carried	 out	 using	 oocytes	 injected	 with	 wild-type	 and	 mutant	 rBAT3F.	
However,	the	oocytes	were	of	poor	quality	and	quickly	disintegrated	when	incubated	with	
the	 protease	 to	 partially	 digest	 the	 vitelline	 membranes	 (see	 Chapter	 2).	 A	 second	






from	 Xenopus	 oocytes.	 The	 optimisation	 of	 these	 protocols	 enabled	 the	 expression	 of	
mutant	 rBAT	protein	 in	oocytes	 to	be	compared	 to	 that	of	 the	wild-type	 (Chapter	5).	To	
confirm	the	results	of	these	immunodetection	studies,	it	was	also	desirable	to	establish	a	
technique	 for	 the	 fluorescent	 immunocytochemical	 detection	 of	 the	 proteins	 at	 the	









Figure	 4.17:	 Western	 blot	 detection	 of	 FrBATF	 in	 total	 oocyte	 membrane	 samples.	 A,	
Schematic	 representation	 of	 rBATF	 cDNA;	 B,	 Schematic	 representation	 of	 FrBATF	 cDNA	 from	
which	 cRNA	 is	 in	 vitro	 transcribed.	 Start,	 start	 codon	 (atg);	 rBAT,	 rBAT	 open	 reading	 frame	
(ORF)	sequence;	FLAG,	position	of	DYKDDDDK	epitope;	Stop,	stop	codon	(tag);	C,	Western	blot	
detection	of	 rBATF	and	 FrBATF	 in	oocyte	 total	membrane	proteins	using	 the	Proteintech	anti-






























Figure	 4.18:	 Detection	 of	 FLAG-tagged	 rBAT	 constructs	 by	 western	 blot	 using	 the	
Proteintech	 anti-FLAG	 primary	 antibody.	 A,	 Schematic	 representation	 of	 FrBATF	 cDNA;	 B,	
Schematic	 representation	of	 rBAT2F	 cDNA;	C,	 Schematic	 representation	of	 rBAT3F	 cDNA	 from	
which	 cRNA	 is	 in	 vitro	 transcribed.	 Start,	 start	 codon	 (atg);	 rBAT,	 rBAT	 open	 reading	 frame	
(ORF)	sequence;	FLAG,	position	of	DYKDDDDK,	DYKDHDI,	or	DYKDHDG	epitope	(as	indicated);	
Stop,	 stop	 codon	 (tag);	 D,	 Western	 blot	 detection	 of	 FrBATF,	 rBAT2F,	 and	 rBAT3F	 with	 the	
Proteintech	anti-FLAG	primary	antibody	(1:100,	20h,	4°C)	in	50μg	total	oocyte	membranes.	The	
































































































Figure	 4.19:	 Detection	 of	 rBAT3F	 by	 western	 blot	 using	 the	 Sigma	 M2	 anti-FLAG	 primary	
antibody.	A,	Schematic	representation	of	untagged	rBAT	cDNA;	B,	Schematic	representation	of	
rBATF	 cDNA;	 C,	 Schematic	 representation	 of	 FrBATF	 cDNA;	 D,	 Schematic	 representation	 of	
rBAT2F	 cDNA;	 E,	 Schematic	 representation	 of	 rBAT3F	 cDNA	 from	 which	 cRNA	 is	 in	 vitro	




25μg	 total	membrane	protein	 samples	 from	oocytes	 injected	with:	a,	water	 (control);	b,	1ng	
rBAT3F;	 c,	 2ng	 rBAT3F;	 d,	 5ng	 rBAT3F;	 e,	 10ng	 rBAT3F;	 f,	 20ng	 rBAT3F;	 g,	 50ng	 rBAT3F	 cRNA.	
Oocytes	were	injected	with	the	different	tagged	rBAT	constructs	to	demonstrate	the	different	












For	 the	 purposes	 of	 immunocytochemical	 detection	 of	 rBAT	 at	 the	 oocyte	 plasma	
membrane,	 whole	 oocytes	 were	 imaged	 by	 confocal	 microscopy	 following	 application	 of	
primary	 and	 secondary	 antibodies	 as	 described	 in	 Chapter	 2.	 Oocytes	 injected	 with	 water	
(control),	rBATF	cRNA	(50ng),	and	FNaPi-IIaF	cRNA	(50ng)	were	incubated	in	one	of	two	primary	
antibodies:	Proteintech	anti-FLAG	(Figure	4.20A),	or	Sigma	M2	anti-FLAG	(Figure	4.20B).	In	the	
earlier	studies	 FNaPi-IIaF	protein	was	detected	with	a	high	 level	of	 sensitivity	using	anti-FLAG	
antibodies	 in	western	blotting	(section	4.3.9).	Therefore,	this	cRNA	was	injected	as	a	positive	
control	for	the	optimisation	of	rBAT	immunocytochemical	detection.	The	mean	fluorescence	of	
water-injected	 control	oocytes	was	measured	and	 the	gain	was	adjusted	accordingly	 so	 that	
minimal	fluorescence	was	visible	(Chapter	2)	(Figure	4.20A-B).	Using	the	Proteintech	antibody	
(Figure	 4.20A)	 a	 faint	 signal	 was	 detected	 in	 rBATF	 expressing	 oocytes	 compared	 to	 water-
injected	controls.	However,	bright	membrane	fluorescence	was	visible	in	FNaPi-IIaF	expressing	
oocytes	 (Figure	4.20A).	Using	 the	Sigma	M2	antibody,	no	 fluorescence	was	detectable	 in	 the	
membrane	of	either	rBATF	or	FNaPi-IIaF	expressing	oocytes	(Figure	4.20B).	Due	to	the	presence	
of	 strong	 membrane	 fluorescence	 detected	 in	 the	 FNaPi-IIaF	 expressing	 oocytes	 using	 the	
Proteintech	 primary	 antibody,	 this	 was	 selected	 for	 use	 in	 rBAT	 detection	 in	 subsequent	
optimisation	experiments.	As	discussed	in	section	4.3.9,	an	rBAT	construct	with	single	N	and	C	
terminal	FLAG-tags	(FrBATF)	was	created	to	try	and	increase	the	sensitivity	of	rBAT	detection	in	



































Following	 the	 production	 of	 FrBATF,	 the	 choice	 and	 concentration	 of	 secondary	
antibody	 was	 also	 optimised	 for	 immunocytochemical	 detection	 (Figure	 4.21).	 Following	
incubation	with	a	Zymed	FITC-conjugated	goat	anti-mouse	secondary	antibody,	only	very	faint	
membrane	 fluorescence	was	measured	 in	 FrBATF	expressing	oocytes	 (Figure	4.21A,	 left-hand	
panel).	However,	bright	membrane	fluorescence	was	observed	 in	oocytes	 injected	with	50ng	
FNaPi-IIaF	cRNA	(Figure	4.21A,	right-hand	panel).		
The	 AlexaFluor	 488,	 goat	 anti-mouse	 secondary	 antibody	 (Life	 Technologies)	 was	
applied	separately	to	oocytes	expressing	FrBATF	and	FNaPi-IIaF	at	two	different	concentrations	
(Figure	 4.20B-C).	 At	 both	 concentrations,	 the	 oocytes	 expressing	 FNaPi-IIaF	 had	 bright	
membrane	 fluorescence	 that	 appeared	 saturated	 in	 some	 cases	 (Figure	 4.21B-C,	 right-hand	
panel).	 Membrane	 fluorescence	 representing	 FrBATF	 was	 observed	 using	 this	 secondary	
antibody	at	both	concentrations	(Figure	4.12B-C,	middle	panel).	However,	the	signal	appeared	
greater	 in	 oocytes	 incubated	 with	 the	 antibody	 at	 a	 1:50	 dilution.	 From	 these	 data	 it	 was	
evident	 that	 both	 the	 choice	 of	 secondary	 antibody,	 and	 the	 concentration	 at	which	 it	 was	







Figure	 4.21:	 Immunocytochemical	 detection	 of	 FrBATF	 in	 the	 oocyte	 membrane	 using	
different	 secondary	 antibodies.	Confocal	microscopy	of	 intact	oocytes	 injected	with	water	
(control,	left-hand	panel),	50ng	FrBATF	cRNA	(middle	panel)	or	50ng	FNaPi-IIaF	cRNA	(right-hand	
panel)	following	incubation	with	the	Proteintech	anti-FLAG	primary	antibody	(1:50).	A,	Oocytes	
incubated	 with	 Zymed	 goat	 anti-mouse	 FITC-conjugated	 secondary	 antibody	 (1:100);	 B,	
Oocytes	 incubated	 with	 AlexaFluor	 488	 goat	 anti-mouse	 secondary	 antibody	 (1:100);	 C,	
Oocytes	incubated	with	AlexaFluor	488	goat	anti-mouse	secondary	antibody	(1:50).	Scale	bar,	

























The	 rBAT3F	 construct	 was	 produced	 in	 our	 laboratory	 for	 the	 purposes	 of	 rBAT	
detection	 by	western	 blot,	 as	 reported	 in	 section	 4.3.9.	 The	 immunocytochemical	 detection	
protocol	was	 repeated	 using	 this	 triple	 FLAG-tagged	 construct.	 The	 cRNA	 (1-50ng)	 of	 rBAT3F	
was	injected	into	oocytes.	Positive	membrane	fluorescence	was	visible	in	oocytes	injected	with	
50ng	 cRNA	 (Figure	 4.22).	 However,	 in	 oocytes	 injected	 with	 1ng	 or	 5ng	 cRNA,	 much	 lower	
levels	 of	 fluorescence	were	 observed,	 and	membranes	 were	 barely	 visible	 (Figure	 4.22).	 To	
calculate	 any	 measurable	 difference	 in	 expression,	 the	 fluorescence	 of	 these	 oocytes	 was	
quantified	and	normalised	per	μm	membrane	 length	using	 ImageJ	 (Figure	4.23A).	 The	mean	






or	 1ng,	 5ng,	 or	 50ng	 rBAT3F	 cRNA	 (Figure	 4.23B).	 In	 oocytes	 injected	 with	 50ng	 (25.5	
pmol.oocyte-1.(60min)-1)	and	5ng	(12.0	pmol.oocyte-1.(60min)-1)	rBAT	cRNA,	significant	uptake	
(p<0.05)	 was	 measured	 compared	 to	 water-injected	 control	 oocytes	 (3.8	 pmol.oocyte-
1.(60min)-1).	 In	 the	 uptake	 experiment,	 there	 was	 a	 significant	 difference	 (p<0.05)	 in	
[3H]arginine	uptake	between	1ng	and	5ng-injected	oocytes.	A	 significant	difference	was	also	
observed	 between	 oocytes	 injected	 with	 5ng	 and	 50ng	 cRNA	 (Figure	 4.23B).	 When	 the	
fluorescence	of	these	oocytes	was	quantified,	there	was	no	detectable	difference	in	expression	
between	 1ng	 and	 5ng-injected	 oocytes	 (Figure	 4.23A).	 This	 indicates	 that	 at	 lower	 levels	 of	
protein	expression,	this	technique	is	not	sensitive	enough	to	detect	a	change	 in	fluorescence	
intensity.		
These	 data	 have	 shown	 successful	 optimisation	 of	 an	 immunocytochemical	 protocol	
for	 detection	 of	 rBAT3F	 at	 the	 plasma	membrane	 of	whole	 oocytes	 at	 high	 levels	 of	 protein	








Figure	 4.22:	 Immunocytochemical	 detection	 of	 rBAT3F	 in	 intact	 oocytes.	 Confocal	
microscopy	of	whole	oocytes	using	Proteintech	mouse	anti-FLAG	(1:50,	3h,	RT)	and	AlexaFluor	
488	 goat	 anti-mouse	 secondary	 antibody	 (1:50,	 1h,	 RT).	 Oocytes	 were	 injected	 with	 water	





Figure	 4.23:	 Quantification	 of	 membrane	 fluorescence	 measured	 by	 confocal	 imaging	

















































































































































The	 second	 immunocytochemical	 technique	 employed	 for	 detection	 of	 rBAT	 utilised	
sectioned	oocytes.	This	allowed	 localisation	of	 the	protein	at	 the	plasma	membrane	or	 in	an	
intracellular	compartment	to	be	determined.		
Intracellular	 protein	 localisation	 is	 undetectable	 using	 confocal	 imaging	 of	 whole	
oocytes	 (Chubb	 et	 al.,	 2006).	 To	 be	 able	 to	 detect	 mutant	 rBAT	 protein	 in	 an	 intracellular	
compartment	of	 the	oocyte,	 it	was	necessary	 to	optimise	an	 immunocytochemical	detection	
technique	on	sectioned	oocytes.	Oocytes	were	injected	with	50ng	rBAT3F	cRNA	and,	following	
3	days’	 expression,	 fixed	 in	methanol	 and	 sliced	 into	15μm	 sections	 in	OCT	 (see	Chapter	 2).	
Water-injected	oocytes	were	 used	 as	 a	 negative	 control	 for	 plasma	membrane	 fluorescence	
(Figure	4.24).	 In	all	negative	control	oocytes	some	intracellular	non-specific	 fluorescence	was	
visible.	However,	no	non-specific	membrane	fluorescence	was	observed.	When	incubated	with	
the	 Proteintech	 anti-FLAG	 antibody,	 oocytes	 expressing	 rBAT3F	 showed	 a	 bright	 band	 of	
fluorescence	in	the	plasma	membrane,	which	was	absent	in	the	controls	(Figure	4.24A).		
To	detect	 the	 cellular	 localisation	of	 the	Xenopus	 light	 chain,	 an	anti-b0,+AT	antibody	
was	 used	 (Figure	 4.24B).	 The	 antibody	 was	 raised	 against	 human	 b0,+AT,	 although	 was	
predicted	to	cross-react	with	the	Xenopus	protein	based	upon	the	sequence	alignment	(Figure	
4.24C).	 Intracellular	 fluorescence	 was	 observed	 in	 water-injected	 oocytes,	 suggesting	 cross-
reactivity	 with	 the	 Xenopus	 light	 chain	 (Figure	 4.24B).	 Upon	 application	 of	 the	 anti-b0,+AT	
antibody	to	rBAT3F-expressing	oocytes	specific	membrane	fluorescence	was	visible,	 indicating	
trafficking	of	the	endogenous	light	chain	to	the	membrane	by	the	human	rBAT	(Figure	4.24B).	
Increased	 intracellular	 fluorescence	 was	 also	 visible	 in	 these	 oocytes,	 from	 which	 we	 can	
hypothesise	 that	expression	of	 rBAT3F	 stimulated	 further	production	of	 the	endogenous	 light	







Figure	 4.24:	 Cellular	 localisation	 of	 rBAT3F	 and	 Xenopus	 b0,+AT	 in	 oocyte	 sections.	
Fluorescence	 microscopy	 of	 15μm	 oocyte	 sections.	 A,	 Sections	 from	 oocytes	 injected	 with	
water	 (control,	 left-hand	panel),	 or	 50ng	 rBAT3F	 cRNA	 (right-hand	panel)	 incubated	with	 the	
Proteintech	anti-FLAG	antibody	(1:50,	16h,	4°C);	B,	Sections	from	oocytes	injected	with	water	
(control,	 left-hand	 panel),	 or	 50ng	 rBAT3F	 cRNA	 (right-hand	 panel)	 incubated	 with	 the	 anti-
b0,+AT	antibody	 (1:50,	16h,	4°C).	 Scale	bar;	50μm;	C,	Multiple	 sequence	alignment	of	human	
(AF_421181),	mouse	(NM_001199016)	and	Xenopus	laevis	(NM_001112863)	b0,+AT	amino	acid	






Human       MGDT--GLRKRREDEKSIQSQEPKTTSLQKELGLISGISIIVGTIIGSGIFVSPKSVLSN 58 
Mouse       MEET--SLRRRREDEKSTHSTELKTTSLQKEVGLLSGICIIVGTIIGSGIFISPKSVLAN 58 
Peptide     ----------------------------------------------------SPKSVLSN 8 
Xenopus     MAKKRKGLQNGDADQKSIQSQESNSMNLKQQVGLISGISLIVGTIIGSGIFISPKSVLSN 60 
                                                                ******:* 
 
Human       TEAVGPCLIIWAACGVLATLGALCFAELGTMITKSGGEYPYLMEAYGPIPAYLFSWASLI 118 
Mouse       TESVGPCLIIWAACGILATLGALCFAELGTMITKSGGEYPYLMEAFGPIPAYLFSWTSLI 118 
Peptide     TE---------------------------------------------------------- 10 
Xenopus     TGAIGPCLIIWAVCGVIATMGALCFAELGTMITKSGGEYPYLMEAFGPIPAFLFSWASLI 120 
            *  
C!
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The	 co-localisation	 of	 the	 two	 System	 b0,+	 proteins	 was	 investigated	 using	 the	 anti-
FLAG	 and	 anti-b0,+AT	 antibodies	 in	 sectioned	 oocytes	 (Figure	 4.25).	 Figure	 4.25A	 shows	 a	
representative	 image	 of	 a	 water-injected	 control	 oocyte	 incubated	 with	 both	 antibodies.	
Oocytes	 injected	 with	 rBAT3F	 cRNA	 (Figure	 4.25B)	 showed	 bright	 membrane	 fluorescence	
representative	 of	 rBAT3F	 protein	 from	 the	 anti-FLAG	 antibody	 (green).	 In	 these	 oocytes,	
intracellular	fluorescence	from	the	anti-b0,+AT	antibody	(red)	was	higher	than	in	water-injected	
control	oocytes	and	the	plasma	membrane	was	also	visible.	The	merged	image	of	fluorescence	
from	 both	 antibodies	 indicated	 co-localisation	 of	 both	 proteins	 in	 the	 plasma	 membrane,	




the	membrane	of	 the	oocyte	with	 the	 anti-FLAG	antibody	 (green).	 Intracellular	 fluorescence	
from	 the	 anti-b0,+AT	 antibody	 (red)	 appeared	 greater	 than	 in	 the	 oocytes	 expressing	 only	




blot	 was	 carried	 out	 using	 total	 membrane	 proteins	 from	 oocytes	 injected	 with	 water	
(control),	 or	 rBAT3F	 cRNA,	 human	 b0,+AT	 cRNA,	 rBAT3F	 and	 human	 b0,+AT	 cRNAs,	 or	 the	
concatenated	 rBATF-b0,+AT	 cRNA	 (Figure	4.26A).	 Protein	 from	oocytes	 injected	with	water	or	
rBAT	alone	were	resolved	alongside	other	samples	and	blotted	separately	with	the	anti-FLAG	
antibody.	As	expected,	no	bands	were	visible	in	water-injected	control	oocytes	(Figure	4.26A,	







System	b0,+,	 and	was	used	as	 	 a	positive	 control	 for	 the	anti-b0,+AT	antibody	 raised	against	a	
human	 immunogen.	 A	 single	 band	 was	 observed	 identical	 in	 size	 to	 that	 observed	 in	 the	
oocyte	samples.		







The	 results	 of	 the	 immunocytochemical	 detection	 of	 rBAT	 and	 b0,+AT	 in	 sectioned	
oocytes	 show	 that	 it	 is	 possible	 to	 successfully	 detect	 protein	 expression	 at	 the	 plasma	
membrane,	and	intracellularly.	This	will	be	a	valuable	tool	to	support	the	functional	expression	
of	rBAT	protein.	These	data	also	support	those	reported	earlier	in	this	chapter.	We	have	shown	
through	 immunocytochemical	detection	of	 the	endogenous	 light	chain	that	co-localisation	of	
rBAT	 and	 the	 Xenopus	 protein	 can	 be	 detected.	 However,	 there	 is	 no	 increase	 in	 the	
fluorescence	 from	human	b0,+AT	at	 the	plasma	membrane	 following	expression	of	 the	cRNA.	
This	 is	 in	agreement	with	the	lack	of	stimulation	of	[3H]arginine	uptake	into	the	oocytes	over	
that	observed	with	expression	of	 rBAT	cRNA	alone.	These	data	 further	support	 the	evidence	







Figure	 4.25:	 Cellular	 localisation	 of	 rBAT3F	 and	 human	 b0,+AT	 in	 sections	 of	 oocytes.	
Fluorescence	microscopy	of	 15μm	oocyte	 sections	 incubated	with	 the	Proteintech	anti-FLAG	
and	 anti-b0,+AT	 antibodies.	 A,	 Water-injected	 oocytes	 (control);	 B,	 rBAT3F	 cRNA-injected	































































































































Figure	4.26:	Validation	of	anti-b0,+AT	antibody	binding	 in	 the	detection	of	 the	Xenopus	





cRNA;	 g,	 50ng	 rBATF-b0,+AT	 concatenated	 cRNA,	 incubated	 with	 the	 anti-SLC7A9	 antibody	
(1:200,	16h,	4°C);	h,	blank	lane;	i,	Caco-2	membrane	protein	(11μg)	incubated	with	anti-b0,+AT	
antibody	(1:200,	16h,	4°C).	B,	[3H]Arginine	uptake	(10μM,	pH	7.4,	Na+-free)	in	Xenopus	oocytes	






The	 objective	 of	 the	 studies	 presented	 in	 this	 chapter	 was	 to	 optimise	 a	 range	 of	
techniques	 that	would	 allow	 the	measurement	 of	 rBAT	 expression	 in	Xenopus	 oocytes.	 This	
has	been	demonstrated	successfully	in	three	distinct	ways.	We	have	shown	that	the	expression	
of	 rBAT	 can	 be	 indirectly	 measured	 through	 the	 function	 of	 induced	 System	 b0,+	 transport	
(Figures	4.1-4.10);	that	rBAT	expression	can	be	detected	in	oocyte	membrane	protein	fractions	
through	 western	 blotting	 (Figure	 4.19);	 and	 that	 immunocytochemical	 detection	 can	 be	







mutations	 in	 proteins	 expressed	 in	 Xenopus	 oocytes	 that	 there	 is	 an	 apparent	 recovery	 of	
function	over	time,	and,	rarely,	that	no	loss	of	function	can	be	detected	(Chillarón	et	al.,	1997;	
Leduc-Nadeau	 et	 al.,	 2010).	 It	 has	 been	 hypothesised	 that	 this	 effect	 is	 due	 to	 the	 high	
translational	capacity	of	the	oocytes,	which	leads	to	an	over-expression	of	the	protein,	in	turn	
overcoming	the	“trafficking”	defect	(Chillarón	et	al.,	1997;	Leduc-Nadeau	et	al.,	2010).	To	this	
end,	 the	 techniques	optimised	 in	 this	 chapter	were	used	 to	monitor	 rBAT	expression	over	 a	
range	of	different	conditions.	Expression	of	rBAT	was	varied	by	injection	of	different	amounts	
of	 cRNA	 (1-50ng)	 and	by	 allowing	 expression	 to	 continue	over	 a	 number	of	 days	 (1-6)	 post-
injection.	 Under	 the	 different	 conditions,	 the	 absolute	 levels	 of	 rBAT	 translation	 and	
movement	 to	 the	 plasma	 membrane	 will	 vary.	 The	 important	 factor	 was	 to	 optimise	 the	
techniques	to	allow	detection	of	different	levels	of	protein	expression.		
4.4.1	Expression	of	human	rBAT	protein	is	associated	with	induced	[3H]arginine	transport	
To	measure	 rBAT	 expression	 by	 function,	we	were	 reliant	 on	 the	 association	 of	 the	






uptake	 following	 injection	 of	 increasing	 amounts	 of	 rBAT	 cRNA	 (Figures	 4.2,	 4.4).	 This	 is	
predicted	 to	be	due	 to	 an	 increased	 abundance	of	 rBAT	protein	 and	 increased	 trafficking	of	
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System	 b0,+	 to	 the	 plasma	 membrane	 of	 oocytes.	 The	 increased	 protein	 levels	 following	
increased	cRNA	injection	was	confirmed	by	western	blot	(Figure	4.19).	However,	variability	in	
absolute	expression	 levels	was	detected	between	different	batches	of	oocytes.	For	example,	
[3H]arginine	 uptake	 after	 3	 days	 incubation	 was	 only	 1.6-2.0	 fold	 higher	 than	 water	 when	
oocytes	were	 injected	with	1	or	2ng	of	rBAT	cRNA,	respectively	 (Figure	4.2).	 In	contrast,	 in	a	
separate	experiment,	 injection	of	0.5ng	cRNA	led	to	a	13-fold	 increase	 in	[3H]arginine	uptake	
after	 only	 one	 day	 (post-injection)	 (Figure	 4.4).	 Calonge	 et	 al.	 (1994)	 reported	 successful	
expression	of	System	b0,+	following	injection	of	as	little	as	0.05ng	rBAT	cRNA.	The	variability	in	
protein	 expression,	 and	 resultant	 uptake	 levels	 observed	 in	 the	 current	 study	 has	 been	
reported	by	other	 research	 groups,	 and	 appears	 common	 to	 the	use	of	 the	Xenopus	oocyte	
expression	system	(Chillarón	et	al.,	1997).	Provided	that	careful	experimental	measurements	
of	mutant	rBAT	function	are	made,	in	which	positive	(wild-type	protein)	and	negative	(water-
injected)	 control	 oocytes	 are	 used	 routinely,	 the	 variability	 in	 expression	 will	 not	 be	
problematic	in	the	subsequent	functional	studies.		
To	measure	 the	 variability	 in	 rBAT	protein	expression	over	 time,	 [3H]arginine	uptake	
was	 measured	 over	 a	 number	 of	 days	 (1-6)	 post-injection.	 Tate	 et	 al.,	 and	 Chillarón	 et	 al.,	
measured	 uptake	 of	 phenylalanine	 and	 cystine,	 respectively,	 in	 oocytes	 injected	 with	 rBAT	
cRNA,	1-8	days	post-injection.	Tate	et	al.,	observed	an	increase	in	expression	in	rBAT-injected	
oocytes	 (5ng)	 from	 days	 1-3,	 after	 which	 the	 uptake	 levels	 plateaued	 (Tate	 et	 al.,	 1992).	




cRNA	 (Figure	 4.4).	 However,	 due	 to	 the	 observed	 variability	 in	 oocyte	 protein	 expression	
between	batches,	only	measurements	made	on	the	same	day	post-injection	will	be	considered	
comparable.	 It	 cannot	be	assumed	 that	maximal	uptake	 levels	will	 always	be	 reached	at	 the	







lysine,	 and	 neutral	 amino	 acid	 leucine	 (Figure	 4.7).	 	 System	 b0,+	 does	 not	 transport	 smaller	
amino	 acids,	 including	 the	 imino	 acid	 proline,	 or	 anionic	 amino	 acids	 such	 as	 glutamic	 acid	
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et	 al.,	 1993;	 Lee	 et	 al.,	 1993).	 The	 functional	 expression	 cloning	 of	 System	 b0,+-associated	
proteins	 and	 substrate	 specificity	 of	 the	 induced	 transport	 system	 is	 discussed	 in	 detail	 in	
Chapter	1.		
4.4.3	Co-expression	of	both	System	b0,+	subunits	in	Xenopus	oocytes	
Although	 not	 the	 main	 focus	 of	 the	 work	 described	 in	 this	 chapter,	 it	 was	 also	
investigated	 whether	 it	 would	 be	 possible	 to	 heterologously	 co-express	 the	 two	 human	
subunits	of	System	b0,+.	 If	successful,	this	would	enable	 injection	of	a	mammalian	(preferably	
human)	 light	 chain	 of	 the	 transport	 system,	 allowing	 studies	 into	 SLC7A9	 mutations	 to	 be	
carried	 out.	 The	 Mus	 musculus	 light	 chain	 of	 System	 b0,+	 was	 first	 cloned	 in	 1999,	 and	
investigated	by	 functional	 co-expression	with	 rBAT	 in	Xenopus	oocytes	 (Chairoungdua	 et	 al.,	
1999;	Pfeiffer	et	al.,	1999a).	Expression	of	mouse	b0,+	AT	in	isolation	in	oocytes	did	not	induce	
[3H]arginine	 uptake	 above	 background	 (Pfeiffer	 et	 al.,	 1999a),	 an	 observation	 made	
independently	 as	 part	 of	 this	 study	 (Figure	 4.10B).	 In	 the	 absence	 of	 rBAT,	 the	 heteromeric	
transport	system	is	not	trafficked	to	the	plasma	membrane.	Pfeiffer	et	al.	also	observed	that	
there	was	no	further	stimulation	of	uptake	of	arginine	in	oocytes	expressing	both	mammalian	
subunits,	 over	 those	 expressing	 rBAT	 alone	 (Pfeiffer	 et	 al.,	 1999a).	 This	 made	 it	 unclear	
whether	observed	uptake	was	via	rBAT	in	association	with	the	co-expressed	mouse	light	chain	
or	 the	 endogenous	 light	 chain.	Western	 blot	 evidence	 of	 light	 chain	 expression	 in	 Xenopus	
oocytes	in	the	absence	of	rBAT	suggests	that	rBAT	preferentially	associates	with	the	Xenopus	
light	 chain	upon	co-injection	 (Pfeiffer	 et	al.,	 1999a).	 This	was	 further	 supported	by	evidence	




hypothesised	 that	 the	apparent	decrease	 in	arginine	uptake	observed	 in	 co-injected	oocytes	
compared	 to	 rBAT-injected	 oocytes	 can	 be	 attributed	 to	 a	 limitation	 on	 the	 translational	
capacity	 of	 the	 oocyte	when	 both	 cRNAs	 are	 injected	 (Pfeiffer	 et	 al.,	 1999a).	 In	 the	 current	
study,	 immunocytochemical	analysis	of	 sectioned	oocytes	expressing	 rBAT	and	human	b0,+AT	
appeared	 to	 support	 the	 hypothesis	 that	 co-injection	 of	 both	 subunits	 did	 not	 lead	 to	
association	 of	 rBAT	 with	 the	 human	 light	 chain	 (Figure	 4.24).	 In	 oocytes	 expressing	 human	
rBAT,	membrane	 localisation	was	 observed,	which	was	 absent	 in	 the	water-injected	 control	
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oocytes,	 confirming	 association	 of	 the	 exogenous	 and	 endogenous	 subunits	 (Figure	 4.25B).	
Bright	 intracellular	 fluorescence	 was	 observed	 upon	 expression	 of	 human	 b0,+AT.	 However,	
plasma	membrane	co-localisation	was	not	detected	(Figure	4.25C).		
Pfeiffer	 et	 al.	 injected	 Xenopus	 oocytes	 with	 mouse	 b0,+AT	 cRNA,	 2	 days	 prior	 to	
injection	 with	 rBAT	 cRNA	 (Pfeiffer	 et	 al.,	 1999a).	 Uptake	 of	 [3H]arginine	 in	 the	 b0,+AT	 pre-
injected	 oocytes	 (150	 pmol.oocyte-1.(60min)-1)	 appeared	 to	 be	 lower	 than	 in	 oocytes	 pre-
injected	 with	 water	 (220	 pmol.oocyte-1.(60min)-1,	 which	 was	 considered	 evidence	 of	
competition	 of	 the	 two	 cRNAs	 for	 the	 translational	machinery	 of	 the	 oocyte	 (Pfeiffer	 et	 al.,	
1999a).	Mouse	b0,+AT	 containing	 the	 loss	of	 function	mutation	E244Q,	was	 also	pre-injected	
into	oocytes.	In	oocytes	pre-injected	with	E244Q	cRNA,	uptake	of	arginine	was	reduced	to	40	
pmol.oocyte-1.(60min)-1,	 which	 was	 not	 significantly	 different	 to	 background,	 despite	 the	
presence	of	the	functional	Xenopus	light	chain.	This	indicated	that	when	the	mouse	light	chain	






the	 two	 subunits	 through	 a	 10	 amino	 acid	 alanine	 and	 proline-rich	 “linker	 sequence”	
connecting	the	intracellular	N-	terminus	of	rBAT	with	the	C-terminus	of	b0,+AT	(Pfeiffer	et	al.,	
1999a).	It	has	been	demonstrated	by	Fernandez	et	al.	that	the	functional	unit	of	System	b0,+	is	
the	 covalently-linked	 heterodimer,	 with	 an	 observed	 molecular	 weight	 of	 135kDa	 when	
resolved	by	SDS-PAGE,	although	the	transport	system	structurally	sits	in	the	plasma	membrane	
as	 a	hetero-tetramer	with	an	apparent	molecular	weight	of	 270kDa	 (Fernandez	 et	 al.,	 2002;	
Fernandez	et	al.,	2006).	However,	the	concatenated	protein	does	not	appear	to	form	a	hetero-
tetramer	 (Fernandez	 et	 al.,	 2006).	 Despite	 this	 difference	 in	 structure,	 significant	 uptake	
(p<0.05)	 of	 System	b0,+	 substrates	 in	 oocytes	 expressing	 the	 concatamer	 has	 been	 observed	
compared	 to	 water-injected	 controls,	 demonstrating	 its	 potential	 as	 a	 method	 of	
characterising	 mutations	 in	 b0,+AT	 (Pfeiffer	 et	 al.,	 1999a).	 In	 the	 current	 study,	 preliminary	
investigations	into	rBAT	and	b0,+AT	expression	in	Xenopus	oocytes	were	carried	out	by	Dr.	Noel	
Edwards,	during	which	time	a	concatenated	human	rBAT-b0,+AT	cRNA	was	made.	However,	we	
were	unable	 to	 express	 this	 protein	 in	oocytes	 and	no	uptake	of	 System	b0,+	 substrates	was	













of	 these	 studies	 turned	 to	 the	 optimisation	 of	 rBAT	 expression	 levels	 by	 immunodetection.	
Due	 to	 the	unavailability	of	 a	 validated	antibody	 raised	against	human	 rBAT,	we	utilised	 the	
FLAG-tag	 system.	 The	 FLAG	 system	 had	 been	 used	 previously	 to	 detect	 expression	 of	 the	
sodium-phosphate	 transporter	 NaPi-IIa	 (Kohl	 et	 al.,	 1998).	 As	 a	 result,	 several	 anti-FLAG	
antibodies	 had	 been	 successfully	 validated	 for	 use	 in	 both	 western	 blotting	 and	
immunocytochemistry.		
In	 the	 current	 study,	 it	 was	 established	 that	 there	 was	 no	 significant	 difference	
(p>0.05)	in	function	of	rBAT	with	added	FLAG-tags	(Figures	4.1	and	4.9A).	To	enhance	protein	
detection,	multiple	FLAG	epitopes	have	been	added	to	proteins	 in	tandem.	In	2004,	Dubel	et	





Variations	 on	 the	 FLAG	 amino	 acid	 sequence	 have	 been	 investigated	 to	 improve	






critical	 residues	 for	 binding	 of	 the	 M2	 antibody	 were	 D1,	 Y2,	 K3,	 and	 D6.	 To	 increase	 the	
sensitivity	 of	 protein	 detection,	 Hernan	 et	 al.	 reported	 a	 triple	 FLAG	 (3xFLAG)	 epitope,	
designed	to	meet	the	detection	criteria	of	the	M2	antibody	(Hernan	et	al.,	2000).	The	designed	
sequence	 DYKDHDG-DYKDHDI-DYKDDDDK	 retained	 the	 critical	 residues,	 whilst	 remaining	 as	
short	as	possible	 to	minimise	the	risk	of	 interference	with	native	protein	 folding	or	 function.	
The	first	two	FLAG	epitopes	do	not	contain	the	enteropeptidase	recognition	sequence,	as	this	
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would	 only	 be	 required	 once	 in	 the	 sequence	 for	 removal	 of	 the	 tag	 (Hernan	 et	 al.,	 2000).	
Hernan	 et	 al.	 compared	 the	multiple	 epitope	 tag	 to	 the	 single	 FLAG	 epitope	 by	 transiently	
expressing	S.	aureus	biofilm	associated	protein	(BAP)	tagged	with	a	single	FLAG	or	with	3xFLAG	
in	COS-7	 cells.	 They	demonstrated	a	10-fold	 increase	 in	 sensitivity	of	western	blot	detection	
using	the	multiple	epitope	tag	(Hernan	et	al.,	2000).	The	reported	 increase	 in	sensitivity	was	
not	observed	using	the	M5	antibody.	These	data	are	strongly	supported	by	the	findings	of	the	
current	 study.	 Through	 western	 blot	 detection	 of	 rBAT3F	 expressed	 in	 Xenopus	 oocytes,	 we	
have	 observed	 an	 increase	 in	 sensitivity	 of	 protein	 detection	 using	 the	M2	 antibody	 (Figure	
4.15).	We	have	also	observed	 that	 the	 increase	 in	 sensitivity	 is	not	 common	 to	all	 anti-FLAG	
antibodies.	 An	 anti-FLAG	 antibody	 from	 Proteintech	 detected	 two	 single	 FLAG	 polypeptides	
(FrBATF)	with	higher	 sensitivity	 than	 the	 triple	 FLAG	epitope	 (Figure	4.15).	 This	 suggests	 that	
D1,	Y2,	K3,	D6	are	not	the	critical	residues	for	the	Proteintech	antibody.		
4.4.5	Immunodetection	of	proteins	in	Xenopus	oocytes		




in	 oocytes	 using	 a	 preparation	 to	 isolate	 total	 membranes,	 adapted	 from	 methods	 first	
reported	by	Geering	et	al.	(1989).	Chillarón	et	al.	(1997)	identified	double	bands	at	85	and	94	




The	 use	 of	 colloidal	 silica	 to	 specifically	 isolate	 the	 plasma	 membrane	 proteins	 in	
Xenopus	 oocytes	 has	 been	 established	 (Leduc-Nadeau	 et	 al.,	 2007).	 Leduc-Nadeau	 et	 al.	
reported	that	this	technique	increased	the	sensitivity	of	detection	of	the	renal	water	channel,	
aquaporin-2	 (AQP2),	 expressed	 in	 oocytes	 10-fold	 compared	 to	 the	 total	 membrane	
preparation	 (Chillarón	 et	 al.,	 1997;	 Leduc-Nadeau	 et	 al.,	 2007).	 This	 technique	 enabled	
identification	and	quantification	of	AQP2	mutants	 at	 the	oocyte	plasma	membrane	at	 lower	
levels	 than	 the	 wild-type,	 which	 was	 not	 detected	 using	 the	 total	 membrane	 isolation	
technique	 (Leduc-Nadeau	 et	al.,	 2010).	 In	 the	 current	 study,	 isolation	of	plasma	membranes	





strongly	 support	 the	 results	 of	 Leduc-Nadeau	et	 al.	 that	 the	 silica-based	 isolation	 of	 plasma	




optimise	the	technique	 fully	 to	produce	a	reliable	 technique.	Consequently,	western	blotting	
was	 performed	 with	 total	 membrane	 proteins	 to	 measure	 protein	 translation,	 and	
immunocytochemical	detection	of	rBAT	in	whole	and	sectioned	oocytes	was	used	to	measure	
plasma	membrane	expression.		
In	 2006,	 Chubb	 et	 al.	 expressed	 CD98	 and	 its	 light	 chain	 y+LAT2	 conjugated	 to	
enhanced	green	fluorescent	protein	(EGFP)	in	Xenopus	oocytes	and	measured	the	fluorescence	
in	 whole	 and	 intact	 oocytes	 (Chubb	 et	 al.,	 2006).	When	 both	 subunits	 were	 expressed	 and	
whole	 oocytes	 viewed	 by	 confocal	microscopy,	 a	 band	 of	 fluorescence	was	 observed	 at	 the	
perimeter	of	the	oocyte.	In	the	absence	of	CD98,	no	fluorescence	was	visible	at	the	membrane	
(Chubb	 et	 al.	 (2006).	 This	 suggested	 that	 the	density	 of	 the	oocyte	 is	 too	 great	 to	 allow	 for	
intracellular	 fluorescence	using	 this	 technique	and	 that	 the	observed	 fluorescence	correlates	
to	proteins	at	the	plasma	membrane.	The	ability	to	detect	proteins	in	the	plasma	membrane	of	
Xenopus	 oocytes	 using	 confocal	 imaging	 of	 intact	 oocytes	 was	 demonstrated	 in	 this	 study	
(Figures	 4.20-4.22).	 Bright,	 positive	 staining	 was	 visualised	 at	 the	 membrane	 of	 oocytes	
expressing	FLAG-tagged	rBAT	or	NaPi-IIa,	which	was	absent	at	the	membrane	of	water-injected	
control	oocytes.	
Chubb	 et	 al.	 confirmed	 that	 the	 observed	 fluorescence	 was	 specific	 to	 the	 plasma	
membrane	 by	 repeating	 the	 experiment	 in	 sectioned	 oocytes.	 They	 observed	 specific	
membrane	 fluorescence	 in	 the	presence	of	both	System	y+L	 subunits	and	bright	 intracellular	
fluorescence	when	y+LAT2	was	expressed	alone	(Chubb	et	al.,	2006).	The	results	of	the	current	
study	demonstrate	 that	 it	was	not	possible	 to	 completely	eliminate	background	 intracellular	
fluorescence	due	to	non-specific	binding	of	the	antibodies	to	the	high-density	yolk	proteins	in	
water-injected	 oocytes	 (Figure	 4.23A),	 consistent	with	 other	 images	 of	 sectioned	 oocytes	 in	
published	reports	(Bianchi	et	al.,	2000).	Despite	this,	specific	plasma	membrane	fluorescence	
was	 only	 visible	 in	 oocytes	 expressing	 FLAG-tagged	 proteins,	 predicted	 to	 be	 located	 in	 the	
membrane	(Figure	4.22-4.23).	These	data	from	the	current	study,	along	with	those	reported	in	
the	literature	(Bianchi	et	al.,	2000;	Chubb	et	al.,	2006),	confirm	the	reliability	of	whole	oocyte	
and	sectioned	oocyte	 immunocytochemistry	as	 techniques	to	 identify	 the	plasma	membrane	
localisation	of	exogenous	and	endogenous	proteins	expressed	in	Xenopus	oocytes.	




and	 immunocytochemistry.	 Western	 blotting	 using	 total	 membrane	 proteins	 has	 allowed	





oocyte	 expression	 system.	 This	 will	 enable	 accurate	measurements	 of	mutant	 rBAT	 protein	
expression	 and	 function	 to	 identify	 the	 underlying	 cause	 of	 the	 cystinuria	 phenotype	 of	 the	
patients	in	the	cohort.		
In	summary:	
• A	 range	 of	 techniques	 has	 been	 optimised	 to	 allow	 the	 measurement	 of	
System	b0,+	function	in	oocytes.	
• The	 function	 of	 System	 b0,+	 provides	 an	 indirect	 measurement	 of	 rBAT	
expression	at	the	oocyte	membrane.	
• Using	 a	 FLAG-tagged	 rBAT	 construct	 (rBAT3F)	 we	 can	 detect	 different	
glycosylated	forms	of	rBAT	by	western	blot.	






The	 heavy	 chain	 subunit	 of	 System	 b0,+,	 known	 as	 rBAT,	 is	 widely	 regarded	 as	 the	
“trafficking”	protein	of	the	transport	heterodimer	(Chillarón	et	al.,	1997;	Chillarón	et	al.,	2010).	
To	date,	91	pathogenic	missense	mutations	have	been	reported	in	SLC3A1,	the	gene	encoding	
this	 protein	 (Stenson	 et	 al.,	 2014).	Of	 these	91	pathogenic	mutations,	 only	 9	have	been	 the	
focus	of	functional	expression	studies:	L89P,	T216M,	S217R,	R270L,	L346P,	R365W,	M467T	and	




(Pineda	 et	 al.,	 2004b;	 Bartoccioni	 et	 al.,	 2008).	 However,	 oocytes	 have	 remained	 the	
predominant	 system	 employed	 for	 the	 functional	 studies	 of	 rBAT	 due	 to	 their	 high	
translational	 capacity,	 reliability	 of	 expression,	 and	 ability	 to	 perform	 post-translational	
modifications.		
Single	nucleotide	polymorphisms	(SNPs)	are	 individual	base	changes	 in	genomic	DNA	
sequences	 that	occur	 in	>1%	of	 the	population	 (Kirk	et	al.,	2002).	Due	to	 their	abundance	 in	
healthy	 individuals,	SNPs	are	commonly	non-pathogenic.	They	can	be	classed	as	synonymous	
or	non-synonymous	depending	on	whether	or	not	the	change	 in	base	sequence	results	 in	an	
alteration	 in	the	translated	amino	acid	sequence.	 In	SLC3A1,	 the	gene	encoding	rBAT,	a	non-
synonymous	SNP,	M618I,	is	found	in	the	genome	of	around	half	of	the	population.	The	online	
resources	UCSC	Genome	Database	and	the	Exome	Aggregation	Consortium	(EXAC),	suggest	the	
prevalence	 of	M618I	 to	 be	 43%	 and	 59%	 of	 the	 population,	 respectively	 (Kent	 et	 al.,	 2002;	
Stenson	 et	 al.,	 2014).	 Literature	 reports	 of	 mutation	 detection	 in	 cystinuric	 patients	
acknowledge	 the	 identification	 of	 this	 polymorphism,	 although	 the	 prevalence	 within	 the	
cohorts	 is	 often	 unspecified	 (Horsford	 et	 al.,	 1996;	 Saadi	 et	 al.,	 1998;	 Egoshi	 et	 al.,	 2000;	
Barbosa	et	al.,	2012).	Ishihara	et	al.,	(2002)	did	report	a	lower	incidence	of	the	SNP	(23%)	in	an	
entirely	 Japanese	 cohort,	 which	 could	 be	 reflective	 of	 the	 frequency	 in	 that	 particular	
population.	 The	 investigation	 of	 M618I	 expression	 in	 oocytes	 has	 been	 reported	 in	 the	
literature	 (Saadi	 et	 al.,	 1998;	 Ishihara	 et	 al.,	 2002).	 No	 difference	 in	 [14C]cystine	 uptake	 in	
M618I-expressing	 oocytes	 was	 detected,	 compared	 to	 wild-type	 rBAT-expressing	 controls	





common	cystinuria-causing	mutation	 in	Mediterranean	populations	 (Bartoccioni	 et	al.,	 2008;	
Barbosa	et	al.,	2012).	The	expression	of	this	mutant	protein	has	been	investigated	in	Xenopus	
oocytes	(Calonge	et	al.,	1994;	Chillarón	et	al.,	1997)	and	MDCK	cells	(Bartoccioni	et	al.,	2008).	
Following	 the	 expression	 of	M467T	 in	 oocytes,	 a	 significant	 reduction	 in	 [14C]cystine	 uptake	
was	measured	compared	 to	wild-type	 rBAT	controls,	one	day	post-injection	 (Chillarón	 et	al.,	
1997).	 	However,	 the	 function	of	 this	mutant	protein	appeared	 to	 “recover”	over	 time.	At	6	
days	post-injection	of	cRNA,	the	function	of	M467T	was	not	significantly	different	(p>0.05)	to	
that	of	the	wild-type	(Chillarón	et	al.,	1997).	 Interestingly,	when	the	sister	mutation,	M467K,	
was	 investigated,	 a	 complete	 recovery	 in	 function	was	not	observed.	 The	authors	 suggested	
that	 this	 was	 due	 to	M467K	 being	 a	more	 “severe”	mutation,	 with	 the	 basic	 lysine	 residue	
conferring	a	more	detrimental	effect	on	protein	 folding	than	the	uncharged,	polar	 threonine	
(Chillarón	 et	 al.,	 1997).	 It	 has	 been	 hypothesised	 that	 the	 observed	 decrease	 in	 function	
following	mutant	protein	expression	in	oocytes	is	due	to	a	mis-folding	of	the	protein,	and	rapid	
degradation	by	the	ER.	The	observed	recovery	in	function	has	been	attributed	to	a	saturation	
of	 these	 pathways,	 allowing	 escape	 of	 the	mutant	 protein	 from	 the	 endoplasmic	 reticulum	
(Chillarón	et	al.,	1997).		
In	Chapter	4,	a	series	of	techniques	was	reported	that	allow	the	measurement	of	rBAT	
expression	 in	oocytes.	 In	 this	 chapter,	we	 report	 the	use	of	 these	 techniques	 to	 identify	 the	
effects	of	the	novel	SLC3A1	mutations,	identified	in	Chapter	3.	To	validate	the	reproducibility	
of	 our	 experimental	 approach,	 we	 first	 investigated	 the	 expression	 of	 common	 SNP	M618I,	
and	 pathogenic	 M467T.	 This	 enabled	 comparison	 of	 our	 findings	 to	 those	 reported	 in	 the	
literature.	 Following	 this,	 we	 were	 able	 to	 utilise	 the	 Xenopus	 oocyte	 expression	 system	 to	
investigate	the	novel	missense	rBAT	mutations	M465K,	N254T,	L416P,	and	Y579D.	
5.2	Methods	
	 Mutant	 rBAT	 proteins	 were	 produced	 by	 site-directed	 mutagenesis	 of	 cDNA	 in	
pSPORT1	 (see	 Chapter	 2).	 [3H]Arginine	 uptake	 experiments	 were	 performed	 in	 oocytes	
injected	 with	 water	 (control),	 or	 1-50ng	 rBAT	 or	 mutant	 cRNA.	 Uptake	 experiments	 were	
performed	1-6	days	post-injection	of	cRNA	to	enable	the	measurement	of	protein	expression	
over	 time.	 Immunodetection	of	protein	 in	oocytes	by	western	blot	or	 immunocytochemistry	
was	performed	as	described	in	Chapter	4.	
Homology	modelling	of	the	rBAT	extracellular	domain	was	performed	as	described	in	
Chapter	 2.	 The	 measurement	 of	 distances	 between	 atoms	 in	 amino	 acid	 side	 chains	 was	
carried	out	using	the	Pymol	measurement	tool.	In	silico	mutagenesis	was	performed	using	the	
	 235	
PyMol	mutagenesis	wizard	 tool.	 The	 PyMol	 polar	 interaction	 tool	was	 used	 to	 estimate	 the	
changes	in	intramolecular	forces	in	the	mutated	protein.	
5.3	Results	
In	 this	 study	we	have	 reported	 the	 identification	of	 four	novel	mutations	 in	SLC3A1,	
the	 gene	 encoding	 rBAT.	 The	 location	 of	 these	mutations	 in	 the	 protein	 structure	 has	 been	
predicted	using	a	homology	model	of	the	rBAT	extracellular	domain	(Chapter	3).	We	have	also	
demonstrated	 that	 rBAT	 expression	 can	 be	 measured	 through	 a	 combination	 of	 functional	
studies	 and	 immunodetection	 techniques	 (Chapter	 4).	 In	 this	 chapter,	we	 report	 the	 use	 of	
these	protocols	to	measure	the	function	of	mutated	rBAT	protein	in	oocytes.	The	function	of	












cystinuria	 mutations.	 Top	 view	 of	 the	 rBAT	 extracellular	 domain	model	 based	 on	 oligo-1,6-













The	 first	 rBAT	mutation	 investigated	 in	 this	 study	was	 the	common	single	nucleotide	





introducing	 this	 mutation	 into	 the	 protein	 sequence	 would	 not	 have	 any	 effect	 on	 rBAT	
function	in	oocytes.		
	[3H]Arginine	 uptake	 was	 performed	 in	 oocytes	 injected	 with	 water	 (control)	 or	 the	
cRNA	for	rBAT	or	M618I	(1-50ng).	Uptake	experiments	were	performed	1-3	days	post-injection	
(Figures	5.2	and	5.3).	On	day	1	post-injection,	 [3H]arginine	uptake	 into	oocytes	 injected	with	
1ng,	5ng,	or	50ng	of	wild-type	cRNA	was	not	significantly	different	(p>0.05)	to	that	measured	
in	 M618I-expressing	 oocytes	 (Figure	 5.2).	 When	 water-injected	 control	 values	 were	
subtracted,	 no	 significant	 difference	 (p>0.05)	 was	 observed	 in	 rBAT	 or	 M618I	 function	
following	the	injection	of	any	amount	of	cRNA	1-3	days	post-injection	(Figure	5.3).		
Concentration-dependent	[3H]arginine	uptake	(0.01-20mM)	was	measured	 in	oocytes	
expressing	 rBAT	 and	 M618I,	 3	 days	 post-injection	 of	 oocytes.	 Following	 the	 subtraction	 of	




almost	 identical	 to	 those	 measured	 in	 the	 uptake	 experiments	 represented	 by	 Figure	 5.2C	
(31±7	 and	 32±6	 pmol.oocyte-1.(60min)-1,	 respectively),	 demonstrative	 of	 inter-experimental	
reproducibility.	 The	 concentration-dependent	 uptake	 data	 were	 also	 transformed	 to	 fit	 the	
linear	 Eadie-Hofstee	 plot	 (Figure	 5.4C).	 This	 confirmed	 that	 the	 gradients	 of	 the	 two	 slopes	
(representative	of	the	Km	values)	were	not	significantly	different	(p=0.87).	Additionally,	t-tests	
were	 performed	 using	 the	 interpolated	 Km	 and	 Vmax	 values	 from	 each	 of	 the	 3	 data	 fits	
displayed	in	Figure	5.3.	No	significant	difference	was	calculated	between	any	of	the	3	Km	values	
(p=0.5-0.9)	 or	 Vmax	 values	 (p=0.1-0.2).	 These	 data	 validate	 the	 use	 of	 the	Michaelis-Menten	
equation	 to	 establish	 reliable	 kinetic	 parameters	 up	 to	 1mM	 [3H]arginine	 (Figure	 5.3B).	
Additionally,	 the	 linear	 transformation	 to	 the	 Eadie-Hofstee	 plot	 identifies	 one-site	 binding	
transport	kinetics	(Figure	5.3C).	These	data,	consistent	between	uptake	experiments,	support	










Figure	 5.2:	 [3H]Arginine	 uptake	 in	 oocytes	 expressing	wild-type	 rBAT	or	 the	 common	 SNP,	
M618I.	 [3H]Arginine	uptake	 (10μM,	pH	7.4,	Na+-free,	60min)	via	oocytes	 injected	with	water	
(controls),	 rBAT,	 or	 M618I	 (1-50ng)	 cRNA.	 A,	 [3H]Arginine	 uptake	 in	 water-injected	 (n=29),	
rBAT-	 (n=29-30),	 and	 M618I-cRNA	 injected	 oocytes	 (n=30-31),	 1	 day	 post-injection;	 B,	
[3H]Arginine	uptake	in	water-injected	(n=27),	rBAT-	(n=28-29),	or	M618I-cRNA	injected	oocytes	
(n=29-30),	2	days	post-injection;	C,	[3H]Arginine		uptake	in	water-injected	(n=27),	rBAT-	(n=29-

































































































































































































































































































































































Figure	 5.3:	 Transporter-specific	 [3H]arginine	 uptake	 induced	 by	 wild-type	 rBAT	 or	 the	
common	SNP,	M618I.	Data	(as	in	Figure	5.2)	are	shown	with	the	water-injected	control	values	
subtracted.	 A,	 [3H]Arginine	 uptake	 in	 oocytes	 injected	with	 rBAT	 (black,	 n=28-30),	 or	M618I	
(blue,	n=30-31)	cRNA	(1ng)	1-3	days	post-injection;	B,	[3H]Arginine	uptake	in	oocytes	injected	
with	 rBAT	 (black,	 n=29-30),	 or	M618I	 (blue,	 n=29-30)	 cRNA	 (5ng)	 1-3	 days	 post-injection;	 C,	




































































































































Figure	 5.4:	 Concentration-dependent	 [3H]arginine	 uptake	 via	 rBAT	 or	 M618I-induced	
transport	 in	 oocytes.	 rBAT	 (black)	 and	 M618I	 (blue)-mediated	 [3H]arginine	 uptake	 (0.01-
20mM,	pH	7.4,	Na+-free)	in	Xenopus	oocytes	injected	with	rBAT	or	M618I	cRNA	(50ng).	Uptake	
was	 carried	 out	 3	 days	 post-injection	 of	 oocytes.	 Water-injected	 control	 values	 have	 been	
subtracted.	Data	are	mean±SEM	of	two	separate	experiments	(n=18-20).	A,	Data	for	rBAT	and	
M618I-mediated	uptakes	 from	0.01-20mM	were	 fitted	 to	Michaelis-Menten	one-site	binding	
kinetics	 (r2=0.46	and	0.42,	 respectively);	B,	Data	 for	 rBAT	and	M618I-mediated	uptakes	 from	
0.01-1mM	 were	 fitted	 to	 Michaelis-Menten	 one-site	 binding	 kinetics	 (r2=0.69	 and	 0.66,	








Western	 blotting	 was	 performed	 to	 detect	 rBAT	 and	 M618I	 protein	 expression	 in	
oocytes.	Total	membrane	protein	samples	were	prepared	from	oocytes	injected	with	water,	or	
rBAT	or	M618I	cRNA	(1-50ng),	1-3days	post-injection	(Figure	5.5).	No	rBAT-specific	bands	were	









this	 chapter,	wild-type	 rBAT	proteins	were	prepared	 from	 the	 same	batch	of	oocytes	 as	 the	
mutant	 samples	 to	control	 for	variability	 in	expression	 levels	between	batches.	This	ensured	
that	 the	 protein	 bands	 detected	 on	 the	 western	 blots	 are	 directly	 comparable.	 From	 the	
western	blot	(Figure	5.5)	it	is	apparent	that	there	is	no	visible	difference	in	band	intensity	from	
oocytes	 injected	with	 the	 same	quantity	 of	 rBAT	or	M618I	 cRNA,	 on	 any	day	 post-injection.	
This	 indicated	 that	 the	 introduction	 of	 M618I	 to	 the	 protein	 sequence	 did	 not	 affect	 the	
amount	of	total	protein	produced	in	oocytes.		
The	localisation	of	rBAT	and	M618I	proteins	at	the	plasma	membrane	of	oocytes	was	
determined	 by	 whole	 oocyte	 fluorescent	 confocal	 microscopy	 (Figure	 5.6).	 Oocytes	 were	




M618I-expressing	 oocytes.	 These	 results	 are	 consistent	 with	 those	 of	 the	 functional	
experiments	 and	 the	western	blotting	of	 total	 protein	 levels,	 indicating	no	effect	upon	 rBAT	
function	 conferred	 by	M618I.	 This	 is	 consistent	with	 a	 polymorphism	 present	 in	 half	 of	 the	
population.	 Following	 measurement	 of	 M618I	 expression	 in	 oocytes,	 which	 served	 as	 a	













































































































































































































































































































M618I	cRNA	 (50ng).	 Images	were	 taken	 from	oocytes	 fixed	3	days	post-injection	of	cRNA.	 In	










The	 expression	 of	 the	 most	 common	 cystinuria-causing	 mutation	 in	 European	
populations,	M467T,	has	been	 characterised	previously	 in	Xenopus	oocytes	 (see	Section	5.1)	





cRNA,	 1-6	 days	 post-injection	 (Figures	 5.7	 and	 5.8).	 On	 day	 1	 post-injection,	 [3H]arginine	
uptake	 in	 oocytes	 expressing	 M467T	 was	 significantly	 lower	 (p<0.05-0.001)	 than	 in	 those	





following	 subtraction	 of	 background	 uptake	 values.	 The	 rate	 of	 recovery	 of	M467T	 function	
was	dependent	on	 the	amount	of	 cRNA	 injected.	No	uptake	of	 [3H]arginine	was	observed	 in	
oocytes	 injected	with	1ng	cRNA	on	days	1-3.	However,	 [3H]arginine	uptake	was	measured	 in	
oocytes	 injected	with	5-50ng	cRNA	at	day	2	post-injection	(Figure	5.8).	These	data	 indicate	a	





due	 to	 a	 decrease	 in	 protein	 at	 the	 oocyte	 membrane,	 or	 a	 change	 in	 the	 affinity	 of	 the	
transport	 system,	concentration-dependent	 [3H]arginine	uptake	 (0.01-1mM)	was	carried	out.	
Background	 uptake	 values	 were	 subtracted	 and	 the	 results	 were	 plotted	 to	 the	 Michaelis-
Menten	non-linear	equation	(Figure	5.9A).	As	shown	in	section	5.3.1,	the	 interpolated	values	
for	these	data	fitted	to	the	Michaelis-Menten	equation	provide	reliable	Km	and	Vmax	values	up	
to	 1mM	 [3H]arginine.	 The	 measured	 affinity	 (Km)	 of	 the	 wild-type	 rBAT-induced	 transport	
system	 was	 85±19μM.	 In	 oocytes	 injected	 with	 M467T	 cRNA,	 the	 affinity	 of	 the	 induced	
transport	 system	 was	 measured	 at	 30±14μM,	 significantly	 higher	 than	 the	 wild-type	
(measured	by	a	decrease	in	Km	p=0.02).	Although	we	did	not	expect	M467T	to	affect	the	Km	of	
the	transport	system,	the	possibility	of	this,	through	an	altered	interaction	of	M467T	rBAT	with	
b0,+AT,	 cannot	 be	 excluded.	 The	 circulating	 plasma	 concentrations	 of	 arginine	 and	 lysine	 in	
adults	have	been	estimated	at	52-126μM	and	121-268μM,	respectively,	depending	upon	the	
	 248	
time	 of	 day	 they	 were	 measured	 and	 the	 protein	 intake	 of	 the	 participants	 (Maher	 et	 al.,	
1984).	As	amino	acids	are	freely	filtered	by	the	glomerulus,	these	values	are	also	reflective	of	
the	 dibasic	 amino	 acid	 concentrations	 in	 the	 renal	 filtrate	 of	 the	 proximal	 tubule.	 The	
concentration	of	these	amino	acids	in	the	renal	filtrate	is	very	close	to	the	measured	affinity	of	
the	 transport	 system.	 Therefore,	 a	 2.8-fold	 decrease	 in	 the	 Km,	 which	 would	 increase	 the	
affinity	of	the	carrier	for	its	substrates	and	thus	increase	the	uptake	at	 lower	concentrations,	
could	have	a	great	impact	on	the	net	arginine	transport	by	System	b0,+.	A	broadly	similar	effect	
was	 measured	 by	 Chillarón	 et	 al.	 (1997).	 They	 measured	 the	 Km	of	 wild-type	 rBAT	 induced	
arginine	 transport	 to	 be	 93±13μM,	 3	 days	 post-injection	 of	 oocytes,	 and	 that	 of	 M467T-
induced	 transport	 to	 be	 51±8.	 However,	 they	 regarded	 this	 decrease	 to	 be	 non-significant.	
Some	 variability	 in	 the	 affinity	 of	 rBAT-induced	 transport	 in	 oocytes	 has	 been	 observed	
amongst	different	research	groups.	Bertran	et	al.	(1992)	calculated	the	affinity	of	System	b0,+	
for	 arginine	 to	 be	 105μM,	 and	 the	 affinity	 for	 cystine	 has	 been	 reported	 to	 range	 from	 30-
67μM	 (Bertran	 et	 al.,	 1992b;	Wells	&	Hediger,	 1992;	 Bertran	 et	 al.,	 1993;	 Lee	 et	 al.,	 1993).	
However,	 this	variability	 is	between	batches	of	oocytes,	and	we	would	expect	 the	affinity	of	
rBAT	and	mutant	transport	measured	within	the	same	experiment	to	be	directly	comparable.	
Further	 investigation	 is	 required,	 perhaps	 using	 a	 different	 rBAT	 expression	 system,	 to	
determine	whether	the	observed	variability	 in	affinity	 is	a	true	measurement,	or	reflective	of	
the	variability	in	oocyte	quality.		
The	 calculated	 Vmax	 values,	 interpolated	 from	 the	 Michaelis-Menten	 kinetics	 were	
356±23,	 and	 28±3	 pmol.oocyte-1.(60min)-1,	 for	 wild-type	 and	mutant	 transport,	 respectively	
(Figure	 5.9A).	 This	 shows	 a	 significant	 reduction	 in	 the	 capacity	 of	 the	 transport	 system	
(p<0.001),	 indicative	 of	 a	 lack	 of	 trafficked	 protein	 at	 the	 oocyte	 membrane.	 This	 is	 in	
accordance	with	what	we	would	 have	 anticipated	 in	 rBAT	mutations.	 Chillarón	et	 al.	 (1997)	
measured	 the	Vmax	 value	of	 [3H]arginine	 transport	via	M467T-expressing	oocytes	 to	be	81±6	
pmol.oocyte-1.(5min)-1,	 compared	 to	 196±16	 in	 the	 wild-type	 expressing	 oocytes.	 The	 data	
were	 transformed	 to	 the	 linear	 Eadie-Hofstee	equation	 to	demonstrate	 the	one-site	binding	
kinetics	 of	 [3H]arginine	 transport	 (Figure	 5.9B).	 When	 fitted	 to	 the	 linear	 equation,	 the	 r2	
values	for	rBAT-	and	M467T-induced	transport	were	0.90	and	0.85,	respectively	(Figure	5.9B).	
Following	 the	 Eadie-Hofstee	 transformation	 the	 gradients	 of	 the	 slopes	 (-Km)	 were	 not	
significantly	 different	 (p=0.45).	 Again,	 this	 raises	 the	 question	 of	 whether	 the	 observed	
difference	in	Km	calculated	by	Michaelis-Menten	kinetics	was	a	true	observation.		





of	 function	 at	 different	 time	 points	 post-injection	 of	 oocytes	 (Figure	 5.7).	 At	 day	 3	 post-
injection	 of	 cRNA	 (50ng),	 10μM	 [3H]arginine	 uptake	 via	M467T-expressing	 oocytes	was	 15%	
and	 43%,	 of	 that	 measured	 in	 wild-type	 expressing	 oocytes	 in	 Figure	 5.9A	 and	 5.7C,	
respectively.	 This	 demonstrates	 some	 variability	 in	 the	 relative	 expression	 and	 subsequent	
function	of	the	mutant	protein	compared	to	wild-type	rBAT.	However,	this	is	reflective	of	the	
variability	 in	 protein	 expression	 between	 oocyte	 batches.	 At	 3	 days	 post-injection	 of	 cRNA,	







Figure	 5.7:	 [3H]Arginine	 uptake	 in	 oocytes	 expressing	 wild-type	 rBAT	 or	 the	 pathogenic	
mutant,	M467T.	 [3H]Arginine	uptake	(10μM,	pH	7.4,	Na+-free)	 in	oocytes	injected	with	water	
(control),	 rBAT,	 or	 M467T	 cRNA	 (1-50ng).	 A,	 [3H]Arginine	 uptake	 in	 water-injected	 (n=20),	
rBAT-	 (n=18-20),	 or	M467T-injected	 oocytes	 (n=19-20),	 1	 day	 post-injection;	 B,	 [3H]Arginine	
uptake	in	water-injected	(n=18),	rBAT-	(n=18-20),	or	M467T-injected	oocytes	(n=18-20),	2	days	
post-injection;	 C,	 [3H]Arginine	 uptake	 in	 water-injected	 (n=20),	 rBAT-	 (n=20),	 or	 M467T-
injected	 oocytes	 (n=14-20),	 3	 days	 post-injection;	 D,	 [3H]Arginine	 uptake	 in	 water-injected	
(n=19),	rBAT-	(n=18-19),	or	M467T-injected	oocytes	(n=10-16),	6	days	post-injection.	Data	are	











































































































































































































































































































































































































Figure	 5.8:	 Transporter-specific	 [3H]arginine	 uptake	 induced	 by	 wild-type	 rBAT	 or	 the	
pathogenic	 cystinuria	 mutant,	M467T.	 Data	 (as	 in	 Figure	 5.6)	 are	 shown	 with	 the	 water-
injected	 control	 values	 subtracted.	 [3H]Arginine	 uptake	 (10μM,	 pH	 7.4,	 Na+-free,	 60min)	 via	
oocytes	injected	with	rBAT	or	M467T	cRNA	(1-50ng).	A,	[3H]Arginine	uptake	in	oocytes	injected	
with	 rBAT	 (black,	 n=18-20),	 or	M467T	 (red,	 n=10-20)	 cRNA	 (1ng),	 1-6	 days	 post-injection;	 B,	
[3H]Arginine	uptake	 in	oocytes	 injected	with	 rBAT	 (black,	n=18-20),	or	M467T	 (red,	n=13-20)	
cRNA	 (5ng),	 1-6	 days	 post-injection;	 C,	 [3H]Arginine	 uptake	 in	 oocytes	 injected	 with	 rBAT	









Figure	 5.9:	 Concentration-dependent	 [3H]arginine	 uptake	 via	 rBAT	 or	 M467T-induced	
transport	 in	 oocytes.	 [3H]Arginine	 uptake	 (0.01-20mM,	 pH	 7.4,	 Na+-free)	 was	 measured	 in	
oocytes	injected	with	rBAT	(black)	or	M467T	(red)	cRNA	(50ng).	Data	are	mean±SEM	(n=27-30,	
from	3	separate	experiments).	A,	Data	 for	rBAT	and	M467T-mediated	uptakes	were	 fitted	to	
Michaelis-Menten	 one-site	 binding	 kinetics	 following	 subtraction	 of	 water-injected	 control	
values	 (r2=0.47	 and	0.08,	 respectively);	 B,	Data	 for	 rBAT	 and	M467T-mediated	uptakes	 from	
panel	 A	 were	 transformed	 to	 the	 linear	 Eadie-Hofstee	 equation	 (r2=0.90	 and	 0.85,	
respectively).	
















































































protein	samples	were	taken	 from	oocytes	 injected	with	water,	 rBAT,	or	M467T	cRNA	(Figure	
5.10A	and	B).	Figure	5.10A	and	B	show	western	blots	carried	out	with	samples	taken	from	two	
different	 batches	 of	 oocytes.	 In	 both	 blots,	 band	 intensity	 increased	 over	 days	 1-3.	 Bands	
appeared	 smeary	 at	 day	 6,	where	 large	 amounts	 of	 protein	were	 resolved	 (Figure	 5.10B).	 A	
reduction	 in	band	 intensity	was	observed	 in	oocytes	expressing	M467T	protein	compared	 to	














oocytes	expressing	M467T,	 the	90kDa	band	appears	 to	be	absent	 (Figure	5.10A	and	B).	 This	
can	 be	most	 clearly	 observed	 from	 the	 1ng	 samples	 taken	 at	 day	 1	 post-injection	 in	 Figure	
5.10A	and	1ng	samples	 taken	at	days	1-3	 in	Figure	5.10B.	This	provides	 further	evidence	 for	
degradation	of	M467T	by	the	ER.	The	mature	glycosylated	form	of	the	protein	(90kDa)	is	only	
produced	 following	 processing	 by	 the	 Golgi	 apparatus.	 These	 data	 support	 the	 results	 of	
Chillarón	et	al.	(1997)	who	observed	a	lack	of	the	mature	glycosylated	form	of	M467T,	yet	did	
not	report	a	decrease	in	the	total	amount	of	85kDa	protein.				
The	detection	of	 rBAT	at	 the	plasma	membrane	was	determined	 through	 imaging	of	
whole	 and	 sectioned	 oocytes	 (Figure	 5.11A-D).	 A	 strong	 signal	 was	 detected	 at	 the	 plasma	
membrane	of	oocytes	expressing	wild-type	rBAT	protein	(Figure	5.11B).	A	much	weaker	signal	
was	visible	in	oocytes	expressing	M467T	(Figure	5.11C).	The	detection	of	low	levels	of	M467T	
protein	 in	 the	plasma	membrane,	 3	days	post-injection,	 is	 consistent	with	 the	 results	 of	 the	
functional	 studies	 (Figures	 5.7C	 and	 5.9A).	 These	 data	 were	 supported	 by	 the	 fluorescence	
measured	 in	 sectioned	 oocytes	 (Figure	 5.11D).	 Bright	 plasma	 membrane	 fluorescence	 was	
visible	 in	 wild-type	 rBAT-expressing	 oocytes	 (middle	 panel),	 with	 some	 intracellular	
fluorescence	 visible	 in	 M467T-expressing	 oocytes.	 However,	 in	 sections	 of	 oocytes	 injected	
	 255	
with	 M467T	 cRNA,	 no	 bright	 membrane	 staining	 was	 observed	 (right-hand	 panel).	 Some	
M467T	 protein	 must	 be	 present	 in	 the	 plasma	 membrane	 as	 [3H]arginine	 uptake	 was	






These	 data	 report	 the	 functional	 expression	 of	 M467T	 in	 oocytes	 and	 indicate	 a	
reduction	in	expression	of	the	protein	and	a	large	reduction	in	Vmax,	which	recovers	over	time.	
A	significant	(p<0.05)	increase	in	the	affinity	of	the	transport	system	was	also	detected	when	
the	 concentration	 dependent	 uptake	 data	 were	 fitted	 to	 the	 Michaelis-Menten	 kinetics.	
However	this	requires	further	investigation.	Furthermore,	it	appears	as	though	only	the	core-
glycosylated	 form	 of	 rBAT	 is	 produced	 following	 the	 introduction	 of	 the	 M467T	 mutation,	
indicating	 that	 the	cell	does	not	process	 this	protein	 in	 the	 same	manner	as	wild-type	 rBAT.	
These	data	are	supported	by	the	broadly	similar	findings	of	Chillarón	et	al.	(1997),	confirming	











































































































rBAT	or	M467T	 cRNA	 (1-50ng),	 1-3	days	post-injection.	 Lanes	 represent	 samples	 taken	 from	
oocytes	injected	with:	a,	water	(control);	b,	rBAT	cRNA	(1ng);	c,	rBAT	cRNA	(5ng);	d,	rBAT	cRNA	
(50ng);	e,	M467T	cRNA	(1ng);	f,	M467T	cRNA	(5ng);	g,	M467T	cRNA	(50ng);	B,	western	blot	of	
total	membrane	protein	samples	 from	oocytes	 injected	with	water	 (control),	 rBAT	or	M467T	
cRNA	 (1-50ng),	 1-6	 days	 post-injection.	 Data	 are	 from	 a	 different	 batch	 of	 oocytes	 to	 those	

























The	 experimental	 measurements	 of	 rBAT	 expression	 described	 in	 section	 5.3.1	 and	
5.3.2	served	as	controls	for	characterisation	of	novel	mutant	function.	Firstly,	we	established,	
through	 investigation	 of	 a	 common	 SNP,	 that	 not	 all	 amino	 acid	 substitutions	 in	 the	 rBAT	
protein	 would	 affect	 function.	 Secondly,	 we	 confirmed	 that	 the	 results	 of	 our	 oocyte	
expression	studies	of	the	pathogenic	mutation,	M467T	replicated	published	findings	(Chillarón	





	[3H]Arginine	 uptake	 was	 performed	 in	 oocytes	 1-6	 days	 post-injection	 of	 water,	 or	
cRNA	for	rBAT	or	M465K	(Figures	5.12-5.13).	One	day	post-injection	of	1-50ng	wild-type	rBAT	
cRNA,	 [3H]arginine	uptake	was	measured	at	3-11	–fold	above	background	 (Figure	5.12A).	No	
significant	 [3H]arginine	 uptake	 (p>0.05)	 was	 measured	 in	 oocytes	 expressing	 M465K	 cRNA.	
Despite	 this,	 some	uptake	was	measured	 in	oocytes	 injected	with	50ng	 cRNA	 for	M465K,	 at	
2.5-fold	 above	 background	 (Figure	 5.12A).	 In	 a	 similar	 manner	 to	 that	 observed	 in	
measurements	of	the	M467T	mutant	protein	(section	5.3.2),	a	recovery	of	M465K	function	was	
observed	over	time	post-injection	(Figure	5.13).	However,	with	M465K,	a	complete	recovery	of	






M465K	mutation	on	 the	kinetic	parameters	of	 [3H]arginine	 transport.	Water-injected	 control	
values	 were	 subtracted	 and	 the	 results	 were	 plotted	 using	 the	 Michaelis-Menten	 equation	
(Figure	 5.14A).	 The	 Km	 of	 the	wild-type	 rBAT	 induced	 transport	 system	 for	 [3H]arginine	was	
measured	at	97±28μM,	1.6-fold	higher	than	the	value	calculated	in	M465K-expressing	oocytes	
(59±25μM).	This	was	a	non-significant	change	 (p=0.3).	The	capacity	of	 the	 induced	 transport	
systems	varied	4-fold	(p<0.001)	between	wild-type	rBAT	(519±30	pmol.oocyte-1.(60min)-1)	and	
M465K-expressing	oocytes	(127±10	pmol.min-1.(60min)-1)	(Figure	5.14B).	The	uptake	of	10μM	
[3H]arginine	via	M465K	at	 3	 days	post-injection	of	 oocytes	was	 52%	of	 the	wild-type.	 In	 the	
previous	 figure,	which	was	 the	mean	of	 two	 single	experiments,	 the	 function	of	M465K	was	
32%	 of	 the	 wild-type	 (Figure	 5.13C).	 This	 demonstrates	 consistency	 in	 the	 measurements	
made	 between	 the	 individual	 experiments.	 	 At	 3	 days	 post-injection	 of	 oocytes	 with	 50ng	
	 260	
cRNA,	 the	 function	of	 the	mutant	 protein	 is	 significantly	 lower	 than	 the	wild-type.	 The	data	
were	transformed	to	the	linear	Eadie-Hofstee	equation	(Figure	5.14B).	The	r2	values	(0.90	and	
0.69	 for	 rBAT	 and	M465K,	 respectively)	 obtained	 following	 the	 transformation	 indicate	 one-
site	binding	kinetics	of	[3H]arginine	transport.	These	values	support	our	hypothesis	that	M465K	









(control),	 rBAT,	 or	 M465K	 cRNA	 (1-50ng).	 A,	 [3H]Arginine	 uptake	 in	 water-injected	 (n=20),	
rBAT-	 (n=20),	 or	 M465K-injected	 oocytes	 (n=19-20),	 1	 day	 post-injection;	 B,	 [3H]Arginine	
uptake	in	water-injected	(n=16),	rBAT-	(n=19-20),	or	M465K-injected	oocytes	(n=19-20),	2	days	
post-injection;	 C,	 [3H]Arginine	 	 uptake	 in	water-injected	 (n=19),	 rBAT-	 (n=19-20),	 or	M465K-
injected	 oocytes	 (n=19-20),	 3	 days	 post-injection;	 D,	 [3H]Arginine	 	 uptake	 in	 water-injected	
(n=17),	rBAT-	(n=16-20),	or	M465K-injected	oocytes	(n=13-21),	6	days	post-injection.	Data	are	
















































































































































































































































































































































































































































values	 subtracted.	 A,	 [3H]Arginine	 uptake	 in	 oocytes	 injected	with	 rBAT	 (black,	 n=19-20),	 or	
M465K	 (red,	n=16-20)	 cRNA	 (1ng),	 1-6	days	post-injection;	B,	 [3H]Arginine	uptake	 in	oocytes	









Figure	 5.14:	 Concentration-dependent	 [3H]arginine	 uptake	 via	 rBAT	 or	 M465K-induced	
transport	 in	 oocytes.	 [3H]Arginine	 uptake	 (0.01-20mM,	 pH	 7.4,	 Na+-free)	 was	 measured	 in	
oocytes	 injected	with	 rBAT	 (black)	 or	M467T	 (red)	 cRNA	 (50ng).	Data	 are	mean±SEM	 (n=10,	
from	a	single	experiment,	representative	of	3).	A,	Data	for	rBAT	and	M465K-mediated	uptakes	
were	 fitted	 to	 Michaelis-Menten	 one-site	 binding	 kinetics	 following	 subtraction	 of	 water-
injected	control	values	(r2=0.47	and	0.25,	respectively);	B,	Data	for	rBAT	and	M467T-mediated	
uptakes	 from	 panel	 A	 were	 transformed	 to	 the	 linear	 Eadie-Hofstee	 equation	 (r2=0.90	 and	
0.69,	respectively).	





















































































expression	 levels	 of	 rBAT	 and	 mutants	 L89P,	 T216M,	 R365W,	 M467T	 and	 M467T	 in	 total	
membrane	 protein	 fractions	 taken	 from	HeLa	 cells,	 they	 did	 not	 see	 any	 reduction	 in	 band	
intensity	of	mutant	proteins	compared	to	the	wild-type.	This	discovery	appears	to	be	unique	to	
our	investigation.	However,	it	could	be	explained	by	an	increase	in	the	rate	of	degradation	of	






in	 oocytes	 expressing	 the	mutant	 protein.	 This	 is	most-clearly	 visible	 at	 day	 6	 post-injection	
(Figure	5.15).	These	data	are	consistent	with	the	report	of	Chillarón	et	al.	(1997)	on	the	cellular	
processing	 of	 the	 M467T	 rBAT	 mutant,	 and	 that	 of	 Bartoccioni	 et	 al.	 (2008)	 regarding	 the	
expression	 of	 L89P,	 T216M,	 R365W,	 M467T	 and	 M467K.	 The	 absence	 of	 the	 mature	
glycosylated	 form	 of	 M465K	 indicates	 degradation	 of	 the	 mutant	 protein	 by	 the	 ERAD	
pathways,	and	a	lack	of	processing	by	the	Golgi	apparatus.	This	is	discussed	in	detail	in	section	
5.4.		
Immunocytochemical	 detection	 of	 rBAT	 protein	 was	 carried	 out	 on	 whole	 oocytes	
(Figure	5.16A-E).	 In	oocytes	 injected	with	 rBAT	cRNA,	bright	 fluorescence	was	observed	at	3	
and	 6	 days	 post-injection	 (Figure	 5.16B	 and	 D,	 respectively).	 A	weak	 signal	was	 detected	 in	
oocytes	 expressing	M465K,	 3	 days	 post-injection	 (Figure	 5.16C).	 By	 day	 6,	 the	 fluorescence	
associated	with	 the	mutant	 protein	 appeared	 to	 be	 brighter	 (Figure	 5.16E),	 correlating	with	
the	recovery	of	function	observed	in	the	uptake	studies.		
The	 data	 from	 whole	 oocyte	 imaging	 were	 supported	 by	 immunocytochemical	
detection	 of	 rBAT	 proteins	 in	 15μm	 oocyte	 sections	 (Figure	 5.16F).	 No	 fluorescence	 was	
detected	at	the	membrane	of	water-injected	control	oocytes	(Figure	5.16F,	left-hand	panel).	A	
bright	band	of	 fluorescence	representing	wild-type	rBAT	protein	was	observed	at	the	plasma	
membrane	 of	 oocytes	 injected	 with	 rBAT	 cRNA	 (Figure	 5.16F,	 middle	 panel).	 In	 oocytes	
expressing	 the	 mutant	 protein,	 no	 membrane	 fluorescence	 was	 identified.	 However,	 bright	
	 266	
intracellular	 staining	 was	 present,	 which	 could	 be	 masking	 any	 weak	 signal	 present	 at	 the	
membrane	(Figure	5.16F,	right-hand	panel).	These	data	complement	the	results	of	the	western	





post-injection	 is	 present	 in	 the	 membrane	 in	 lower	 amounts	 than	 the	 wild-type	 protein,	
resulting	in	a	decrease	in	the	Vmax	of	the	transport	system.	This	lag	in	trafficking	recovers	to	a	
certain	 extent	 over	 time	 post-injection,	 but	 not	 fully.	 Additionally	 it	 appears	 that	 the	 total	
amount	of	M465K	protein	in	the	oocyte	is	reduced,	compared	to	the	wild-type	protein	(Figure	






















































































Figure	 5.15:	 Immunodetection	 of	 rBAT	 and	 M465K	 in	 oocyte	 membranes	 by	 western	
blot.Western	 blot	 of	 total	 membrane	 protein	 samples	 from	 oocytes	 injected	 with	 water	
(control),	 rBAT	 or	 M465K	 cRNA	 (1-50ng),	 1-6	 days	 post-injection.	 Lanes	 represent	 samples	
taken	 from	oocytes	 injected	with:	a,	water;	b,	 rBAT	cRNA	 (1ng);	 c,	 rBAT	cRNA	 (5ng);	d,	 rBAT	






Figure	 5.16:	 Immunocytochemical	 detection	 of	 wild-type	 rBAT	 and	 novel	 mutant	 protein,	






















The	 novel	 pathogenic	 variant,	 N254T,	 was	 identified	 as	 a	 heterozygous	mutation	 in	
Patient	2	of	the	cohort	(see	Chapter	3).	This	previously	unreported	mutation	is	predicted	to	be	
located	 in	 loop-rich	 domain	 B	 of	 the	 rBAT	 extracellular	 domain	 (Figure	 5.1).	 The	 functional	
effect	 of	 N254T	 on	 rBAT	 was	 determined	 by	 [3H]arginine	 uptake	 in	 oocytes	 1-6	 days	 post-
injection	of	wild-type	rBAT	or	N254T	cRNA	(Figures	5.17-5.18).	[3H]Arginine	uptake	via	oocytes	
expressing	N254T	was	not	significantly	different	(p>0.05)	to	uptake	levels	in	equivalent	oocytes	
expressing	wild-type	protein	 on	 any	 day	 post-injection	 (Figure	 5.17).	 In	 the	 oocytes	 injected	
with	lower	amounts	of	cRNA	(1-5ng)	[3H]arginine	uptake	continued	to	increase	from	day	1-6	in	
both	 the	 wild-type	 and	mutant	 induced	 transport	 systems	 (Figure	 5.17A	 and	 B).	 In	 oocytes	
injected	with	50ng	wild-type	or	mutant	cRNA,	expressing	higher	levels	of	protein,	[3H]arginine	
uptake	reached	maximum	levels	by	day	2	(Figure	5.18).		
	 To	 identify	 any	 change	 in	 the	 kinetic	 parameters	 of	 System	 b0,+	transport	 by	 N254T,	
concentration-dependent	 (0.01-1mM)	 [3H]arginine	 uptake	 was	 performed,	 3	 days	 post-
injection	 of	 oocytes	 (Figure	 5.19).	 Following	 subtraction	 of	 water-injected	 control	 oocyte	
values,	 the	 data	 were	 plotted	 using	 the	Michaelis-Menten	 equation	 (Figure	 5.19A).	 The	 Km	
values	for	wild-type	rBAT	and	N254T-induced	[3H]arginine	transport	in	oocytes	were	calculated	




transformed	 to	 the	Eadie-Hofstee	equation	 (Figure	5.19B).	The	 r2	value	of	 the	data	 following	
transformation	 to	 the	 linear	 equation	were	 0.91,	 indicating	 one-site	 binding	 kinetics	 (Figure	
5.19B).	 Although	 no	 reduction	 in	 [3H]arginine	 transport	was	 detected	 in	 the	 series	 of	 10μM	
uptake	experiments	presented	in	Figure	5.17,	the	significant	reduction	in	Vmax	measured	in	the	
concentration-dependent	uptakes	(Figure	5.19)	suggests	that	N254T	is	a	pathogenic	mutation.	
Additionally,	 the	evidence	that	 it	was	the	only	variant	discovered	 in	the	genotype	analysis	of	
Patient	2	of	our	cohort	(see	Chapter	3)	indicates	that	it	is	responsible,	at	least	in	part,	for	the	
phenotype	 of	 this	 patient.	 Saadi	 et	 al.	 (1998)	 reported	 no	 significant	 (p>0.05)	 reduction	 in	
uptake	of	[14C]cystine	in	oocytes	following	expression	of	rBAT	containing	the	SLC3A1	mutation	
S217R,	 24h	 post-injection	 of	 cRNA.	 However,	 when	 the	 experiment	 was	 repeated	 6h	 post-
injection	a	>50%	reduction	 in	 transport	was	observed	 (Saadi	et	al.,	1998).	This	 indicates	 that	
some	rBAT	mutants	show	a	shorter	delay	in	trafficking	than	others	when	expressed	in	oocytes.	
The	“milder”	effect	of	N254T	on	rBAT	function	than	other	mutations	is	also	evidenced	by	the	
fact	 that	 the	 reduction	 in	 Vmax	 (49%)	 is	 less	 than	 that	 observed	 in	 mutant	 proteins	 M467T	














Figure	 5.17:	 [3H]Arginine	 uptake	 in	 oocytes	 following	 the	 expression	 of	 rBAT	 or	 the	 novel	
mutant,	N254T.	[3H]Arginine	uptake	(10μM,	pH	7.4,	Na+-free,	60min)	via	oocytes	injected	with	
water	 (controls),	 rBAT	 (1-50ng),	 or	 N254T	 (1-50ng)	 cRNA.	 A,	 [3H]Arginine	 uptake	 in	 water-
injected	(n=20),	rBAT-	(n=19-20),	or	N254T-injected	oocytes	(n=19-20),	1	day	post-injection;	B,	
[3H]Arginine	 uptake	 in	 water-injected	 (n=19),	 rBAT-	 (n=18-20),	 or	 N254T-injected	 oocytes	
(n=19-20),	2	days	post-injection;	C,	[3H]Arginine		uptake	in	water-injected	(n=18),	rBAT-	(n=18-
20),	 or	 N254T-injected	 oocytes	 (n=18-20),	 3	 days	 post-injection;	 D,	 [3H]Arginine	 	 uptake	 in	






















































































































































































































































































































































































































Figure	 5.19:	 Concentration-dependent	 [3H]arginine	 uptake	 via	 rBAT	 or	 N254T-induced	
transport	 in	 oocytes.	 [3H]Arginine	 uptake	 (0.01-5mM,	 pH	 7.4,	 Na+-free)	 was	 measured	 in	
oocytes	 injected	 with	 rBAT	 (black)	 or	 N254T	 (red)	 cRNA	 (50ng),	 3	 days	 post-injection	 of	

















































































	 Western	 blot	 analysis	 of	 total	 oocyte	 membrane	 proteins	 was	 carried	 out	 1-6	 days	
post-injection	of	wild-type	rBAT	or	N254T	cRNA	(Figure	5.20).	Doublet	bands	between	85	and	
90kDa	were	visible	1	day	post-injection	in	lanes	representing	oocytes	injected	with	both	rBAT	
and	 N254T	 cRNA	 (Figure	 5.20,	 Day	 1,	 lanes	 b-g).	 The	 bands	 representing	 N254T-injected	
oocytes	appeared	slightly	smaller	in	intensity	than	those	from	comparable	wild-type	samples,	
yet	 closer	 in	 intensity	 to	 the	 wild-type	 bands	 than	 was	 observed	 with	mutants	M467T	 and	
M465K	 (Figures	 5.10	 and	5.15,	 respectively).	 The	 lower	 intensity	 is	 particularly	 noticeable	 in	
oocytes	 injected	with	50ng	 cRNA.	However,	 the	 small	 size	of	 the	band	 in	 lane	 g	on	day	6	 is	
likely	a	blotting	error,	due	to	the	proximity	to	the	end	of	the	membrane.	Unfortunately,	due	to	
time	 constraints	 this	 is	 the	only	 available	blot	 for	N254T.	However,	 the	oocytes	used	 in	 this	
western	blot	were	from	the	same	batch	as	those	used	for	one	of	the	two	uptakes	presented	in	








forms	 of	 the	 protein	 are	 detected	 in	wild-type	 and	N254T	 expressing	 oocytes	 (Figure	 5.20),	
indicating	processing	of	the	protein	by	the	Golgi	apparatus	(Bartoccioni	et	al.,	2008).		
	 The	 localisation	 of	 rBAT	 protein	 at	 the	 membrane	 of	 whole	 oocytes	 by	
immunofluorescent	detection	did	not	reveal	any	visible	difference	between	the	wild-type	and	





visible	 in	 the	 N254T-expressing	 oocytes	 (Figure	 5.21E)	 than	 the	 wild-type	 controls	 (Figure	
5.21D).		
	 Immunocytochemical	 detection	 of	 these	 proteins	 was	 also	 carried	 out	 in	 oocyte	
sections,	 3	 days	 post-injection	 (Figure	 5.21F).	 Strong	 signals	 representative	 of	 plasma	
membrane	 protein	 were	 detected	 in	 oocytes	 expressing	 wild-type	 rBAT	 and	 N254T	 (Figure	
5.21F,	 middle	 panel	 and	 right-hand	 panel,	 respectively).	 However,	 the	 fluorescence	 in	 the	





the	 wild-type	 protein,	 although	 with	 a	 reduced	 Vmax	 (Figure	 5.17-19).	 Less	 protein	 was	
detected	by	western	blot.	This	novel	mutation	was	 identified	 in	 the	genotype	of	a	cystinuric	
patient,	with	no	other	causal	variants	(Chapter	3).	To	date,	only	mutations	present	in	the	TIM	
barrel	 region	 of	 rBAT,	 along	 with	 one	 transmembrane	 domain	 mutation	 (L89P)	 have	 been	
characterised	 (Bartoccioni	 et	 al.,	 2010).	 The	 milder	 effect	 of	 this	 mutation	 on	 membrane	







































































































































































































































































































































	 The	 novel	 cystinuria	mutation,	 L416P,	was	 identified	 in	 the	 compound	heterozygous	
genotype	of	Patient	26	of	our	cohort,	along	with	known	cystinuria	mutation	M467T	(Chapter	
3).	Based	on	the	predicted	structure	of	 the	rBAT	extracellular	domain,	 the	 leucine	residue	at	






rBAT	 cRNA	 at	 any	 time	 post-injection	 (Figure	 5.22).	 Following	 subtraction	 of	 background	
uptake	measurements,	 [3H]arginine	uptake	 levels	 rose	 from	10±2	pmol.oocyte-1.(60min)-1	 on	
day	1	to		32±5	pmol.oocyte-1.(60min)-1	by	day	6	in	oocytes	injected	with	50ng	wild-type	cRNA	




injection	 of	 oocytes	 with	 water,	 or	 wild-type	 rBAT	 or	 L416P	 cRNA	 (Figure	 5.24).	 Data	 were	
plotted	 to	 one-site	 binding	 Michaelis	 Menten	 kinetics	 following	 the	 subtraction	 of	 water-
injected	control	values	(Figure	5.24A).	The	Km	of	the	induced	wild-type	(96±17μM)	and	L416P	
(53±23μM)	 transport	 systems	 were	 not	 significantly	 different	 (p=0.17),	 despite	 a	 1.8-fold	
change.	However,	a	large	reduction	(64%)	in	Vmax	was	observed	(p<0.001).	The	fit	of	the	L416P	
data	 to	 the	 curve	 was	 poor	 (r2=0.19)	 (Figure	 5.24A).	 This	 was	 also	 observed	 following	
transformation	of	the	data	to	the	Eadie-Hofstee	equation	(r2=0.60,	Figure	5.24B).	The	affinities	
(Km),	 calculated	 by	 the	 gradients	 of	 the	 slopes	 in	 Figure	 5.24B,	 were	 significantly	 different	
following	 the	 linear	 transformation	 of	 the	 data	 (p=0.01)	 (Figure	 5.24B).	 This	 is	 further	
supported	by	 the	 fact	 that	 in	 the	concentration-dependent	experiment,	 the	10μM	uptake	 in	
oocytes	expressing	L416P	was	97%	of	those	measured	in	wild-type	expressing	oocytes	(Figure	
5.24A).	 This	 is	 consistent	 with	 the	 results	 of	 the	 time-dependent	 expression	 studies	
represented	in	Figure	5.22C,	where	[3H]arginine	uptake	in	L416P-expressing	oocytes	was	95%	
of	that	via	the	wild-type	transport	system.	However,	 in	the	concentration-dependent	uptake,	
the	 function	 of	 L416P	was	 only	 63%	of	 the	wild-type	 transport	 system	 at	 1mM	 [3H]arginine	
(Figure	 5.24A).	 These	 data,	 in	 addition	 to	 the	 significant	 reduction	 in	 Vmax	 measured	 in	 the	
concentration-dependent	uptakes	(Figure	5.24)	suggests	that	L416P	is	a	pathogenic	mutation.	




rBAT	 with	 b0,+AT.	 This	 effect	 of	 mutations	 in	 rBAT	 has	 not	 been	 reported	 previously	 in	 the	
literature.	As	discussed	in	Chapter	1,	it	was	observed	that	CD98	can	induce	System	b0,+	activity	
when	 co-expressed	 with	 b0,+AT	 in	 HRPE	 cells	 (Rajan	 et	 al.,	 2000).	 However,	 the	 induced	
transport	system	had	a	significantly	lower	(p<0.05)	affinity	for	the	prototypical	substrates	than	
when	 transport	 was	 induced	 by	 rBAT	 and	 b0,+AT	 co-expression	 (Rajan	 et	 al.,	 2000).	
Additionally,	 the	 measurements	 of	 transport	 affinity	 in	 oocytes	 have	 varied	 following	 the	
expression	 of	 rBAT	 protein	 from	 different	 species	 (see	 Chapter	 1).	 This	 implies	 that	 small	
changes	 to	 the	 tertiary	 structure	 of	 the	 heavy	 chain	 used	 to	 traffic	 b0,+AT	 to	 the	membrane	
could	potentially	 influence	the	substrate	specificity	of	the	transport	system.	In	our	study,	the	
poor	fit	of	the	data	to	the	two	equations	makes	 it	 impossible	to	draw	a	definitive	conclusion	






Figure	 5.22:	 [3H]Arginine	 uptake	 in	 oocytes	 expressing	 wild-type	 rBAT	 or	 the	 novel	 rBAT	
mutant,	L416P.	[3H]Arginine	uptake	(10μM,	pH	7.4,	Na+-free,	60min)	via	oocytes	injected	with	
water	 (controls),	 rBAT,	 or	 L416P	 cRNA	 (1-50ng).	 A,	 [3H]Arginine	 uptake	 in	 water-injected	
(n=10),	 rBAT-	 (n=9-10),	 and	 L416P-expressing	 oocytes	 (n=6-10),	 1	 day	 post-injection;	 B,	
[3H]Arginine	 uptake	 in	 water-injected	 (n=10),	 rBAT-	 (n=6-10),	 and	 L416P-expressing	 oocytes	
(n=8-10),	 2	 days	 post-injection;	 C,	 [3H]Arginine	 uptake	 in	water-injected	 (n=9),	 rBAT-	 (n=10),	
and	L416P-expressing	oocytes	(n=7-9),	3	days	post-injection;	D,	[3H]Arginine	uptake	in	water-





































































































































































































































































































































































































































Figure	 5.24:	 Concentration-dependent	 [3H]arginine	 uptake	 via	 rBAT	 or	 L416P-induced	
transport	 in	 oocytes.	 [3H]Arginine	 uptake	 (0.01-5mM,	 pH	 7.4,	 Na+-free)	 was	 measured	 in	
oocytes	3	days	post-injection	of	oocytes	with	 rBAT	 (black)	or	N254T	 (red)	cRNA	 (50ng).	Data	
are	mean±SEM	(n=18-20,	from	2	separate	experiments).	A,	Data	for	rBAT	and	N254T-mediated	
uptakes	 were	 fitted	 to	 Michaelis-Menten	 one-site	 binding	 kinetics	 following	 subtraction	 of	
water-injected	 control	 values	 (r2=0.73	 and	 0.19,	 respectively);	 B,	 Data	 from	 panel	 A	 was	
transformed	to	the	Eadie-Hofstee	equation	(r2=0.91	and	0.60,	respectively).		
	












































































out	 in	 total	 membrane	 proteins	 from	 oocytes	 1-6	 days	 post-injection	 (Figure	 5.25).	 A	 non-
specific	band	was	observed	at	75kDa	 in	water-injected	control	oocytes	and	all	cRNA-injected	
oocyte	samples,	 related	to	a	new	batch	of	 the	M2	anti-FLAG	antibody	 (Figure	5.25).	A	single	
rBAT	 band	 at	 85kDa	was	 detected	with	 increasing	 intensity	 in	 oocytes	 injected	with	 1-50ng	
wild-type	cRNA	on	day	1	 (Figure	5.25,	 lanes	b-d).	At	days	3	and	6,	a	doublet	 rBAT	band	was	




injection.	 It	 appeared	 from	 the	band	 intensity	 that	 less	 total	 L416P	protein	was	produced	 in	
the	oocytes	than	those	expressing	the	wild-type	protein,	at	day	1	post-injection.	However,	by	
day	6,	 the	band	observed	 in	50ng	 L416P-injected	oocytes	 appears	 closer	 in	 size	 to	 the	50ng	
rBAT-injected	oocytes	(Figure	5.25,	day	6,	lanes	d	and	g,	respectively).		
	 Fluorescent	 confocal	 imaging	of	whole	oocytes	 expressing	both	proteins	was	 carried	
out	to	detect	plasma	membrane	 localisation	(Figure	5.26A-E).	Bright	membrane	fluorescence	
was	 visible	 in	 oocytes	 injected	 with	 rBAT	 and	 L416P	 cRNA,	 3	 days	 (Figure	 5.26B	 and	 C,	
respectively)	 and	 6	 days	 (Figure	 5.26D	 and	 E,	 respectively)	 post-injection.		
Immunocytochemical	 detection	 of	 wild-type	 rBAT	 and	 L416P	 protein	 was	 carried	 out	 on	
sectioned	 oocytes	 injected	with	water	 (control),	 or	 50ng	 rBAT	 or	 L416P	 cRNA,	 3	 days	 post-
injection	(Figure	5.26F).	In	water-injected	control	oocytes	there	was	a	low	level	of	non-specific	
intracellular	fluorescence.	However,	no	specific	membrane	signal	was	detected	(Figure	5.26F,	
left-hand	 panel).	 In	 oocytes	 expressing	 the	 wild-type	 rBAT	 protein,	 bright	 membrane	
fluorescence	 was	 visible,	 along	 with	 a	 greater	 intracellular	 staining	 (Figure	 5.26F,	 middle	
panel).	 Similarly,	 oocytes	 expressing	 L416P	 showed	 fluorescence	 at	 the	 plasma	 membrane	
(Figure	 5.26F,	 right-hand	panel).	However,	 this	 appeared	more	diffuse	 that	 that	 recorded	 in	




As	 expected,	 a	 significant	 (p<0.001)	 reduction	 in	 Vmax	 was	 observed	 in	 the	 concentration	
dependent	 experiments	 (Figure	 5.24).	However,	 a	 reduction	 in	 Km	was	 also	observed,	which	
was	significant	 (p<0.001)	 following	transformation	of	 the	data	to	the	Eadie-Hofstee	equation	
(Figure	5.24B).	Although	these	values	may	not	be	accurate	due	to	a	poor	fit	of	the	data	to	the	
equations,	 it	 can	 be	 observed	 from	 the	 concentration-dependent	 uptake	 that	 the	 value	 at	
10μM	 is	 not	 significantly	 different	 to	 the	 wild-type	 (p>0.05).	 However,	 with	 increasing	
	 287	
concentration,	 a	 reduction	 in	 uptake	 in	 L416P-expressing	 oocytes,	 relative	 to	 the	 wild-type	
controls	 can	 be	 observed	 (Figure	 5.24A).	 This	 is	 consistent	 with	 a	 change	 in	 affinity	 of	 the	
transport	system.	No	difference	 in	membrane	expression	between	L416P	and	wild-type	rBAT	
was	 observed	 with	 immunocytochemistry,	 consistent	 with	 the	 results	 displayed	 in	 Figures	
3.22-3.23.	However,	a	slight	reduction	in	total	protein	was	detected	by	western	blot.	Overall,	









































































































































































































































































































































(50ng)	 6	 days	 post-injection.	 	 Scale	 bar,	 150µm;	 white	 arrows	 indicate	 the	 location	 of	 the	
plasma	membrane	in	water-injected	oocytes;	F,	Representative	microscopy	images	(n=3-4)	of	


















The	 final	 rBAT	 mutation	 investigated	 in	 this	 study	 was	 the	 novel	 mutation	 Y579D,	
identified	 in	 two	 unrelated	 patients	 (6	 and	 20)	 of	 the	 current	 cohort	 (see	 Chapter	 3).	 The	
tyrosine	 residue	 at	 position	 579	 in	 the	 molecule	 is	 predicted	 to	 be	 located	 in	 the	 β	 sheet	
structure	 of	 rBAT	 extracellular	 domain	 C,	 based	 on	 the	model	 of	 rBAT	 created	 using	 the	B.	
cereus	oligo-1,6-glucosidase	crystal	structure	(Figure	5.1).		
	[3H]Arginine	uptake	was	measured	in	oocytes	1-6	days	post	injection	of	water,	or	wild-
type	 rBAT,	 or	 Y579D	 cRNA	 (1-50ng)	 (Figures	 5.27-5.28).	 At	 day	 1	 post-injection,	 [3H]arginine	
uptake	was	observed	in	oocytes	expressing	the	wild-type	protein.	However,	no	uptake	above	
background	 was	 observed	 in	 oocytes	 injected	 with	 any	 amount	 of	 Y579D	 cRNA.	 Over	 time	
post-injection,	 the	 levels	 of	 [3H]arginine	 uptake	 increased	 in	 all	 cRNA	 injected-oocytes.	 As	
observed	 in	M467T	 and	M465K	 rBAT	mutants,	 a	 recovery	 of	 Y579D	 function	was	measured	
over	time	post-injection	(Figure	5.27).	Following	subtraction	of	water-injected	control	values,	
[3H]arginine	uptake	in	oocytes	injected	with	Y579D	cRNA	(50ng)	was	not	significantly	different	
(p>0.05)	 to	 that	 in	oocytes	 injected	with	wild-type	cRNA	at	day	6	 (Figure	5.28C).	A	complete	




injection	 of	 oocytes	 with	 water,	 wild-type	 rBAT,	 or	 Y579D	 cRNA.	 Following	 subtraction	 of	
water-injected	control	values,	the	data	were	plotted	using	the	Michaelis-Menten	equation	to	
determine	 the	 transport	 kinetics	 of	 the	 induced	 transport	 system	 (Figure	 5.29A).	 The	 Km	 of	
arginine	 transport	 in	 wild-type	 rBAT-injected	 oocytes	 was	 92±15μM,	 and	 in	 Y579D-injected	
oocytes,	 53±30μM.	 These	 values	were	 not	 significantly	 different	 (p=0.25),	 despite	 a	 1.7-fold	
change.	 The	 calculated	 Vmax	 values	 for	wild-type	 and	 Y579D-induced	 transport	were	 300±17	
and	 16±3	 pmol.oocyte-1.(60min)-1,	 respectively.	 This	 19-fold	 reduction	 (p<0.001)	 in	 Vmax	 is	
associated	 with	 a	 lower	 amount	 of	 transport	 protein	 at	 the	 oocyte	 membrane.	 The	 mean	
10μM	 [3H]arginine	 uptake	 calculated	 in	 the	 Y579D	 concentration-dependent	 experiments	
(Figure	 5.29A)	 was	 10%	 of	 that	 measured	 in	 wild-type	 expressing	 oocytes	 (Figure	 5.29B).	
However,	in	two	previous	batches	of	oocytes,	the	mean	Y579D	function	was	53%	of	the	wild-
type	 at	 day	 3	 post-injection	 (Figure	 5.27C).	 This	 is	 reflective	 of	 poorer	 oocyte	 quality	 in	 the	
batches	used	to	perform	the	concentration-dependent	uptake	experiments	(Figure	5.29).	The	
lower	expression	levels	at	day	3	post-injection	in	Figure	5.29A,	provide	results	similar	to	those	




poorer	 quality.	 The	 levels	 of	 wild-type	 expression	 were	 also	 lower	 in	 Figure	 5.29A	 (22.6±3	
pmol.oocyte-1.(60min)-1)	than	the	mean	values	from	the	two	batches	used	in	the	experiments	
presented	in	Figure	5.28C	(40.3±9	pmol.oocyte-1.(60min)-1).	The	poor	expression	of	Y579D	at	3	
days	 post-injection	 of	 oocytes	 in	 Figure	 5.29A,	 led	 to	 a	 poor	 fit	 of	 the	 data	 to	 the	 curve	
(r2=0.12).	 Following	 transformation	 of	 the	 data	 to	 the	 Eadie-Hofstee	 equation,	 the	 data	
indicated	one-site	binding	kinetics	of	 [3H]arginine	 transport	 induced	by	both	proteins	 (Figure	
5.29B).	 Despite	 the	 52%	 reduction	 in	 the	 interpolated	 Km	 value	 from	 the	 Eadie-Hofstee	
equation,	 the	 gradients	 of	 the	 slopes	 were	 not	 significantly	 different	 (p=0.7),	 further	
demonstrating	a	lack	of	change	to	the	affinity	of	the	transport	system	by	novel	mutant	Y579D.	
Although	the	relative	function	of	Y579D-induced	transport	compared	to	the	wild-type	is	lower	
in	 Figure	 5.29	 than	 that	 demonstrated	 at	 day	 3	 in	 Figure	 5.27C,	 we	 hypothesise	 that	 the	
function	would	still	have	recovered	over	time.	We	have	observed	a	fluidity	of	rBAT	and	mutant	
protein	expression	in	oocytes	over	time.	The	data	presented	in	Figures	5.27	and	5.28	provide	a	
“snapshot”	 of	 this	 process	 at	 different	 time	 points.	 In	 Figure	 5.29,	 a	 “snapshot”	 is	 also	
presented,	 however,	 the	 poorer	 quality	 of	 these	 oocytes	 has	 led	 to	 a	 greater	 delay	 in	 the	
expression	 of	 the	 mutant	 protein.	 Amongst	 all	 experiments	 we	 have	 shown	 that	 Y579D	












days	 post-injection;	 C,	 [3H]Arginine	 uptake	 in	 water-injected	 (n=19),	 rBAT-	 (n=19-20),	 and	
Y579D	cRNA-injected	oocytes	(n=18-20),	3	days	post-injection;	D,	[3H]Arginine	uptake	in	water-
injected	 (n=19),	 rBAT	 (n=19-20),	 and	 Y579D	 cRNA-injected	 oocytes	 (n=12-20),	 6	 days	 post-











































































































































































































































































































































values	 subtracted.	 A,	 [3H]Arginine	 uptake	 in	 oocytes	 injected	with	 rBAT	 (black,	 n=19-20),	 or	
Y579D	 (red,	 n=12-20)	 cRNA	 (1ng),	 1-6	 days	 post-injection;	 B,	 [3H]Arginine	 uptake	 in	 oocytes	






Figure	 5.29:	 Concentration-dependent	 [3H]arginine	 uptake	 via	 rBAT	 or	 Y579D-induced	
transport	 in	 oocytes.	 [3H]Arginine	 uptake	 (0.01-1mM,	 pH	 7.4,	 Na+-free)	 was	 measured	 in	
oocytes	 at	 day	 3	 post-injection	 of	 rBAT	 (black)	 or	 Y579D	 (red)	 cRNA	 (50ng).	 Data	 are	
mean±SEM	 (n=19-20,	 from	 2	 separate	 experiments).	 A,	 Data	 for	 rBAT	 and	 Y579D-mediated	
uptakes	 were	 fitted	 to	 Michaelis-Menten	 one-site	 binding	 kinetics	 following	 subtraction	 of	
water-injected	 control	 values	 (r2=0.68	 and	 0.12,	 respectively);	 B,	 Data	 from	 panel	 A	 were	
transformed	to	the	linear	Eadie-Hofstee	equation	(r2=0.88	and	0.73,	respectively).		
	 	



















































































wild-type	 expressing	 oocytes,	 indicating	 a	 translation	 of	 mutant	 protein	 despite	 the	 lack	 of	
function	 at	 1	 day	 post-injection	 (Figure	 5.30A).	 Doublet	 bands	 were	 detected	 in	 lanes	
representing	 both	wild-type	 and	mutant	 samples,	 indicating	 the	 presence	 of	 both	 the	 core-	
and	mature-glycosylated	forms	of	rBAT.	It	can	be	noted	from	this	western	blot	image	that	the	
mature-glycosylated	 band	 (90kDa)	 in	 the	 wild-type	 samples	 is	 greater	 than	 the	 core-




relative	 to	 the	mutant	 protein.	 In	 the	 bands	 representing	 oocytes	 injected	with	 5	 and	 50ng	
cRNA,	 the	mutant	 protein	 appeared	 to	 be	 produced	 in	 lower	 quantities	 than	 the	 wild-type	
(Figure	 5.30A	 lands	 c-d	 and	 f-g).	 A	 second	western	 blot	was	 carried	 out	 using	 protein	 from	
oocytes	 1-6	 days	 post-injection	 (Figure	 5.30B).	 As	 observed	 in	 the	 western	 blot	 of	 L416P	
protein	 (Figure	5.25)	 a	 non-specific	 band	was	detected	 at	 75	 kDa,	 associated	with	 the	 same	
batch	 of	 antibody.	 This	 band	was	 present	 in	 the	water-injected	 oocyte	 protein	 lane	 (Figure	







Whole	 oocyte	 immunocytochemistry	 was	 carried	 out	 to	 support	 the	 data	 from	 the	
functional	 studies.	 At	 day	 3	 post-injection,	 membrane	 fluorescence	 in	 Y579D-expressing	
oocytes	 (Figure	 5.31C)	 was	 greater	 than	 water-injected	 controls	 (Figure	 5.31A),	 but	 visibly	
lower	than	wild-type	rBAT-expressing	oocytes	(Figure	5.31B).	However,	by	day	6,	the	detected	
membrane	 fluorescence	 of	 Y579D-expressing	 oocytes	 (Figure	 5.31E)	 appeared	 brighter.	 The	
apparent	 increase	 over	 time	 in	 the	 amount	 of	 mutant	 protein	 relative	 to	 the	 wild-type	





with	water,	 rBAT	 or	 Y579D	 cRNA	 (Figure	 5.31F).	 In	 oocytes	 injected	with	wild-type	 cRNA,	 a	
strong	 signal	 was	 detected	 at	 the	 plasma	 membrane,	 along	 with	 some	 intracellular	
fluorescence	(Figure	5.31F,	middle	panel).	This	intracellular	fluorescence	was	greater	than	the	
background	signal	visible	in	the	water-injected	control	oocytes	(Figure	5.31F,	left-hand	panel).	
No	 membrane	 fluorescence	 was	 visible	 in	 Y579D-expressing	 oocyte	 sections	 (Figure	 5.25G,	
right-hand	 panel),	 yet	 the	 intracellular	 fluorescence	 was	 visibly	 brighter	 than	 in	 the	 water-
injected	 controls.	 It	 is	 possible	 that	 fluorescence	was	 detected	 at	 the	membrane	 as	well	 as	
intracellularly,	 however	 in	 the	 absence	 of	 a	membrane-specific	 fluorescent	marker	 it	 is	 not	
possible	to	determine	this	from	these	images	alone.		
In	 conclusion,	 the	 data	 presented	 in	 this	 section	 indicate	 that	 Y579D	 protein	 is	
translated	 following	 injection	 into	 oocytes,	 and	 is	 present	 in	 the	 oocyte	 24h	 post-injection	
(Figure	 5.30),	 despite	 a	 lack	 of	 function	 (Figure	 5.27-5-28).	 Over	 time,	 the	 function	 of	 the	
protein	 was	 seen	 to	 recover	 (Figure	 5.28).	 This	 functional	 data	 was	 supported	 by	
immunocytochemical	detection	of	Y579D,	which	 indicated	that	 the	amount	of	protein	at	 the	
membrane	 increased	 over	 time	 (Figure	 5.31).	 The	 results	 of	 the	 concentration-dependent	
uptake	are	consistent	with	a	mutation	that	leads	to	a	trafficking	defect,	and	lack	of	protein	at	
the	membrane	 (Figure	5.29).	Although	some	decrease	 in	 the	affinity	of	 the	 transport	system	
was	 observed,	 the	 standard	 error	 values	 were	 large	 and	 the	 decrease	 was	 not	 significant	
(p>0.05).	The	observed	decrease	is	 likely	due	to	a	poor	fit	of	the	data	to	the	equation	due	to	
the	low	levels	of	uptake.	Despite	inconsistencies	with	the	levels	of	Y579D	expression	compared	
to	 the	wild-type	protein	between	experiments,	we	have	 shown	 that	 the	expression	of	 these	















































































































































M465K,	 N254T,	 L416P	 and	 Y579D.	 In	 this	 chapter,	 the	 effects	 of	 these	 mutations	 on	 the	
expression	of	 rBAT	have	been	measured	 in	Xenopus	oocytes.	Additionally,	 the	effects	of	 the	
common	 SNP	 M618I	 and	 the	 pathogenic	 mutation	 M467T	 upon	 rBAT	 expression	 were	




distinguishable	 from	 wild-type.	 As	 expected,	 a	 reduction	 in	 Vmax	 occurs	 with	 most	 of	 the	
mutants	 although	 the	 absolute	 decrease	 in	 uptake	 is	 not	 easily	 comparable	 between	 the	
mutants	 as	 each	 mutant	 was	 compared	 with	 the	 control	 wild-type	 in	 distinct	 data	 sets.	
However,	 the	 time	 dependent	 expression	 gives	 a	 better	 indicator	 of	 the	mutation	 severity.	
Reduced	 activity	 was	 observed	 following	 injection	 with	 M465K,	 M467T	 and	 Y579D.	 A	 full	
recovery	was	observed	with	M467T	and	Y579D,	but	only	partial	recovery	with	M465K.	It	seems	
likely	 that	 a	 full	 recovery	would	 be	 observed	with	M465K	 if	 the	 incubation	 period	 could	 be	
extended	beyond	6	days.	 Similarly,	 it	 seems	equally	 likely	 that	 reduced	expression	would	be	
observed	with	N254T	and	 L416P	 if	 the	 incubation	period	was	 reduced	 to	 less	 than	one	day.	
Even	 a	 small	 time	 delay	 in	 expression	 would	 lead	 to	 a	 large	 decrease	 in	 transport	 capacity	
during	 the	 early	 days	 of	 incubation	 when	 the	 levels	 of	 protein	 expression	 in	 the	 oocyte	
membranes	are	yet	to	reach	equilibrium.	The	saturation	curves	support	this	idea.	Additionally,	
it	is	worth	noting	that	no	mutant	was	associated	with	an	increase	in	Vmax.	Thus,	it	seems	that	a	
time	 and	 cRNA-dependent	 over-expression	 is	 seen	with	 all	 of	 the	mutants	 to	 one	 extent	 or	
another.	This	is	possibly	the	best	indicator	of	the	severity	of	the	trafficking	defect.		
In	 a	 broad	 sense,	 the	 western	 blots	 and	 immunocytochemical	 data	 support	 these	
conclusions.	 The	 absolute	 levels	 of	 function	 are	 likely	 related	 to	 expression	 of	 the	 mature	
protein,	 thus	a	 second	 indicator	of	 the	 relative	severity	of	 the	mutants	could	be	 the	 ratio	of	
membrane	 expression	 of	 the	 two	 protein	 bands.	 We	 predict	 that	 a	 relatively	 high	 level	 of	
expression	 of	 the	 mature-glycosylated	 (90kDa)	 band	 would	 be	 observed	 in	 mild	 cases	 (as	
observed	with	N254T)	but	that	a	relatively	low	level	would	be	seen	in	more	severe	cases	(e.g.	













To	 extend	 these	 general	 observations	 some	 preliminary	 studies	 were	 performed	 to	
identify	 how	 these	 “Type	 A”	 (SLC3A1)	 mutations	 cause	 a	 phenotype	 in	 patients,	 but	 not	 in	
obligate	 heterozygote	 carriers,	 by	 co-expression	 of	wild-type	 and	mutant	 rBAT.	 [3H]Arginine	
uptake	was	measured	in	oocytes	injected	with	25-50ng	wild-type	cRNA,	3	days	post-injection	
of	oocytes	(Figure	5.32).	No	significant	difference	(p>0.05)	in	uptake	was	measured,	confirming	
our	 earlier	 findings	 that	 amounts	 of	 rBAT	 cRNA	 greater	 than	 10ng	 produce	maximal	 uptake	
levels	 in	 oocytes	 (Figure	 4.2).	 In	 oocytes	 injected	 with	 25-50ng	 M467T	 cRNA,	 [3H]arginine	








5.3.4,	 it	 was	 reported	 that	 an	 effect	 on	 rBAT	 function	 by	 L416P	was	 not	 always	 detectable	
following	 expression	 in	 oocytes	 (Figures	 5.22-23).	 In	 Figure	 5.32B,	 no	 significant	 difference	
(p>0.05)	was	measured	in	oocytes	expressing	wild-type	rBAT,	L416P,	or	a	combination	of	both.	
However,	 the	 results	 from	 [3H]arginine	 uptake	 into	 Y579D-expressing	 oocytes	 were	 broadly	
similar	to	those	of	M467T	(Figure	5.32C).	[3H]Arginine	uptake	in	oocytes	injected	with	25-50ng	
Y579D	cRNA	was	significantly	lower	(p<0.001)	than	in	those	injected	with	50ng	cRNA	for	wild-
type	 rBAT	 (Figure	 5.32C).	 When	 Y579D	 cRNA	 (25ng)	 was	 co-injected	 with	 wild-type	 cRNA	
(25ng),	uptake	 levels	were	equivalent	 to	 those	 in	oocytes	 injected	with	50ng	wild-type	cRNA	
(Figure	 5.32C).	 These	 data	 indicate	 that	 one	mutated	 rBAT	 allele	would	 not	 be	 sufficient	 to	
























































































































































	Figure	 5.32:	 System	 b0,+	 activity	 in	 oocytes	 co-expressing	 wild-type	 and	 mutant	 rBAT.	
[3H]Arginine	uptake	(10μM,	Na+-free,	pH7.4)	in	oocytes	injected	with	wild-type	rBAT	cRNA	(25-
50ng),	mutant	 cRNA	 (25-50ng)	 or	 a	 combination	 of	 both	 cRNAs	 (50ng	 total).	 A,	 [3H]Arginine	
uptake	 in	 oocytes	 injected	 with	 water	 (control,	 n=10),	 wild-type	 rBAT	 or	M467T	 cRNA	 (25-
50ng,	 n=10),	 or	 the	 cRNA	 for	 both	 constructs	 (25ng	 each,	 n=10);	 B,	 [3H]Arginine	 uptake	 in	
oocytes	injected	with	water	(control,	n=10),	wild-type	or	L416P	cRNA	(25-50ng,	n=10),	or	the	
cRNA	 for	both	 constructs	 (25ng	each,	 n=10);	 C,	 [3H]Arginine	uptake	 in	oocytes	 injected	with	
water	 (control,	 n=10),	 wild-type	 or	 Y579D	 cRNA	 (25-50ng,	 n=10),	 or	 the	 cRNA	 for	 both	





The	pathogenic	mutation	M467T	was	 identified	 in	9/84	alleles	 included	 in	 this	 study	





(Figure	 5.33).	 As	 indicated	 in	 Figure	 5.32,	 the	 co-injection	 of	M467T	 or	 Y579D	 cRNA	 (25ng)	
along	with	that	of	the	wild-type	protein	(25ng)	led	to	[3H]arginine	uptake	values	that	were	not	
significantly	different	 (p>0.05)	 to	 those	 in	oocytes	 injected	with	50ng	wild-type	cRNA	(Figure	
5.32A).	However,	co-injection	of	M467T	and	Y579D	led	to	a	significant	reduction	(p<0.001)	in	
uptake	of	 [3H]arginine	versus	wild-type	rBAT	(Figure	5.33A).	This	 indicates	that	both	of	 these	
mutations	are	pathogenic,	and	the	combination	of	the	two	in	the	genotype	of	a	patient	would	
cause	 a	 cystinuria	 phenotype.	 Unfortunately,	 we	 were	 unable	 to	 obtain	 any	 gDNA	 samples	
from	 relatives	 of	 Patient	 20	 (M467M/T	 and	 Y579Y/D).	 The	 novel	 mutation	 Y579D	 was	 also	
identified	 in	Patient	6	of	 the	 cohort,	 along	with	pathogenic	mutation	R452W	 (Figure	5.33B).	
The	sister	of	Patient	6	was	a	heterozygous	carrier	of	Y579D,	yet	had	no	cystinuria	phenotype.	
The	segregation	data	for	Patient	6	are	shown	here	to	complement	the	uptake	data,	indicating	
the	 recessive	 inheritance	 of	 Y579D	 (Figure	 5.33B).	 R452W	has	 also	 been	 proposed	 to	 be	 an	
autosomal	 recessive	 mutation	 (Font-Llitjos	 et	 al.,	 2005).	 Due	 to	 time	 limitations	 on	 these	
studies,	we	were	unable	to	produce	the	rBAT	mutant	R452W	to	investigate	the	co-expression	
of	R452W	and	Y579D,	reflective	of	the	genotype	of	Patient	6	(Figure	5.33B).	However,	together	
these	 data	 support	 the	 hypothesis	 that	 the	 novel	 mutation	 Y579D,	 and	 the	 known	 variant	
M467T,	are	a	pathogenic	missense	mutations,	with	recessive	modes	of	inheritance.	
	 [3H]Arginine	uptake	was	performed	in	oocytes	co-injected	with	the	cRNAs	for	M467T	
and	 L416P	 (Figure	 5.33C).	 This	 combination	of	mutations	was	 identified	 in	 Patient	 26	of	 the	









	 These	data	 support	 the	hypothesis	 that	 co-expression	of	M467T	and	Y579D	mutants	
does	not	lead	to	successful	trafficking	of	System	b0,+	to	the	plasma	membrane.	This	provides	an	
	 306	
explanation	 for	 the	 cystinuria	 phenotype	 in	 Patient	 26	 of	 the	 cohort	 who	 had	 a	 compound	
heterozygous	genotype	for	these	two	mutations.	The	variability	in	a	reduction	of	[3H]arginine	
transport	 following	the	expression	of	L416P	creates	the	need	for	further	 investigation	of	this	
mutant	 protein.	 It	 would	 be	 desirable	 to	 repeat	 these	 experiments	 using	 lower	 amounts	 of	
cRNA,	 and	 at	 shorter	 time-points	 post-injection	 of	 cRNA.	 Additionally,	 an	 alternative	









uptake	 in	 oocytes	 injected	with	water	 (control,	 n=10),	wild-type	 rBAT	 (25-50ng,	 n=10),	 rBAT	
plus	M467T	cRNA	(50ng	total,	n=10),	rBAT	plus	Y579D	(50ng	total,	n=10),	or	M467T	plus	Y579D	
cRNA	(50ng	total,	n=10);	B,	Pedigree	diagram	of	the	family	of	Patient	6	who	was	heterozygous	
for	 R452R/W	 and	 Y579Y/D;	 C,	 [3H]Arginine	 uptake	 in	 oocytes	 injected	 with	 water	 (control,	
n=10),	wild-type	 rBAT	 (25-50ng,	n=10),	 rBAT	plus	M467T	 cRNA	 (50ng	 total,	 n=10),	 rBAT	plus	
Y579D	(50ng	total,	n=10),	or	M467T	plus	Y579D	cRNA	(50ng	total,	n=10);	D,	Pedigree	diagram	
of	 the	 family	 of	 Patient	 20,	 who	was	 heterozygous	 for	 L416L/P	 and	M467M/T;	 half-shaded	
symbols	represent	heterozygous	carriers.	Data	are	mean±SEM.	***,	p<0.001;	ns,	p>0.05	versus	
oocytes	 injected	with	 50ng	wild-type	 rBAT	 cRNA.	 The	 experiments	 were	 carried	 out	 3	 days	
post-injection.		
	 	











































































































Amino	 acid	 substitutions	 in	 a	 protein	 structure	 can	 arise	 when	missense	 mutations	
occur	 in	 the	 DNA	 sequence,	 altering	 the	 resultant	 codon.	 It	 has	 been	 identified	 that	 these	
amino	 acid	 substitutions	 in	 the	 nascent	 polypeptide	 chain	 can	 confer	 changes	 in	 protein	
stability,	 ligand	 binding,	 catalysis,	 allosteric	 regulation,	 and	 post-translational	 modifications	
(Wang	 &	 Moult,	 2001).	 The	 rBAT	 protein	 does	 not	 appear	 to	 have	 any	 enzymatic	 activity,	
despite	its	structural	homology	to	glucosidase	enzymes	(Wells	&	Hediger,	1992).	Additionally,	
it	 is	not	expected	 to	confer	 transport	 function	 to	System	b0,+.	Thus,	we	can	hypothesise	 that	
the	 most	 likely	 effects	 of	 SLC3A1	 missense	 mutations	 upon	 rBAT	 expression	 would	 be	 a	
decrease	 in	 protein	 stability,	 leading	 to	 early	 degradation	 in	 the	 endoplasmic	 reticulum.	





proteins	 in	Xenopus	oocytes	 (Calonge	 et	 al.,	 1994;	 Chillarón	 et	 al.,	 1997;	 Saadi	 et	 al.,	 1998;	
Ishihara	 et	 al.,	 2002;	 Pineda	 et	 al.,	 2004b;	 Bartoccioni	 et	 al.,	 2008).	 The	 majority	 of	 these	
studies	 report	 a	 decrease	 in	 function	 of	 mutant	 rBAT	 compared	 to	 the	 wild-type	 through	
uptake	 measurements	 of	 radiolabelled	 prototypical	 b0,+	 substrates.	 One	 report,	 in	 which	
[14C]cystine	 uptake	 was	 measured	 1-8	 days	 post-injection	 of	 cRNA,	 demonstrated	 a	 >90%	
recovery	 in	 function	of	M467T	compared	to	wild-type	rBAT,	by	day	7	(Chillarón	et	al.,	1997).	
The	expression	of	M467T	was	also	measured	as	part	of	the	current	study,	and	a	broadly	similar	
observation	was	made	 (Figure	 5.7).	 Additionally,	 Chillarón	et	 al.	 reported	 that	 following	 the	
substitution	of	hydrophobic	methionine	at	position	467	for	the	polar	amino	acid	lysine,	M467K	
function	 only	 reached	 20%	 of	 the	 wild-type	 protein	 by	 day	 7	 (Chillarón	 et	 al.,	 1997).	 This	
indicates	that	less	conservative	amino	acid	changes	in	the	molecule	confer	a	greater	effect	on	
protein	stability.		
From	 homology	models	 of	 the	 rBAT	 extracellular	 domain	we	 can	 predict	 how	 these	
mutations	 could	 affect	 the	 stability	 of	 the	 folded	 protein.	 A	model	 of	 the	 rBAT	 extracellular	
domain	was	created,	based	on	the	known	crystal	 structure	of	B.	cereus	oligo-1,6-glucosidase	
(PDB	 code	 1UOK,	 Figure	 5.34A).	 The	 methionine	 residue	 at	 position	 467	 in	 the	 rBAT	







formed	 (≈4Å)	 (Figure	 5.34B).	 The	 substitution	 of	 methionine	 for	 lysine	 at	 position	 467	 is	
predicted	 to	 introduce	 a	 long,	 cationic	 side	 chain	 into	 the	 hydrophobic	 interior	 of	 the	 rBAT	
extracellular	 domain	 (Figure	 5.34D).	 This	 mutation	 has	 great	 potential	 for	 disrupting	 steric	




Through	 S217R	 expression	 in	 oocytes,	 they	 detected	 no	 change	 in	 [3H]arginine	 uptake	
compared	 to	 wild-type	 control	 oocytes,	 24h	 post-injection	 of	 cRNA.	 However,	 when	 this	
measurement	was	 repeated	 6h	 post-injection,	 the	 function	 of	 the	mutant	 protein	was	 only	
40%	of	the	wild-type	(Saadi	et	al.,	1998).	Similarly,	the	R452W	missense	mutation,	identified	in	
two	Italian	patients,	showed	a	“mild”	delay	in	expression	in	oocytes,	which	recovered	after	3	
days	 (Bartoccioni	 et	 al.,	 2008).	 Together,	 these	 reported	 data	 indicate	 that	 the	 extent	 of	









Figure	 5.34:	 A	 close-up	 view	 of	 the	 putative	 location	 of	 M467	 in	 the	 rBAT	 extracellular	
domain.	The	homology	model	was	created	based	on	the	known	crystal	structure	of	B.	cereus	
oligo-1,6-glucosidase	(PDB	code	1UOK).	A,	Side-view	of	the	rBAT	extracellular	domain	with	the	
residues	 in	 panels	 B-D	 indicated	 by	 the	 presence	 of	 a	 black	 box;	 B,	 Putative	 location	 of	
methionine	at	position	467	and	the	location	of	the	side	chain;	C,	Putative	location	of	M467T.	
The	predicted	distance	of	 the	 threonine	hydroxyl	 group	 from	 the	nearest	main	 chain	 amino	













































Of	 the	 four	 novel	mutations	 investigated	 in	 this	 study,	 two	mutant	 proteins,	M465K	
and	 Y579D,	 showed	 a	 broadly	 similar	 expression	 pattern	 to	 other	 mutant	 rBAT	 proteins	
reported	 in	 the	 literature.	 Our	 data	 correlated	 with	 the	 results	 of	 M467T	 and	 M467K	
expression	in	oocytes	where	a	recovery	in	function	was	observed	over	a	number	of	days	post-
injection	 (Chillarón	 et	 al.,	 1997).	 It	 is	 worthwhile	 noting	 that	 the	 expression	 of	M465K	 was	
more	similar	to	that	of	M467K	than	M467T.	In	the	current	study,	[3H]arginine	uptake	levels	in	
M465K-expressing	 oocytes	 were	 never	 equivalent	 to	 that	 of	 wild-type	 rBAT,	 remaining	
significantly	 lower	 (p<0.05)	even	by	day	6	 (Figure	5.12).	 In	oocytes	 injected	with	 the	highest	
amount	 of	 cRNA	 (50ng),	 [3H]arginine	 uptake	 only	 reached	 46%	 of	 the	 wild-type	 by	 day	 6	
(Figure	5.13).		
A	homology	model	of	rBAT	supports	the	hypothesis	that	the	M465K	mutation	leads	to	
protein	mis-folding	 and	 instability	 (Figure	 5.35A).	 The	methionine	 residue	 at	 position	 465	 is	
predicted	 to	 sit	 on	 the	 7th	 α-helix	 of	 the	 TIM	 barrel	 structure	 (Figure	 5.35Ai).	 The	 short,	
hydrophobic	side	chain	putatively	faces	into	the	centre	of	the	molecule	and	is	not	predicted	to	
contribute	 to	 intramolecular	bonding	 (Figure	5.35Aii).	When	 this	 residue	 is	mutated	 in	 silico,	
the	cationic	amino	group	on	the	long	side	chain	of	lysine	is	predicted	to	sit	2.0Å	from	the	main	
chain	 carboxyl	 group	 of	 neighbouring	 residue	 L453	 (Figure	 5.35Aiii).	 This	 is	 a	 comfortable	
distance	 over	 which	 polar	 interactions	 can	 occur	 (<4Å).	 Irrespective	 of	 this,	 introducing	 a	
charged	 residue	 into	an	 internal	hydrophobic	 region	of	a	protein	 creates	a	 rational	basis	 for	
suggesting	conferred	protein	instability.	
The	 second	 novel	 missense	 mutation	 that	 was	 shown	 to	 negatively	 affect	 rBAT	
expression	 was	 the	 tyrosine	 to	 aspartic	 acid	 substitution,	 Y579D.	 Putatively	 located	 on	 the	
second	strand	of	 the	β-sheet	of	domain	C,	 the	aromatic	 side	chain	of	 the	 tyrosine	 residue	 is	
predicted	 to	be	orientated	away	 from	 the	A2	domain	 (Figure	5.35Bi).	 The	orientation	of	 this	
side	 chain	 putatively	 allows	 polar	 interactions	 with	 residues	 of	 the	 loop	 (598-617),	 which	
connects	 strands	 3	 and	 4	 of	 the	β-sheet	 (Figure	 5.35Bii).	 The	mutagenesis	 of	 tyrosine	 (Y)	 to	
aspartic	 acid	 (D),	 a	 negatively-charged	 amino	 acid,	 provides	 scope	 for	 incorrect	 folding	 and	
assembly	 of	 the	 protein	 through	 altered	 interactions	 with	 domain	 C	 (Figure	 5.35Biii).	
Additionally,	 as	 the	 30	 amino	 acid	 “tail”	 of	 rBAT	 does	 not	 model	 to	 any	 known	 crystal	
structure,	 and	 is	 not	 included	 in	 the	 homology	model	 of	 the	 rBAT	 extracellular	 domain	 (see	
Chapter	1),	the	model	does	not	indicate	how	this	region	is	predicted	to	interact	with	residues	
in	 the	 C-terminal	 region	 of	 the	 protein.	 Deora	 et	 al.	 (1998)	 reported	 that	 progressive	 C-
terminal	 deletions	 of	 the	 rBAT	protein	 led	 to	 an	 abolition	of	 [3H]arginine	uptake	 in	 oocytes,	
indicating	 that	 this	 region	of	 the	 protein	 is	 essential	 for	 the	 function	 of	 rBAT	 	 (Deora	 et	 al.,	
1998).		
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Further	 investigation	 of	 the	 structure-function	 relationship	 in	 the	 rBAT	 protein	 is	
beyond	the	scope	of	this	investigation.	All	mutations	investigated	in	this	study	were	identified	
in	 the	 gDNA	 of	 cystinuric	 patients.	 However,	 separate	 studies	 investigating	more	 conserved	
substitutions	 of	 methionine	 at	 critical	 residues	 M465	 and	 M467,	 could	 prove	 highly	
informative.	In	the	absence	of	a	crystal	structure	of	rBAT,	and	due	to	the	predicted	differences	






















































amino	 group,	 in	 L453,	 is	 only	 2.0Å;	 Bi,	 Side-view	 of	 the	 rBAT	 extracellular	 domain	with	 the	
residues	 in	 panels	 ii-iii	 indicated	 by	 the	 presence	 of	 a	 black	 box;	 Bii,	 Putative	 location	 of	
tyrosine	at	position	579	and	the	location	of	the	side	chain.	The	distances	of	the	hydroxyl	group	
of	the	tyrosine	side	chain	from	the	nearest	main	chain	amino	group	 in	L604,	and	main	chain	
carboxyl	 groups	 in	 S602	and	 L640,	 are	3.0,	 2.9,	 and	2.4Å,	 respectively.	 This	 is	 a	 comfortable	








in	 oocytes.	 The	 presence	 of	 these	 rare	 mutations	 in	 SLC3A1	 of	 cystinuric	 patients	 strongly	
suggests	that	they	are	pathogenic.	No	measurable	change	 in	protein	function	 in	oocytes	was	
detected	when	 10μM	 [3H]arginine	 uptake	was	 carried	 out	 at	 day	 3	 (Figures	 5.17,	 5.22,	 and	




(Figure	 5.24).	 A	 change	 in	 the	 Km	has	 been	observed	 following	 the	 interaction	of	 CD98	with	
b0,+AT,	indicating	that	the	structure	of	the	heavy	chain	modulates	transport	via	System	b0,+	(see	
Chapter	 1,	 Rajan	 et	 al.,	 2000).	 	We	 hypothesise	 that	 these	mutations	 cause	 a	milder	 effect	
upon	 rBAT	 function	 than	M465K,	M467T,	 and	 Y579D.	We	 predict	 that	 these	 two	mutations	
would	lead	to	a	reduction	in	System	b0,+	function	if	uptake	experiments	were	carried	out	<24h	
post-injection	of	cRNA.	This	was	observed	by	Saadi	et	al.	(1998),	when	measuring	the	function	
of	 S217R	 in	 oocytes,	 6h	 post-injection.	 However,	 due	 to	 time	 restrictions	 on	 this	 study,	 we	
were	unable	to	perform	these	experiments.	
The	 inability	 to	 detect	 the	 effects	 of	 mutations	 on	 protein	 expression	 in	 oocytes	
following	the	 introduction	of	potentially	pathogenic	mutations	has	been	reported	previously.	
Leduc-Nadeau	 et	 al.	 (2010)	 reported	 a	 similar	 result	 in	 oocytes	 from	 their	 investigation	 of	
novel	aquaporin-2	(AQP2)	mutations	identified	in	patients	with	nephrogenic	diabetes	insipidus	
(NDI).	No	reduction	in	function	of	the	AQP2	channel	was	observed	following	the	incorporation	
of	 novel	 mutations	 K228E	 or	 V24A	 into	 the	 protein	 sequence	 (Leduc-Nadeau	 et	 al.,	 2010).	
Channel	function	was	measured	through	incubation	of	the	oocytes	in	a	hyposmotic	solution	to	
induce	 uptake	 of	 water	 and	 oocyte	 swelling	 (Leduc-Nadeau	 et	 al.,	 2010).	 Similarly,	 no	
reduction	 in	membrane	 localisation	was	detected	through	 immunocytochemical	detection	of	
FLAG-tagged	 AQP2	 mutants	 in	 oocyte	 sections	 or	 western	 blotting	 of	 oocyte	 plasma	
membrane	samples	(Leduc-Nadeau	et	al.,	2010).	However,	a	distinct	mutation	in	AQP2,	R187C,	
led	 to	 reduced	 functionality	of	 the	protein	 in	oocytes,	and	a	 reduction	 in	plasma	membrane	
localisation	 measured	 by	 immunocytochemistry	 and	 western	 blotting	 (Leduc-Nadeau	 et	 al.,	
2010).	 In	 the	 current	 study,	 we	 were	 unable	 to	 successfully	 use	 the	 plasma	 membrane	
preparation	 to	 detect	 mutant	 rBAT	 proteins	 by	 western	 blot.	 Despite	 this,	 the	 data	 from	
Leduc-Nadeau	 et	 al.	 demonstrate	 that	 the	 use	 of	 sectioned	 oocytes	 to	 identify	 plasma	




blotting	 and	 immunocytochemical	 detection	 (Leduc-Nadeau	 et	 al.,	 2010).	 Although,	 in	 the	
current	 study,	 the	 use	 of	 this	 technique	 was	 desirable	 to	 support	 the	 data	 from	
immunocytochemical	detection,	 it	 is	unlikely	 that	 it	would	have	provided	 further	 insight	 into	
the	function	of	mutant	proteins	L416P	and	N254T,	which	appear	to	localise	in	the	membrane.	
Leuduc-Nadeau	 et	 al.,	 also	 transfected	 a	 mouse	 inner	 medullary	 collecting	 duct	 cell	 line	
(mIMCD-3)	with	the	wild-type	and	mutant	AQP2	proteins	and	detected	membrane	localisation	
of	 the	 wild-type	 channel	 16-24h	 post-transfection.	 However,	 when	 all	 three	 AQP2	mutants	
(V24A,	 R187C,	 and	 K228E)	 were	 transfected	 in	 the	 cell	 line,	 no	membrane	 localisation	 was	
detected,	with	the	mutant	proteins	appearing	to	be	trapped	in	an	intracellular	compartment.	
These	 data	 support	 the	 hypothesis	 that	 L416P	 and	 N254T	 are	 pathogenic	 mutations,	 but	
perhaps	convey	a	less	severe	effect	on	the	protein,	rendering	it	 less	detectable	in	the	oocyte	






that	 the	measurements	made	 in	Xenopus	oocytes	 remain	 a	 robust	measurement	 of	 protein	
expression.	However,	 it	 is	 important	to	recognise	the	likelihood	of	protein	over-expression	in	
oocytes	(Moeller	&	Fenton,	2010).		
Another	 important	 factor	 to	 consider	 when	 using	 the	 Xenopus	 oocyte	 expression	
system	 is	 the	phenomenon	of	 temperature-dependent	protein	 release	 from	the	ER.	This	has	
been	 reported	 previously	 in	 studies	 of	 the	 Cystic	 Fibrosis	 Transmembrane	 Conductance	
Regulator	 protein	 (CFTR)	 (Denning	 et	 al.,	 1992).	 In	 a	 similar	 manner	 to	 rBAT,	 CFTR	 is	 a	
glycosylated	membrane	protein	 and,	 following	electrophoretic	 resolution,	 bands	of	 different	
molecular	weights	can	be	detected	(Denning	et	al.,	1992).	In	the	case	of	CFTR,	three	bands	are	
detected	in	the	wild-type	protein	expressed	in	cells	cultured	at	37°C:	unglycosylated	(band	A,	
120kDa),	 endoplasmic	 reticulum	 core-glycosylated	 (band	 B,	 140kDa),	 and	 Golgi-associated	
mature-glycosylated	 (band	 C,	 170kDa)	 protein	 (Cheng	 et	 al.,	 1990;	 Gregory	 et	 al.,	 1991;	
Denning	et	al.,	1992).	In	the	presence	of	a	phenylalanine	deletion	in	the	protein,	ΔF508,	found	
in	90%	of	cystic	fibrosis	patients,	band	C	is	not	detected	in	fibroblasts.	This	indicates	that	the	
mis-folded	 polypeptide	 does	 not	 leave	 the	 ER	 to	 be	 processed	 by	 the	Golgi	 (Denning	 et	 al.,	
1992).	 However,	 it	was	 discovered	 that	when	 the	 incubation	 temperature	 of	 the	 fibroblasts	
was	reduced	to	26°C,	a	reversible	recovery	of	 function	and	plasma	membrane	 localisation	of	
mature-glycosylated	protein	was	observed	 (Denning	 et	al.,	1992).	This	 temperature-sensitive	
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release	of	protein	from	the	endoplasmic	reticulum	explained	the	wild-type	function	of	ΔF508-
CFTR	 in	Xenopus	oocytes	when	cAMP-dependent	Cl-	 currents	were	measured	 (Drumm	 et	al.,	
1991).	 Temperature-dependence	 was	 shown	 to	 be	 a	 factor	 in	 the	 release	 of	 R365W	 rBAT	
mutant	 from	 the	 ER	 of	 HeLa	 cells	 transiently	 transfected	 with	 both	 subunits	 of	 System	 b0,+	
(Pineda	 et	 al.,	 2004b).	 The	 reduction	 in	 [14C]cystine	 transport	 and	 expression	 of	 R452W,	
compared	to	wild-type	rBAT,	was	more	pronounced	in	the	cell	line	than	in	oocytes	(Pineda	et	




be	 released	 from	 the	 ER	 when	 expressed	 in	 cell	 systems	 that	 are	 incubated	 at	 lower	
temperatures	(below	26oC).	We	hypothesise	that	at	higher	temperatures,	we	would	observe	a	
reduced	 trafficking	 of	 rBAT	 mutants	 N254T	 and	 L416P.	 To	 confirm	 this	 hypothesis,	 the	
expression	of	FLAG-tagged	rBAT	in	a	mammalian	cell	line	is	desirable.	Successful	expression	of	
rBAT	 in	 a	 mammalian	 cell	 line	 would	 allow	 the	 effects	 of	 incubation	 temperature	 to	 be	
investigated.	 It	 is	 not	 possible	 to	 incubate	Xenopus	 ooyctes	 at	 temperatures	 above	 26°C	 for	
prolonged	periods	as	their	viability	would	rapidly	decline.	To	see	any	effect	of	temperature	on	
protein	 release	 from	 the	 ER,	 an	 expression	 system	 that	 can	 be	 incubated	 at	 temperatures	
exceeding	26°C,	for	longer	than	the	expected	turnover	rate	of	rBAT	protein,	is	necessary.		
The	 potential	 alteration	 on	 protein	 folding	 caused	 by	 N254T	 and	 L416P	 can	 be	
predicted	 by	 homology	modelling	 (Figure	 5.36).	 To	 date,	 no	 data	 has	 been	 reported	 in	 the	
literature	regarding	the	function	of	loop-rich	rBAT	extracellular	domain	B.	This	is	the	putative	
location	 of	 novel	 mutation	 N254T	 (Figure	 5.36Ai).	 In	 related	 glucosidase	 structures,	 this	
domain	 forms	 the	cleft	of	 the	enzyme	active	 site	 (see	Chapter	1).	This	domain	 is	 completely	
absent	in	the	only	other	member	of	the	mammalian	SLC3	family,	CD98	(SLC3A2).	However,	its	
importance	 in	 the	 function	 of	 rBAT	 is	 suggested	 by	 the	 location	 of	 11	 reported	 cystinuria	
mutations	falling	in	this	184-residue	domain	(Stenson	et	al.,	2014).	Notably,	mutations	N253K	
and	W255C	have	been	 reported	 in	 the	 literature,	which	 flank	 the	site	of	our	novel	mutation	
(Harnevik	et	al.,	2001;	Bisceglia	et	al.,	2007).	 In	silico	modelling	of	 rBAT	predicts	 interactions	
between	 the	 long,	 polar	 side	 chain	 of	 asparagine	 at	 position	 254	 and	 the	 side	 chain	 amide	
group	of	Q335,	 and	 the	main	 chain	 amino	 group	of	 E238	 (Figure	5.36Aii).	 Following	 in	 silico	
mutagenesis	of	this	residue	to	threonine	in	PyMol,	these	interactions	are	putatively	 lost,	due	
to	 an	 increased	distance	between	 the	 atoms	possibly	 decreasing	 the	 stability	 of	 the	 protein	
(Figure	5.36iii).	Additionally,	 a	 cystinuria	mutation	E328K	has	been	 reported	 (Bisceglia	 et	al.,	
2007),	which	would	also	affect	 the	 folding	of	 the	protein	 in	 this	 region.	These	data	highlight	
the	importance	of	the	correct	protein	assembly	in	this	region	of	the	rBAT	extracellular	domain.		
	 318	
	 The	 leucine	 residue	 at	 position	 416	 in	 the	 rBAT	 extracellular	 domain	 is	 putatively	
located	in	the	N-terminal	region	of	the	6th	α-helix	of	the	TIM	barrel	(Figure	5.36Bi).	This	α-helix	
is	 predicted	 to	 be	 non-continuous,	 due	 to	 the	 presence	 of	 a	 5-amino	 acid	 unwound	 region	























































Figure	 5.36:	 A	 close-up	 view	 of	 the	 putative	 location	 of	 N254	 and	 L416	 in	 the	 rBAT	
extracellular	domain.	A	homology	model	of	the	rBAT	extracellular	domain	was	created	based	
on	 the	 known	 crystal	 structure	 of	B.	 cereus	 oligo-1,6-glucosidase	 (PDB	 code	 1UOK).	Ai,	 Top-
view	 of	 the	 rBAT	 extracellular	 domain	 with	 the	 residues	 in	 panels	 ii-iii	 indicated	 by	 the	
presence	of	a	black	box;	Aii,	Putative	location	of	asparagine	at	position	254	and	the	location	of	
the	 polar	 side	 chain.	 The	 distances	 of	 the	 side	 chain	 amide	 group	 of	 asparagine	 from	 the	
nearest	 side	 chain	amide	group	of	Q335,	main	 chain	amino	group	of	E328,	 are	only	2.7	and	
3.2Å,	 respectively;	 Aiii,	 Putative	 location	 of	 N254T.	 The	 distance	 of	 the	 side	 chain	 hydroxyl	
group	of	the	threonine	residue	from	the	nearest	main	chain	amino	group,	in	E328,	is	4.2Å;	Bi,	













In	 the	 current	 study,	 a	 reduction	 in	 the	 total	 amount	 of	 rBAT	 protein	 produced	 in	




equivalent	 intensity	 to	 that	 detected	 in	 oocytes	 injected	with	 5ng	mutant	 AQP2	 cRNA.	 Our	
data,	in	accordance	with	those	reported	by	Leduc-Nadeau,	support	the	hypothesis	that	mutant	
protein	is	being	retained	and	rapidly	degraded	by	the	ER.	This	could	account	for	an	observed	
reduction	 in	 total	 protein	 detection	 at	 the	 early	 time-points	 post-injection.	However,	 as	 the	
protein	 is	 over-expressed	 in	 the	 oocyte	 potential	 degradation	 pathways	 may	 become	
saturated	over	time,	with	the	rate	of	protein	translation	exceeding	the	rate	of	degradation.		




rapidly,	 preventing	 degradation	 of	 the	 heavy	 chain.	 Through	 co-expression	 of	 rBAT	 mutant	
proteins	 M467T,	 M467K,	 and	 T216M,	 Bartoccioni	 et	 al.	 identified	 a	 complete	 lack	 of	
[14C]cystine	 uptake.	 Additionally,	 all	 three	 mutant	 proteins	 did	 not	 acquire	 complex	 N-
glycosylation,	indicating	a	lack	of	processing	by	the	Golgi	apparatus	due	to	degradation	by	the	
Endoplasmic	Reticulum-Associated	Degradation	(ERAD)	pathway	(Bartoccioni	et	al.,	2008).	The	
lack	 of	 mature	 glycosylated	 form	 of	 R365W	 and	 M467T	 has	 also	 been	 reported	 following	
protein	expression	in	oocytes	(Chillarón	et	al.,	1997;	Pineda	et	al.,	2004b).	In	the	current	study,	
total	membrane	proteins	were	 isolated	 from	oocytes	 expressing	wild-type	 and	mutant	 rBAT	
proteins	and	used	for	western	blot	detection.	As	expected,	both	the	core	glycosylated	(85kDa)	
and	 mature	 glycosylated	 (90kDa)	 forms	 of	 rBAT	 were	 detected	 following	 expression	 of	 the	
common	variant,	M618I	(Figure	5.5A).	When	mutant	rBAT	proteins	M467T,	M465K	and	L416P	
were	 expressed	 in	 oocytes,	 only	 the	 core-glycosylated	 form	 (85kDa)	 of	 the	 protein	 was	
detected	by	western	 blot	 (Figures	 5.9A,	 5.13A,	 and	 5.21A,	 respectively).	 The	 absence	of	 the	
mature	glycosylated	form	of	L416P	in	oocytes	further	supports	the	potential	of	this	variant	as	a	
pathogenic	mutation.	 In	 the	 case	 of	 the	 Y579D	mutant	 protein,	 a	 doublet	 band	was	 visible,	
however	in	the	wild-type	sample,	the	ratio	of	the	mature	glycosylated	to	the	core	glycosylated	
form	was	higher	 (Figure	5.25A).	This	 is	 consistent	with	 the	 results	of	western	blotting	of	 the	





R365W	was	 co-transfected	 with	 b0,+AT	 in	 HeLa	 cells,	 and	 incubated	 at	 37°C,	 only	 the	 core-
glycosylated	form	of	the	protein	was	detected	(Pineda	et	al.,	2004b).		
These	 data	 indicate	 that	 whilst	 the	 transfer	 of	 rBAT	 mutant	 proteins	 to	 the	 Golgi	
appears	to	be	eliminated	in	some	mutants,	the	extent	of	the	reduction	in	this	processing	step	
varies	 between	 mutants.	 Bartoccioni	 et	 al.	 (2008)	 found	 that	 transmembrane	 domain	




not	a	TIM	barrel	mutant,	but	 is	predicted	to	be	 located	in	 loop-rich	domain	B	(Figure	5.28A).	
These	 data	 support	 the	 hypothesis	 that	 the	 location	 of	 mutations	 in	 the	 protein	 may	
contribute	to	the	variation	in	cellular	processing.	
In	 this	 Chapter	 we	 have	 utilised	 the	 range	 of	 techniques	 optimised	 in	 Chapter	 4	 to	
successfully	measure	 the	expression	of	wild-type	 rBAT	and	 rBAT	mutant	proteins	 in	oocytes.	
We	have	 reported	data	 that	 support	 the	hypothesis	 that	mutations	 in	 rBAT	can	 lead	 to	mis-
folding	of	the	protein,	causing	degradation	by	the	ER.	In	the	case	of	novel	mutant,	L416P,	some	
evidence	 was	 found	 to	 indicate	 that	 the	 rBAT	 mutation	 alters	 the	 affinity	 of	 the	 transport	
system	 for	 the	 prototypical	 b0,+	 substrate,	 arginine.	 However,	 this	 requires	 confirmation	
through	 further	 investigation.	 These	 data	 support	 the	 evidence	 that	 rBAT	 serves	 as	 a	
modulator	of	b0,+	transport,	and	does	not	form	the	substrate	binding	site.	In	this	chapter,	the	
data	present	the	“typical”	observed	pattern	of	mutant	rBAT	expression	in	oocytes.			
Based	 on	 these	 observations,	 the	 next	 stage	 of	 this	 investigation	 focussed	 on	 the	




1).	However,	no	effects	of	 these	 treatments	upon	the	 transport	 system	have	been	reported.	
Any	variation	 in	 the	 function	of	 the	different	mutant	proteins	 to	 incubation	with	 thiol	drugs	











• Novel	 mutants	 N254T	 and	 L416P	 showed	 a	 much	 milder	 effect	 on	 rBAT	
expression.			
• Even	when	mutant	rBAT	proteins	reached	the	membrane	of	the	oocyte,	only	












urinary	 cystine	 excretion,	 and	 animal	 proteins,	 due	 to	 their	 high	 cystine	 and	 methionine	




due	 to	 the	 increased	 amount	 of	 cystine	 excretion	 associated	 with	 sodium	 bicarbonate	 or	
sodium	citrate	(Fjellstedt	et	al.,	2001).	If	treatment	of	patients	with	increased	fluid	intake	and	
urinary	 alkalisation	 fails	 to	 control	 their	 cystinuria,	 then	 they	 are	 treated	 with	 the	 cystine-
binding	thiol	drugs	(CBTD)	captopril,	tiopronin,	and	D-penicillamine	(Barbey	et	al.,	2000).	These	
drugs	 work	 by	 breaking	 down	 cystine	 into	 monomeric	 cysteine	 amino	 acids,	 through	
conjugation	 via	 disulphide	 bond	 formation.	 These	 cystine-drug	 conjugates	 have	 been	
estimated	to	increase	the	solubility	of	cystine	in	the	urine	by	50-fold	(Lotz	&	Bartter,	1965).	Of	
these	 three	 drugs,	 captopril	 is	 associated	 with	 the	 lowest	 incidence	 of	 adverse	 reactions.	
However,	 its	efficacy	 in	the	management	of	cystinuria	 is	uncertain	 (Goldfarb	et	al.,	2006).	To	
date,	 no	 reports	 have	 emerged	 on	 the	 investigation	 of	 the	 direct	 effects	 of	 these	 drug	





expression	of	 the	 transport	 system.	Additionally,	 if	 they	 are	 substrates	 for	 System	b0,+,	 their	
presence	 in	 the	 renal	 filtrate	 could	 competitively	 inhibit	 the	 transport	 of	 cystine	 or	 dibasic	
amino	 acids.	 In	 this	 chapter,	 we	 consider	 the	 effect	 of	 short	 and	 long-term	 incubation	 of	
oocytes	and	Caco-2	cells	upon	the	function	of	System	b0,+.	
The	 Endoplasmic	 Reticulum	 Associated	 Degradation	 (ERAD)	 pathway	 in	 cells	 is	 a	
collection	 of	 processes	 that	 remove	mis-folded	 proteins	 from	 the	 ER	 into	 the	 cytoplasm	 for	
proteasomal	 degradation	 (Meusser	 et	 al.,	 2005;	 Molinari,	 2007).	 The	 pathways	 putatively	





degradation	of	 rBAT	mutant	proteins	 following	 their	assembly	with	b0,+AT	 (Bartoccioni	 et	al.,	
2008).	The	kinetics	of	 rBAT	mutant	degradation	post-assembly	with	b0,+AT	were	 the	same	as	
those	of	unassembled,	wild-type	rBAT	expressed	in	the	absence	of	the	light	chain	(Bartoccioni	
et	 al.,	 2008).	 Using	 pulse-chase	 experiments	 in	 MDCK	 cells,	 Bartoccioni	 et	 al.	 (2008)	




Another	 process	 by	 which	 the	 ERAD	 pathway	 can	 be	 inhibited	 is	 through	 the	
incubation	 of	 cell	 lines	 at	 low	 temperatures.	 Denning	 et	 al.	 (1992)	 demonstrated	 that	
incubation	of	 fibroblasts	 at	 26°C	 restored	 the	 function	of	 ΔF508-CFTR,	which,	 at	 the	 normal	
incubation	 temperature	 of	 37°C,	 is	 degraded	 by	 the	 ERAD	 pathway.	 This	 phenomenon	 was	
confirmed	 by	 the	 Cl-	 channel	 function	 in	 Xenopus	 oocytes	 and	 Sf9	 insect	 cells	 expressing	
ΔF508-CFTR,	 which	 are	 routinely	 incubated	 at	 18°C	 and	 28°C,	 respectively	 (Denning	 et	 al.,	
1992).	Pineda	et	al.	(2004)	demonstrated	the	same	effect	with	the	expression	of	rBAT	mutant	
R365W	in	HeLa	cells.	Wild-type	and	R365W	rBAT	were	co-expressed	 in	HeLa	cells	along	with	






through	N-	 or	O-	 glycosidic	 bonds.	 The	 oligosaccharides	 serve	 as	 universal	markers	 to	 allow	
essential	 Endoplasmic	 Reticulum	 (ER)	 functions	 to	 occur.	 This	 can	 include	 protein	 folding,	
transfer	to	the	Golgi,	and	intracellular	targeting	of	translated	proteins	(Helenius	&	Aebi,	2001).	
The	 oligosaccharyl	 transferase	 responsible	 for	 the	 addition	 of	 N-glycans	 in	 the	 ER	 lumen	
recognises	a	specific	motif	within	the	nascent	polypeptide	chain:	Asn-Xaa-Ser/Thr,	where	Xaa	
can	 be	 any	 amino	 acid	 except	 proline	 (Roitsch	 &	 Lehle,	 1989;	 Gavel	 &	 von	 Heijne,	 1990).	
Although	necessary,	this	motif	is	not	sufficient	for	glycosylation	to	occur	(Gavel	&	von	Heijne,	
1990).		
	 The	 fact	 that	 these	 modifications	 can	 occur	 co-translationally	 implies	 a	 putative	
influence	of	glycosylation	upon	protein	secondary	structure	and	subsequent	function	(Paulson,	
1989).	 Studies,	 however,	 have	 revealed	 a	 great	 deal	 of	 variability	 in	 the	 importance	 of	








epithelial	 cells	 with	 peptide:N-glycosidase-F	 (PNG-F)	 was	 shown	 to	 have	 no	 effect	 on	 the	





insight	 into	 the	 importance	 of	 specific	 glycan	 residues	 as	 opposed	 to	 glycosylation	 of	 the	
protein	as	a	whole.	Dubé	et	al.	 (1998)	demonstrated	 that	whilst	 there	 is	an	aggregation	and	
lack	of	trafficking	of	unglycosylated	Erythropoetin	produced	in	the	presence	of	TM,	only	two	of	
the	three	glycosylation	sites	affect	function	when	individually	mutated.		
	 Several	groups	have	 investigated	the	effect	of	N-glycosylation	on	apical	 trafficking	of	
epithelial	 transporters	 (Vagin	 et	 al.,	 2009).	 Vagin	et	 al.	 (2005)	 demonstrated	 that	 sequential	
addition	 of	 five	 extra	 N-glycosylation	 motifs	 to	 the	 beta	 subunit	 of	 Na-K-ATPase	 (normally	
basolaterally-located)	caused	the	protein	to	be	increasingly	distributed	in	the	apical	membrane	
of	HGT-1	cells,	when	expressed	in	vitro	(Vagin	et	al.,	2005).	A	comprehensive	review	by	Vagin	
et	 al.	 (2009)	 discussed	 the	 effects	 of	 N-oligosaccharides	 on	 apical	 targeting	 of	 membrane	
proteins.	 Fifteen	 different	membrane	 proteins	were	 considered	 that	 had	 been	 studied	 in	 in	
vitro	 polarised	 cell	 systems	 where	 glycosylation	 was	 inhibited	 either	 by	 tunicamycin	 or	
mutagenesis	 (Vagin	et	al.,	2009).	Apical	 localisation	of	 five	of	 these	proteins	was	unaffected,	
six	were	retained	in	the	Golgi	or	other	intracellular	compartments,	and	four	had	a	decrease	in	
apical:basolateral	distribution	(Vagin	et	al.,	2009).	
	 Results	 from	 studies	 investigating	 the	 role	 of	 N-glycosylation	 in	 protein	 folding	 and	
targeting	vary	greatly	between	different	molecules.	However,	there	is	a	strong	indication	that	
glycosylation	 is	 involved	 in	 the	 targeting	 of	 apical	 membrane	 proteins	 (Hayes	 et	 al.,	 1994;	
Olivares	 et	 al.,	 1995;	 Lee	 et	 al.,	 2003;	 Vagin	 et	 al.,	 2009).	 Despite	 the	 range	 of	 apical	
transporters	 considered,	no	work	has	 yet	been	published	on	 the	 role	of	 glycosylation	 in	 the	
folding	 and	 specific	membrane	 targeting	 of	 the	 heavy	 chains	 of	 heterodimeric	 transporters,	
rBAT	and	CD98.		
	 In	 this	 chapter	 we	 consider	 how	 the	 glycosylation	 of	 rBAT	 affects	 the	 plasma	
membrane	 localisation	 of	 the	 protein.	 Additionally,	 modifications	 that	 could	 affect	 rBAT	





escape	 of	 mis-folded	 protein	 from	 the	 ER,	 and	 the	 inhibition	 of	 proteasomal	 degradation	
through	 incubation	 with	 MG132.	 We	 investigated	 the	 effect	 of	 current	 pharmacological	
therapies	 used	 in	 cystinuria	 on	 the	 expression	 and	 function	 of	 System	 b0,+.	 Any	measurable	
differences	 in	 the	 way	 rBAT	 mutant	 proteins	 react	 to	 particular	 cystine-binding	 thiol	 drugs	
(CBTDs)	would	allow	exploitation	of	 the	effect,	and	a	pharmacogenetic	approach	to	 therapy.	




A	 homology	 model	 of	 the	 rBAT	 extracellular	 domain	 was	 created	 as	 described	 in	
Chapter	 2.	 To	 predict	 the	 sites	 of	 N-linked	 glycosylation	 and	 to	 add	 glycan	 residues	 to	 the	
appropriate	 residues,	 the	 rBAT	 PDB	 file	 was	 uploaded	 to	 the	 online	 tool	 Glyprot	












6.1A).	Significant	 (p<0.001)	 [3H]arginine	uptake	was	measured	 in	oocytes	 injected	with	cRNA	
for	rBAT,	N254T,	and	L416P	(Figure	6.1A).	Uptake	into	oocytes	expressing	M467T,	M465K,	and	
Y579D	 was	 not	 significantly	 higher	 (p>0.05)	 than	 background	 uptake	 in	 water-injected	
controls.	 No	 significant	 difference	 (p>0.05)	 in	 [3H]arginine	 uptake	 was	 measured	 between	
control	oocytes,	those	incubated	with	DMSO	alone,	or	those	incubated	with	MG132	in	DMSO	
(Figure	 6.1A).	 This	 indicated	 that	 although	 MG132	 can	 cause	 a	 lag	 in	 degradation	 of	






this	 compound	 upon	 the	 expression	 of	 the	mutant	 proteins,	 further	 investigation	would	 be	
required.	 It	 may	 be	 necessary	 to	 incubate	 the	 oocytes	 at	 a	 different	 concentration	 at	 the	
compound	 for	 extended	 time	 periods	 in	 order	 to	 see	 an	 effect.	 Alternatively,	 co-incubation	
with	a	molecular	chaperone	may	aid	 the	escape	of	 the	molecule	 from	the	ER,	whilst	MG132	
inhibits	the	activation	of	the	ERAD	pathways.	




(Denning	 et	 al.,	 1992).	 However,	 it	 is	 not	 possible	 to	 incubate	 oocytes	 at	 temperatures	
exceeding	 26°C	 for	 prolonged	 periods.	 Therefore,	 to	 investigate	 the	 effect	 of	 short-term	
incubation	at	higher	 temperatures,	 [3H]arginine	uptake	was	performed	at	 room	temperature	
(22°C)	and	at	30°C	(Figure	6.1B).	At	higher	temperatures,	we	would	hypothesise	that	a	greater	









































































































Figure	 6.1:	 The	 effect	 of	 proteasomal	 inhibition	 and	 high	 temperatures	 on	 ER-mediated	
degradation	 of	 rBAT	 mutant	 proteins.	 [3H]Arginine	 uptake	 (10μM,	 Na+-free,	 pH7.4)	 3	 days	
post-injection	 of	 oocytes	 with	 water,	 rBAT	 (50ng),	 or	 mutant	 rBAT	 cRNA.	 A,	 [3H]Arginine	
uptake	 in	 oocytes	 injected	 with	 water	 (n=10),	 or	 50ng	 cRNA	 for	 wild-type	 rBAT	 (n=8-10),	
M467T	 (n=9-10),	 M465K	 (n=10),	 N254T	 (n=8-10),	 L416P	 (n=8-9),	 or	 Y579D	 (n=10).	 Oocytes	
were	 pre-incubated	 for	 6h	 in	 MBS	 alone	 (open	 bars),	 or	 MBS	 containing	 0.1%	 (v/v)	 DMSO	
(black	 bars),	 or	 0.1%	 (v/v)	 DMSO	 and	 10μM	 MG132	 (grey	 bars);	 B,	 [3H]Arginine	 uptake	 in	
oocytes	injected	with	water	(n=10),	or	50ng	cRNA	for	wild-type	rBAT	(n=10),	M467T	(n=9-10),	
M465K	 (n=10),	N254T	 (n=8-10),	 L416P	 (n=8-10),	 or	 Y579D	 (n=10).	Uptake	was	 performed	 at	











forming	 patients	 is	 long-term	hyperdiuresis	 and	 urinary	 alkalinisation	 (Goldfarb	 et	 al.,	 2006;	
Chillarón	 et	 al.,	 2010;	 Thomas	 et	 al.,	 2014).	 The	 first	 report	 of	 System	 b0,+	 activity	 by	 Van	
Winkle	 et	 al.	 (1988)	 noted	 that	 there	 was	 no	 effect	 of	 pH	 in	 the	 range	 6.3-8.0	 in	 mouse	




Following	 an	 intravenous	 infusion	 of	 sodium	 bicarbonate,	 the	 pH	 of	 the	 proximal	 tubular	
filtrate	in	rats	has	been	shown	to	reach	≈pH	7.6	(Rector	et	al.,	1965).	We	investigated	whether	




observed	 in	 rBAT-injected	 oocytes	 measured	 at	 any	 of	 the	 pH	 values	 (Figure	 6.2).	 This	
supported	 the	 findings	of	Van	Winkle	et	al.	 (1988).	We	 then	 investigated	 the	effect	of	 long-
term	incubation	of	oocytes	at	different	pH	values	to	detect	any	alteration	in	the	expression	or	
function	of	System	b0,+.	Oocytes	injected	with	water	or	rBAT	cRNA	were	pre-incubated	for	6h	
at	 pH	 6.7,	 7.4,	 or	 7.7.	 [3H]Arginine	 uptake	was	 then	 performed	over	 60min	 at	 pH	 6.7-7.7	 in	
oocytes	 that	 had	 been	 pre-incubated	 at	 all	 3	 pH	 values	 (Figure	 6.3).	 No	 significant	 change	
(p>0.05)	 in	 uptake	was	 observed	 following	 pre-incubation	 at	 pH	 6.7-7.7.	 This	 indicated	 that	
alkalinisation	of	the	renal	filtrate	likely	has	no	effect	upon	the	expression	of	System	b0,+.	The	in	











6-9)	 in	 oocytes	 injected	 with	 water	 (control),	 or	 rBAT	 cRNA	 (50ng),	 3	 days	 post-injection.	
Oocytes	were	incubated	at	pH	7.5	until	the	start	of	the	uptake	measurement	when	they	were	


















































































































































































Figure	 6.3:	 The	 effect	 of	 pre-incubation	 pH	 on	 measurements	 of	 System	 b0,+	 activity	 in	
oocytes.	[3H]Arginine	uptake	(10μM,	pH	6.7-7.7,	60min)	in	oocytes	injected	with	water	or	rBAT	
















Cystine-binding	 thiol	 drugs	 are	 used	 in	 an	 estimated	 30%	of	 patients	with	 cystinuria	
(Thomas	 et	 al.,	 2014).	 Their	 use	 can	 lead	 to	 a	 50-fold	 increase	 in	 the	 solubility	 of	 cystine	





urinary	 concentrations	 (Goldfarb	 et	 al.,	 2006).	Despite	 the	 investigations	 into	 the	efficacy	of	
these	 drugs	 in	 increasing	 cystine	 solubility,	 no	 data	 has	 been	 published	 which	 reports	 any	
direct	 interaction	 with	 the	 transport	 system.	 To	 estimate	 concentrations	 of	 the	 CBTD	 that	
would	 be	 deemed	 “physiological”	 in	 the	 renal	 filtrate,	 peak	 plasma	 concentration	 data	was	
taken	from	the	literature	(Table	6.1).	As	all	of	these	drugs	had	a	molecular	weight	<5kDa	they	
were	considered	to	be	freely	filtered	from	the	glomerulus.		
[3H]Arginine	 uptake	 was	 performed	 in	 oocytes	 injected	 with	 water	 or	 rBAT	 cRNA	




in	 the	 uptake	 solution	 did	 not	 significantly	 change	 (p>0.05)	 the	 binding	 or	 translocation	 of	
[3H]arginine	 by	 the	 transport	 system	 in	 oocytes.	 No	 significant	 difference	 (p>0.05)	 in	
[3H]arginine	uptake	was	observed	 in	oocytes	 following	pre-incubation	with	 captopril	 nor	 the	
introduction	of	captopril	into	the	uptake	solution	at	physiological	concentrations	(Figure	6.4A).	

































































































































































































































































































































































































































































































































































































drugs	 at	 physiological	 concentrations.	 [3H]Arginine	 uptake	 in	 oocytes	 injected	 with	 water	
(control)	or	 rBAT	cRNA	 (50ng)	 in	 the	presence	 (+)	or	absence	 (-)	of	 thiol	drugs	used	 to	 treat	
cystinuria,	 with	 (+)	 or	 without	 (-)	 pre-incubation	 (24h).	 A,	 [3H]Arginine	 uptake	 in	 oocytes	
injected	 with	 water	 (control,	 n=18-20)	 or	 rBAT	 cRNA	 (50ng,	 n=19-20)	 in	 the	 presence	 or	
absence	 of	 3.7μM	 captopril;	 B,	 [3H]Arginine	 uptake	 in	 oocytes	 injected	with	water	 (control,	
n=20)	 or	 rBAT	 cRNA	 (50ng,	 n=18-20)	 in	 the	 presence	 or	 absence	 of	 24μM	 tiopronin;	 C,	
[3H]Arginine	 uptake	 in	 oocytes	 injected	 with	 water	 (control,	 n=19-20)	 or	 rBAT	 cRNA	 (50ng,	
n=19-20)	in	the	presence	or	absence	of	134nM	D-penicillamine.	-/-,	no	drug	pre-incubation	or	










difference	 in	 patient	 response	 based	 upon	 their	 genotype.	 Potentially,	 this	 could	 lead	 to	
personalised	 therapies	 for	 patients	 with	 cystinuria	 and	 improved	 treatment	 outcomes.	 The	
24h	pre-incubation	of	oocytes	with	the	CBTD	was	repeated	in	oocytes	expressing	the	wild-type	
rBAT	 or	 the	mutant	 proteins.	 It	 had	 been	 established	 that	 the	 presence	 of	 the	 CBTD	 in	 the	
uptake	 solution	 at	 physiological	 concentrations	 did	 not	 compete	 for	 transport	 with	
[3H]arginine	(Figure	6.4).		
[3H]Arginine	uptake	was	performed	in	oocytes	injected	with	water,	rBAT	cRNA	or	the	
cRNA	 for	 rBAT	 mutants	 M467T,	 M456K,	 N254T,	 L416P,	 or	 Y579D	 (Figure	 6.5).	 In	 oocytes	
expressing	 rBAT,	 [3H]arginine	 uptake	 was	 17-fold	 greater	 than	 in	 water-injected	 control	
oocytes	 (Figure	 6.5).	 Following	 pre-incubation	 with	 tiopronin	 (24μM)	 or	 D-penicillamine,	
uptake	via	wild-type	expressing	oocytes	was	not	significantly	different	(p>0.05)	to	the	control	
group	(Figure	6.5).	However,	pre-incubation	with	captopril	(3.7μM)	led	to	a	2-fold	decrease	in	
[3H]arginine	uptake	 (p>0.05).	 This	was	 likely	due	 to	deterioration	 in	quality	of	 this	particular	
group	 of	 oocytes	 during	 pre-incubation	with	 the	 thiol	 drug.	 In	 oocytes	 expressing	 the	 rBAT	
mutant	proteins	M467T,	M465K,	and	Y579D,	the	control	uptake	was	significantly	lower	than	in	
oocytes	 expressing	 the	wild-type	protein	 (p<0.001)	 (Figure	 6.5A,	 B,	 and	 E,	 respectively).	 The	
uptake	levels	of	all	mutant	proteins	following	24h	incubation	with	the	CBTDs	were	unaltered.		
When	[3H]arginine	uptake	was	carried	out	in	oocytes	expressing	rBAT	mutants	N254T	
and	 L416P,	 the	 levels	 of	 uptake	 were	 significantly	 lower	 than	 the	 wild-type	 uptake	 values	
(Figure	 6.5C	 and	 D).	 This	 is	 consistent	 with	 the	 reduction	 in	 Vmax	 observed	 following	
concentration-dependent	uptake	of	[3H]arginine	 in	Chapter	5	(Figures	5.19	and	5.24),	 further	
evidencing	that	these	mutations	are	pathogenic.	However,	as	observed	with	the	other	mutant	
rBAT	 proteins,	 [3H]arginine	 uptake	 via	 N254T	 and	 L416P-mediated	 transport	 following	 pre-












































































































































































































































been	 pre-incubated	 in	 the	 drugs	 for	 24h	 at	 these	 concentrations.	 A,	 [3H]Arginine	 uptake	 in	
oocytes	 injected	 with	 water	 (control,	 n=10)	 ,	 wild-type	 rBAT	 cRNA	 (50ng,	 n=10),	 or	 M467T	
cRNA	(n=10);	B,	[3H]Arginine	uptake	in	oocytes	injected	with	water	(control,	n=10)	,	wild-type	
rBAT	 cRNA	 (50ng,	 n=10),	 or	M465K	 cRNA	 (n=10);	 C,	 [3H]Arginine	 uptake	 in	 oocytes	 injected	
with	 water	 (control,	 n=10)	 ,	 wild-type	 rBAT	 cRNA	 (50ng,	 n=10),	 or	 N254T	 cRNA	 (n=10);	 D,	
[3H]Arginine	 uptake	 in	 oocytes	 injected	 with	 water	 (control,	 n=10)	 ,	 wild-type	 rBAT	 cRNA	
(50ng,	 n=10),	 or	 L416P	 cRNA	 (n=10);	 E,	 [3H]Arginine	 uptake	 in	 oocytes	 injected	 with	 water	









System	 b0,+,	 mediating	 Na+-independent	 uptake	 of	 dibasic	 amino	 acids	 across	 the	 apical	
membrane	 (Thwaites	 et	 al.,	 1996;	 Anderson	 et	 al.,	 2004).	 To	 demonstrate	 this,	 [3H]arginine	
uptake	 was	 carried	 out	 across	 the	 apical	 membrane	 of	 Caco-2	 monolayers	 in	 the	 absence	
(control)	or	presence	of	5mM	competitor	compounds	lysine,	leucine,	and	proline	(Figure	6.6).	
[3H]Arginine	uptake	was	 inhibited	 in	 the	order:	arginine>	 lysine>	 leucine>>proline.	Uptake	 in	




the	 same	 drug	 in	 the	 uptake	 solution	 (Figure	 6.7).	 No	 significant	 difference	 (p>0.05)	 in	
[3H]arginine	 uptake	was	measured	 following	 pre-incubation	with	 any	 of	 the	 three	 CBTDs	 at	
physiological	concentrations	(Figure	6.7).	This	measurement	was	then	repeated	with	all	three	
drugs	 at	 1mM	 concentration	 to	 identify	 if	 any	 drug-induced	 effects	 would	 occur	 at	 higher	
concentrations	 (Figure	 6.8).	 No	 effect	 on	 System	 b0,+	 function	 was	 observed	 following	
incubation	 with	 captopril	 or	 tiopronin	 (Figure	 6.8A	 and	 B,	 respectively).	 Cell	 monolayers	




	 In	 conclusion,	 these	 data	 present	 no	 evidence	 for	 any	 direct	 effect	 of	 current	
pharmacological	therapies	on	the	transport	system.	Such	evidence	could	have	provided	scope	
for	 a	 pharmacogenetic	 approach	 to	 cystinuria	 therapy	 in	 the	 case	 of	 mutant	 proteins	











inhibition	 of	 [3H]arginine	 uptake.	 [3H]Arginine	 uptake	 (10μM,	 Na+-free,	 pH	 7.4)	 in	 Caco-2	
monolayers.	Uptake	was	performed	over	5min	 in	 the	absence	 (control)	or	presence	of	5mM	
competitor	compounds	arginine	(n=10),	 lysine	(n=10),	 leucine	(n=10),	and	proline	(n=8).	Data	
are	mean±SEM.			








































































































































































































































































































Figure	6.8:	 The	effect	 of	 1mM	cystine-binding	 thiol	 drugs	on	 the	 function	of	 System	b0,+	in	
Caco-2	cells.	 [3H]Arginine	uptake	(10μM,	Na+-free,	pH	7.4)	in	Caco-2	monolayers.	Uptake	was	
performed	 without	 pre-incubation	 of	 cells	 over	 5min	 in	 the	 presence	 (-/+)	 of	 1mM	 CBTD.	
Uptake	 was	 also	 performed	 following	 24h	 pre-incubation	 of	 monolayers	 with:	 A,	 1mM	




































As	 part	 of	 this	 investigation,	 it	 was	 desirable	 to	 express	 exogenous	 rBAT3F	 in	 a	
mammalian	cell	 line.	This	would	enable	the	FLAG-tagged	construct	to	be	expressed,	allowing	
immunodetection	 of	 the	 transiently	 expressed	 protein.	 Following	 the	 optimisation	 of	 rBAT3F	










highest	 densities	 appeared	 at	 optimum	 confluency	 for	 transfection	 (Figure	 6.9).	 Cells	 were	
transfected	as	described	in	Chapter	2	using	the	plasmid	vector	pEGFP-N2,	which	contains	the	
open	 reading	 frame	 for	 enhanced	 green	 fluorescent	 protein	 (EGFP).	 This	 allowed	 successful	
transfection	to	be	visualised	by	fluorescent	microscopy	following	excitation	at	452-500nm.	The	
highest	number	of	cells	expressing	EGFP	was	observed	in	cells	seeded	at	1.5x105.cm-2	(Figure	
6.10C).	 This	 indicated	 that	 transfection	 of	 Caco-2	 cells	 24h	 post-seeding	was	 optimal	 at	 this	
density.	 In	 cells	 seeded	 at	 0.5-1x105.cm-2,	 less	 fluorescence	 was	 observed	 (Figure	 6.10A).	 It	
appeared	as	though	the	confluence	of	cells	seeded	at	a	density	of	2.5x105.cm-2	was	too	high	
for	 transfection	 of	 the	 cDNA.	 No	 fluorescence	 was	 visualised	 in	 these	 cells	 24h	 post-
transfection,	indicating	an	absence	of	EGFP	expression	(Figure	6.10D).	Subsequent	transfection	












































































































































































2	 cells	were	 seeded	 at	 a	 range	 of	 densities	 and	 transfected	with	 cDNA	 for	 EGFP.	 24h	 post-































Caco-2	 cells	 were	 transfected	 with	 cDNA	 for	 rBAT3F	 as	 described	 in	 Chapter	 2.	 To	
maximise	 the	 amount	 of	 rBAT3F	 successfully	 targeted	 to	 the	 Caco-2	 apical	 membrane,	
monolayers	 were	 fixed	 72h	 post-transfection.	 Immunocytochemical	 detection	 of	 rBAT	 using	
the	M2	anti-FLAG	antibody	was	performed	as	described	in	Chapter	2.	Additionally,	monolayers	





525nm)	 and	 TRITC	 (ezrin,	 emission	 at	 570nm)	 (Figure	 6.11Aii	 and	 Bii).	 This	 meant	 that	 the	
fluorescence	 visible	 from	 rBAT	 was	 also	 visible	 when	 detecting	 ezrin,	 making	 it	 appear	
intracellular.	However,	the	ezrin-associated	fluorescence	was	not	detected	as	rBAT.	This	meant	
that	 although	 some	 intracellular	 “ezrin”	 fluorescence	 was	 visible,	 only	 rBAT-associated	 FITC	
fluorescence	was	a	true	measurement	of	its	location.		
At	 72h	post-transfection,	 it	 did	 appear	 as	 though	 some	 rBAT	protein	was	present	 at	
the	apical	membrane	of	Caco-2	monolayers,	co-localising	with	the	ezrin	protein	(Figure	6.11Aiii	
and	 Biii).	 However,	much	 of	 the	 protein	 remained	 intracellular	 (Figure	 6.11).	 Unfortunately,	
due	 to	 time	restrictions	on	 this	 study,	we	were	unable	 to	 transfect	Caco-2	cells	with	mutant	
rBAT	 cDNA	 to	 identify	 differences	 in	 mutant	 protein	 expression	 patterns.	 McCloy	 (2002)	
identified	 that	 there	 is	 a	 delay	 in	 the	 apical	 membrane	 localisation	 of	 rBAT	 relative	 to	 the	
polarisation	of	the	epithelium	in	Caco-2	cells.	Caco-2	cell	monolayers	are	routinely	grown	for	
14-21	 days	 to	 ensure	 full	 differentiation	 although	 are	 polarised	 within	 1-2	 days	 following	
seeding	 at	 high	 density	 (2.5x105cells.cm-2).	 This	 would	 not	 be	 possible	 with	 transiently	
transfected	Caco-2	cell	monolayers	but	future	experiments	would	be	designed	to	increase	the	










Z	 section	 fluorescent	 confocal	microscopy	 images	 of	 Caco-2	monolayers	 (x63	magnification)	






























































Genistein	 is	 an	 isoflavone	 compound	 that	 has	 been	 shown	 to	 inhibit	 tyrosine	 kinase	
activity	 in	mammalian	cells	 (Akiyama	et	al.,	1987).	Many	studies	have	reported	the	ability	of	
genistein	 to	activate	 the	epithelial	 cAMP-activated	Cl-	 channel,	CFTR,	 in	 transfected	cell	 lines	




1997).	 However,	 when	 the	 effects	 of	 genistein	 were	 investigated	 in	 epithelial	 transporters	
GLUT-1	 (Vera	 et	 al.,	 1996)	 and	 MDR1	 (Versantvoort	 et	 al.,	 1993),	 an	 inhibitory	 effect	 was	
observed.	In	2001,	Mizoguchi	et	al.	reported	a	stimulation	of	System	b0,+	activity	in	COS-7	cells	
transiently	expressing	rBAT	and	b0,+AT	following	a	20min	pre-incubation	with	2-50μM	genistein	
(Mizoguchi	 et	 al.,	 2001).	 The	 authors	 attributed	 this	 increase	 in	 [14C]cystine	 uptake	 in	 the	
presence	 of	 genistein	 to	 be	 due	 to	 an	 increased	 rate	 of	 transport.	 It	was	 hypothesised	 that	
PKA-dependent	 tyrosine	 phosphorylation	 of	 b0,+AT	 could	 negatively	 regulate	 transport	
function,	 leading	 to	a	decrease	 in	 [14C]cystine	 transport	 (Mizoguchi	 et	 al.,	 2001).	 If	 genistein	
was	 confirmed	 to	 stimulate	 System	 b0,+	 activity,	 it	 could	 have	 therapeutic	 potential	 in	
cystinuria	 patients.	 A	 similar	 application	 of	 genistein	 has	 been	 proposed	 in	 Cystic	 Fibrosis	
(French	et	al.,	1997).	
In	the	current	study,	the	effect	of	genistein	on	System	b0,+	 function	was	measured	 in	
oocytes.	 [3H]Arginine	uptake	was	performed	 in	oocytes	 injected	with	water	 (control)	or	rBAT	
cRNA	 following	 20min	 pre-incubation	 with	 0-50μM	 genistein	 (Figure	 6.12).	 No	 significant	
difference	(p>0.05)	in	uptake	was	measured	following	treatment	of	the	oocytes	with	genistein	




6.13).	 No	 significant	 difference	 in	 [3H]arginine	 uptake	 was	 observed	 in	 monolayers	 pre-
incubated	with	genistein	at	any	concentration	(Figure	6.13).	The	pre-incubation	of	monolayers	
with	 0.1%	DMSO	did	 not	 have	 any	 significant	 (p>0.05)	 effect	 on	 System	b0,+	function	 (Figure	
6.13).		
These	data	do	not	support	the	results	from	the	literature	that	show	genistein	to	be	a	

































































uptake	 (10μM,	 pH	 7.4,	 5min)	 in	 Caco-2	monolayers	 following	 30min	 pre-incubation	 with	 0-
50μM	 genistein	 (n=8).	 Open	 bars,	 control	 cell	 monolayers;	 black	 bars,	 monolayers	 pre-





































To	 investigate	 the	 effect	 of	 glycosylation	 on	 the	 expression	of	 rBAT,	 the	 putative	N-
linked	glycosylation	sites	were	identified.	In	proteins,	the	glycosylation	consensus	sequence	is	
N-X-S/T,	were	X	is	any	amino	acid,	apart	from	proline	(Gavel	&	von	Heijne,	1990).	In	rBAT,	this	






Of	 the	 6	 putative	 glycosylation	 sites	 in	 rBAT,	 only	 one	 has	 been	 investigated	 in	 the	
literature	(Bartoccioni	et	al.,	2008).	This	is	due	to	the	presence	of	cystinuria	mutation	T216M,	
which	 removes	 the	consensus	 sequence	N214-H215-T216.	T216M	was	characterised	 in	1998	
by	 Saadi	 et	 al.	 (1998)	 as	 an	 rBAT	 trafficking	mutation,	 shown	 to	 cause	 an	 80%	 decrease	 in	
[14C]cystine	uptake	compared	to	wild-type	function	when	expressed	in	oocytes.	Bartoccioni	et	
al.	 (2008)	 identified	 an	 absence	 in	 band	 shift	 following	 electrophoretic	 resolution	 of	 T216M	
compared	to	the	wild-type	protein.	This	indicates	that	the	removal	of	the	consensus	site	does	
not	 remove	 a	 glycan	 residue	 from	 the	 protein,	 and	 that	 N214	 is	 not	 glycosylated	 in	 vivo.	
Additionally,	 this	 glycosylation	 motif	 appears	 to	 be	 in	 a	 cleft	 on	 the	 model	 of	 the	 rBAT	
extracellular	domain	(Figure	6.17).	Based	on	this	finding,	online	tool	GlyProt,	which	was	used	
to	 add	 oligosaccharide	 residues	 to	 the	 structure,	 ruled	 this	 out	 as	 a	 candidate	 site	 for	
glycosylation	 (Figure	 6.18).	Homology	modelling	was	 used	 to	 add	oligosaccharide	 chains	 the	
five	 remaining	 putative	 sites	 of	 N-glycosylation	 (Figure	 6.18).	 From	 this	 model	 it	 can	 be	




















of	 percentage	 conservation	of	 the	motifs	 is	 based	upon	 the	multiple	 sequence	 alignment	of	





Asn	Residue	Number	 Motif	 Conserved	 Mutation	
214	 NHT	 100%	 T216M	
261	 NSS	 100%	 --	
332	 NKT	 100%	 --	
495	 NES	 66%	 --	
513	 NSS	 100%	 --	





Mouse         KEIDPIFGTMKDFENLVAAIHDKGLKLIIDFIPNHTSDKHPWFQSSRTRSGKYTDYYIWH 239 
Rat           KEIDPIFGTMKDFENLVAAVHDKGLKLIIDFIPNHTSDKHPWFQSSRTRSGKYTDYYIWH 237 
Rabbit        REIDPIFGTMEDFENLLAAIHDKGLKLIIDFIPNHTSDKHAWFQLSRTRTGKYTDYYIWH 232 
Human         REVDPIFGTMEDFENLVAAIHDKGLKLIIDFIPNHTSDKHIWFQLSRTRTGKYTDYYIWH 240 
Pig           REIDPIFGTMKDFENLVAAIHDKGLKLIIDFIPNHTSDKHAWFQLSRTRTGKYTDYYIWH 23 
Cow           REIDPIFGTMKDFENLVAAIHDKGLKLIIDFIPNHTSDKHAWFQWSRNQTGKYTDYYIWH 240 
              :*:*******:*****:**:******************** *** **.::********** 
 
Mouse         NCTHVNGVTTPPNNWLSVYGNSSWHFDEVRKQCYFHQFLKEQPDLNFRNPAVQEEIKEII 299 
Rat           NCTHANGVTTPPNNWLSVYGNSSWQFDEERKQCYFHQFLKEQPDLNFRNPAVQEEIKEII 297 
Rabbit        DCAHENGITTPPNNWLSVYGNSSWHFDEVRNQCYFHQFLKEQPDLNFRNPDVQEEIKEIM 292 
Human         DCTHENGKTIPPNNWLSVYGNSSWHFDEVRNQCYFHQFMKEQPDLNFRNPDVQEEIKEIL 300 
Pig           DCTQEDGITIPPNNWLSVYGNSSWHFDEIRNQCYFHQFLKEQPDLNFRNPDVQEEIKEII 297 
Cow           DCNRENGTTIPPNNWLSVYGNSSWHFDEVRKQCYFHQFMKEQPDLNFRNPDVQEEIKEII 300 
              :* : :* * **************:*** *:*******:*********** ********: 
 
Mouse         TFWLSKGVDGFSFDAVKFLLEAKDLRNEIQVNTSQIPDTVTHYSELYHDFTTTQVGMHDI 359 
Rat           KFWLSKGVDGFSFDAVKFLLEAKDLRNEIQVNTSQIPDTVTRYSELYHDFTTTQVGMHDL 357 
Rabbit        QFWLTKGVDGFSFNAVKFLLEAMHLRNEIQVNASQIPDTVTRYSELYHDFTTTQEGMHDL 352 
Human         RFWLTKGVDGFSLDAVKFLLEAKHLRDEIQVNKTQIPDTVTQYSELYHDFTTTQVGMHDI 360 
Pig           QFWLSKGVDGFSFDAVQFLLEAKHLRDETQVNKTQIPATITHYSELYHDFTTTQVGMHDI 357 
Cow           QFWLSKGVDGFSFDALPFLLEAKHLRDEAQVNKTQIPDMVTHYSQLHHDFTTTQVGMHDI 360 
              ***:*******::*: ***** .**:* *** :***  :*:**:*:******* ****: 
 
Mouse         VRDFRQTMNQYSREPGRYRFMGAEASAESIERTMMYYGLPFIQEADFPFNKYFTTIGTLS 419 
Rat           VRDFRQTMNQFSREPGRYRFMGTEVSAESTERTMVYYGLSFIQEADFPFNKYLATLDTLS 417 
Rabbit        VRSFRQTMDKYSREPGRYRFLGTEAYAESIDRTMRYYGLSFIQEADFPFNNYFTTLDTLS 412 
Human         VRSFRQTMDQYSTEPGRYRFMGTEAYAESIDRTVMYYGLPFIQEADFPFNNYLSMLDTVS 420 
Pig           VRSFRQMMDQYSREPGRYRFMGTEAQGESIAGTMMYYGLPFIQEADFPFNSYFGQLDSPS 417 
Cow           VRSFRQTMNQYSREPGRYRFMGTEAHGESITKTMVYYGLPFIQEADFPFNSYLSKLDKPS 420 
              **.*** *:::* *******:*:*. .**   *: ****.**********.*:  :.. * 
 
Mouse         GHTVYEVITSWMENMPEGKWPNWMTGGPETPRLTSRVGSEYVNAMHMLLFTLPGTPITYY 479 
Rat           GHTVYEAITSWMENMPEGKWPNWMIGGPETSRLTSRVGSEYVNAMNMLLFTLPGTPITYY 477 
Rabbit        GNTVYEVITAWMENMPEGKWPNWMTGGPDITRLTSRLGNQYVNIMNMLLFTLPGTPITYY 472 
Human         GNSVYEVITSWMENMPEGKWPNWMIGGPDSSRLTSRLGNQYVNVMNMLLFTLPGTPITYY 480 
Pig           GDSVAEVILSWMENMPEGKWPNWMTCGPDNARLTSRLGEEYVNVMNMLIFTLPGTPITYY 477 
Cow           GNSVSEIITSWMENMPEGKWPNWMTGGPDSVRLTSRLGEKYVNIMNMLVFTLPGTPITYY 480 
              *.:* * * :**************  **:  *****:*.:*** *:**:*********** 
 
Mouse         GEEIGMGDISVTNFNESYDSTTLVSKSPMQWDNSSNAGFTEANHTWLPTNSDYHTVNVDV 539 
Rat           GEEIGMGDISITNLNERYDTNALLSKSPMQWDNSSNAGFTEANHTWLPTNSDYHTVNVDV 537 
Rabbit        GEEIGMGNILATNLNESYDVNTLLSKSPMQWDNSSNAGFSEGNHTWLPTSSDYHTVNVDV 532 
Human         GEEIGMGNIVAANLNESYDINTLRSKSPMQWDNSSNAGFSEASNTWLPTNSDYHTVNVDV 540 
Pig           GEEIGMRNILATSLYETYDADTLLSKSPMQWDNSSNAGFSEGSHTWLPTRSDYPTVNGDV 537 
Cow           GEEIGMRNILAANLNETYDAGTLFSKSPMQWDNSSNAGFSEGNHTWLPTSSDYHTVNVDV 540 
              ****** :*  :.: * **  :* ***************:*..:***** *** *** ** 
 
Mouse         QKTQPSSALRLYQDLSLLHATELVLSRGWFCLLRDDSHSVVYTRELDGIDNVFLVVLNFG 599 
Rat           QKTQPSSALRLYQDLSLLHARELLLSRGWFCLLRDDNHSVVYTRELDGIDKVFLVVLNFG 597 
Rabbit        QKTQPTSALKLYQALSLLHANELLLSRGWFCLLRNDSRVLVYTRELDGIDRVFIVVLNFG 592 
Human         QKTQPRSALKLYQDLSLLHANELLLNRGWFCHLRNDSHYVVYTRELDGIDRIFIVVLNFG 600 
Pig           QKTQPKSALKLYQELSLLHANELLLSRGWFCYLRNDNYSVVYTRELNGIDRVLLMVLNFG 597 
Cow           QKTQPRSALKLYQELSLLHANELLLGRGWFCFLGNYNHSIMYTRELDGINRIFLMVLNFG 600 
















alignment	 of	 rBAT.	 Multiple	 sequence	 alignment	 of	 human	 (NM_000341.3),	 mouse	
(NM_009205.2),	 rat	 (NM_017216.1),	 rabbit	 (NM_001082242.1),	 pig	 (NM_001123042.1),	 and	
cow	 (NM_001034633.2)	 rBAT.	 Consensus	 symbols	 are	 displayed	 below	 aligned	 residues.	 *,	
fully	 conserved	 residues;	 :,	 conservation	 between	 groups	 with	 strongly	 similar	 properties	
(scoring	 >0.5	 in	 the	 Gonnet	 PAM	 250	matrix);	 .,	 conservation	 between	 groups	 with	 weakly	











to	 show	 the	 putative	 location	 of	N214,	 located	 internally	 in	 the	 hydrophobic	 interior	 of	 the	
model,	 denoted	 by	 a	 black	 circle.	 Domains	 are	 labelled	 in	 the	 same	 colour	 as	 shown	 in	 the	














































































to	 the	protein	 is	 indicated.	Domains	are	 labelled	 in	 the	same	colour	as	shown	 in	 the	protein	
structure	 with	 amino	 acid	 residue	 numbers	 in	 brackets.	 Red,	 domain	 A1;	 yellow,	 domain	 B;	
green,	domain	A2;	blue,	domain	C.	The	transmembrane	domain	and	30	amino	acid	“tail”	of	the	







Of	 the	 five	 candidate	 glycosylation	 sites	 in	 rBAT,	 three	 are	 fully	 conserved	 in	 the	
multiple	 alignment	 of	 mammalian	 rBAT	 sequences	 (Figure	 6.14).	 These	 residues	 are	 N261,	
N332,	and	N513,	highlighted	in	Figure	6.16A.	In	this	study,	site	directed	mutagenesis	was	used	
to	mutate	these	three	residues	to	aspartic	acid	(D),	thereby	removing	the	consensus	sequence.	
Mutant	 cDNA	 sequences	 created	 single,	 double,	 and	 triple	 mutants.	 The	 following	 mutant	
rBAT	 sequences	 were	 created:	 N261D,	 N332D,	 N513D,	 N261D/N332D,	 N261D/N513D,	
N261D/N332D/N513D.		
[3H]Arginine	uptake	was	measured	in	oocytes	injected	with	water	or	the	cRNA	for	wild-
type	 rBAT,	 or	 each	 of	 the	 glycosylation	 mutants	 (Figure	 6.17A).	 No	 significant	 difference	
(p>0.05)	 was	 measured	 in	 uptake	 between	 wild-type	 rBAT	 expressing	 oocytes	 or	 those	
expressing	 the	mutant	 proteins	 N332D,	 N513D,	 N261D/N332D,	 N332D/N513D,	 or	 the	 triple	
mutant	 N261D/N332D/N513D	 (Figure	 6.17A).	 Oocytes	 expressing	 N213D	 showed	 no	
significant	uptake	(p>0.05)	above	that	measured	 in	water-injected	controls,	which	 is	 thought	
to	be	due	 to	non-functional	 cRNA	 (Figure	6.17A).	 This	was	 confirmed	by	 the	absence	of	any	
translated	protein	in	western	blotting	of	total	membrane	proteins	from	oocytes	injected	with	
N261D	 cRNA	 (Figure	 6.17B,	 lane	 C).	 Uptake	 in	 oocytes	 expressing	 the	 double	 mutant	
N261D/N513D	was	significantly	greater	 (p<0.001)	 than	 in	oocytes	expressing	wild-type	 rBAT.	
These	are	the	results	of	a	single	experiment	(n=10),	which,	due	to	time	restrictions,	could	not	
be	 repeated.	 To	 confirm	 the	 reproducibility	 of	 this	 observation,	 further	 investigation	 is	
required.	 Although	 improbable,	 it	 is	 not	 impossible	 that	 the	 selective	 removal	 of	 N-
glycosylation	at	these	two	sites	can	increase	expression.	Dubé	et	al.,	demonstrated	that	whilst	
there	is	an	aggregation	and	lack	of	trafficking	of	unglycosylated	Erythropoetin	produced	in	the	
presence	 of	 tunicamycin,	 only	 two	 of	 the	 three	 glycosylation	 sites	 affect	 function	 when	
individually	mutated	(Dubé	et	al.,	1988).	
Western	 blotting	 was	 used	 to	 detect	 the	 size	 of	 rBAT	 proteins	 containing	 the	
glycosylation	 mutations	 (Figure	 6.18).	 As	 demonstrated	 previously,	 wild-type	 rBAT	 protein	
produces	a	doublet	band	at	85	and	90kDa	(Figure	6.18A,	lanes	b	and	j).	With	the	exception	of	
N231D,	 in	 which	 no	 protein	 was	 translated,	 all	 mutant	 proteins	 investigated	 led	 to	 the	
detection	of	doublet	bands	by	western	blot	 (Figure	6.18A,	 lanes	d-i).	 	This	 indicated	 that	we	
had	not	removed	all	sites	of	N-glycosylation	in	the	rBAT	triple	mutant,	and	that	at	least	one	of	
the	 two	other	putative	 sites	 (N495	and	N575)	 is	 glycosylated	 in	 vitro.	Despite	 this,	 a	 shift	 in	
band	 size	 was	 observed	 compared	 to	 wild-type	 rBAT	 (Figure	 5.18B).	 In	 lanes	 d	 and	 e,	
representing	 single	mutant	proteins	N332D	and	N513D,	 respectively,	bands	between	75	and	





double	 mutants	 (lanes	 f-h)	 and	 the	 triple	 mutant	 (lane	 j).	 Despite	 the	 increase	 in	 uptake	













Figure	 6.17:	 The	 effect	 of	 N-linked	 glycosylation	 on	 the	 function	 of	 rBAT	 in	 oocytes.		
[3H]Arginine	 uptake	 (10μM,	 pH	 7.4,	 60min)	 3	 days	 post-injection	 of	 oocytes	 with	 water	
(control)	or	the	cRNA	for	rBAT	or	the	glycosylation	knock-out	mutants:	N261D,	N332D,	N513D,	




















































Figure	6.18:	 The	effect	of	N-linked	glycosylation	on	 the	 function	and	 cellular	processing	of	
rBAT	in	oocytes.	A,	Western	blot	of	total	oocyte	membranes	taken	from	the	same	batches	of	
oocytes	used	for	the	uptake	experiment	in	panel	(A).	Lanes	a-j	represent	oocytes	injected	with:	
a,	 water	 (control);	 b,	 wild-type	 rBAT;	 c,	 N261D;	 d,	 N332D;	 e,	 N513D;	 f,	 N261D/N332D;	 g,	
N261D/N513D;	 h,	 N332D/N513D;	 i,	 N261D/N332D/N513D;	 j,	 wild-type	 rBAT;	 B,	 the	 same	
western	 blot	 image	 is	 shown	 as	 in	 panel	 (A)	 with	 dotted	 lines	 representing	 the	 two	 bands	






























To	 determine	 whether	 a	 complete	 absence	 of	 N-glycosylation	 in	 rBAT	 affected	
function,	 [3H]arginine	 uptake	was	 carried	 out	 in	 oocytes	 co-injected	with	water	 (control)	 or	




cells	 that	 had	been	pre-incubated	with	 TM,	 compared	 to	 those	 that	 had	not	 (Figure	 6.19B).	









from	 90kDa	 to	 72kDa	 following	 injection	 of	 oocytes	 with	 rBAT	 cRNA	 and	 tunicamycin.	 The	
results	 indicate	 that	 the	membrane	 localisation	 of	 rBAT	 is	 not	mediated	 by	 N-glycosylation.	
The	lack	of	conservation	of	N495	and	N575	in	some	species,	and	their	apparent	glycosylation	











































































































rBAT	 cRNA	 (50ng),	 with	 or	 without	 co-injection	 of	 20ng	 tunicamycin	 (n=25-30).	 Data	 are	
mean±SEM.	 ns,	 p>0.05	 versus	 uptake	 in	 rBAT-expressing	 oocytes	 without	 tunicamycin;	 B,	
[3H]Arginine	uptake	(10μM,	pH	7.4,	5min)	across	the	apical	membrane	of	Caco-2	monolayers	
following	24h	pre-incubation	with	DMEM	(control),	DMEM	plus	0.01%	DMSO,	or	DMEM	plus	











In	 this	 chapter	 we	 have	 investigated	 how	 modifications	 to	 the	 rBAT	 protein	 can	
potentially	effect	the	expression	or	function	of	the	transport	system.	The	ultimate	aim	of	these	
modifications	 was	 to	 try	 to	 identify	 ways	 in	 which	 current	 cystinuria	 therapies	 could	 be	
optimised	 for	 individual	 patients	 based	 upon	 their	 genotype,	 or	 to	 suggest	 the	 potential	 of	
other	compounds	for	a	pharmacological	purpose	in	the	treatment	of	cystinuria.		
6.4.1	A	pharmacogenetic	approach	to	cystinuria	
Following	 the	 completion	 of	 the	 Human	 Genome	 Project	 in	 2000,	 the	 field	 of	
pharmacogenetics	 appeared	 highly	 promising	 (Roses,	 2000).	 The	 ability	 to	 use	 the	 genetic	
information	 of	 a	 patient	 to	 tailor	 their	 response	 to	 therapy	 and	 provide	 a	 personalised	
treatment	moving	away	from	the	“one	drug	fits	all”	paradigm	appeared	 imminent.	However,	
more	 than	 a	 decade	 on,	 the	 results	 in	 clinical	 practice	 have	 fallen	 somewhat	 short	 of	 this	
promise	 (Crews	 et	 al.,	 2012).	 Despite	 this,	 some	 advances	 have	 been	 made.	 The	 best-
established	 use	 of	 pharmacogenetic	 testing	 in	 clinical	 practice	 is	 the	 genotyping	 of	 the	
thiopurine	 methyltransferase	 gene	 TMPT,	 which	 occurs	 prior	 to	 prescription	 of	 the	
immunomodulating	 thiopurine	 drug,	 azathioprine	 (McLeod	 et	 al.,	 2000;	Holme	 et	 al.,	 2002).	
This	prevents	 severe	myelosuppression	 in	around	11%	of	 the	population	who	are	carriers	of	
the	 TMPT	 polymorphisms	 and	 require	 a	 reduced	 dosage	 of	 the	 drug	 (McLeod	 et	 al.,	 2000).	
Despite	the	 lack	of	progress	 in	this	field,	the	potential	 for	personalised	treatments	 in	genetic	
disease,	through	identification	of	new	therapeutic	targets,	remains	great.		
In	 this	 chapter	 we	 investigated	 whether	 the	 current	 cystinuria	 therapies	 used	 to	
increase	 the	 solubility	 of	 cystine	 had	 any	 effect	 upon	 the	 transporter	 (Figure	 6.4-6.6).	 No	
change	in	[3H]arginine	uptake	was	observed	following	alkalinisation	of	the	incubation	medium	
and	 uptake	 solution	 of	 oocytes	 expressing	 rBAT	 (Figures	 6.4-6.5).	 We	 also	 investigated	
whether	pre-incubation	of	 rBAT-expressing	oocytes	with	CBTDs	 captopril,	 D-penicillamine,	or	
tiopronin	would	affect	the	protein	expression.	Similarly,	no	change	 in	function	was	detected,	
nor	 did	 any	 of	 the	 investigated	 rBAT	 mutant	 proteins	 (M467T,	 M465K,	 N254T,	 L416P,	 or	
Y579D)	respond	differently	to	treatment	with	the	CBTD	(Figures	6.7-6.8).	This	experiment	was	
also	carried	out	in	Caco-2	cells	with	the	drugs	at	estimated	physiological	concentrations,	and	at	
a	 1mM	 concentration	 (Figures	 6.9	 and	 6.10,	 respectively).	 The	 experimental	 data	 obtained	
using	the	mammalian	cell	line	confirmed	that	the	drugs	had	no	direct	effect	upon	the	transport	






From	 these	 data	 we	 can	 conclude	 that	 there	 is	 no	 scope	 for	 a	 pharmacogenetic	
approach	to	cystinuria	therapy	using	established	treatments.	However,	the	knowledge	of	the	




following	 co-expression	 of	 rBAT	 and	 b0,+AT	 in	 COS-7	 and	HeLa	 cells,	 a	 complete	 abolition	 in	
[34S]cystine	 uptake	 was	 observed	 following	 the	 introduction	 of	 the	 following	 SLC7A9	
mutations:	A70V,	G105R,	V170M,	and	R333W	(Feliubadalo	et	al.,	1999;	Font	et	al.,	2001).	The	
SLC7A9	mutations	A182T	and	A354T	caused	a	20-40%	in	transport	activity	following	expression	
in	HeLa	 cells,	 compared	 to	 those	expressing	wild-type	b0,+AT	 (Font	et	al.,	2001).	Despite	 the	
lack	of	data	collected	on	 the	effect	of	SLC7A9	mutations	on	 the	 function	of	System	b0,+,	 it	 is	
predicted	 that	 mutations	 in	 the	 12-transmembrane	 domain	 transport	 pore	 would	 affect	
substrate	 binding,	 or	 translocation	 across	 the	 membrane.	 As	 a	 result	 of	 this,	 it	 could	 be	
possible	 to	 design	 novel	 therapies	 for	 cystinuria	 treatment	 based	upon	 the	 genotype	of	 the	




domain	 (A1	 and	A2)	 of	 the	 translated	polypeptide	 caused	 a	 rapid	degradation	of	 the	protein	
following	its	assembly	with	b0,+AT	in	HeLa	cells.	However,	rBAT	mutation	L89P,	located	in	the	
putative	 transmembrane	 domain	 of	 the	 protein,	 led	 to	 a	 lack	 of	 assembly	 with	 b0,+AT	
(Bartoccioni	 et	 al,	 2008).	 No	 L89P	 protein	 could	 be	 co-precipitated	 with	 an	 anti-b0,+AT	
antibody,	unlike	 the	other	 translated	mutant	proteins	 (Bartoccioni	et	al.,	2008).	 The	authors	






2007).	 	 An	 alternative	 mechanism	 of	 molecular	 chaperone	 function	 is	 the	 inhibition	 of	 ER	
stress,	 which	 allows	 the	 maturation	 of	 polypeptides	 (Molinari,	 2007).	 For	 example,	 4-
phenylbutyrate	 (PBA)	 has	 been	 shown	 to	 allow	 the	 exit	 of	 ΔF508	 CFTR	 from	 the	 ER,	 and	








studied	 in	 detail,	 enabling	 the	 identification	 of	 many	 potential	 targets	 for	 these	 chemical	
correctors	 (Wang	 et	 al.,	 2006).	 In	 order	 to	 discover	 potential	 targets	 for	 rBAT	mutant	 mis-




an	 increase	 in	 [14C]cystine	 uptake	 in	 COS-7	 cells	 transfected	with	 both	 System	b0,+	 subunits,	
following	incubation	with	2-50μM	genistein.	The	authors	hypothesised	that	this	increase	could	
be	 due	 to	 the	 PKA-dependent	 phosphorylation	 of	 b0,+AT	 negatively	 regulating	 the	 rate	 of	
transport.	 It	was	demonstrated	that	PKA	activator,	db-cAMP,	also	decreased	uptake	 levels	 in	
COS-7	cells,	the	effect	of	which	was	abolished	in	the	presence	of	the	inhibitor	compound	H-89	
(Mizoguchi	 et	 al.,	 2001).	 Despite	 this	 observation	 by	 Mizoguchi	 et	 al.	 (2001),	 no	 effect	 of	




to	 tailored	 therapies	 for	 patients	 with	 type	 B	 cystinuria.	 If	 selective	 treatment	 with	 PKA-





investigated	 (Figures	 6.11-6.13).	 Caco-2	 cells	 endogenously	 express	 both	 subunits	 of	 System	
b0,+,	which	was	demonstrated	in	the	current	study	through	apical	Na+-independent	uptake	of	
the	 dibasic	 amino	 acid	 [3H]arginine,	 and	 its	 selective	 inhibition	 through	 competition	 with	
excess	 (5mM)	amino	acids	 (Figure	6.10).	The	aim	of	 transfection	 in	 the	current	study	was	 to	
express	 a	 FLAG-tagged	 rBAT	 protein	 (rBAT3F),	 which	 could	 be	 detected	 by	
immunocytochemical	methods.	Due	to	the	difficulties	 in	 transfecting	confluent	cells,	and	the	








been	 translated	 and	 rBAT3F	 was	 expressed	 (Figure	 6.13).	 Through	 co-localisation	 with	 the	
apical	 membrane	 protein	 ezrin,	 it	 appeared	 as	 though	 some	 rBAT3F	 was	 present	 at	 the	
membrane.	 However,	 the	majority	 of	 the	 protein	 was	 intracellular	 (Figure	 6.13).	 As	 Caco-2	
cells	endogenously	express	 rBAT,	we	would	expect	 that,	over	 time,	 the	majority	of	 the	wild-
type	 protein	 would	 traffic	 to	 the	 apical	 membrane.	 Despite	 this,	 at	 72h	 post-transfection,	
there	is	no	clear	indication	that	this	has	happened	sufficiently	to	allow	comparison	of	wild-type	
and	mutant	 rBAT.	 Unfortunately,	 due	 to	 time	 restrictions	 on	 this	 study,	we	were	 unable	 to	
transfect	Caco-2	cells	with	the	mutant	proteins	to	compare	the	expression	patterns.	In	future	
studies,	 this	 would	 be	 desirable	 for	 detection	 of	 the	 sub-cellular	 localisation	 of	 the	 rBAT	
mutants.	 Additionally,	 this	 would	 allow	 experiments	 to	 be	 carried	 out	 to	 detect	 any	





In	 the	 current	 study,	oocytes	were	 incubated	at	 30°C	during	a	60min	uptake	 (Figure	






was	 greater	 following	 protein	 expression	 in	 HeLa	 cells,	 than	 in	 oocytes.	 The	 effect	 of	 this	





Chapter	5).	However,	 to	detect	 this	 in	oocytes,	 they	would	need	to	be	 incubated	at	30°C	 for	









has	been	measured,	 indicating	 the	correct	cellular	processing	and	trafficking	of	 the	proteins.	
Additionally,	Feliubadalo	et	al.	(1999)	used	immunocytochemical	detection	to	show	that	when	
rBAT	 was	 transfected	 in	 COS-1	 cells	 alone,	 it	 localised	 to	 an	 intracellular	 compartment.	
However,	when	both	System	b0,+	subunits	were	co-transfected	in	the	cell	line,	fluorescence	was	
detected	at	the	plasma	membrane	(Feliubadalo	et	al.,	1999).	These	results,	along	with	the	data	
presented	 in	 the	 current	 study	 appear	 promising	 for	 the	 optimisation	 of	 rBAT	 expression	 in	
Caco-2	 cells.	 However,	 further	 optimisation	 of	 this	 technique	 is	 required.	 The	 successful	
expression	of	 rBAT	and	mutant	proteins	 in	 the	cell	 line	would	also	provide	scope	 for	 further	
research	 into	 the	biogenesis	of	 rBAT,	 and	 treatment	of	 the	 cells	with	 chemical	 correctors	of	
mis-folded	rBAT,	as	discussed	in	section	6.4.1.	
6.4.3	N-glycosylation	of	rBAT		
The	 high	 affinity	 glycine	 transporter,	 GLYT1,	 has	 four	 potential	 glycosylation	 sites	
(Olivares	et	al.,	1995).	Olivares	et	al.	(1995)	transfected	COS-7	cells	with	both	wild-type	protein	
and	mutated	GLYT1	to	measure	the	effect	of	N-glycosylation	on	apical	targeting	and	activity	of	
the	 transporter.	 In	 the	 mutated	 protein,	 the	 asparagine	 (Asn)	 residues	 of	 the	 motif	 were	
substituted	 for	 glutamine	 (Gln).	When	 cells	 transfected	with	wild-type	 protein	were	 treated	
with	 tunicamycin,	 there	 was	 a	 30%	 inhibition	 in	 [3H]glycine	 uptake	 (Olivares	 et	 al.,	 1995).	
Mutated	 protein	 had	 either	 two,	 three,	 or	 four	 of	 the	 potential	 glycosylation	 motifs	
substituted	 and	 the	 removal	 of	 oligosaccharide	 residues	 was	 shown	 to	 have	 a	 cumulative	
effect	on	uptake	inhibition	(Olivares	et	al.,	1995).	
In	 2003	 Lee	 et	 al.,	 demonstrated	 that	 complete	 inhibition	 of	 N-glycosylation	 of	 the	
organic	anion	transporter	Oatp1	 (SLC21A1)	when	expressed	 in	 tunicamycin	 -treated	Xenopus	
oocytes	 reduced	uptake	of	 [3H]taurocholate	by	over	70%	 (Lee	 et	al.,	 2003).	 The	 same	group	
also	 used	 site-directed	 mutagenesis	 to	 individually	 substitute	 the	 Asn	 residues	 of	 the	 four	
glycosylation	motifs.	Whilst	western	 blotting	 showed	 a	molecule	 of	 lower	molecular	weight	
compared	to	the	native	protein,	there	was	no	effect	on	function	in	single	mutants	(Lee	et	al.,	
2003).	 However,	 when	 double	 and	 triple	mutants	 were	made,	 an	 additive	 effect	 was	 seen,	








in	 Xenopus	 oocytes	 and	 treated	 with	 both	 PNG-F	 and	 Endo-H	 for	 total	 inhibition	 of	 N-




gels	 (Hayes	 et	 al.,	 1994).	 Immunocytochemical	 detection	 techniques	 in	 sections	 of	 oocytes	
expressing	 NaPi-II	 showed	 presence	 of	 both	 the	 mutant	 and	 wild-type	 protein	 in	 the	
membrane.	 However,	 in	 the	 double	 mutant,	 diffuse	 staining	 was	 also	 observed	 inside	 the	
oocyte,	 implying	 incomplete	 trafficking	 of	 the	 protein	 (Hayes	 et	 al.,	 1994).	 Radiolabelled	
phosphate	uptake	into	oocytes	expressing	the	double	mutant	was	reduced	by	50%	compared	
to	the	wild-type	protein	(Hayes	et	al.,	1994).	
In	 the	 current	 study,	we	 investigated	 the	 role	of	N-linked	glycans	on	 the	 function	of	
rBAT	 (Section	 6.3.4).	 Of	 the	 six	 N-linked	 glycosylation	 consensus	 sites	 present	 in	 the	 rBAT	
amino	 acid	 sequence	 (N-X-S/T),	 we	 predict	 five	 of	 these	 to	 be	 glycosylated	 based	 upon	 a	
homology	model	of	 the	extracellular	domain	 (Figure	6.16).	 Individual	mutation	of	 two	of	 the	
five	potential	glycosylation	sites	(N332	and	N513)	to	aspartic	acid	(D)	residues	did	not	lead	to	a	
reduced	function	in	System	b0,+	measured	by	[3H]arginine	uptake	(Figure	6.17A).	To	determine	
whether	 N261D	 affects	 the	 function	 of	 rBAT,	 the	 experiment	 requires	 repeating	 with	
functional	cRNA.	One	combination	of	glycosylation	mutations	(N261D/N513D)	lead	to	a	2-fold	
increase	 in	 uptake	 compared	 to	 wild-type	 rBAT.	 However,	 these	 results	 are	 of	 a	 single	
experiment	 and	 would	 require	 repeating	 before	 conclusion	 could	 be	 made	 about	 this	






rBAT.	Following	the	 inhibition	of	N-glycosylation	 in	rBAT,	no	significant	change	 in	System	b0,+	
function	was	measured	in	oocytes	or	Caco-2	cells	following	the	tunicamycin	treatment	(Figure	
6.19).	 In	a	 similar	manner,	 the	elimination	of	N-glycosylation	appeared	 to	have	no	effect	on	
the	function	or	expression	of	the	apical	membrane	protein	CFTR	(O'Riordan	et	al.,	2000).	From	








the	 nature	 of	mutations	 in	 the	 proteins	 of	 System	 b0,+	 could	 be	 exploited	 to	 provide	 novel	
therapeutic	targets	for	cystinuria.	Despite	the	lack	of	results	indicating	any	selective	response	
of	particular	mutations	to	therapy,	our	increasing	knowledge	of	the	effect	of	these	individual	











the	 transport	 of	 these	 small,	 zwitterionic	 molecules	 across	 the	 phospholipid	 bilayer	 of	 the	
apical	 and	 basolateral	 membranes	 of	 the	 epithelium.	 To	mediate	 this,	 a	 range	 of	 transport	
systems	with	distinct	substrate	specificities	and	ion-coupling	mechanisms,	is	present	along	the	
length	 of	 the	 proximal	 tubule	 (Bröer,	 2008).	 Mutations	 in	 the	 genes	 that	 encode	 these	
transport	 systems	 can	 confer	 changes	 to	 the	 structural	 conformation	 of	 the	 translated	
proteins,	 preventing	 the	 efficient	 reabsorption	 of	 their	 native	 substrates	 (Bröer,	 2008).	 This	





1994;	 Yan	 et	 al.,	 1994).	 Mutations	 in	 either	 of	 these	 two	 genes	 prevent	 the	 successful	
reabsorption	of	the	dibasic	amino	acids	arginine,	ornithine,	and	lysine,	causing	a	benign	dibasic	
aminoaciduria	 (Harris	 et	 al.,	 1955).	 However,	 System	b0,+	 is	 the	 only	 known	 apical	 transport	
system	 capable	 of	 re-absorbing	 cystine	 from	 the	 proximal	 tubule,	 where	 >90%	 of	 cystine	
reabsorption	 occurs	 (Volkl	 &	 Silbernagl,	 1982).	 Cystine	 is	 poorly	 soluble	 in	 the	 renal	 filtrate	
(<1mM)	and	a	reduction	in	the	reabsorption	leads	to	precipitation	of	the	cysteine	dimer,	and	
the	formation	of	renal	calculi	(Goldfarb	et	al.,	2006).	The	phenotype	of	patients	with	cystinuria	
varies	greatly,	and	current	 therapies	are	not	 curative.	 In	 fact,	 the	cystine	binding	 thiol	drugs	
used	 in	 the	 treatment	 of	 cystinuria	 are	 poorly	 tolerated	 by	 many	 patients	 (Goldfarb	 et	 al.,	
2006;	 Thomas	 et	 al.,	 2014).	 For	 this	 reason,	 research	 has	 turned	 to	 the	 investigation	 of	 the	
structure	and	biogenesis	of	rBAT	and	b0,+AT	(Bartoccioni	et	al.,	2008).	This	will	enable	further	
understanding	 of	 the	 effect	 that	 cystinuria	 mutations	 have	 on	 these	 two	 proteins,	 and	
ultimately	 lead	 to	 the	 identification	 of	 novel	 therapeutic	 targets.	 To	 date,	 only	 9	 of	 the	 91	
reported	 SLC3A1	 missense	 mutations	 have	 been	 characterised	 functionally	 (Calonge	 et	 al.,	
1994;	 Chillarón	 et	 al.,	 1997;	 Saadi	 et	 al.,	 1998;	 Ishihara	 et	 al.,	 2002;	 Pineda	 et	 al.,	 2004b;	
Bartoccioni	 et	 al.,	 2008).	 Through	 the	 investigations	 included	 in	 this	 study,	 we	 aimed	 to	
contribute	to	this	body	of	knowledge,	by	identifying	the	effects	that	novel	rBAT	mutations	had	
upon	the	System	b0,+	transport	heterodimer.		









and	 section	 3.4.1).	 Eggermann	 et	 al.	 (2012)	 reported	 an	 average	mutation	detection	 rate	 of	
85%	amongst	 cystinuria	 cohorts	worldwide.	 The	 consistency	of	 this	 value	with	our	mutation	
detection	 rate	 validated	 the	 efficacy	 of	 our	 detection	 protocols.	 Patients	 were	 classified	 as	
genetically	“solved”	following	the	identification	of	two	SLC3A1	mutations,	(Type	AA;	26%),	the	
presence	of	 the	heterozygous	SLC3A1	duplication	of	 exons	5-9	 (Type	A;	 5%),	or	 at	 least	one	
SLC7A9	mutation	 (Type	B	or	BB;	31%	and	21%,	respectively).	No	patients	 in	our	cohort	were	
found	 to	 have	 Type	 AB	 cystinuria	 (Table	 3.6),	 consistent	 with	 reports	 in	 the	 literature.	 This	
genotype	has	been	reported	with	an	average	rate	of	2.7%	in	cohort	studies	(Font-Llitjos	et	al.,	
2005;	Rhodes	et	al.,	2015;	Wong	et	al.,	2015).	However,	it	has	not	been	explained	why,	when	
Type	 A	 and	 Type	 B	 mutations	 are	 equally	 common,	 patients	 rarely	 present	 with	 Type	 AB	
cystinuria	(Dello	Strologo	et	al.,	2002).			
	 It	 has	 not	 been	 possible	 to	 explain	 the	 missing	 heredity	 in	 cystinuria	 through	 the	
involvement	of	a	third	gene	(Leclerc	et	al.,	2001;	Pineda	et	al.,	2004a;	Schmidt	et	al.,	2004b;	
Brauers	et	al.,	2005;	Chatzikyriakidou	et	al.,	2005),	and	 linkage	analysis	 in	cystinuric	patients	
only	maps	the	 locations	of	gene	 involvement	to	2p21	and	19q13.11,	 the	 locations	of	SLC3A1	
and	SLC7A9,	respectively	(Yan	et	al.,	1994).	In	Chapter	3,	we	reported	the	screening	of	patients	
32-44	through	next	generation	sequencing	(Table	3.5).	These	patients	were	investigated	in	30	
genes	 known	 to	 be	 involved	 in	 nephrolithiasis	 or	 nephrocalcinosis,	 including	 SLC3A1	 and	
SLC7A9	 (Halbritter	et	al.,	2014).	No	causal	variants	were	 identified	 in	any	of	 the	other	genes	
screened	 in	 the	 cystinuria	 patients,	 eliminating	 their	 putative	 role	 in	 the	 phenotype	 of	 the	
unsolved	patients	 (35	and	38,	Table	3.5).	 In	 the	course	of	 these	 investigations,	we	 identified	
four	 novel	 missense	 mutations	 in	 the	 System	 b0,+	 heavy	 chain	 protein	 rBAT.	 These	 were:	
M465K,	N254T,	L416P	and	Y579D	(Table	3.6,	Figure	3.12).		
In	 Chapter	 4	 we	 reported	 the	 optimisation	 of	 a	 range	 of	 techniques	 that	 allowed	
detection	of	 rBAT	 function	and	expression	 in	Xenopus	oocytes,	 following	 its	association	with	
the	 endogenous	 light	 chain,	 homologous	 to	 b0,+AT.	 It	 was	 essential	 that	 we	 established	
accurate	methods	of	measuring	the	expression	of	rBAT	to	enable	the	subsequent	comparison	
of	the	wild-type	protein	and	the	novel	mutants	identified	in	Chapter	3.	In	Chapter	5,	we	used	






Of	 the	 four	 novel	mutations	 investigated	 in	 this	 study,	 two	mutant	 proteins,	M465K	
and	 Y579D,	 showed	 a	 broadly	 similar	 expression	 pattern	 to	 other	 mutant	 rBAT	 proteins	
reported	 in	 the	 literature,	 in	 which	 a	 significant	 reduction	 of	 [3H]arginine	 uptake	 was	
measured,	 which	 recovered	 over	 time.	 Our	 data	 correlated	 with	 the	 results	 of	 M467T	 and	
M467K	 expression	 in	 oocytes	where	 a	 recovery	 in	 function	was	 observed	 over	 a	 number	 of	
days	post-injection	(Chillarón	et	al.,	1997).	In	concentration-dependent	(0.01-1mM)	uptakes,	a	
significant	 (p<0.001)	 reduction	 in	 the	capacity	 (Vmax)	of	 the	 transport	 system	 for	 [3H]arginine	
was	measured.	The	investigation	of	novel	mutations	N254T	and	L416P	led	to	some	variability	
in	 their	 measured	 effects	 on	 protein	 function	 following	 expression	 in	 oocytes.	 When	
[3H]arginine	uptake	(10μM)	was	conducted	at	day	3,	no	reduction	 in	uptake	was	observed	 in	
the	mutant	proteins	(Figures	5.17	and	5.22).	However,	when	concentration-dependent	uptake	
was	 measured,	 a	 significant	 (p<0.001)	 reduction	 in	 Vmax	 was	 measured	 with	 both	 mutant	
proteins	 (Figures	 5.19	 and	 5.24).	 Overall,	 these	mutations	 cause	 a	milder	 effect	 upon	 rBAT	
function	 than	 M465K,	 M467T,	 and	 Y579D.	 The	 functional	 data	 were	 broadly	 supported	 by	
western	blots	and	immunocytochemical	data.	From	these	data	we	conclude	that	the	severity	
of	 defect	 conveyed	 upon	 rBAT	 by	 the	 different	 mutations	 was	 M465K	 >	 M467T=Y579D	 >	
N254T	 =	 L416P	 >M618I	 =	 wild-type.	 The	 novel	 mutant	 M465K	 caused	 the	 most	 “severe”	
defect,	as	the	recovery	of	function	observed	6	days	post-injection	of	oocytes	was	incomplete.	






Watanabe	el	al.	1997).	When	 these	mutated	 residues	are	mapped	 to	 the	multiple	 sequence	
alignment	 of	 rBAT	with	 CD98	 and	B.	 cereus	 oligo-1,6-glucosidase,	 as	 displayed	 in	 Chapter	 1,	
along	 with	 the	 four	 novel	 mutations	 identified	 in	 this	 study,	 36	 residues	 (50%)	 were	 fully-
conserved	 between	 rBAT	 and	 the	 prokaryotic	 enzyme,	 whilst	 only	 16	 (22%)	 were	 fully	
conserved	with	CD98.	Only	10	residues	identified	as	mutations	in	cystinuria	patients	were	fully	
conserved	 in	all	 three	proteins.	From	mapping	the	mutated	residues	 in	cystinuric	patients	 to	
the	multiple	sequence	alignment,	several	regions	of	interest	can	be	identified.		
The	first	of	these	regions	is	Trp117-Tyr151	in	rBAT,	which	corresponds	to	Trp5-Tyr39	in	
the	 glucosidase	 enzyme,	 and	 Trp117-Tyr149	 in	 CD98	 (Figure	 7.1A).	 Over	 this	 region	 of	 35	







is	 striking,	 and	 highlights	 the	 importance	 of	 its	 structural	 integrity.	 To	 date,	 no	 further	
information	 is	 available	 about	 the	 function	of	 residues	 in	 this	 region	of	 proteins	 structurally	
related	 to	 rBAT.	 Therefore,	 we	 cannot	 infer	 any	 further	 hypotheses	 as	 to	 why	 so	 many	
cystinuria	mutations	fall	in	this	region.	
In	 Chapter	 3,	 we	 reported	 the	 discovery	 of	 a	 novel	 cystinuria	 mutation,	 M465K,	
identified	homozygously	in	Patient	25	of	the	cohort	(Table	3.6).	This	mutation	was	of	particular	




mutations	 include:	 R452W,	 R452Q,	 S455L,	 R456H,	 R456C,	 G458E,	 Y461H,	 and	 Y461X	 (Figure	
7.2B).	With	no	data	available	on	the	structures	related	to	rBAT,	it	is	difficult	to	hypothesise	the	
importance	of	 this	region	of	 the	TIM	barrel	 to	the	function	of	rBAT.	 In	general,	 this	region	 is	
less	conserved	(44%	identity)	than	β1/α1	(Figure	7.1A).	Furthermore,	the	glucosidase	enzyme	
has	an	additional	sequence	of	6	amino	acids	in	this	region,	which	are	absent	in	rBAT	and	CD98	
(Figure	 7.2A).	 However,	 the	 unwound	 structure	 of	 α7	 in	 the	 homology	 model	 of	 rBAT	 is	
present	in	the	crystal	structures	of	1UOK	and	CD98	(Watanabe	et	al.,	1997;	Fort	et	al.,	2007).		
Despite	the	fact	that	little	information	is	available	on	the	function	of	specific	residues	
of	 TIM	 barrel	 domains	 in	 structures	 related	 to	 rBAT,	 we	 can	 use	 an	 in	 silico	 approach	 to	






of	 enzymes	 that	 have	 been	 lost	 in	 the	 evolution	 of	 CD98	 (Gabrisko	 &	 Janecek,	 2009).	 In	
addition	to	the	catalytic	triad,	rBAT	also	retains	one	of	the	two	histidine	residues	(His215)	from	
oligo-1,6-glucosidase	 (His103),	 that	 is	 involved	 in	 substrate	 binding	 (Watanabe	et	 al.,	1997).	
These	 residues	 are	 not	 conserved	 in	 CD98,	 nor	 are	 the	 three	 residues	 of	 the	 catalytic	 triad	
(Fort	et	al.,	2007;	Gabrisko	&	Janecek,	2009).		
Despite	 the	 lack	of	 enzymatic	 activity	detected	 in	 rBAT	 (Wells	&	Hediger,	 1991),	 the	





ectodomain	 of	 the	 protein,	 possesses	 a	 function	 as	 yet	 undetermined	 (Fort	 et	 al.,	 2007).	
Members	of	the	SLC6	family	of	membrane	transport	proteins,	including	B0AT1,	involved	in	the	
pathophysiology	of	Hartnup	disease,	along	with	SIT1,	XT2,	and	EAATC1,	have	been	shown	to	
require	 co-localisation	 with	 an	 accessory	 protein	 to	 function	 (Danilczyk	 et	 al.,	 2006).	 In	 the	
intestine,	this	protein	is	Angiotensin	Converting	Enzyme	2	(ACE2)	a	carboxypeptidase	enzyme	
involved	 in	the	renin-angiotensin	system	(Camargo	et	al.,	2009).	 In	the	kidney,	however,	 this	
protein	 is	 collectrin,	 a	 homologue	 of	 ACE2,	 which	 shares	 48%	 sequence	 identity	 with	 the	
cytoplasmic,	 transmembrane,	 and	 extracellular	 domains	 of	 ACE2,	 but	 lacks	 the	 dipeptidyl	
carboxypeptidase	 catalytic	 domain	 (Zhang	 et	 al.,	 2001).	 Studies	 of	 collectrin	 knockout	 mice	
have	shown	a	lack	of	B0AT1	activity	in	kidney	brush-border	membrane	vesicles,	leading	to	loss	
of	 amino	 acids	 in	 the	 urine	 (Danilczyk	 et	 al.,	 2006).	 These	 data	 were	 further	 supported	 by	
immunoblotting	of	total	kidney	membranes,	which	showed	a	lack	of	B0AT1	localisation	at	the	
apical	membranes	 of	 the	 proximal	 tubule	 (Danilczyk	 et	 al.,	 2006).	 Na+-dependent	 uptake	 of	
leucine	 in	Xenopus	oocytes	 is	only	observed	following	co-expression	of	collectrin	with	B0AT1,	
and	 not	 following	 the	 expression	 of	 either	 protein	 in	 isolation	 (Danilczyk	 et	 al.,	 2006).	
Collectrin,	like	rBAT	and	CD98,	is	a	Type-II	membrane	glycoprotein,	passing	only	once	through	
the	 plasma	 membrane.	 However,	 unlike	 the	 SLC3	 and	 SLC7	 families	 of	 heterodimeric	
transporters,	 collectrin	 and	 ACE2	 do	 not	 appear	 to	 associate	 covalently	with	 the	 light	 chain	
subunits	(Danilczyk	et	al.,	2006).	It	has	been	hypothesised	that	the	physiological	significance	of	
the	association	of	ACE2	with	the	SLC6	transporters	in	the	intestine	could	be	that	the	release	of	
the	 neutral	 and	 cationic	 terminal	 amino	 acids	 that	 are	 cleaved	 from	 angiotensinogen,	 are	























Figure	 7.1:	 The	 conservation	of	 rBAT	domain	A1	with	 oligo-1,6-glucosidase	 from	B.	 cereus.	
The	 conservation	 of	 residues	 117-151	 in	 rBAT,	 which	 putatively	 lie	 in	 the	 β1/α1	 region	 of	
extracellular	 domain	 A1.	 A,	 Multiple	 sequence	 alignment	 of	 human	 rBAT	 (NM_000341.3)	
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Figure	 7.2:	 The	 conservation	 of	 rBAT	domain	A2	with	 oligo-1,6-glucosidase	 from	B.	 cereus.	
The	 conservation	 of	 residues	 452-467	 in	 rBAT,	 which	 putatively	 lie	 in	 the	 α7	 region	 of	
extracellular	 domain	 A2.	 A,	 Multiple	 sequence	 alignment	 of	 human	 rBAT	 (NM_000341.3)	
residues	 452-467	 with	 human	 CD98	 (NM_0001013251.2),	 and	 oligo-1,6-glucosidase	 from	 B.	
cereus	(GI:	4558191).	Grey	boxes	indicate	residues	conserved	with	rBAT.	X,	mutated	residues	
identified	 in	 the	 genotype	 of	 cystinuria	 patients	 (Stenson	 et	 al.,	 2014);	 *,	 novel	 mutations	
identified	in	this	study;	B,	Homology	model	of	rBAT	based	upon	the	crystal	structure	of	oligo-
1,6-glucosidase	from	B.	cereus	(PDB	code	1UOK,	Watanabe	et	al.,	1997).	Residues	452-467	are	












The	 final	 aims	 of	 this	 study	 were	 to	 determine	 how	 rBAT	 expression	 in	 Xenopus	
oocytes	and	Caco-2	cells	could	be	modified	through	incubation	with	different	compounds	that	
would	 differentially	 affect	 the	 biogenesis	 of	 the	 native	 and	mutant	 protein	 (Chapter	 6).	 The	
global	aim	of	these	modifications	was	to	identify	novel	therapeutic	strategies	that	would	allow	




cystine,	 including	 alkalinisation	 and	 incubation	with	 the	 CBTDs	 captopril,	 D-penicillamine,	 or	
tiopronin	had	no	effect	upon	the	protein	expression	(Figures	6.2-6.4,	and	6.7-6.8).	Similarly,	no	
change	 in	 function	 was	 detected	 in	 the	 wild-type	 or	 rBAT	mutant	 proteins	M467T,	M465K,	
N254T,	 L416P,	 or	 Y579D	 (Figure	 6.5).	 These	 data	 indicate	 that	 there	 is	 no	 scope	 for	 a	
pharmacogenetic	approach	to	cystinuria	therapy	using	established	treatments.		
Following	 this,	 we	 investigated	 the	 biogenesis	 of	 rBAT	 in	 the	 ER	 by	 considering	
whether	the	proteasomal	inhibitor	MG132	would	allow	the	localisation	of	mutant	proteins	to	
the	 plasma	 membrane.	 No	 increase	 in	 function	 of	 rBAT	 mutant	 proteins	 was	 measured	
following	 incubation	of	oocytes	with	MG132	 (Figure	6.1A).	However,	 these	were	preliminary	
studies,	and	 it	would	be	desirable	 to	repeat	 these	at	a	 range	of	 incubation	conditions.	Using	
pulse-chase	experiments	in	MDCK	cells,	Bartoccioni	et	al.	(2008)	demonstrated	that	use	of	the	
proteasome	inhibitor	MG132	delayed	the	degradation	of	unassembled	rBAT.	However,	it	was	
not	 demonstrated	 that	 this	 “lag”	 in	 degradation,	 measured	 by	 immunoblotting	 of	 rBAT	
proteins,	caused	an	increase	in	trafficking	of	the	protein	to	the	plasma	membrane	(Bartoccioni	
et	 al.,	 2008).	 It	 would	 be	 interesting	 to	 investigate	 the	 use	 of	 the	 proteasomal	 inhibitor	
MG132,	 in	 combination	with	 a	molecular	 chaperone	 such	 as	 4-phenylbutyrate	 (PBA),	 which	
has	been	 shown	 to	 allow	 the	exit	 of	ΔF508	CFTR	 from	 the	ER,	 and	 restore	 function	 in	nasal	
epithelia	in	a	cohort	of	adult	patients	(Zeitlin	et	al.,	2002).		
Xenopus	 oocytes	 are	 a	 robust	 expression	 system	 for	 the	 functional	 expression	 of	
membrane	 transport	 proteins,	 and	 are	widely	 reported	 in	 the	 literature	 (Moeller	&	 Fenton,	
2010).	 However,	 in	 mutant	 proteins	 that	 cause	 trafficking	 defects	 due	 to	 ER-associated	
degradation,	 it	 has	 been	 shown	 that	 the	 low	 incubation	 temperatures	 can	 allow	 release	 of	
mutant	 proteins	 from	 the	 ER,	 which	 would	 not	 occur	 in	 vivo	 (Denning	 et	 al.,	 1992;	 Leduc-
Nadeau	 et	 al.,	 2010).	This	 is	due	 to	 temperature-dependent	 inhibition	of	 the	ERAD	pathway	
(Denning	 et	 al.,	 1992).	 No	 effect	 of	 increasing	 the	 oocyte	 incubation	 temperature	 on	 the	
function	 of	 System	 b0,+	 function	 was	 measured	 in	 this	 study	 (Figure	 6.1B).	 However,	 we	
hypothesised	 that	 if	 rBAT	 mutant	 protein	 can	 be	 released	 from	 the	 ER	 in	 a	 temperature-
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sensitive	manner	a	greater	effect	of	 the	mutations	would	be	measured	 in	a	mammalian	 cell	
line	 (incubated	at	37°C)	 than	 in	oocytes,	 as	observed	by	Pineda	et	al.	 (2004).	 Therefore,	 the	
transient	 expression	 of	 rBAT	 in	 the	 mammalian	 cell	 line	 Caco-2	 was	 investigated.	 Through	
preliminary	investigations	it	appeared	as	though	some	wild-type	rBAT	protein	was	present	at	
the	apical	membrane	 (Figure	6.11).	Unfortunately,	due	 to	 time	restrictions	on	 this	 study,	we	
were	 unable	 to	 transfect	 Caco-2	 cells	 with	 the	mutant	 proteins	 to	 compare	 the	 expression	
patterns.	In	future	studies,	this	would	be	desirable	for	detection	of	the	sub-cellular	localisation	
of	the	rBAT	mutants.	Additionally,	this	would	allow	experiments	to	be	carried	out	to	detect	any	
temperature-sensitive	 release	of	 rBAT	mutant	proteins	 from	the	endoplasmic	 reticulum.	The	
expression	 of	 wild-type	 rBAT	 and	 mutant	 proteins	 in	 a	 cell	 line	 would	 also	 enable	 the	
determination	 of	 the	 cellular	 localisation	 of	 any	 protein	 not	 trafficked	 to	 the	 plasma	
membrane	through	the	use	of	immunofluorescent	markers.		






In	 conclusion,	 we	 have	 identified	 four	 novel	 mutations	 in	 SLC3A1,	 one	 of	 the	 two	
genes	known	 to	contribute	 to	 the	pathophysiology	of	 cystinuria	 (Chapter	3)	 (Chillarón	 et	al.,	
2010).	We	have	established	a	series	of	techniques	to	allow	the	accurate	measurement	of	rBAT	
expression	and	function	in	Xenopus	oocytes	(Chapter	4).	These	techniques	were	then	utilised	
to	 identify	 key	 changes	 in	 rBAT	 function	 and	 expression	 compared	 to	 the	wild-type	 protein	
(Chapter	5).	As	observed	with	other	rBAT	mutant	proteins	(Chillarón	et	al.,	1997;	Bartoccioni	et	
al.,	 2008)	 it	 appeared	 as	 though	 the	 mutations	 led	 to	 trafficking	 defects,	 resulting	 in	 a	
reduction	 in	 Vmax	 in	 concentration-dependent	 uptakes.	 Following	 on	 from	 this,	 a	 series	 of	
modifications	 to	 the	 incubation	 conditions	 of	 rBAT	 were	 attempted	 to	 determine	 how	 the	
biogenesis	of	the	protein	could	be	influenced	(Chapter	6).		
Further	 investigations	 into	 the	 effect	 of	 cystinuria	mutations	 upon	 the	 biogenesis	 of	
rBAT,	 coupled	 with	 studies	 into	 the	 use	 of	 molecular	 chaperones	 that	 enable	 successful	
targeting	of	the	protein	to	the	membrane,	are	required.	This	will	allow	novel	therapies	to	be	
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